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Abstract
Molecular testing for Lynch syndrome in people
with colorectal cancer: systematic reviews and
economic evaluation
Tristan Snowsill,1* Helen Coelho,1 Nicola Huxley,1
Tracey Jones-Hughes,1 Simon Briscoe,1 Ian M Frayling2
and Chris Hyde1
1Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2Institute of Cancer and Genetics, University Hospital of Wales, Cardiff, UK
*Corresponding author t.m.snowsill@exeter.ac.uk
Background: Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR) genes lead to an
increased risk of colorectal cancer (CRC), gynaecological cancers and other cancers, known as Lynch
syndrome (LS). Risk-reducing interventions can be offered to individuals with known LS-causing mutations.
The mutations can be identified by comprehensive testing of the MMR genes, but this would be
prohibitively expensive in the general population. Tumour-based tests – microsatellite instability (MSI) and
MMR immunohistochemistry (IHC) – are used in CRC patients to identify individuals at high risk of LS for
genetic testing. MLH1 (MutL homologue 1) promoter methylation and BRAF V600E testing can be
conducted on tumour material to rule out certain sporadic cancers.
Objectives: To investigate whether testing for LS in CRC patients using MSI or IHC (with or without MLH1
promoter methylation testing and BRAF V600E testing) is clinically effective (in terms of identifying Lynch
syndrome and improving outcomes for patients) and represents a cost-effective use of NHS resources.
Review methods: Systematic reviews were conducted of the published literature on diagnostic test
accuracy studies of MSI and/or IHC testing for LS, end-to-end studies of screening for LS in CRC patients
and economic evaluations of screening for LS in CRC patients. A model-based economic evaluation was
conducted to extrapolate long-term outcomes from the results of the diagnostic test accuracy review.
The model was extended from a model previously developed by the authors.
Results: Ten studies were identified that evaluated the diagnostic test accuracy of MSI and/or IHC testing
for identifying LS in CRC patients. For MSI testing, sensitivity ranged from 66.7% to 100.0% and
specificity ranged from 61.1% to 92.5%. For IHC, sensitivity ranged from 80.8% to 100.0% and
specificity ranged from 80.5% to 91.9%. When tumours showing low levels of MSI were treated as a
positive result, the sensitivity of MSI testing increased but specificity fell. No end-to-end studies of
screening for LS in CRC patients were identified. Nine economic evaluations of screening for LS in CRC
were identified. None of the included studies fully matched the decision problem and hence a new
economic evaluation was required. The base-case results in the economic evaluation suggest that
screening for LS in CRC patients using IHC, BRAF V600E and MLH1 promoter methylation testing
would be cost-effective at a threshold of £20,000 per quality-adjusted life-year (QALY). The incremental
cost-effectiveness ratio for this strategy was £11,008 per QALY compared with no screening. Screening
without tumour tests is not predicted to be cost-effective.
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Limitations: Most of the diagnostic test accuracy studies identified were rated as having a risk of bias
or were conducted in unrepresentative samples. There was no direct evidence that screening improves
long-term outcomes. No probabilistic sensitivity analysis was conducted.
Conclusions: Systematic review evidence suggests that MSI- and IHC-based testing can be used to identify
LS in CRC patients, although there was heterogeneity in the methods used in the studies identified and
the results of the studies. There was no high-quality empirical evidence that screening improves long-term
outcomes and so an evidence linkage approach using modelling was necessary. Key determinants of
whether or not screening is cost-effective are the accuracy of tumour-based tests, CRC risk without
surveillance, the number of relatives identified for cascade testing, colonoscopic surveillance effectiveness
and the acceptance of genetic testing. Future work should investigate screening for more causes of
hereditary CRC and screening for LS in endometrial cancer patients.
Study registration: This study is registered as PROSPERO CRD42016033879.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Adenoma A benign tumour formed from glandular structures in epithelial tissue.
Adjuvant chemotherapy Additional cancer treatment given after the primary treatment to lower the risk
that the cancer will come back.
Amsterdam criteria A set of diagnostic criteria used by doctors to help identify families that are likely to
have Lynch syndrome.
Anastomosis A connection made surgically between adjacent blood vessels, parts of the intestine or
other channels of the body.
Anterior resection Removal of an area of the rectum and/or left side of the bowel.
Array-based comparative genomic hybridisation A cytogenetic technology that evaluates areas of the
human genome for gains or losses of chromosome segments.
Base case The expected case using the assumptions deemed most likely to occur.
Bethesda panel of microsatellite instability markers A panel of five microsatellite markers (BAT25,
BAT26, D2S123, D5S346, D17S250) proposed in the original Bethesda guidelines to describe microsatellite
instability in Lynch syndrome.
Bimodal distribution of microsatellite instability markers Tumours defined as positive or negative for
microsatellite instability.
BRAF A human gene that makes a protein called B-raf (a member of the Raf kinase family).
BRAF V600E A mutation of the BRAF gene detected in a range of carcinomas, including colorectal cancer.
BRCA mutation Mutation in the BRCA1 or BRCA2 tumour-suppressor gene that causes hereditary
breast–ovarian cancer syndrome.
Cancer antigen 125 analysis Blood test for ovarian cancer.
Carcinoembryonic antigen test Carcinoembryonic antigens are harmful substances (usually proteins)
that are produced by some types of cancer. In response to the antigens, the body produces antibodies
to help fight them. A carcinoembryonic antigen test is often carried out after surgery to check for
carcinoembryonic antigen levels.
Carcinogenesis The formation of a cancer whereby normal cells are transformed into cancer cells.
Cascade testing The identification of close relatives of an individual with a disorder to determine whether
the relatives are also affected or are carriers of the same disorder.
Chemoprevention The use of pharmacological or natural agents that inhibit the development of invasive
cancer either by blocking the deoxyribonucleic acid damage that initiates carcinogenesis or by arresting or
reversing the progression of premalignant cells in which such damage has already occurred.
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Colonoscopic surveillance A screening programme in people at high risk of developing colorectal cancer
with the aim of detecting precancerous changes early on and potentially preventing progression.
Concordance The degree of agreement between two diagnostic tests.
Conformation-sensitive gel electrophoresis A method for the rapid detection of single-base
differences in double-stranded polymerase chain reaction products and deoxyribonucleic acid fragments.
Confounder A third variable that can make it appear (sometimes incorrectly) that an observed exposure is
associated with an outcome.
Constitutional genetic testing Tests for mutations that affect all cells in the body and have been there
since conception (also known as germ-line testing).
Constitutional mutation A genetic mutation present in all cells (also known as germ-line mutation).
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gains.
Cytotoxicity The quality of being toxic to cells.
Decision modelling A theoretical construct that allows analysis of the relationship between costs and
outcomes of alternative health-care interventions.
Decision tree A decision support tool that uses a tree-like graph or model of decisions and their possible
consequences, including chance event outcomes, resource costs and utility.
Deletion Change in the number of deoxyribonucleic acid bases by removing a piece of
deoxyribonucleic acid.
Denaturing gradient gel electrophoresis A molecular fingerprinting method that separates polymerase
chain reaction-generated deoxyribonucleic acid products.
Denaturing high-performance liquid chromatography A method of chromatography for the detection
of base substitutions, small deletions or small insertions in the deoxyribonucleic acid.
Deoxyribonucleic acid mismatch repair A process that corrects mismatches generated during
deoxyribonucleic acid replication.
Diagnostic yield The number of positive test results divided by the number of samples.
Dinucleotide A molecule consisting primarily of two nucleotides.
Discounting Weighting future effects on expenditure and health outcomes less heavily than effects in the
present. Health economic evaluations for the National Institute for Health and Care Excellence discount
future costs and benefits at a constant rate of 3.5% per year.
Disutility The adverse or harmful effects associated with a particular activity or process, especially when
carried out over a long period of time.
Dukes’ stage The Dukes’ cancer staging system is divided into four groups: A, B, C and D. Dukes’ A is
early bowel cancer and Dukes’ D is advanced bowel cancer.
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Duplication A piece of deoxyribonucleic acid that is abnormally copied one or more times. This type of
mutation may alter the function of the resulting protein.
Dysplasia The enlargement of an organ or tissue by the proliferation of cells of an abnormal type, as a
developmental disorder or an early stage in the development of cancer.
End-to-end study Studies that follow patients from testing through treatment to final outcomes.
EuroQol-5 Dimensions A generic health-related quality-of-life questionnaire.
Exteriorisation The transposition of an internal organ to the exterior of the body.
False negative Incorrect negative test result – number of diseased people with a negative test result.
False positive Incorrect positive test result – number of non-diseased people with a positive test result.
First-degree relative A person’s parent, sibling or child.
Frameshift mutation Occurs when the addition or loss of deoxyribonucleic acid bases changes a gene’s
reading frame. The resulting protein is usually non-functional.
Functional Assessment of Cancer Therapy – General A health-related quality-of-life questionnaire for
cancer therapy.
Germ line Inherited material that comes from the eggs or sperm and is passed on to offspring.
Germ-line mutation A detectable and heritable variation in the lineage of germ cells, which is
subsequently transferred to offspring and gives rise to a constitutional mutation.
Hazard ratio A measure of how often a particular event happens in one group compared with how often
it happens in another group over time.
Hereditary non-polyposis colorectal cancer Previous name for Lynch syndrome, a hereditary disorder
that causes an increase in the risk of several types of cancer.
Hypermethylation An increase in the epigenetic methylation of cytosine and adenosine residues in
deoxyribonucleic acid.
Hysterectomy A surgical procedure to remove the womb (uterus).
Immunoreactivity A measure of the immune reaction caused by an antigen.
Incidence The rate of occurrence of new (or newly diagnosed) cases of a disease.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Insertion Changes in the number of deoxyribonucleic acid bases in a gene by adding a piece of
deoxyribonucleic acid. As a result, the protein made by the gene may not function properly.
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Intention-to-treat analysis Includes every subject who is randomised according to their randomised
treatment assignment. It ignores non-compliance, protocol deviations, withdrawals and anything that
happens after randomisation.
Inter-rater variability The degree of agreement among raters (histopathologists for immunohistochemistry).
Likelihood ratio The likelihood that a given test result would be expected in a patient with the target
disorder compared with the likelihood that that same result would be expected in a patient without the
target disorder.
Locoregional metastases Metastasis (spread) of a cancer only within the region in which it arose.
Markov model A stochastic model describing a sequence of possible events in which the probability of
each event depends only on the state attained in the previous event.
Meta-analysis A statistical technique used to combine the results of two or more studies and obtain a
combined estimate of effect.
Metachronous tumours Primary tumours not occurring at the same time (usually occurring
> 6 months apart).
Metastatic disease The spread of cancer from one organ or body part to another organ or body part.
Methylation A process by which methyl groups are added to deoxyribonucleic acid.
Microdissection Refers to a variety of techniques in which a microscope is used to assist in dissection.
Microsatellite instability Abnormal patterns of microsatellite repeats observed when deoxyribonucleic
acid is amplified from a tumour with defective mismatch repair compared with deoxyribonucleic acid
amplified from surrounding normal tissue.
Microsatellite stable No evidence of abnormal patterns of microsatellite repeats or defective
mismatch repair.
Missense A change in one deoxyribonucleic acid base pair that results in the substitution of one amino
acid for another in the protein made by a gene.
Mixed-effects logistic regression Used to model binary outcome variables, with the log odds of the
outcomes modelled as a linear combination of the predictor variables when data are clustered or there are
both fixed and random effects.
Mononucleotide A single nucleotide molecule (with one nitrogenous base, one sugar and one
phosphate group).
Mortality bias When mutation carriers are more likely to have died before being able to receive
predictive testing.
Multiplex ligation-dependent probe amplification A multiplex polymerase chain reaction method that
is capable of detecting abnormal copy numbers of up to 50 different genomic deoxyribonucleic acid or
ribonucleic acid sequences and which is able to distinguish sequences differing by only one nucleotide.
Negative predictive value The probability of someone with a negative test result actually not having
the disease.
GLOSSARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
Net survival The survival calculated from the estimated excess hazard of mortality caused by a condition.
Next-generation sequencing Non-Sanger-based high-throughput deoxyribonucleic acid
sequencing technologies.
Nonsense A change in one deoxyribonucleic acid base pair that results in a premature signal to stop
building a protein. This type of mutation results in a shortened protein that may function improperly or not
at all.
Nucleotide Small molecules that make up deoxyribonucleic acid strands. Nucleotides consist of a
nitrogenous base, a sugar and a phosphate group.
Optimum cut-off The cut-off score that demonstrates the best trade-off between sensitivity
and specificity.
Pathogenic mutation A mutation capable of causing disease.
Penetrance The proportion of individuals carrying a particular variant of a gene (allele or genotype) that
also expresses an associated trait.
Per-protocol analysis A comparison of treatment groups that includes only those patients who
completed the treatment that they were originally allocated to.
Polymerase chain reaction A technology used for amplifying deoxyribonucleic acid sequences.
Positive predictive value The probability of someone with a positive result actually having the disease.
Predictive testing Testing for known mutations.
Prevalence The proportion of cases in the population at a given time.
Primary tumour A tumour growing at the anatomical site where tumour progression began.
Probabilistic sensitivity analysis A technique to quantify the level of confidence that a decision-maker
has in the conclusions of an economic evaluation.
Proband The first affected family member.
Proctocolectomy Surgical removal of the rectum and all or part of the colon.
Promoter A region of deoxyribonucleic acid that initiates transcription of a particular gene.
Proximal colon The first and middle parts of the colon.
QLQ-C30 A health-related quality-of-life questionnaire for cancer patients.
QLQ-CR29 An add-on module to the QLQ-C30 for colorectal cancer patients.
Quality-adjusted life-year A measure of health gain used in economic evaluations in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) A tool for the quality assessment of
studies of diagnostic accuracy included in systematic reviews.
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Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference costs The average unit costs to the NHS of providing secondary health care to NHS patients.
Reference standard The best currently available diagnostic test, against which the index test
is compared.
Reference standard-positive study A study that uses a variation on a two-gate study design in which
only participants who are reference standard positive are recruited (authors’ own term).
Reflex testing Testing performed automatically in response to patient characteristics or the results of
other tests.
Regional metastases The spread of cancer beyond the initial site to regional lymph nodes.
Relative survival The observed survival within a group (e.g. people with colorectal cancer) as a
proportion of the expected survival for a group with the same age and sex distribution.
Revised Bethesda guidelines Recommendations for identifying individuals with Lynch syndrome.
Salpingo-oophorectomy Surgical removal of a fallopian tube and an ovary.
Scenario analysis A process of analysing possible future costs by considering alternative
possible outcomes.
Second-degree relative Someone who shares 25% of a person’s genes. This includes uncles, aunts,
nephews, nieces, grandparents, grandchildren and half-siblings.
Segmental resection Removal of the cancer, a section of normal colon on either side of the cancer and
nearby lymph nodes, with the sections of the remaining colon then reattached.
Sensitivity Proportion of individuals with the target disorder who have a positive test result.
Sensitivity analysis A technique used to determine how different values of an independent variable
impact on a particular dependent variable under a given set of assumptions.
Short Form questionnaire-6 Dimensions (SF-6D) A general health-related quality-of-life tool.
Short Form questionnaire-12 items (SF-12) A general health-related quality-of-life tool.
Short Form questionnaire-36 items (SF-36) A general health-related quality-of-life tool.
Single-gate study A test accuracy study design in which a single cohort of individuals is assessed by both
the index test and the reference standard.
Single-strand conformational polymorphism A conformational difference of single-stranded
nucleotide sequences of identical length as induced by differences in the sequences under certain
experimental conditions. This allows sequences to be distinguished by means of gel electrophoresis.
Somatic Referring to the cells of the body in contrast to the germ-line cells.
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Southern blot analysis A procedure for identifying specific sequences of deoxyribonucleic acid in which
fragments separated by gel electrophoresis are transferred directly to a second medium on which a
hybridisation assay is carried out.
Specificity Proportion of individuals without the target disorder who have a negative test result.
Spectrum bias The phenomenon that the performance of a diagnostic test may vary in different clinical
settings because each setting has a different mix of patients.
Splenic flexure A curvature on the left of the transverse colon.
Splice site Causes abnormal messenger ribonucleic acid processing.
Sporadic colorectal cancer Colorectal cancer with no apparent hereditary component.
Subtotal colectomy An operation to remove the colon, leaving the rectum behind.
Synchronous tumours Primary tumours diagnosed within 6 months of each other.
Trimodal distribution of microsatellite instability Threshold distribution that includes microsatellite
instability-high, microsatellite instability-low and microsatellite stable.
Tumorigenesis The production or formation of a tumour or tumours.
Two-gate study A study that employs separate sampling schemes for diseased and non-diseased
participants, with both groups being assessed by the index test.
Unclassified variant A variation in a genetic sequence whose association with disease risk has not yet
been established.
Univariate analysis The examination of one variable at a time.
Variant of uncertain significance A variation in a genetic sequence that after interpretation efforts still
cannot be classified as likely pathogenic or non-pathogenic. Also called variant of unknown significance.
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Plain English summary
The DNA mismatch repair system corrects errors in DNA replication that occur when cells in the bodydivide. Without the mismatch repair system, errors in DNA multiply and this can lead to cancer
developing, especially in the bowel and in the female reproductive organs.
Most people are born with two working copies of the genes responsible for the mismatch repair system,
but some people inherit a faulty (mutated) copy of one of the genes. As they have only one working copy
they are more likely to lose the function in the mismatch repair system and subsequently develop cancer.
This leads to patterns of cancer in a family, which is known as Lynch syndrome.
Around two in five people with Lynch syndrome will develop bowel cancer during their lifetime and
around one in three women with Lynch syndrome will develop womb cancer. People with Lynch syndrome
are also more likely to develop ovarian cancer and a number of other cancers.
The aim of this study was to find out whether it would be clinically effective (i.e. good for patients and
their families) and cost-effective (i.e. a good use of limited NHS resources) to screen bowel cancer patients
for Lynch syndrome by testing their tumours. If tests on the tumours show signs of Lynch syndrome they
can be offered genetic testing to search for the mutated gene responsible. Family members can then be
offered a blood test to see if they have the mutated gene. The benefit of knowing that someone has
Lynch syndrome is that surveillance can be offered, such as colonoscopy, to reduce the risk of cancer in
the future.
Published evidence shows that tumour tests can help to identify Lynch syndrome. Although it has not been
proven in practice, a mathematical model suggests that screening would be clinically effective and
cost-effective.
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Lynch syndrome (LS) is the most common form of genetically defined hereditary colorectal cancer (CRC),
accounting for 3.3% of colorectal tumours. In the UK, it is estimated that 175,000 people have LS and this
leads to > 1100 CRCs per year.
Lynch syndrome is caused by constitutional pathogenic mutations in any one of four deoxyribonucleic acid
(DNA) mismatch repair (MMR) genes: MLH1 (MutL homologue 1), MSH2 (MutS homologue 2), MSH6
(MutS homologue 6) and PMS2 (postmeiotic segregation increased 2). Some constitutional mutations in
the EPCAM (epithelial cell adhesion molecule) gene also lead to LS through epigenetic silencing of MSH2.
For simplicity, the term ‘Lynch syndrome’ refers to the presence of mutations that cause LS, whether or not
an individual has been affected by cancer.
Lynch syndrome is inherited in an autosomal dominant pattern, so if one parent has LS there is a 50%
chance of each child inheriting it.
Lynch syndrome increases the risk of CRC, as well as the risks of gynaecological and other cancers. These
cancers are frequently observed at younger ages than is typically seen with sporadic cancers.
Frequent colonoscopy with polypectomy in individuals with LS is believed to reduce the incidence of
CRC (by allowing the removal of precancerous adenomatous polyps) and improve the survival of CRC
(by diagnosing CRC at an earlier stage). Other risk-reducing measures have varying levels of evidence for
their effectiveness.
There are usually no signs or symptoms of LS prior to developing cancer, but a blood test can identify
constitutional pathogenic mutations. Individuals unaffected by cancer but at high risk of LS can be
identified through family history. If a pathogenic mutation is already identified in a relative then a simple
predictive genetic test can be performed.
Colorectal cancer patients at risk of LS can also be identified through tests on their tumour cells or DNA.
The majority of colorectal tumours from individuals with LS have two distinguishing characteristics:
microsatellite instability (MSI) and loss of expression of the MMR proteins.
Deoxyribonucleic acid microsatellites are short repetitive sequences found throughout the human genome.
When the MMR system is defective, the lengths of these sequences become variable as errors go
uncorrected; this is known as MSI. Molecular MSI testing involves polymerase chain reaction amplification
of DNA markers from a microdissected tumour tissue sample and a matched healthy tissue sample from
the same patient. Instability in ≥ 30% of markers is usually denoted as MSI-high (MSI-H), instability in
< 30% of markers is denoted as MSI-low (MSI-L) and no instability in any markers is denoted as
microsatellite stable (MSS).
Loss of expression of MMR proteins can be identified using immunohistochemistry (IHC). Antibodies for
the four MMR proteins are used to stain tumour and non-tumour cells. If nuclear staining is abnormal for
any MMR protein(s), this suggests that the MMR system is affected.
Some non-LS colorectal tumours display MSI and/or abnormal staining. These are often caused by acquired
hypermethylation of the MLH1 promoter, which can be tested for directly. This is often accompanied by a
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somatic V600E mutation in the BRAF gene, which is rarely seen in cancers from individuals with LS.
MLH1 promoter methylation and/or BRAF V600E testing are used to rule out LS.
If tumour-based tests are suggestive of LS then testing for pathogenic mutations in the MMR and EPCAM
genes is offered to patients, after genetic counselling.
It is suggested that testing for LS in CRC patients (and then cascading testing to relatives if appropriate)
can improve health outcomes and be a cost-effective use of health-care resources.
Objectives
To investigate whether testing for LS in CRC patients using MSI or IHC (with or without MLH1 promoter
methylation testing and BRAF V600E testing) is clinically effective (in terms of identifying LS and improving
outcomes for patients) and whether or not it represents a cost-effective use of NHS resources.
Review of test accuracy studies
Methods
A systematic review was conducted to assess the diagnostic accuracy of MSI testing and MMR IHC for
identifying LS in CRC patients.
Bibliographic databases (including MEDLINE, EMBASE, Web of Science and The Cochrane Library) were
searched using terms for LS and terms for MSI or IHC. The search results were limited by date from 2006
and to English-language studies. To identify relevant studies published before 2006 (and any additional
studies published after 2006) prespecified and newly identified systematic reviews were screened.
Two reviewers independently assessed titles and abstracts, as well as full-text papers, using prespecified
inclusion and exclusion criteria. References were included if they described single-gate or two-gate
diagnostic studies recruiting individuals with CRC and investigating the test accuracy of MSI testing and/or
MMR IHC, with or without BRAF V600E mutation testing and with or without MLH1 promoter methylation
testing. The index test(s) must have been compared with a reference standard and data had to be
provided to enable the estimation of sensitivity. Other outcomes were specificity, positive and negative
likelihood ratios (LR+ and LR–), positive and negative predictive values (PPV and NPV), concordance with
the reference standard, diagnostic yield and test failure rates.
The reference standard was constitutional MMR mutation testing, which had to include DNA sequencing
of MLH1, MSH2 and MSH6 and multiplex ligation-dependant probe amplification (or another appropriate
technique for detecting large genomic abnormalities). All participants had to have received both the index
test and the reference standard, although for studies recruiting a representative sample of all CRC patients
(including studies with age limits) it was acceptable for the reference standard to be applied to all index
test positives and to a representative sample of index test negatives.
Data extraction and quality appraisal [using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy
Studies) tool] was performed by one reviewer and checked by a second. For studies that were not based
on high-risk samples, sensitivity, specificity, LR+, LR–, PPV and NPV were independently calculated. For
studies based on high-risk samples, only the sensitivity of the index test(s) was calculated. Studies that
provided estimates of both sensitivity and specificity had their point estimates plotted in receiver operating
characteristic (ROC) space. Because of insufficient data and heterogeneity in methods and results of
studies, meta-analysis was not conducted. Narrative synthesis was conducted.
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Results
Ten studies met the diagnostic test accuracy review inclusion criteria. One study had two distinct samples;
the results from all 11 samples were considered.
Quality appraisal did not indicate a high risk of bias for any of the studies.
Three of the studies were single-gate studies with population-based samples, with age limits. Four studies
were single-gate studies based on high-risk populations. One study had two single-gate samples: a
population-based sample (apparently unselected) and a sample based on a high-risk population. The
remaining two studies used a variation on the two-gate study design, with only participants with positive
reference standard results included. These studies have been termed ‘reference standard positive’ studies.
Across the studies the reference standard varied in terms of the sequencing methods and genes tested, the
techniques used to test for large genomic alterations and deletions, the genes tested for large genomic
alterations and deletions and whether unclassified variants were investigated. None of the included studies
made a direct comparison between MSI and IHC.
Nine samples provided data on MSI. There was variation between studies in the MSI testing procedures
used with regard to microdissection techniques, the panel of markers used and the categories of and
thresholds for MSI.
In primary analyses unclassified variants were categorised as negative reference standard results and MSI-L
was considered a negative index test result. Sensitivity estimates ranged from 66.7% to 100.0%. The
specificity for MSI was calculated from three population-based samples (61.1–92.5%).
When MSI-L was considered to be a positive index test result sensitivity increased and specificity decreased.
Seven samples provided data to assess the accuracy of IHC. Five study samples split IHC data according to
the protein assessed (MLH1, MSH2, MSH6 or PMS2), enabling assessment within those studies of the
accuracy of IHC for individual proteins (i.e. whether the absence of a particular protein accurately identifies
a mutation in that particular gene).
In primary analyses unclassified variants were categorised as negative reference standard results. Sensitivity
estimates ranged from 80.8% to 100.0%. For the two population-based studies specificity was estimated
as 91.9% and 80.5%.
Three studies provided data for the sensitivity of MLH1 loss of expression (range 50.0–100.0%), three
studies provided data for the sensitivity of MSH2 loss of expression (range 22.2–81.8%) and four studies
provided data for the sensitivity of MSH6 loss of expression (range 44.4–75.0%). Specificities were also
generated for the population-based studies. For MLH1 these ranged from 70.6% to 96.0%, whereas for
MSH2 and MSH6 both studies estimated a specificity of > 92%. Only one study provided data for PMS2,
providing a sensitivity estimate of 55.6% and a specificity estimate of 87.8%.
Review of end-to-end studies
Methods
The diagnostic test accuracy searches were used to identify end-to-end studies of screening for LS in CRC
patients, that is, studies that compared patients receiving screening with patients not receiving screening in
terms of long-term outcomes such as survival and cancer incidence.
One experienced researcher screened all titles and abstracts for eligibility and a second researcher checked
a 10% random sample.
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Results
No eligible studies were identified. Some studies that compared outcomes before and after the
introduction of screening were identified but they had been published in only abstract form and could not
be included.
Review of economic evaluations
Methods
A systematic review was conducted to assess the cost-effectiveness of testing for LS in CRC patients using
MSI testing and/or IHC.
Bibliographic databases including MEDLINE, EMBASE, Web of Science, NHS Economic Evaluation Database
(NHS EED) and EconLit were searched for economic studies. A date limit of 2013 was used to reflect that
this was an update of a previous systematic review of cost-effectiveness.
After two reviewers had completed the screening process, the bibliographies of included papers were
scrutinised for further potentially relevant studies. To be eligible for inclusion, studies had to include a
population of people with newly diagnosed CRC and had to evaluate MSI and/or IHC.
Studies were quality appraised and their results were tabulated. A narrative synthesis was conducted.
Results
Nine studies were eligible for inclusion. Seven studies were based in the USA, one study was based in
Germany and one in the UK. All studies included strategies to identify LS in people with CRC and their
relatives. Modelling was similar across studies, with a diagnostic model to identify LS and a long-term
model to estimate the costs and benefits associated with the outcomes of the diagnostic model. Five
studies were cost–utility studies.
The studies reported a wide variety of analyses, with varying quality of reporting. No single study answered
the decision problem in full, generally because not all of the interventions identified by the National
Institute for Health and Care Excellence scope were included or a UK perspective was not used.
Most studies stated that at least one strategy to identify LS could be cost-effective and, when a universal
genetic testing strategy was included, strategies that used tumour-based tests to enrich the population
appeared to improve cost-effectiveness [reducing incremental cost-effective ratios (ICERs)]. Most studies
agreed that the effectiveness of colonoscopy screening, the number of relatives and the prevalence of LS
had the biggest effects on cost-effectiveness.
Independent economic evaluation
Methods
A model-based economic evaluation was conducted to extrapolate outcomes based on the results of the
diagnostic test accuracy review.
The model estimated costs from a NHS and personal social services perspective and quality-adjusted
life-years (QALYs). These were discounted at 3.5% per year.
A decision tree was used to estimate how many individuals would be diagnosed with LS (correctly or
incorrectly) using 10 possible strategies. One strategy involved no testing for LS, four involved MSI testing,
four involved IHC and one involved direct MMR mutation screening.
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An individual patient simulation was used to predict long-term outcomes for individuals according to their
baseline characteristics and diagnosis. Individuals were simulated until death or age 100 years.
Colorectal cancer and endometrial cancer were modelled. Colonoscopy, gynaecological surveillance,
prophylactic gynaecological surgery and aspirin chemoprevention were included. Colonoscopic surveillance
was assumed to reduce the incidence of CRC and to affect the stage distribution of CRCs, as estimated
from the published literature.
The health-related quality of life for individuals was modelled using an age- and sex-dependent baseline
utility and utility decrements for cancer estimated from the published literature.
Results
In the base-case analysis, four strategies were on the cost-effectiveness frontier. Strategy 1 (no testing) was
the cheapest and least effective. Strategy 5 (IHC, BRAF V600E and MLH1 promoter methylation testing)
was cost-effective at a conventional cost-effectiveness threshold of £20,000 per QALY. Strategy 3 (IHC and
BRAF V600E testing) and strategy 2 (testing with IHC) would be cost-effective at higher cost-effectiveness
thresholds.
Life expectancy for individuals with LS was improved by 1.2 years for probands and 2.1 years for relatives
(strategy 5 vs. strategy 1). Over 300 CRCs were expected to be prevented over the lifetime of each
annual cohort.
Subgroup analyses were conducted according to the age of the probands (< 50, < 60, < 70, > 70 years).
In all subgroup analyses strategy 5 remained cost-effective compared with strategy 1. When an age limit of
50 years was imposed for probands, strategy 3 was marginally cost-effective, with an ICER of £19,903
per QALY.
A number of scenario and sensitivity analyses were conducted, but strategy 5 remained cost-effective
throughout, although cost-effectiveness was marginal when a worst-case assumption (that colonoscopy
does not reduce the incidence of CRC) was considered and was also marginal when the CRC risk for
individuals with LS was low.
Conclusions
The review of diagnostic test accuracy studies suggests that MSI testing and IHC are effective, but
imperfect, tests to identify LS in CRC patients.
There was no high-quality evidence from end-to-end studies that screening for LS in CRC patients
improves long-term outcomes.
Previous economic evaluations suggested that it may be cost-effective to screen for LS in CRC patients
using clinical criteria, decision tools and/or tumour-based tests.
The current economic evaluation, which directly addressed the decision problem, suggests that screening
for LS is cost-effective at a cost-effectiveness threshold of £20,000–30,000 per QALY.
Two parameters that cannot be easily estimated had a significant impact on cost-effectiveness: the
effectiveness of surveillance colonoscopy in reducing the incidence of CRC and the lifetime risk of CRC for
individuals with LS. The estimates used for modelling are believed to be the most suitable from the
scientific literature, considering the possible sources of bias and the size of the relevant studies.
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Research recommendations include:
l evaluate screening for LS in endometrial cancer patients
l evaluate the use of next-generation sequencing panels covering a wide range of cancer predisposition
genes in CRC patients.
Study registration
This study is registered as PROSPERO CRD42016033879.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem
Colorectal cancer (CRC) is the second most common cause of death from cancer in the UK, with 16,187deaths in 2012, which accounted for 10% of all cancers.1 It is considered to be a multifactorial disease,
with environment and inheritance playing varying roles in different patients.2 The majority of individuals
with CRC have sporadic disease (approximately 70–80%). However, the remaining 20–30% have a family
history of the disease, with 5–6% of these having mutations involved in a known hereditary cancer
syndrome.3 The most common form of genetically defined hereditary CRC is Lynch syndrome (LS), which
accounts for approximately 3.3% of these tumours. Previously referred to as hereditary non-polyposis
colorectal cancer (HNPCC), LS is inherited as an autosomal dominant disorder.4,5 Therefore, if one parent
has the disease, there is a 50% chance that each of their children will inherit it. Although characterised
by an increased risk of CRC, individuals with LS are also at increased risk of other cancers such as
endometrial, ovarian, stomach, small intestine, hepatobiliary tract, urinary tract, brain and skin cancers.4
It is important to identify families with LS so that risk-reducing measures can be taken to address the
elevated risk and earlier onset of CRC and other cancers.
It should be noted that, although LS is characterised by a particular collection of cancers because of a
mutation in one of a number of mismatch repair (MMR) genes, for simplicity, in this report ‘individuals
with LS’ should be interpreted as ‘individuals born with LS-causing mutations’.
Condition and aetiology
Aetiology, pathology and prognosis
Lynch syndrome is caused by constitutional pathogenic mutations in deoxyribonucleic acid (DNA) MMR
genes. MMR proteins are involved in recognising and repairing errors during DNA replication.
Although a person with LS still has a functioning MMR system (as they inherit a normal ‘wild-type’ allele
from one parent in addition to the mutant allele from the parent with LS), there is a high risk that MMR
function will be lost because of somatic mutation of the normal copy of the gene. This loss of MMR
function during cell division leads to an inability to repair mutations such as DNA base–base mismatches
and small insertions and deletions, eventually resulting in tumorigenesis.4
In cells that have lost MMR function, mutations occur all over the genome, but especially in repetitive DNA
sequences such as microsatellites.4 Consequently, in tumours that have lost MMR function, a large number
of mutations are present at microsatellite sequences (compared with surrounding normal tissue) and this is
known as microsatellite instability (MSI).
The five currently known genes mutated in LS are:4
1. MutL homologue 1 (MLH1)
2. MutS homologue 2 (MSH2)
3. MutS homologue 6 (MSH6)
4. postmeiotic segregation increased 2 (PMS2)
5. epithelial cell adhesion molecule (EPCAM).
It should be noted that EPCAM, which is not a MMR gene, plays an indirect role in LS.6 Located upstream
of MSH2, deletions in the EPCAM gene have been shown to result in hypermethylation of the MSH2
promoter region, leading to a loss of MSH2 expression.6,7 In some people it ‘switches off’ the MSH2 gene,
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which causes an increase in cases of CRC but not the other MSH2-associated cancers. In other individuals,
the EPCAM deletion stops the MSH2 gene from working, just like a mutation in the MSH2 gene itself, in
which case all of the MSH2 cancer risks are present.7 Because of the tissue-dependent levels of epithelial
cellular adhesion molecule (EpCAM) expression, carriers have a high risk of CRC, whereas extra-colonic
cancers are rarely found and the risk for endometrial cancer is reduced.8,9
Colorectal cancers associated with LS develop at a young age and are believed to arise from pre-existing
discrete proximal colonic adenomas. Although people with LS develop adenomas at the same rate as
individuals in the general population, the adenomas are more likely to progress to cancer. Furthermore,
carcinogenesis may progress more rapidly in these patients (in 2–3 years) than in patients with sporadic
adenomas (8–10 years).10 Recent evidence also shows that, in addition to the adenoma–carcinoma
pathway, CRCs in LS can arise directly from abnormal colonic crypts that have lost MMR proficiency.11 This
gives rise to cancers that do not go through an adenomatous polyp phase and therefore has implications
for detection and surveillance.11 The age at onset of CRC in LS varies by MMR gene, but is typically
42 years, that is, younger than the age at which the new bowel scope screening is gradually being
introduced by the NHS (55 years) and much younger than the usual 60–74 years.3,5
Synchronous colorectal tumours (primary tumours diagnosed within 6 months of each other) and
metachronous colorectal tumours (primary tumours occurring > 6 months apart) are also more common in
people with LS.10 However, there is evidence to suggest that patients with CRC from LS families survive
longer than sporadic CRC patients with same-stage tumours, which may be because of a reduced
propensity to metastasise. Explanations for this include that immunological host defence mechanisms may
be more active in tumours of the MSI phenotype and that the relatively high mutational load that occurs in
tumours with defective DNA repair systems is detrimental to their survival.12
Epidemiology
Lynch syndrome affects both men and women, although certain cancers will be specific to each sex, for
example ovarian and prostate cancer.13 However, the highest cancer risk is from CRC, with individuals
with LS having a risk to age 70 years of 33–46%, as opposed to 5.5% and 7.3% for women and men,
respectively, in the general population.1,5
The average age at CRC onset is 44 years in members of families that meet the criteria for LS, whereas for
the general population it is 60–65 years.10 Two-thirds of the CRCs occur in the proximal colon (proximal
to the splenic flexure) and the risk of a second primary CRC in patients is high (estimated at 16% within
10 years and 60% if the first CRC was diagnosed before the age of 25 years).14,15
The risk of cancer in people with LS varies according to the affected MMR gene, with mutations in MLH1
and MSH2 conferring the highest cancer risk (Table 1). In individuals ascertained through family history
clinics, nearly 90% of mutations are located in MLH1 and MSH2, with approximately 10% in MSH6 and
PMS2.18 Previous estimates of the cumulative risk of CRC at 70 years in MLH1 or MSH2 mutation carriers
range from 22% to 74%.18 Mutations in MSH6 and PMS2 genes have lower penetrance and different
patterns of expression: MSH6 mutation carriers may have a high risk of endometrial cancer, similar to that
in MLH1 and MSH2 mutation carriers, but have a later age at onset and a lower risk of CRC.5
It is interesting to note that the pattern of the cancer sites associated with LS has changed over time.
In the first family with the syndrome, gastric and endometrial cancer were the most common cancers
whereas in the generations of the same family described by Lynch in 1971 CRC was the most frequent
tumour.19 In addition, current differences in expression of the LS between families from Western countries
and families from the Far East reflect the variation in incidence of cancers in the respective populations.19
This, and more recent work, confirms the importance of lifestyle and environmental effects in LS and
strengthens the opportunity to give directed advice to those known to have LS.20
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Incidence and/or prevalence
There were 34,024 new cases of CRC diagnosed in England in 2014, 18,789 in men and 15,236 in
women.21 LS accounts for approximately 2–3% of cases of CRC, with the population prevalence estimated
as 1 in 440.3,22 However, according to Hampel and de la Chapelle,23 individuals with LS are grossly
underdiagnosed. They estimate that the population incidence of LS in the USA is approximately 1 in 370,
which is based on the 2.8% incidence of LS among newly diagnosed CRC patients and the 5% lifetime
risk for CRC.23 As the penetrance of a mutation in the MMR genes for CRC is approximately 50%, the
incidence of LS in the general population is about double the incidence among CRC patients, or
0.028 × 0.05 × 2 = 0.0028, which is 1 in 370 individuals.23 On this basis, an estimated 175,000 people in
the UK have LS and this leads to > 1100 CRCs per year across the UK.
Although the prevalence of LS is not believed to differ significantly across countries and cultures,
population-specific ‘founder’ mutations are well described, for example in Finnish and Swedish populations.
A specific founder mutation in the MSH2 gene is found in 2–3% of all CRCs in Ashkenazi Jews aged
< 60 years. This mutation is rarely found in the non-Ashkenazi population. In Ashkenazi individuals in whom
CRC is diagnosed at age ≤ 40 years, 7% have been found to carry this mutation. Conversely, the mutation is
found in < 1% of Ashkenazi individuals in whom CRC is diagnosed after age 60 years.10
Impact of the health problem
In terms of the impact of LS on an individual, he or she may develop several characteristic clinical and
pathological features: colorectal, endometrial, gastric, ovarian and other cancers, early onset of cancer,
multiple independent cancers discovered simultaneously (synchronous) or apart (metachronous), more
right-sided/proximal CRCs, improved survival and morphological features such as poor differentiation and
Crohn’s-like infiltration of lymphocytes.24
Frequent colonoscopy with polypectomy decreases the mortality of CRC in patients with LS.3,5 The current
screening protocol recommended by the European Hereditary Tumour Group (formerly the Mallorca Group)
is for colonoscopy every 1–2 years starting from age 25 years.19 Unfortunately, there is currently no proven
surveillance regime for women at risk of endometrial or ovarian cancer.19





MLH1 or MSH2 MSH6 PMS2
Male Female Risk (%)
Mean age at
onset (years) Risk (%)
Mean age at
onset (years) Risk (%)
Mean age at
onset (years)
Colon 7.27 5.47 40–80 44–61 10–22 54 15–20 61–66
Endometrial NA 2.44 25–60 48–62 16–26 55 15 49
Stomach 1.51 0.76 1–13 56 ≤ 3 63 70–78




Urinary tract 1–4 54–60 < 1 65
Small bowel 0.01 3–6 47–49 54 59




CNS, central nervous system; NA, not applicable.
Sources: Cancer Research UK,1 National Comprehensive Cancer Network16 and Bonis et al.17
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The risk of gastric cancer in LS in Western countries is low. Screening by endoscopy has been suggested
but is unproven and therefore gastric surveillance should be discussed only in those families that have a
high incidence of this tumour.19 The usefulness of screening of the urothelial tract is also debatable.
Although urinary tract cancer patients most likely have MSH2 and MSH6 mutations, patients with MLH1
and possibly PMS2 mutations are also at risk and so a pragmatic approach has been to offer yearly
urinalysis, urine cytology and renal ultrasound from age 30–35 years, but only to families in whom these
cancers have been recorded. There is now evidence that the presence or absence of urinary tumours in a
family does not predict their occurrence in other family members.19,25
Genetic testing for relatives
Understandably, there may be considerable anxiety and distress associated with genetic testing for hereditary
cancer syndromes. For example, the knowledge of being at increased risk of cancer but not knowing if cancer
will actually develop can be particularly concerning. Furthermore, parents of children with LS may express feelings
of guilt. As people may be anxious about many aspects of genetic testing and screening or whether to have
risk-reducing surgery, detailed information provided by an experienced clinical geneticist with psychosocial
support is essential. Therefore, it is recommended that relatives opting for genetic testing should receive one or
more individual pretest counselling sessions with psychological support throughout the whole testing procedure.19
Genetic counselling helps explain what a positive or negative result means and what the implications are
for the person and his or her extended family. It can also help people understand the importance of
informing their extended family about the risk of having LS and the benefits of being tested [see www.
macmillan.org, www.lynch-syndrome-uk.org, www.ihavelynchsyndrome.com (accessed 13 July 2017)].
Once people fully understand the implications of being diagnosed with LS for them and their families, the
associated anxiety may substantially reduce. Studies evaluating the psychological distress associated with
genetic testing for LS showed that, immediately after disclosure of the test result, distress significantly
increases, but this decreases again after 6 months.19 Long-term studies have demonstrated that post-result
increases in distress return to baseline by 1–3 years.19
Surgical management
An individual with LS who does not undergo a partial or total colectomy after the first mass is diagnosed
as malignant has an estimated 30–40% risk of developing a metachronous tumour within 10 years and a
50% risk of developing a metachronous tumour within 15 years. It is also now known that the risks from
age 40 to 70 years of a metachronous CRC (mCRC) in those who have had surgery for an initial primary
CRC are 46% for MLH1 mutation carriers, 48% for MSH2 mutation carriers and 23% for MSH6 mutation
carriers.15 This compares with risks in the general population of 3% within 10 years and 5% within
15 years.10 Furthermore, because of the risk of a synchronous tumour in individuals with LS, the complete
colon should be visualised before resection. In view of this substantial risk, it is possible that a subtotal
colectomy instead of a segmental resection might be the preferred treatment in patients from LS families
with a primary tumour. Vasen et al.19 also suggest that a colectomy with ileorectal anastomosis may be
considered if CRC is detected in a young patient participating in a surveillance programme.
Prophylactic surgery may also be an option for certain extracolonic cancers, for example hysterectomy and
oophorectomy after childbearing is complete nearly eliminate the risk of endometrial and ovarian cancer in
women with LS,26 but the potential effectiveness and place of such prophylactic surgery is now open to
reconsideration given that mortality from endometrial and ovarian cancer in LS is not as high as
previously thought.3,15
Chemotherapy
Fluorouracil (5-FU)-based regimes represent the current gold standard in adjuvant chemotherapy for bowel
cancer. In contrast, in vitro studies indicate that MMR-proficient cells treated with 5-FU grow more slowly
than MMR-deficient cells, suggesting that a competent MMR system is a critical condition for 5-FU
cytotoxicity.19 Clinical studies on the efficacy of 5-FU in MSI-high (MSI-H) colon cancer are, however,
contradictory.19 A systematic review and meta-analysis did not find evidence that the chemotherapy
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response was determined by MSI status,27 but it is understood that individuals with stage II CRC may
receive MSI testing or MMR immunohistochemistry (IHC) testing to aid clinical decision-making. Stage II
tumours showing MSI (i.e. that are MMR deficient) are usually not treated with (5-FU-based) chemotherapy
as it is associated with toxicity in some patients and is believed to be of marginal clinical benefit.
There is also increasing evidence to show that MMR-deficient cancers respond especially well to
programmed cell death protein 1 inhibitors.28
Chemoprevention
There is evidence to suggest that LS may be susceptible to environmental manipulation, as demonstrated
by the decrease in the incidence of gastric cancer and also perhaps by the apparent differences in
penetrance between men and women.19 This is supported by investigations into the role of aspirin in
bowel cancer prevention. Several large studies have demonstrated that aspirin reduces the risk of bowel
cancer in the general population, although the mechanisms by which this occurs are unknown.4 One study
has shown that a daily dose of aspirin reduced the incidence of CRC in carriers of LS after 56 months’
follow-up.29 Furthermore, the Colorectal Adenoma/Carcinoma Prevention Programme 2 (CAPP2) trial of
aspirin prophylaxis in LS has demonstrated that aspirin treatment for up to 3 years reduces, a decade later,
the overall incidence of LS-associated cancers, including CRC, by 63%.4,29
The development of vaccines directed at tumours with MSI are also showing promise that this may be an
especially good way of preventing otherwise un-addressable LS-associated cancers with a poor prognosis,
as well as potentially any cancer in the general population with MSI.15
Measurement of disease
In current practice, testing for LS in people with CRC is targeted using the Amsterdam II criteria30 and
revised Bethesda guidelines31 (Table 2). The Amsterdam criteria were originally developed to identify LS for
research studies and the Bethesda guidelines were developed to identify patients with CRC for evaluation
for MMR deficiency through tumour testing. Both guidelines use criteria mainly based on family cancer
history and age at onset.
These methods are unlikely to be sensitive enough to detect all patients with LS because family history is
not always reliable or available and some people with LS may not meet all of the criteria. Furthermore,
there is currently no National Institute for Health and Care Excellence (NICE) guidance on the population to
be tested or the testing strategy for LS and as a result there is considerable variation in clinical practice.
TABLE 2 Criteria used to assist diagnosis of LS
Amsterdam II criteria30 Revised Bethesda guidelines31
All criteria must be met:
l at least three separate relatives with CRC or a
LS-associated cancer
l one relative must be a FDR of the other two
l at least two successive generations affected
l at least one tumour should be diagnosed before the
age of 50 years
l FAP excluded in CRC case(s)
l tumours pathologically verified
Only one criterion must be met:
l CRC diagnosed in a patient aged < 50 years
l presence of synchronous, mCRC or other LS-related
tumours, regardless of age
l CRC with MSI-H phenotype diagnosed in a patient
aged < 60 years
l patient with CRC and a FDR with a LS-related tumour,
with one of the cancers diagnosed at age < 50 years
l patient with CRC with two or more FDRs or SDRs with
a LS-related tumour, regardless of age
FAP, familial adenomatous polyposis; FDR, first-degree relative; SDR, second-degree relative.
Source: reproduced from Snowsill et al.4 under the terms of the UK government’s non-commercial licence for public
sector information.32
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Description of the technologies under assessment
Summary of the technologies
Overall, the majority of CRCs from individuals with LS genes have two distinguishing characteristics and
therefore the diagnostic technologies focus on these aspects:
1. MSI – polymerase chain reaction (PCR)-based MSI testing as carried out by United Kingdom
Accreditation Service (UKAS)-accredited regional genetics laboratories using validated in-house tests
(including the Promega MSI Analysis System, which is licensed for research use only; any version,
Promega Corporation, Madison, WI, USA).
2. Loss of expression or reduced levels of expression of the MMR proteins in the tumour compared with
normal tissue – IHC testing for MMR proficiency using antibodies against MMR proteins.
Tumour-based tests
Microsatellite instability testing
As previously mentioned, MSI refers to the variety of patterns of microsatellite repeats observed when DNA is
amplified from a MMR-deficient tumour compared with DNA amplified from surrounding normal colonic tissue.4
Repetitive mono- or dinucleotide DNA sequences (microsatellites) are particularly vulnerable to defective MMR.17
Microsatellite instability testing involves PCR amplification of standardised DNA markers from a tumour tissue
sample and a matched (i.e. from the same patient) healthy tissue sample. The tissue samples must be
microdissected, in which a microscope is used to aid dissection, before DNA is extracted, amplified and
observed on a DNA fragment length analyser. MSI is indicated when DNA extracted from tumour tissue
displays additional peaks on the analyser output (i.e. microsatellite markers of a different size) compared with
normal tissue DNA. Tumour samples with microsatellite marker sizes identical to those seen in non-tumour
tissue DNA are considered microsatellite stable (MSS).
Laboratories may use a panel of ≥ 10 markers and, more recently, a commercially available kit based on
five mononucleotide markers has become popular as mononucleotide microsatellites may be the most
sensitive markers for use in detecting MSI.33 Table 3 provides examples of the panels used.
Instability in ≥ 30% of the markers is considered MSI-H, instability in < 30% of markers is considered
MSI-low (MSI-L) and no shifts or additional peaks is considered MSS. However, if instability is observed in
any mononucleotide markers, MSI may be diagnosed. For this reason, MSI testing is moving to a smaller
panel of mononucleotide markers, making the process more efficient and cheaper. MSI-H is associated
with LS but is also present in around 10–15% of sporadic cancers.19
TABLE 3 Example panels of markers for MSI testing
Panel Mononucleotide Dinucleotide Other Notes
Bethesda/NCI31 BAT-25 and BAT-26 D2S123, D5S346
and D17S250
If only dinucleotide repeats are
mutated, test a secondary panel
of microsatellite markers with
mononucleotide markers to
exclude MSI-low
10-marker panel34 BAT-25, BAT-26, BAT-40,












NCI, National Cancer Institute.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
There is ongoing debate whether or not MSI-L, which appears to be more common for MSH6 mutations,
should be considered as an indication of MSI. As a result, some studies do not report MSI-L separately and
include it with either MSS or MSI-H. This obviously provides a challenge when comparing studies. There is
also some heterogeneity in the composition of microsatellite markers in MSI panels (both in the nature and
in the number of markers), which may lead to differences in test performance and/or threshold effects.
Personal communication from Ian M Frayling (Institute of Cancer and Genetics, University Hospital of
Wales, Cardiff, UK, 18 August 2017) indicates that MSI test failures occur in a small proportion of tests
(around 5%), largely because of technical challenges surrounding the collection of sufficient DNA from
poorly fixed tumour tissue.
Mismatch repair immunohistochemistry
Mismatch repair IHC tests for the presence or absence of MMR proteins in colorectal tumour cells. Antibodies
against the MMR proteins are used to stain both tumour cells and non-tumour cells (as an internal control).
If nuclear staining is present for all MMR proteins, this suggests that the MMR system is intact. In contrast to
MSI, a number of patterns of abnormal MMR expression are seen in Lynch/HNPCC tumours (Table 4).
Table 4 highlights that, for some individuals with abnormal MMR IHC results in the tumour, no germ-line
mutation can be found. Somatic mutations in MMR genes can occur (with attendant loss of MMR protein
expression) as secondary events in other CRC predisposition syndromes, which can mimic LS, such as
inherited mutations in MUTYH or POLD1.38,39
TABLE 4 Underlying causes of MSI in colorectal and endometrial cancers in genetics clinic patients by associated
pattern of MMR IHC abnormality
MMR mutation


















Constitutional MSH2 mutation 14.2 0.4 14.6
Constitutional EPCAM mutation 2.0 2.0
Constitutional MSH6 mutation 0.8 10.2 11.0





Acquired MLH1 mutation 6.7 6.7
Acquired MSH2 mutation 2.4 2.4
Unexplained 10.2 5.9 1.6 1.6 19.3
Total 53.1 25.3 12.2 9.5 100
a Constitutional MLH1 epimutations are not universally recognised as being LS-causing mutations as they are not always
inherited.36
Source: reproduced from Diagnostic Histopathology, vol. 21, issue 4. Frayling and Arends, How can histopathologists help
clinical genetics in the investigation of suspected hereditary gastrointestinal cancer? Pages 137–146, Copyright (2015)37
with permission from Elsevier.
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It is also important to realise that a small proportion of possibly Lynch-related tumours do not exhibit any
abnormality on analysis by IHC, even though they have lost MMR function as demonstrated by MSI. This
may be because they have mutations that allow expression of a stable protein with nuclear localisation and
an intact epitope but which is functionally inactive.40
Immunohistochemistry panels may use two MMR antibodies (either MLH1 and MSH2 or MSH6 and PMS2)
or four antibodies (MLH1, MSH2, MSH6 and PMS2). However, a panel with only MLH1 and MSH2
antibodies is unlikely to detect MMR deficiency in MSH6 and PMS2, will be expected to have a lower
sensitivity than a four-antibody panel and will not be able to fully diagnose the pattern of abnormal
expression seen in all tumours.37 Furthermore, the heterodimeric association of proteins such that loss of
MLH1 expression is almost always accompanied by loss of PMS2 expression and loss of MSH2 expression is
almost always associated with loss of MSH6 acts as a very useful confirmatory finding, especially in CRCs
that are prone to suboptimal fixation.37,40 A four-antibody panel is recommended in the UK.41
Test failure is a recognised issue with IHC and usually results from incomplete tissue fixation (a common
problem with CRCs). Palomaki et al.42 counted six test failures across a number of studies (n = 136
patients), corresponding to a failure rate of 4.4%.
BRAF V600E mutation testing and MLH1 promoter methylation testing
Around 10–15% of sporadic CRCs show MSI-H and in the vast majority of these tumours this is the result
of acquired promoter methylation of the MLH1 gene, leading to loss of MLH1 protein expression.
However, a small proportion of sporadic MSI-H CRCs will occur because of the loss of the MSH2, MSH6 or
PMS2 gene and germ-line MLH1 hypermethylation will be observed in a very small number of CRCs as a
result of LS.40,43 Approximately half of the sporadic CRCs with MSI-H will also have a BRAF V600E
mutation. This is a specific mutation in the BRAF gene that almost never occurs in tumours arising in LS.
Therefore, testing for MLH1 promoter methylation and the BRAF V600E mutation represents a way of
distinguishing sporadic CRCs from LS in a proportion of MLH1-negative tumours.40
Identification of important subgroups
First-degree relatives of a LS mutation carrier have a 50% risk of inheriting the mutation. Therefore, when
the familial mutation has been identified, cascade testing should be offered to the first- and second- and,
when possible, third-degree biological relatives. Studies have shown that the uptake of genetic testing in
families with LS varies from 43% in the USA to 57% in the Netherlands and 75% in Finland.19 Suggested
reasons for this variation include differences in the study setting or fundamental differences between the
health-care and social security systems.
As CRC in an individual with LS is likely to be diagnosed at a younger age, the prevalence of LS in people
with CRC will vary across age groups. For example, the prevalence of LS falls from 8.4% at 50 years to
5.7% at 60 years and 3.8% at 70 years.4 This is because the incidence of CRC in the general population
rises more rapidly than the incidence of CRC in people with LS. The total annual incidence of cases of CRC
in England in 2014 increased from 2107 at 50 years, to 5880 at 60 years and 13,823 at 70 years.21
Current usage in the NHS
Microsatellite instability testing for the purpose of identifying LS is currently only carried out in people
considered to be at high risk of having LS, that is, people with a family history of cancer and/or who are
aged < 50 years at the onset of cancer. For cancer for which there is no suspicion of LS, MSI or IHC testing
may yet be conducted to inform prognosis or guide therapy. Expanding diagnostic testing to all people
with CRC and identification of families who could benefit from cascade genetic testing may lead to
increased surveillance and consequently improved patient outcomes through earlier diagnosis and
treatment. Currently, testing for LS may occur using a number of different strategies (Figure 1).
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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Anticipated costs associated with the intervention
Microsatellite instability and IHC testing are both tumour-based tests, the costs of which need to include
the costs of preparing the sample, analysing the sample and reporting the test results as well as the costs
of administration, transportation, additional wear and tear on machinery, training time and repeat tests.
As a LS diagnosis cannot be confirmed with just MSI or IHC testing, the cost of downstream testing also
impacts on the overall costs of the interventions, as well as the number of downstream tests that will be
run as a result of MSI or IHC testing being indicative of LS.
The costs for constitutional DNA tests in the study by Snowsill et al.4 were assumed to be all-inclusive; all
laboratory, processing and transportation costs were assumed to be accounted for through core funding.
It is not clear if this will continue with the increase in the number of tests requested. There is also the
additional factor that gene sequencing costs in particular have reduced in the last 2 years in UK regional
genetics laboratories with the increasing introduction of next-generation sequencing (NGS).
The costs of the diagnostic tests are detailed further in Chapter 5 (see Diagnostic tests). Unit costs for MSI
and IHC testing are estimated to be £178 and £210 respectively. This is equivalent to ≈£7M (without
additional testing) for a cohort of ≈34,000 individuals with newly diagnosed CRC,21 increased from an
estimated ≈£2M for the same cohort under a no-reflex diagnostic testing strategy (assuming that some
people with CRC will receive MSI and IHC testing for therapeutic/prognostic purposes). However, this total
cost is unlikely to remain constant, as the number of individuals with newly diagnosed CRC, and the
number of families with LS identified (for whom MSI and IHC diagnostic testing will be unnecessary), are
likely to differ in the future.
Comparators
Constitutional deoxyribonucleic acid tests
The gold standard for the diagnosis of LS is comprehensive screening for constitutional mutations in the
MMR genes and the EPCAM gene. This screening is conducted using a DNA sequencing method to detect
point mutations, small insertions and small deletions and multiplex ligation-dependant probe amplification
(MLPA) to detect large structural DNA abnormalities such as genomic deletions, duplications and
rearrangements.4 Sequencing is usually performed on lymphocytic DNA from a blood sample. The various
forms of mutations are described in Box 1.
Other techniques for genetic testing in LS, as listed in Table 5, may be found in older studies.
Although comprehensive screening for constitutional mutations should accurately detect the majority of
known LS-causing mutations, there are some occasions when a novel mutation may be identified that
is of uncertain significance. As this variant or mutation cannot be demonstrated to be pathological or
non-pathological, it is not possible to make a diagnosis or recommendation for management, such as
colorectal surveillance. However, a major advance has been the establishment by the International Society for
Gastrointestinal Hereditary Tumours (InSiGHT) of an internationally recognised reference database together
with a multidisciplinary team of experts to maximise the number of mutations interpreted as being either of
clinical consequence or innocuous, thus minimising the number of mutations in the ‘uncertain’ bracket.
Before this work, 58% of the 12,006 mutations listed were unclassified variants; this has now been reduced
to 32%, that is, those mutations that now fall into the category of ‘variants of uncertain significance’,
otherwise known as class 3.45 Hence, this now enables a variant of uncertain significance to be pursued by
testing for the variant in other family members with LS-related cancers or by testing stored tumour tissue for
MMR deficiency.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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BOX 1 Types of genetic mutation
l Missense: a change in one DNA base pair that results in the substitution of one amino acid for another in
the protein made by a gene.
l Nonsense: a change in one DNA base pair that results in a premature signal to stop building a protein. This
type of mutation results in a shortened protein that may function improperly or not at all.
l Insertion: changes the number of DNA bases in a gene by adding a piece of DNA. As a result, the protein
made by the gene may not function properly.
l Deletion: changes the number of DNA bases by removing a piece of DNA. Small deletions may remove one
or a few base pairs within a gene whereas larger deletions can remove an entire gene or several
neighbouring genes. Deletion of the DNA may alter the function of the resulting protein(s).
l Duplication: consists of a piece of DNA that is abnormally copied one or more times. This type of mutation
may alter the function of the resulting protein.
l Frameshift mutation: occurs when the addition or loss of DNA bases changes a gene’s reading frame.
A reading frame consists of groups of three bases that each code for one amino acid. A frameshift
mutation shifts the grouping of these bases and changes the code for amino acids. The resulting protein is
usually non-functional. Insertions, deletions and duplications can all be frameshift mutations.
l Splice site: causes abnormal messenger ribonucleic acid (mRNA) processing, generally leading to in-frame
deletions of whole exons or out-of-frame mRNA mutations leading to nonsense-mediated decay of mRNA.
Mutations may be located deep in intronic sequences.
l Promoter: mutations (occurring) in the controlling region of a gene (the promoter) leading to its
non-expression. Epigenetic mutations in the promoter (i.e. abnormal methylation of CpG sites) may give rise
to the same effect.
CpG, cytosine–phosphate–guanine (sequence of DNA bases).
Adapted from the US National Library of Medicine44 (public domain).





(SSCP), conformation-sensitive gel electrophoresis
(CSGE), denaturing gradient gel electrophoresis
(DGGE), denaturing high-performance liquid
chromatography (DHPLC)
These methods use the change in chemical
properties of altered DNA to differentiate
it from normal DNA (now considered
obsolescent/obsolete in the UK)
DNA sequencing Can be used following high-output screening or as
a primary approach when directed by IHC patterns
The main method used in the UK for detecting
most MMR gene mutations. However, it does




MLPA MLPA is the preferred technique in the UK.
Large structural DNA abnormalities are an
important cause of LS (5–25% of cases,
depending on the gene) but are not
generally detected by high-output screening
techniques or DNA sequencing. MLPA,
which involves measurement of the relative
copy number of DNA sequences, has
evolved to become a standard approach for
analysing MMR genes for deletions
Conversion analysis Only a single allele is analysed at a time. This can
increase the yield of genetic testing but is technically
complicated, expensive and not widely available
Source: reproduced from Snowsill et al.4 under the terms of the UK government’s non-commercial licence for public
sector information.32
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Care pathways
There is currently no NICE guidance on the diagnosis and management of LS. However the diagnosis
and management of LS is described in several national and international guidelines:
l British Society of Gastroenterology (BSG) (2010): Guidelines for Colorectal Cancer Screening
and Surveillance in Moderate and High Risk Groups46
l European guidelines (2013): Revised Guidelines for the Clinical Management of Lynch
Syndrome (HNPCC)19
l Bethesda guidelines (2004): Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal
Cancer (Lynch Syndrome) and Microsatellite Instability31
l Amsterdam II criteria (1999): New Clinical Criteria for Hereditary Nonpolyposis Colorectal Cancer
(HNPCC, Lynch syndrome) Proposed by the International Collaborative Group on HNPCC.24
In the NHS, CRC in LS patients is generally treated as per NICE clinical guideline 13147 (Figure 2).
The European Society for Medical Oncology guidelines48 are also used by clinicians in the NHS to guide
treatment decisions. The guidelines state that ‘MSI/MMR may be useful to identify a small (10–15%)
subset (those with microsatellite instability) of stage II colorectal cancer patients who are at a very low risk
of recurrence and in whom the benefits of chemotherapy are very unlikely’ (p. vi67).48
The Royal College of Pathologists’ minimum data set (July 2014) for CRC mandates the use of IHC or
other testing for molecular features of LS in CRC or Lynch-associated cancer patients aged < 50 years
at the time of diagnosis.49 However, the results of a 2015 Bowel Cancer UK survey on reflex testing for
LS in people diagnosed with bowel cancer aged < 50 years highlighted that there is variability in who
receives testing among the different trusts and health boards.50 Ideally, MSI and IHC testing will usually
be conducted on tumour tissue obtained during surgical treatment or via biopsy. A histopathologist
selects tissue for testing and performs microdissection for MSI testing or sectioning and staining for IHC.
Microdissected samples for MSI testing are processed by a laboratory genetics centre where PCR-based
MSI testing is performed and reported to the histopathologist, who in turn informs the cancer team
(usually a consultant colorectal surgeon) along with recommendations for further testing.
If the results of MSI and/or IHC testing are suggestive of LS further tumour tissue-based tests may be
ordered [e.g. IHC (if not already conducted), BRAF V600E mutation testing, MLH1 promoter methylation
testing] or the patient may be referred directly to the clinical genetics department. At this point, the clinical
genetics department will discuss the findings with the patient, describe LS and take a detailed family
history (pretest genetic counselling). If the clinical genetics team and the patient agree that constitutional
MMR mutation testing is appropriate then a blood sample will be sent to the genetics laboratory
for testing.
If a pathogenic constitutional MMR mutation is not found, a variant of uncertain significance is
found or the mutation identified is inconsistent with existing findings, the genetics team will provide
appropriate counselling and further testing and propose an appropriate management strategy for
the patient.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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Outcomes
The accuracy of MSI and IHC testing of tumour tissue for LS has been evaluated against the reference
(gold) standard of constitutional genetic testing. Clinically important outcomes relevant to test
accuracy include:
l Sensitivity – the probability of detecting LS in someone with LS:
Sensitivity =
True positive





















Person with suspected 
colorectal cancer
2
NICE pathway on 
patient experience 









FIGURE 2 Overview of pathway for CRC. Source: National Institute for Health and Care Excellence. Colorectal
Cancer: the Diagnosis and Management of Colorectal Cancer. Clinical guideline CG131.47 © National Institute
for Health and Care Excellence 2017. All rights reserved and subject to NICE ‘Notice of Rights’. Available from
https://pathways.nice.org.uk/pathways/colorectal-cancer. NICE guidance is prepared for the National Health Service
in England. It is subject to regular review and updating and may be withdrawn.
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l Specificity – the probability of not detecting LS in someone without LS:
Specificity =
True negative





l Likelihood ratio (LR) – the likelihood that a given test result would be expected in a patient with the
target disorder compared with the likelihood that that same result would be expected in a patient
without the target disorder.
l LR for positive test result (LR+) – the relative likelihood that a positive test result occurs in people with
the disease compared with those without the disease:
LR+ =
Pr(T + jD +)




l LR for negative test result (LR–) – the relative likelihood that a negative test result occurs in people with


















l Diagnostic yield (also known as test positivity rate or apparent prevalence) – the number of positive test
results divided by the number of samples.
l Test failure (non-informative test result) rate.
Outcomes relevant to cost-effectiveness are:
l the number of individuals with LS receiving LS surveillance
l the number of individuals with LS not receiving LS surveillance
l the number of individuals without LS receiving LS surveillance
l the number of individuals without LS not receiving LS surveillance
l the sensitivity and specificity of each diagnostic strategy (as opposed to individual tests)
l the costs of each strategy (discounted and undiscounted), including disaggregated costs of diagnosis
and outcomes
l quality-adjusted life-years (QALYs) (discounted and undiscounted)
l overall survival (and whether censored on reaching age 100 years)
l CRC-, endometrial cancer- and overall cancer-free survival (and whether censored because of death or
on reaching age 100 years)
l event-free survival (and whether censored on reaching age 100 years)
l the number of incident CRCs
l the number of incident endometrial cancers
l the number of colonoscopies performed.
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Chapter 2 Assessment of test accuracy
Methods for reviewing effectiveness
The diagnostic accuracy of molecular MSI testing and MMR IHC (each with or without BRAF V600E
mutation testing and with or without MLH1 promoter methylation testing) was assessed in a systematic
review of the research evidence. The review was undertaken following the principles published by the
University of York Centre for Reviews and Dissemination.51
Identification of studies
The following bibliographic databases were searched to identify relevant studies: MEDLINE, MEDLINE
In-Process & Other Non-Indexed Citations, EMBASE and the Health Management Information Consortium
(HMIC) (all via Ovid); Web of Science (including conference proceedings, via Thomson Reuters); and the
Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials
(CENTRAL) and Health Technology Assessment (HTA) database (all via The Cochrane Library). The search
strategies were developed by an information specialist (SB) and consisted of population terms for LS or
HNPCC and intervention terms for MSI or IHC. Methodological filters for test accuracy studies were not
used to limit the study designs retrieved as these have been shown to reduce sensitivity.52 Search results
were limited by date from 2006 (searches were run in February 2016) and to English-language studies.
The full search strategies for each database are reproduced in Appendix 1.
The search results were exported to EndNote X7 (Thomson Reuters, CA, USA) and deduplicated using
automatic and manual checking.
To identify relevant studies published before 2006, the study by Bonis et al.17 was screened. In addition,
the studies by Palomaki et al.,42 Snowsill et al.4 and Vasen et al.,19 as well as any other systematic reviews
identified by the bibliographic database searches, were used to source relevant studies published before
2006 and additional studies published after 2006. For the purpose of this review, a systematic review was
defined as one that includes a focused research question, explicit search criteria that are available to view,
explicit inclusion/exclusion criteria, a critical appraisal of included studies, including consideration of internal
and external validity of the research, and a synthesis of the included evidence (narrative or quantitative).
Items included after full-text screening were forward citation chased using Scopus (Elsevier). The reference
lists of included studies were also screened for any other relevant studies.
Relevant studies were then identified in two stages. First, titles and abstracts returned by the search
strategy were examined independently by two researchers (HC and TJH) and screened for possible
inclusion, using prespecified inclusion and exclusion criteria (see following section). Disagreements were
resolved by discussion. Full texts of studies included at the title and abstract screening stage were
obtained, as were full texts of studies identified from systematic reviews and from forward and backward
citation chasing. Two researchers (HC and TJH) independently examined full texts for inclusion or exclusion.
Disagreements were again resolved by discussion.
Inclusion and exclusion criteria
Population
Studies of individuals with CRC were included. This included fresh samples taken from people who were
newly diagnosed with CRC or samples that had been retained in storage.
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The unit of assessment was individual patients. If results were presented according to individual cancers
(e.g. when patients had multiple primary colorectal malignancies), when possible the earliest CRC tested
with an index test was used as the unit of assessment.
Studies in which clinical or family history criteria were used to select CRC patients were eligible for
inclusion under certain circumstances (see Study design).
Index tests
The index tests to be considered were:
l molecular MSI testing with or without BRAF V600E mutation testing and with or without MLH1
promoter methylation testing
l MMR IHC with or without BRAF V600E mutation testing and with or without MLH1 promoter
methylation testing.
Studies in which BRAF V600E and/or MLH1 promoter methylation tests were performed only on certain
patients according to their MSI or IHC test results were eligible for inclusion.
Studies were eligible for inclusion if one or more index test was assessed against a reference standard.
Reference standard
The reference standard was constitutional MMR mutation testing (for abnormalities that provide a genetic
diagnosis of LS), which, as a minimum, included DNA sequencing and MLPA (or another appropriate
technique for detecting large genomic abnormalities). Other appropriate techniques were Southern blot
analysis, gene-targeted array-based comparative genomic hybridisation (aGCH) and NGS. However, NGS
alone (i.e. without MLPA) was accepted as an includable technique for detecting large genomic abnormalities
only if the study described or cited peer-reviewed methodology for identifying structural variants in LS based
on output data. If no such methodology was described it was assumed that NGS would not detect structural
variants and would not be an includable technique. Studies were eligible for inclusion if MLPA, Southern blot,
aGCH or NGS (as described above) was conducted only when sequencing found no clearly pathogenic
mutations. Studies in which IHC results directed the MMR genes to be tested were eligible for inclusion
(e.g. if MLH1 was not tested when only MSH2 and MSH6 proteins were absent on IHC).
Unless the aim of a study was to investigate the test accuracy of an index test in individuals with mutations
in a particular MMR gene, studies must have tested MLH1, MSH2 and MSH6 as a minimum (unless IHC
results directed otherwise).
Outcomes







l accuracy or concordance with the reference standard: the proportion of test results correctly identified
by the test, that is, the rate of agreement with the reference standard:
Accuracy =
True positive + True negative
Total number of subjects
=
TP + TN
TP + FP + FN + TN
, (7)
l diagnostic yield (also known as test positivity rate or apparent prevalence)
l test failure (non-informative test result) rate.
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Study design
Single-gate diagnostic studies with random or consecutively recruited participants were considered the
optimal design for evaluating the test accuracy of MSI and IHC testing and were therefore eligible for
inclusion. Two-gate diagnostic studies were also included.
Studies were included if all participants received the index test(s) and the reference standard. Studies that
recruited a representative sample of all CRC patients but did not apply the reference standard to all
patients were included if the reference standard was applied to all patients testing positive for one or more
index test(s) and to a representative (e.g. random) sample of patients testing negative for all index tests.
Studies that limited recruitment to high-risk populations (except by applying an age limit to an otherwise
population-based sample) were included only to estimate sensitivity and only if the index test(s) and
reference standard had been applied to all participants.
Data abstraction strategy
Data were extracted by one reviewer (TJH) using a standardised data extraction form (see Appendix 3) and
were checked by a second reviewer (HC). Disagreements were resolved by discussion, with involvement of
a third reviewer if necessary. Data were then transferred to standardised tables.
Critical appraisal strategy
The methodological quality of the studies was assessed according to criteria specified by phase 3 of the
QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool53 (see Appendix 2). This was carried
out alongside data extraction using the same form.
Assessments were conducted by one reviewer (TJH) and judgements were checked by a second (HC).
Any disagreement was resolved by discussion, with involvement of a third reviewer as necessary.
Methods of data synthesis
The data extracted from each study were analysed in Stata® 13 (StataCorp LP, College Station, TX, USA).
For studies based on high-risk samples the sensitivity of the index test(s), with 95% confidence intervals
(CIs), were calculated. For studies that were not based on high-risk samples (including studies in which the
population was age limited), sensitivity, specificity, LR+, LR–, PPV and NPV, with 95% CIs, were calculated
when data permitted. Of these latter studies, those that provided estimates of both sensitivity and
specificity had their point estimates plotted in receiver operating characteristic (ROC) space.
The data extracted from each study, the results obtained from analysing individual studies and the quality
assessment for each study are presented in structured tables and in a narrative synthesis. Any possible
effects of study quality on the data are discussed.
Data from individual studies were not pooled in meta-analysis; once data from individual studies were sorted
into categories (e.g. high-risk population or age-limited population; MSI-L defined as positive or defined as
negative) there were insufficient methodologically homogeneous data sets to enable meaningful data pooling.
Results
Quantity and quality of research available
The electronic searches retrieved a total of 3921 unique titles and abstracts, of which 3844 articles were
excluded based on screening titles and abstracts. The remaining 77 articles were requested as full texts for
more in-depth screening.
After screening systematic reviews, including those that were prespecified,4,17,19,42 a further 41 articles were
retrieved as full texts for in-depth screening.
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Of the 118 articles retrieved as full texts (identified from electronic searches and systematic reviews), 109
were excluded. The reasons for exclusion were that the study design (n = 47), reference standard (n = 33)
or outcomes (n = 3) did not match the review inclusion criteria, the article was a duplicate publication
(n = 3) or the article was an abstract that both reported insufficient information to be included in the
review and was unconnected to any of the included studies (n = 23). The bibliographic details of the
studies retrieved as full papers and subsequently excluded, along with the reasons for their exclusion, are
detailed in Appendix 3. The remaining nine studies were included.
After backward and forward citation chasing, a further 16 full-text papers were obtained, of which one
study was included and 15 were excluded because the reference standard (n = 9), study design (n = 3),
population (n = 2) or index test (n = 1) did not match the review inclusion criteria. The bibliographic details
of these excluded studies, along with the reasons for their exclusion, are also provided in Appendix 3.
In total, therefore, 133 full-text articles were assessed, of which 10 studies34,54–62 met the review inclusion
criteria. The process of study selection is shown in Figure 3. It should be noted that one of the included
Full-text articles excluded
From searches (n = 71)
 • Reference standard, n = 11
 • Outcomes, n = 3
 • Study design, n = 31
 • Duplicate, n = 3
 • Abstract,a n = 23 
From systematic reviews (n = 38)
 • Reference standard, n = 22
 • Study design, n = 16
From forward searching (n = 4)
 • Population, n = 1
 • Study design, n = 3
From backward searching 
(n = 11)
 • Reference standard, n = 9
 • Index test, n = 1
 • Population, n = 1
Records identified through 
database searching (2006–16)
(n = 6682)
Records after duplicates 
removed (records screened)
(n = 3921)
Full-text articles assessed 
for eligibility (from searches)
(n = 77)




 • Studies, n = 6
 • Records, n = 6
From systematic reviews
 • Studies, n = 3
 • Records, n = 3
From forward searching
 • Study, n = 1


























Systematic reviews checked 
for additional records
• From searches, n = 1
• Prespecified in protocol, n = 4
Additional full texts assessed 
(identified through systematic
reviews)
• Pre 2006, n = 40
• Post 2006, n = 1
Forward citation searching
• Records screened, n = 569
• Full texts screened, n = 5
Backward citation searching
• Full texts screened, n = 11
FIGURE 3 Summary of the selection process. a, Abstracts were excluded when they were not linked to an included
study and did not provide sufficient methodological information to meet the review inclusion criteria or allow data
to be extracted. b, One of these studies included two distinct populations,34 both of which are included in this
review. Although there are 10 included studies, there are, therefore, 11 included data sets. Source: adapted from
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 6(7):e1000097.63 https://doi.org/10.1371/
journal.pmed1000097
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studies had two distinct samples (a population-based sample and a high-risk sample) and therefore had
two distinct sets of data.34 These two samples are treated separately in this review; therefore, although
there are 10 included studies, there are, in fact, 11 included populations/data sets. The results from all
11 populations are included in the narrative synthesis.
Description of the included studies
Four of the included studies reported data from a population-based sample. The study by Poynter et al.34
reported data from two populations, one of which appeared to be an unselected CRC population,
although this is not entirely clear because participant inclusion criteria were not reported. The other three
population-based studies54–56 included CRC populations to which an age limit had been applied. All of
these, and the study by Poynter et al.,34 were single-gate studies.
The remaining studies (including the other sample reported in the study by Poynter et al.34) were based on
participants with CRC who were also selected for being at high risk for LS. Five of these studies used a
single-gate design.34,57–60 The remaining two studies used variations on a two-gate study design;61,62 in
these two studies participants with positive reference standard results were recruited but no reference
standard negatives were recruited, thus resembling half of a two-gate design from which sensitivity
estimates could be obtained. These studies do not, therefore, have two gates and from this point forward,
for clarity, they will be referred to as reference standard-positive studies.
Table 6 provides a summary of all studies included in the test accuracy review. A narrative summary of the
included studies and their population characteristics is provided in the following sections.
Single-gate studies recruiting population-based samples
As mentioned earlier, the population-based sample included in the study by Poynter et al.34 appeared to be
completely unselected. The other three population-based studies included in this review54–56 were based on
CRC populations to which an age limit had been applied. For all three of these studies this limit was for
age at diagnosis (rather than age at recruitment) and was < 55 years for Barnetson et al.,54 < 50 years for
Limburg et al.55 and < 45 years for Southey et al.56 These four studies varied in size; the studies by
Barnetson et al.54 and Poynter et al.34 were the largest, recruiting 1259 participants and 1061 participants
respectively. The studies by Limburg et al.55 and Southey et al.56 recruited similar numbers of participants
(n = 195 and n = 131 respectively).
With regard to the population characteristics of these four studies, all provided details on the participants’
sex and for all studies the ratio of men to women was similar (Table 7). Although the study by Poynter
et al.34 included the only unselected CRC population identified by this review, the age of the participants
was not reported. The age of the participants in the other three studies ranged from a median of
37.1 years (range 24–42 years) for those receiving the reference standard in the study by Southey et al.56
to a mean of 49.0 years (± 3.9 years) for one of the subgroups in the study by Barnetson et al.54 These low
mean and median ages, which were similar across the three studies, are unsurprising given that all three
applied an age limit to participants for inclusion in the study. The four studies recruiting population-based
samples all reported a low proportion of participants meeting Amsterdam II criteria, ranging from 0.1% in
one of the subgroups in the study by Poynter et al.34 to 12% in the study by Southey et al.56 Two studies34,54
also reported the proportion of participants meeting the revised Bethesda guidelines. The specific location
of the CRC was reported by Barnetson et al.54 and Poynter et al.34 but not by Limburg et al.55 or Southey
et al.56 None of the studies provided details on the ethnicity of the participants.
Three54–56 of the studies recruiting population-based samples assessed MSI and IHC, with the study by
Limburg et al.55 assessing only IHC (see Table 6).
Single-gate studies recruiting high-risk populations
The five single-gate studies34,57–60 that were based on high-risk populations all applied different criteria to
select participants for inclusion. For two34,57 of these studies the participant inclusion criteria were unclear,
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although for the study by Caldes et al.57 it was reported that participants were recruited from a familial
cancer clinic and for the study by Poynter et al.34 it was reported that participants were recruited through
high-risk clinics and that some clinics selected participants with a ‘family history or early age at onset’.
The remaining three single-gate studies appeared to include participants who were at high risk because
of their family history (see Table 6). These five studies varied in size, with the largest study being that by
Poynter et al.,34 which recruited 172 participants, and the smallest being that by Mueller et al.,58 which
recruited 48 participants.
With regard to the population characteristics of these five studies (see Table 7), only one60 provided details
on the participants’ sex (56.3% female). The age of participants was reported in two of the five studies,59,60
ranging from 29 to 51 years in the study by Overbeek et al.59 and from 23 to 78 years in the study by Shia
et al.60 Only one60 of the five studies reported the proportion of participants meeting Amsterdam II criteria
(38.2%) or the revised Bethesda guidelines (8.2%) and the specific location of the CRC was reported only
by Overbeek et al.59 None of the studies provided details on the ethnicity of the participants.
All five of the single-gate studies recruiting high-risk populations assessed both MSI and IHC (see Table 6).
Reference standard-positive studies
There were two reference standard-positive studies (i.e. studies that used a variation on a two-gate study
design in which only participants who were reference standard positives were recruited).61,62 The study by
Hendriks et al.61 recruited participants with a germ-line mutation in MLH1, MSH2 or MSH6 and assessed
both MSI and IHC whereas the study by Okkels et al.62 was focused on the identification of a germ-line
mutation in MSH6 and assessed only IHC (see Table 6). It should be noted that, although the study by
Okkels et al.62 provides an assessment of the test accuracy of four proteins (MLH1, MSH2, MSH6, PMS2)
and data are provided for all proteins combined, these data are not included in this review. Instead, the
IHC results for MSH6 only are included.
Both of the reference standard-positive studies included in this review were quite small, with Hendriks et al.61
recruiting 45 participants and Okkels et al.62 recruiting 56 participants.
The study by Okkels et al.62 did not provide details on participants’ age, sex or cancer location or the
number of participants meeting Amsterdam II criteria or the revised Bethesda guidelines. The study by
Hendriks et al.61 included a similar number of men and women (44% female), participants ranged in age
from 23 to 90 years and the specific locations of the CRCs were reported (see Table 7). The proportions
meeting Amsterdam II criteria and the revised Bethesda guidelines were not reported. Neither of the
reference standard-positive studies reported the ethnicity of the participants.
Summary of the reference standard in the included studies
Three of the four studies that recruited a population-based sample used a combination of direct
sequencing and denaturing high-performance liquid chromatography (DHPLC) as the reference standard
followed by MLPA to detect large genomic alterations or deletions.34,54,56 The study by Limburg et al.55
used direct sequencing, but not DHPLC, followed by MLPA and Southern blot analysis. All four studies
investigated mutations in MLH1, MSH2 and MSH6. However, in the study by Poynter et al.,34 direct
sequencing was used only to detect MSH6 mutations in cases with absent IHC staining of MSH6 and in
the study by Southey et al.56 mutations in PMS2 were also investigated. In all four of these studies, large
alterations or deletions were assessed in MLH1 and MSH2 but not MSH6, although in the study by
Southey et al.56 this was conducted only for participants who had tumours lacking expression of at least
one MMR protein and for whom no previous mutation had been identified by sequencing. In addition,
it should be noted that in the population-based sample reported in the study by Poynter et al.,34 the
reference standard was applied to all MSI-H and MSI-L participants and a random sample of MSS
participants. Further details are provided in Table 8. It should also be noted that three34,54,55 of the four
population-based studies reported on unclassified variants (i.e. mutations for which the association with LS
is unclear). This can complicate the assessment of MSI in particular; mutations may be considered to be
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TABLE 8 Summary of the reference standard used in included studies
Study Description Participants receiving the reference standard
Single-gate studies recruiting population-based samples
Barnetson et al.,
200654
Germ-line DNA obtained from blood leucocytes
was analysed for MLH1, MSH2 and MSH6
mutations. DHPLC was used for MSH2 and MLH1.
Variants noted on chromatography were then
sequenced. Mutations were confirmed by
reamplification of an independent sample of DNA
and resequencing in both directions. MLH1 and
MSH2 were assessed for deletions by MLPA, with
products separated on a genetic analyser
Mutational analysis and follow-up were




DNA samples extracted from peripheral blood
leucocytes received full mutation analyses of
MLH1, MSH2 and MSH6. DNA from each subject
was amplified by PCR and directly sequenced
in the forward and reverse directions using
fluorescent dye-labelled sequencing primers:
MLH1, MSH2 and MSH6. All potential genetic
variants were independently confirmed by repeat
PCR amplification of the indicated gene region(s)
and sequence determination. Large rearrangement
testing for MLH1 and MSH2 was performed by
Southern blot analysis in conjunction with MLPA
Germ-line MLH1, MSH2 and MSH6 sequencing
data were obtained for 195 (100%), 195
(100%) and 189 (97%) subjects respectively
aPoynter et al.,
200834
Mutations in MSH2 and MLH1 were detected
using a combined approach of DHPLC/direct
sequencing and MLPA. Direct sequencing was
used to detect MSH6 mutations in cases with
absent IHC staining of MSH6
Population-based and clinic-based probands with
CRC were tested for mutations in the MMR
genes MSH2, MLH1, MSH6 and PMS2. MMR
gene mutation testing for MSH2 and MLH1 was
conducted for all clinic-based probands and all
MSI-H or MSI-L population-based probands and
in a random sample of 300 MSS population-
based probands. MMR germ-line mutation status
was available for 324/374 population-based




MLH1, MSH2, MSH6 and PMS2 genes were
screened for germ-line mutations using
sequencing approaches or DHPLC. Confirmation
of putative mutations was sought using an
independent PCR for direct automated
sequencing. MLPA was used to detect large
genomic alterations in MLH1 and MSH2 in
samples from 10 patients who had tumours
lacking expression of at least one MMR protein
and for whom no previous mutation had been
identified by sequencing
Ninety-two of 110 participants received
germ-line mutation analysis. This included
participants with one or more of the following
characteristics: a family history that fulfilled the
Amsterdam criteria for HNPCC; having a tumour
that was MSI-H or MSI-L or that lacked expression
of at least one MMR protein; and presence in a
random sample of 23 patients selected from
those who had tumours that were MSS and did
not lack expression of any MMR protein
Single-gate studies recruiting populations at high-risk for LS
Caldes et al.,
200457
Genomic DNA isolated from peripheral blood
lymphocytes was analysed for MLH1, MSH2 and
MSH6 mutations. DNA was amplified using PCR
and all amplicons were subjected to DGGE or
cycle sequencing. The MSI-H cases that were
negative for mutations were analysed for genomic
deletions in MLH1 and MSH2 by Southern
blotting
Total population of 58 participants received
germ-line mutation analysis
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unclassified variants, with uncertain pathogenicity, because the variant may occur in cases with either
MSI-H or MSS tumours. In this review, in primary analyses, unclassified variants have been counted as
reference standard negatives. Secondary analyses have been conducted, as appropriate, in which
unclassified variants are considered to be reference standard positives. None of the population-based
studies provided sufficient data on unclassified variants to be included in secondary analyses.
Of the five studies that reported data for high-risk populations,34,57–60 two57,59 used a combination of
sequencing and denaturing gradient gel electrophoresis (DGGE), although in the study by Overbeek et al.59
single-strand conformation polymorphism analysis was sometimes used instead of DGGE. The study by
Caldes et al.57 followed this with Southern blot analysis to detect large deletions whereas Overbeek et al.59
TABLE 8 Summary of the reference standard used in included studies (continued )
Study Description Participants receiving the reference standard
Mueller et al.,
200958
Limited details. Deletion analysis was performed
using MLPA
Seventy-one CRC cases suspected to be LS cases
were analysed for MSH2, MLH1, MSH6 and
PMS2 gene defects. Mutation-negative cases
were screened for MLH1 promoter methylation
and mutations in PMS2
Overbeek et al.,
200759
Mutation analysis of MLH1, PMS2, MSH2 and
MSH6 was performed in DNA from peripheral
blood lymphocytes by a combination of either
single-strand conformation polymorphism analysis
or DGGE and direct sequence analysis. For the
detection of large deletions and duplications in
MLH1, MSH2, MSH6 and PMS2, MLPA was used.
All deletions and duplications were confirmed by
Southern blot analysis or with a specific PCR
Mutation analysis of germ-line DNA was
performed as the first test in 83 families who
fulfilled clinical criteria for LS
aPoynter et al.,
200834
Mutations in MSH2 and MLH1 were detected
using a combined approach of DHPLC/direct
sequencing and MLPA. Direct sequencing was
used to detect MSH6 mutations in cases with
absent IHC staining of MSH6
Population-based and clinic-based probands with
CRC were tested for mutations in the MMR
genes MSH2, MLH1, MSH6 and PMS2. MMR
gene mutation testing for MSH2 and MLH1 was
conducted for all clinic-based probands and all
MSI-H or MSI-L population-based probands and
in a random sample of 300 MSS population-
based probands. MMR germ-line mutation status
was available for 324/374 population-based




Each of the exons of MLH1, MSH2 and MSH6 was
amplified by PCR and heteroduplex analyses were
performed using DHPLC. DNA fragments that
displayed an abnormal chromatogram were
sequenced directly. Cases with tumours that
exhibited MSI but in whom a point mutation was
not detected were analysed for large deletions in
MLH1 and MSH2 using a procedure based on
multiplex PCR amplification of short fluorescent
fragments
Mutation analysis of germ-line DNA was
performed in 83 participants with a carcinoma
Reference standard-positive studies (recruiting populations with known mutation status)
Hendriks et al.,
200361
Limited details. Among the 35 HNPCC families
with a known MMR defect, 27 different germ-line
mutations were identified by DGGE or Southern
blotting
All 45 patients (25 men and 20 women) had a




Limited details. Standard sequencing of genomic
DNA and MLPA
A total of 815 families were screened for MSH6
mutations
DGGE, denaturing gradient gel electrophoresis.
a Poynter et al.34 report data from two distinct samples, a population-based sample and a high-risk sample.
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used a combination of MLPA and Southern blot analysis to detect large deletions. As reported above,
Poynter et al.34 used a combination of direct sequencing and DHPLC as the reference standard followed by
MLPA to detect large genomic alterations or deletions. Similarly, Shia et al.60 used DHPLC analysis and
direct sequencing but this was followed by multiplex PCR of short fluorescent fragments for the detection
of large deletions. The study by Mueller et al.58 provided limited details on the reference standard,
although it was clearly specified that MLPA was used.
All five of the single-gate studies based on high-risk populations investigated mutations in MLH1, MSH2
and MSH6,34,57–60 although, as mentioned above, Poynter et al.34 used only direct sequencing to detect
MSH6 mutations in cases with absent IHC staining of MSH6. In addition, Overbeek et al.59 investigated
mutations in PMS2 in all cases and Mueller et al.58 investigated mutations in PMS2 only in cases that were
negative for mutations in MLH1, MSH2 and MSH6. For three34,57,60 of the five studies large alterations or
deletions were assessed in MLH1 and MSH2 but not MSH6. It should be noted that in the studies by
Caldes et al.57 and Shia et al.60 it was reported that large alterations or deletions were assessed only for
MSI-positive cases that were mutation negative. Mueller et al.58 did not clearly report which genes were
assessed for large alterations or deletions. In the study by Overbeek et al.59 large deletions and duplications
were assessed in MLH1, MSH2, MSH6 and PMS2. Two57,60 of these studies providing data from high-risk
populations reported on unclassified variants, but only one57 provided sufficient data to be included in
secondary analyses (in which unclassified variants were considered to be reference standard positives).
Both of the reference standard-positive studies provided limited details on the reference standard.61,62 The
study by Okkels et al.62 used sequencing followed by MLPA and was focused only on MSH6. The study by
Hendriks et al.61 used DGGE followed by Southern blot analysis and assessed MLH1, MSH2 and MSH6.
Both studies recruited only reference standard-positive participants and both studies recruited participants
with, and reported on, unclassified variants. However, only the study by Hendriks et al.61 provided
sufficient data to be included in secondary analyses (in which unclassified variants are considered to be
reference standard positives).
Quality appraisal of included studies
Quality appraisal was conducted using phase 3 of the QUADAS-2 tool53 for all 11 data sets (all 10 studies,
including both the population-based and high-risk samples reported by Poynter34). Phase 3 of the
QUADAS-2 tool contains four domains: patient selection, index tests, reference standard and flow and
timing. The quality of the included studies is discussed in the following sections according to these
domains and is summarised in Table 9.
Patient selection
Four of the studies were rated as having a low risk of bias for patient selection. Three of these were
population-based single-gate studies.54–56 The other was a reference standard-positive study62 from which
only sensitivity estimates could be ascertained. All four of these studies enrolled either a consecutive or a
random sample of participants and avoided inappropriate exclusions.
For the remaining seven studies34,57–62 it was unclear whether patient selection could have introduced bias.
In all of these studies it was unclear whether inappropriate exclusions were avoided by enrolling a
consecutive or a random selection of participants.
For all studies included in the review there were no concerns about whether or not the included
participants matched the review question.
Index tests
All of the studies included in the review of test accuracy evaluated IHC. With the exception of the studies
by Limburg et al.55 and Okkels et al.,62 all studies also assessed MSI. For both of these index tests, all
studies were rated as unclear with regard to whether the conduct and interpretation of the test could
have introduced bias. None of the studies clearly reported whether the thresholds used were prespecified.
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In addition, none of the studies reported whether MSI results were interpreted without knowledge of the
results of the reference standard. The study by Shia et al.60 reported that IHC results were interpreted
without knowledge of the results of the reference standard, but for the remaining studies this was
not reported.
There were no concerns (in any of the studies) that the conduct or interpretation of either of the index
tests was different from the review question.
Reference standard
In all of the included studies the reference standard was assessed as being likely to correctly classify the
target condition. However, it should be noted that it has not been established in any study that the
reference standard is 100% accurate and that there is between-study variation in the reference standard
(see Summary of the reference standard in the included studies). Nevertheless, because a genetic definition
of LS was used in this review (i.e. the reference standard is LS as indicated by a genetic mutation rather
than, for example, LS defined by clinical criteria) and because the inclusion criteria for the reference
standard were set so that only studies using the best current methods, or other similarly appropriate
methods, for detecting LS-based gene defects were included (see Reference standard), the assumption
remains that any specific disagreements between the reference standard and the index test are assumed to
result from incorrect classification by the index test. Indeed, there were no concerns (in any of the studies)
that the target condition, as defined by the reference standard, did not match the review question.
Despite this, all of the included studies apart from that by Hendriks et al.61 were rated as unclear with
regard to whether or not the conduct or interpretation of the reference standard could have introduced
bias. This was because only Hendriks et al.61 specified that the reference standard results were interpreted
without knowledge of the results of the index test, with the rest of the studies not reporting this
information. It is therefore unclear for the other studies34,54–60,62 whether there was any prior knowledge
that could have influenced the interpretation of the reference standard.
Flow and timing
For all of the included studies it was unclear whether the flow of participants through the study could have
introduced bias. In most of the included studies (including the high-risk sample reported by Poynter et al.34),
all of the participants received a reference standard,34,54,55,57–62, although only one54 of these studies provided
information to indicate that all of the participants received the same reference standard. In five of these
studies55,58,59,61,62 it was not clear whether all participants received the same reference standard and in three
of these studies34,57,60 it was clear that not all participants received the same reference standard. Indeed, in
the study by Caldes et al.,57 only the MSI-H cases that were negative for mutations were analysed for
genomic deletions, by Southern blot analysis, in MLH1 and MSH2. Similarly, in the study by Shia et al.,60
only cases with tumours that exhibited MSI but in whom a point mutation was not detected were analysed
for large deletions in MLH1 and MSH2. In the high-risk sample in Poynter et al.,34 direct sequencing was
used only to detect MSH6 mutations in cases with absent IHC staining of MSH6. However, in these three
studies it was not believed that this would constitute a high risk of bias; it is acceptable for large deletions
to be investigated only when a mutation is not found57,60 and for the reference standard to be directed by
IHC results.34
In the study by Southey et al.56 and the population-based sample reported by Poynter et al.,34 not all
patients received the reference standard. In both of these samples this was because the reference standard
was applied to a random sample of participants who were index test negative. In addition, in both of these
samples it was clear that not all of the patients who received the reference standard received the same
reference standard. In the study by Southey et al.56 MLPA was used to detect large genomic alterations in
MLH1 and MSH2 for cases with tumours lacking expression of at least one MMR protein and for whom no
previous mutation had been identified by sequencing and, as with the high-risk sample in the study by
Poynter et al.,34 in the population-based sample reported by Poynter et al.,34 direct sequencing was used to
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detect MSH6 mutations only in cases with absent IHC staining of MSH6. As discussed earlier, these
variations in study design would not be thought to constitute a high risk of bias.
None of the studies included in the test accuracy review clearly specified the interval between the index
tests and the reference standard. However, as the results for the index tests and the reference standard
would be expected to be stable over time, this information is of little importance in itself; variations in
timing between the index tests and the reference standard would not lead to a high risk of bias.
With regard to missing data, it was clear that in most of the studies some of the participants were
excluded from the analysis,34,54–57,61,62 although details regarding the characteristics of these participants
were not provided. However, the study by Mueller et al.58 clearly specified that data were analysed from all
participants who received tests. In the studies by Overbeek et al.59 and Shia et al.60 it was unclear whether
or not all tested participants were analysed.
Quality appraisal summary
Overall, no evidence was found to indicate that any of the included studies was at a high risk of bias. Of
course, the single-gate studies based on a high-risk population34,57–60 would necessarily confer a risk of bias
(i.e. if the results were used to make assumptions about the general population with CRC). Indeed, when
studies recruit only from high-risk populations this would obviously lead to biased estimates of PPV, NPV
and yield. It would also possibly lead to biased estimates of sensitivity and specificity because of spectrum
bias,64 although in a previous review this did not appear to lead to significant bias in estimates of
sensitivity.42 As a result, this was dealt with in this review by prespecifying that single-gate studies based
on high-risk populations would be used only to estimate sensitivity. Ordinarily, two-gate studies would also
be at risk of inflating diagnostic accuracy.65,66 However, the two studies included in this review that were
not single-gate studies were not in fact two-gate studies but reference standard-positive studies;61,62 no
reference standard negatives were included in these two studies and so an unbiased estimate of sensitivity
could be made.
It is important to note that an absence of evidence to suggest that the included studies were at high risk
of bias does not suggest that the studies were at low risk of bias. In fact, for all studies it was unclear
whether the index tests or the flow and timing of the study would have introduced bias. Similarly, in all
but one study61 it was unclear whether the conduct of the reference standard would have introduced bias
and only four studies54–56,62 provided sufficient information to establish that the selection of participants
was unlikely to have introduced bias.
Assessment of test accuracy
The index tests included in this review (MSI and IHC) are highly susceptible to spectrum effects in
populations that have been selected on the basis of clinical characteristics. Indeed, preselecting participants
in this way will result in a population that differs from an unselected population in terms of the clinical
predictor in a non-random way. Thus, the sensitivity and specificity estimates would likely be different
among unselected CRC populations compared with CRC populations selected on the basis of age or
because of characteristics that make them high risk for LS (such as a family history of LS or meeting clinical
criteria for defining LS). In particular, the increased presence of MMR mutation carriers in a population
would change the apparent sensitivity and specificity of the index tests.54 However, a previous review did
not find that this issue led to significant bias in estimates of sensitivity.42
Because of this, the studies included in this review were grouped by population and the results are
presented accordingly. In addition, studies recruiting high-risk populations were used only to estimate
sensitivity. As previously described, four of the samples included in this review can be described as
population-based samples, although only one recruited an unselected CRC population,34 with the other
three recruiting age-limited populations,54–56 for which some spectrum bias may be expected. The
remaining seven samples included in this review were all high risk; five of the remaining studies had a
single-gate design and recruited high-risk participants,34,57–60 with the other two studies recruiting only
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participants who were reference standard positives.61,62 For the five single-gate studies based on high-risk
populations, only sensitivity is reported, even if data were available for other outcomes. For the two studies
based on participants who were reference standard positives, only sensitivity is estimable from the
data reported.
It is important to mention that none of the studies included in this review made a direct comparison
between MSI and IHC. As such, results are reported separately for these tests.
Assessment of test accuracy: microsatellite instability testing
Microsatellite instability was assessed in eight of the 10 studies (nine of the 11 samples) included in the
review of test accuracy: three of the four population-based samples,34,54,56 all five high-risk samples34,57–60
and one of the reference standard-positive studies.61
Microsatellite instability testing methods
A summary of the MSI testing methods used in these studies is provided in Table 10. It is evident that a
variety of between-study differences exist in the MSI testing procedures used. In addition, differences
between studies in MSI testing methods were not always clear because methods were not always reported
in sufficient detail. For example, three34,58,59 of the eight studies assessing MSI did not report microdissection
techniques (microdissection assists in ensuring that malignant tissue that does not contain DNA from
surrounding, healthy colonic tissue is analysed). A further two studies60,61 reported only very limited details
about microdissection. Among the three studies54,56,57 that did report details regarding microdissection, there
was some variation in the technique used (see Table 10 for details). The panel of markers used also differed
between studies (see Table 10). None of the population-based studies assessed the same panel of markers.
Two54,56 of the three population-based studies included an assessment of the Bethesda panel of markers
(BAT25, BAT26, D2S123, D5S346, D17S250), with the study by Southey et al.56 also assessing five additional
markers (BAT40, MYB, TGFRII, IGFIIR and BAX). The other population-based study (the population-based
sample included in the study by Poynter et al.34) did not assess D2S123, even though the other Bethesda
panel markers were included. This study also assessed six additional markers (BAT40, MYCL, ACTC, Dl 8S55,
D1OS197 and BAT34C4). The same panel of markers was used for the single-gate, high-risk sample
included in the study by Poynter et al.34 Of the other four single-gate studies based on high-risk populations,
three57–59 included the Bethesda panel of markers. However, Overbeek et al.59 also assessed BAT40 for some
participants (it is unclear which ones) and Mueller et al.58 used a 10-marker panel (BAT26, BAT4O, Mfdl5,
D2S123, APC, BAT25, D10S197, D18S58, D18S69 and MYCLJ) as well as a five-marker panel (the Bethesda
panel), although it is unclear which participants received which panel of markers and which panel of markers
the reported data are based on. The remaining single-gate study by Shia et al.60 did not assess D5S346 but
did assess the other markers in the Bethesda panel, as well as BAT40, PAX6 and MYCL1. It appears,
therefore, that none of the single-gate studies based on high-risk samples used the same panel of markers
(although this is unclear in the case of Mueller et al.58). The reference standard-positive study that assessed
MSI61 also included a different panel of markers: the Bethesda panel plus BAT40, MSH3 and MSH6.
The eight studies that assessed MSI also varied in the way in which MSI was categorised (as a bimodal
or a trimodal distribution) and in the thresholds used to define these categories. Indeed, of the studies
included in this review, five34,54,56,58,61 defined tumours as MSI-H, MSI-L or MSS, also known as a trimodal
distribution, two59,60 defined tumours as MSI positive or MSI negative, also known as a bimodal distribution,
and one57 used a bimodal distribution but defined tumours as either MSI-H or MSS.
It is also unsurprising that the thresholds used to categorise tumours (as MSI-H, MSI-L or MSS or as MSI
positive or MSI negative) differed between studies; the distinction between these categories is dependent
on both the type and the number of microsatellites analysed and, as discussed above, the studies included
in this review used various different panels of markers.69 Indeed, with regard to the trimodal distribution of
MSI, many research groups have defined MSI-H tumours as those with > 30–40% of unstable markers,
MSI-L as instability lower than this threshold and MSS as no instability.69 However, in the five studies
included in the review that used the MSI-H, MSI-L and MSS categories (trimodal distribution), the
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TABLE 10 Details of MSI testing in the included studies
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> 1 marker 1 marker 0 markers
Southey et al.,
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performed on invasive tumour cells
from paraffin-embedded archival
tumour tissue stained with 1% methyl
green and normal cells from colonic or







> 5 markers 2–5 markers < 2 markers
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et al., 200834






≥ 30% > 0% and
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Mueller et al.,
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a,bPoynter
et al., 200834
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reported, paired tumour and normal















a The study by Poynter et al.34 includes both a population-based sample and a high-risk sample.
b Poynter et al.34 and Shia et al.60 give thresholds as proportions of successfully typed loci rather than as the number
of markers.
c References are provided to Boland et al.,67 who recommend the use of BAT25, BAT26, D2S123, D5S346 and D17S250,
and Dietmaier et al.,68 who recommend the use of BAT26, BAT4O, Mfdl5, D2S123, APC, BAT25, D10S197, D18S58,
D18S69 and MYCLJ.
d Defined as MSI-H, MSI-L and MSS, but thresholds are not described.
e BAT40 was added to the standard set of markers for 273/667 tumours (no further details provided by authors).
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thresholds used to categorise the tumours varied greatly, with one34 of these studies using the commonly
used threshold of ≥ 30% of unstable markers to define MSI-H tumours, three54,56,61 using differing
numbers of unstable markers to define MSI-H tumours and one58 not providing details on the thresholds
used to categorise the tumours (see Table 10 for details). Of the two studies that defined tumours as
positive or negative (bimodal distribution), one60 reported using a threshold of ≥ 30% of unstable markers
to define MSI-positive tumours and the other59 defined MSI-positive tumours as those with more than two
unstable Bethesda panel markers. The study by Caldes et al.57 defined MSI-H tumours as those with two or
more unstable Bethesda panel markers (or one marker in the case of BAT26) and MSS tumours as those
showing no instability. It is not clear how cases with only one unstable marker (other than BAT26) were
categorised, but in any case data are presented only for tumours that were categorised as MSS and MSI-H.
It has been asserted by Pawlik et al.69 that a bimodal distribution of MSI (as used in the studies by Shia
et al.60 and Overbeek et al.59) may be more useful than a trimodal distribution of MSI (as used in the studies
by Barnetson et al.,54 Southey et al.,56 Poynter et al.,34 Caldes et al.,57 Mueller et al.58 and Hendriks et al.61).
Indeed, in studies using a trimodal distribution, MSI-L can be considered as either positive or negative and,
although MSI-L tumours may behave more similarly to MSS tumours in clinical and prognostic terms, the
significance of MSI-L is still uncertain and would vary according to the particular markers used.69 Clearly,
a range of markers were used in the studies included in this review. Thus, for studies using a trimodal
distribution of MSI, and for which data were available, the sensitivity and specificity of the MSI test were
estimated with MSI-L values considered as index test positives and with MSI-L values considered as index
test negatives.
Microsatellite instability-high compared with microsatellite stable and microsatellite
instability-low
Three population-based samples,34,54,56 two high-risk single-gate study samples34,58 and one reference
standard-positive study sample61 provided test accuracy data for MSI in which MSI-L cases were considered
to be index test negative results. In the other three studies assessing MSI,57,59,60 MSI was already
categorised using a bimodal distribution (MSI positive or negative in the studies by Overbeek et al.59 and
Shia et al.;60 MSI-H or MSS in the study by Caldes et al.57). For ease of reference, the results from these
three studies are included here and again in the section reporting data in which MSI-L tumours are
considered to be positive index text results.
Sensitivity and specificity estimates Sensitivity was calculated for all studies that provided data in
which MSI-L was considered to be a negative index test result (as well as the studies categorising MSI
using a bimodal distribution), whereas specificity was calculated only for the three population-based
studies.34,54,56 These sensitivity and specificity estimates are reported in Table 11.
Only one study34 included a population that was unselected (not limited by age or risk) and the data from
this study produced a sensitivity estimate of 100% (95% CI 93.9% to 100.0%) and a specificity estimate
of 61.1% (95% CI 57.0% to 65.1%). It should be noted that in this sample and in the data reported for
this study in Table 11, unclassified variants were considered to be reference standard negatives. Two of the
studies that reported data in which MSI-L was considered to denote an index test negative were based on
age-limited populations.54,56 The study by Barnetson et al.54 included unclassified variants as reference
standard negative results and is reported in this section as such. In these two studies, sensitivity and
specificity estimates were fairly similar, despite the fact that different panels of markers and different
thresholds were used to categorise the tumours (see Table 10), with a sensitivity of 66.7% (95% CI 47.2%
to 82.7%) in the study by Barnetson et al.54 and 72.2% (95% CI 46.5% to 90.3%) in the study by
Southey et al.56 and a specificity of 92.5% (95% CI 89.1% to 95.2%) in the study by Barnetson et al.54
and 87.8% (95% CI 73.8% to 95.9%) in the study by Southey et al.56 (see Table 11).
For the five single-gate, high-risk samples presented in Table 11,34,57–60 sensitivity estimates ranged from
79.4% (95% CI 62.1% to 91.3%) in the study by Caldes et al.57 to 100.0% (95% CI 85.8% to 100.0%)
in the study by Shia et al.60 (see Table 11). Two of these high-risk, single-gate studies mentioned
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unclassified variants57,60 and these are counted as reference standard negative results in these analyses.
Between-study variation in sensitivity estimates may be the result of a variety of factors, including
differences in the panel of markers used and in the MSI thresholds used to denote cases, as well as
differences in the reference standard. Nevertheless, all of these sensitivity estimates were > 79%. It should
be noted that Caldes et al.57 reported that the sensitivity of MSI-H in predicting a pathogenic mutation was
96.0% (95% CI 90.0% to 100.0%) in contrast to our calculation of 79.4% (95% CI 62.1% to 91.3%).
This is because Caldes et al.57 excluded five cases from their MSI analyses that did not also have IHC data,
whereas these cases were included in our calculations. The data from the reference standard-positive study
that assessed MSI61 was also used to generate a sensitivity estimate; when MSI-L cases were considered to
be index test negatives, sensitivity was 88.0% (95% CI 68.8% to 97.5%).
Because of a potential for spectrum bias, it would be expected that studies recruiting high-risk populations
would have higher sensitivity estimates than those estimated from population-based studies. However, as
discussed in a systematic review by Palomaki et al.,42 we did not find great differences between the
sensitivity estimates in the population-based studies and the sensitivity estimates in the high-risk studies.
Indeed, although two of the three population-based studies produced the lowest sensitivity estimates,54,56
the other population-based study produced a sensitivity estimate of 100.0% (95% CI 93.9% to 100.0%).
In fact, the two population-based studies with the lower sensitivity estimates would, in theory, be more
likely to be subject to some spectrum bias than the study by Poynter et al.34 because they are based on
age-limited populations. This highlights how comparison between the studies included in this review may
not be meaningful. Other factors such as the particular MSI testing methods, panel of markers and
thresholds used, as well as methods used to conduct the reference standard, varied between studies.
For three34,58,59 of the five single-gate high-risk samples, data regarding methylation were reported. In the
study by Poynter et al.34 it was reported that the prevalence of MLH1 promoter methylation in MSI-H
tumours was much lower in the high-risk sample than in the population-based sample (13% vs. 60%;
p < 0.0001), with no MLH1 promoter methylation at all in the MSI-L or MSS tumours from the high-risk
sample. The authors suggest that this may be the result of the higher frequency of clinic-based MSI-H
cases with a MMR germ-line mutation and because the MSI-H cases in the population-based series were
TABLE 11 Sensitivity and specificity for MSI (MSI-H vs. MSI-L or MSS)
Study Sensitivity (95% CI) (%) Specificity (95% CI) (%)
Population-based single-gate studies
aPoynter et al., 200834 100.0 (93.9 to 100.0) 61.1 (57.0 to 65.1)
Barnetson et al., 200654 66.7 (47.2 to 82.7) 92.5 (89.1 to 95.2)
Southey et al., 200556 72.2 (46.5 to 90.3) 87.8 (73.8 to 95.9)
Single-gate studies recruiting high-risk samples
bCaldes et al., 200457 79.4 (62.1 to 91.3) –
Mueller et al., 200958 91.3 (72.0 to 98.9) –
bOverbeek et al., 200759 90.0 (59.6 to 98.2) –
cPoynter et al., 200834 86.8 (71.9 to 95.6) –
bShia et al., 200560 100.0 (85.8 to 100.0) –
Reference standard-positive study
Hendriks et al., 200361 88.0 (68.8 to 97.5) –
a Population-based sample.
b MSI-L not defined.
c Clinic based sample.
ASSESSMENT OF TEST ACCURACY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
diagnosed at an older age than those in the clinic-based series (median 63 years, range 22–75 years vs.
median 44 years, range 19–77 years). Despite recruiting a high-risk population, Mueller et al.58 reported
that, of the seven MSI-H cases for which no mutation was identified by the reference standard, four
had somatic silencing of MLH1 and were likely to be sporadic cases. Overbeek et al.59 did not test all
participants relevant to this review for MLH1 promoter methylation; however, of those tested, none had a
positive result.
Other test accuracy estimates The other test accuracy outcomes included in this review were LRs
(LR+ and LR–), PPV and NPV, accuracy or concordance with the reference standard, diagnostic yield and
test failure rates. The last three outcomes (accuracy or concordance with the reference standard, diagnostic
yield and test failure rates) were not reported in any of the included studies. The other four outcomes
(LR+, LR–, PPV and NPV) were calculated for the three population-based studies reporting MSI data.34,54,56
These outcomes are reported in Table 12 and are based on data in which MSI-L was assumed to be a
negative index test result and the unclassified variants reported in the studies by Barnetson et al.54 and
Poynter et al.34 were assumed to be negative reference standard results.
As can be seen in Table 12, the results were fairly consistent among the three studies.34,54,56 The LR+
ranged from 2.57 (95% CI 2.32 to 2.85)34 to 8.94 (95% CI 5.54 to 14.20).54 The LR– could be estimated
for only two of the studies54,56 because there were no false-negative MSI results in the study by Poynter
et al.34 LR– was similar in both studies. The PPV varied a lot more between the studies, with the lowest
estimate coming from the study by Poynter et al.34 (20.8%, 95% CI 16.2% to 26.0%) and the highest
estimate coming from the study by Southey et al.56 (72.2%, 95% CI 46.5% to 90.3%). It should be noted
that the CIs generated from the study by Southey et al.56 are relatively wide, which reflects the smaller
sample size of 59, as opposed to the sample size of 638 for Poynter et al.34 and 352 for Barnetson et al.54
The NPV was consistent across the studies, with all estimates being > 87%.
Secondary analyses (unclassified variants as reference test positives) Secondary analyses were
conducted in which unclassified variants were considered to indicate a positive reference standard test
result. It was not possible to include all studies reporting MSI data in these analyses (because sufficient
data were not reported). Five studies34,54,57,60,61 reported unclassified variants in their assessment of MSI. Of
these five studies, only two57,61 provided sufficient data to conduct secondary analyses. However, because
the study by Caldes et al.57 was based on a high-risk population and that by Hendriks et al.61 was a
reference standard-positive study, only sensitivity estimates were made.
Therefore, when unclassified variants were considered to be reference standard positives and MSI-L was
considered to be an index test negative, Caldes et al.57 reported a sensitivity of 81.6% (95% CI 65.7% to
92.3%) and Hendriks et al.61 reported a sensitivity of 84.8% (95% CI 69.0% to 93.3%). These results
were similar to those obtained when unclassified variants were considered to be reference standard
negatives (79.4%, 95% CI 62.1% to 91.3% in the study by Caldes et al.57 and 88.8%, 95% CI 68.8% to
97.5% in the study by Hendriks et al.;61 see Table 11).
TABLE 12 Likelihood ratios and predictive values for MSI (MSI-H vs. MSI-L or MSS)
Study LR+ (95% CI) LR– (95% CI) PPV (95% CI) (%) NPV (95% CI) (%)
Population-based single-gate studies
aPoynter et al., 200834 2.57 (2.32 to 2.85) 0.00 (NE) 20.8 (16.2 to 26.0) 100.0 (99.0 to 100.0)
Barnetson et al., 200654 8.94 (5.54 to 14.20) 0.36 (0.21 to 0.60) 45.5 (30.4 to 61.2) 96.8 (94.1 to 98.4)
Southey et al., 200556 5.92 (2.48 to 14.10) 0.32 (0.15 to 0.67) 72.2 (46.5 to 90.3) 87.8 (73.8 to 95.9)
NE, not estimable.
a Population-based sample.
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Microsatellite instability-high and microsatellite instability-low compared with
microsatellite stable
When MSI-L tumours were considered to be index test positives, data were available from all three
population-based samples that assessed MSI,34,54,56 two high-risk single-gate study samples34,58 and one
reference standard-positive study sample.61 As previously discussed, the other three studies assessing
MSI57,59,60 already categorised MSI using a bimodal distribution (MSI positive or MSI negative in the study by
Overbeek et al.59 and Shia et al.60; MSI-H or MSS in the study by Caldes et al.57). The results from these
three studies are included here as well as previously in Microsatellite instability-high compared with
microsatellite stable and microsatellite instability-low.
Sensitivity and specificity estimates Sensitivity was calculated for all studies that provided data in
which MSI-L was considered to be index test positive (as well as the studies categorising MSI using a
bimodal distribution). Specificity was calculated only for the three population-based study samples.34,54,56
These sensitivity and specificity estimates are reported in Table 13. For the five studies that mentioned
assessing unclassified variants in addition to pathogenic mutations,34,54,57,60,61 the unclassified variants were
considered to be reference standard negatives.
The data from the study that included an unselected CRC population34 produced a sensitivity estimate of
100.0% (95% CI 93.9% to 100.0%) and therefore sensitivity was unchanged from when MSI-L cases
were considered to be index test negatives (see Microsatellite instability-high compared with microsatellite
stable and microsatellite instability-low). However, specificity was much lower at 29.5% (95% CI 25.8% to
33.4%), compared with 61.1% (95% CI 57.0% to 65.1%) when MSI-L cases were considered to be index
test negatives, reflecting a large increase in false-positive results. The two studies based on age-limited
populations that reported data in which MSI-L cases were considered to be index test positives reported
sensitivities of 93.3% (95% CI 77.9% to 99.2%)54 and 94.4% (95% CI 72.7% to 99.9%)56 respectively.
These sensitivities were higher than those estimated when MSI-L cases were considered to be index test
negatives, with sensitivities of 66.7% (95% CI 47.2% to 82.7%) for the study by Barnetson et al.54 and
72.2% (95% CI 46.5% to 90.3%) for the study by Southey et al.56 (see Table 11). As would be expected
TABLE 13 Sensitivity and specificity for MSI (MSI-H or MSI-L vs. MSS)
Study Sensitivity (95% CI) (%) Specificity (95% CI) (%)
Population-based single-gate studies
aPoynter et al., 200834 100.0 (93.9 to 100.0) 29.5 (25.8 to 33.4)
Barnetson et al., 200654 93.3 (77.9 to 99.2) 84.5 (80.0 to 88.2)
Southey et al., 200556 94.4 (72.7 to 99.9) 58.5 (42.1 to 73.7)
Single-gate studies recruiting high-risk samples
bCaldes et al., 200457 79.4 (62.1 to 91.3) –
Mueller et al., 200958 93.1 (77.2 to 99.2) –
bOverbeek et al., 200759 90.0 (59.6 to 98.2) –
cPoynter et al., 200834 94.7 (82.3 to 99.4) –
bShia et al., 200560 100.0 (85.8 to 100.0) –
Reference standard-positive study
Hendriks et al., 200361 92.0 (74.0 to 99.0) –
a Population-based sample.
b MSI-L not defined.
c Clinic-based sample.
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in a trade-off between sensitivity and specificity, specificities were reduced for these two studies when
MSI-L cases were considered to be index test positives. However, in the study by Barnetson et al.54 this
reduction was small, with specificity estimated as 84.5% (95% CI 80.0% to 88.2%) when MSI-L cases
were considered to be index test positives (see Table 13) and 92.5% (95% CI 89.1% to 95.2%) when
MSI-L cases were considered to be index test negatives (see Table 11). For Southey et al.,56 specificity was
estimated as 58.5% (95% CI 42.1% to 73.7%) when MSI-L was considered to be a positive index test
result (see Table 13) and 87.8% (95% CI 73.8% to 95.9%) when MSI-L was considered to be a negative
index test result (see Table 11). To further demonstrate the differences in test performance between MSI-L
as a positive test result and MSI-L as a negative test result, sensitivities and specificities were graphically
summarised using a summary receiver operating characteristic (SROC) curve (Figure 4). This visually
elucidates the trade-off between sensitivity and specificity across the three population-based study samples
used to assess MSI.34,54,56 In this SROC curve, the unclassified variants mentioned in the studies by Poynter
et al.34 and Barnetson et al.54 were assumed to be negative reference standard results.
The ideal diagnostic test would generate a point in the upper left corner of the ROC space, representing
100% sensitivity [no false negatives (FNs)] and 100% specificity [no false positives (FPs)]. The closest point
to this is found for the study by Barnetson et al.54 when MSI-L cases are considered to be index test
positive results. When MSI-L cases are considered to be index test negative results, specificity improves
slightly but sensitivity is reduced.54 This was also the case for the study by Southey et al.;56 however,
because of the wider discrepancy between sensitivity and specificity, the points are further away from a
perfect classification. With regard to the study by Poynter et al.,34 the lack of FNs ensured that sensitivity
remained constant, with only specificity altering according to the allocation of MSI-L results.
It is unsurprising that, on the whole, sensitivity was higher and specificity was lower when MSI-L cases
were considered to be index test positive results rather than index test negative results; including MSI-L
















FIGURE 4 Summary receiver operating characteristic curve graph for MSI testing in which unclassified variants are
assumed to be negative reference standard results. Solid black circles, Barnetson et al.;54 solid green circles, Southey
et al.;56 open circles, Poynter et al.;34 +, MSI-L is positive; –, MSI-L is negative.
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results presented above, Barnetson et al.54 also reported that MSI-H has a sensitivity of 83% for the
detection of MLH1 mutations, 75% for the detection of MSH2 mutations and 17% for the detection of
MSH6 mutations, whereas MSI-L has sensitivities of 17%, 25% and 50% respectively. Therefore, the
usefulness of including MSI-L as a positive index test result will likely vary according to which gene is
mutated. Indeed, according to Mueller et al.,58 the vast majority of mutations detected are usually in the
MSH2 or MLH1 gene, followed by the MSH6 gene and finally the PMS2 gene; however, it is not clear
what thresholds were used in this study to define MSI-H, MSI-L and MSS. Similarly, Caldes et al.57 suggest
that mutations in MSH6 do not always produce instability in tumours but in this study an MSI-L
categorisation is not used (see Table 10).
For the five single-gate, high-risk samples presented in Table 13,34,57–60 sensitivity estimates ranged from
79.4% (95% CI 62.1% to 91.3%) in the study by Caldes et al.57 to 100.0% (85.8% to 100.0%) in the
study by Shia et al.60 when MSI-L cases were considered to be index test positive results. Therefore, all of
these sensitivity estimates were > 79%. It is important to remember that, for three of these studies,57,59,60
MSI was already categorised bimodally and therefore the estimates presented in Table 13 are identical to
those presented in Table 11 (and are based on the same data). For the other two single-gate, high-risk
studies,34,58 sensitivities were very similar, albeit slightly higher when MSI-L cases were considered to be
index test positive results (93.1%, 95% CI 77.2% to 99.2% in the study by Mueller et al.58 and 94.7%,
95% CI 82.3% to 99.4% in the study by Poynter et al.34) than when they were considered to be index test
negative results (91.3%, 95% CI 72.0% to 98.9% in the study by Mueller et al.58 and 86.8%, 95% CI
71.9% to 95.6% in the study by Poynter et al.;34 see Table 11). The MSI data from the reference standard-
positive study61 was also used to generate sensitivity estimates (see Table 13) and, similarly, sensitivity was
slightly higher when MSI-L cases were considered to be index test positives (92.0%, 95% CI 74.0% to
99.0%) than when they were considered to be index test negatives (88.0%, 95% CI 68.8% to 97.5%;
see Table 11).
Other test accuracy estimates Likelihood ratios (LR+ and LR–), PPV and NPV were calculated for the
three population-based studies reporting MSI data34,54,56 when MSI-L cases were assumed to be positive
index test results (and the unclassified variants reported in the studies by Barnetson et al.54 and Poynter et al.34
were assumed to be negative reference standard results). These estimates are summarised in Table 14.
For all three population-based studies, the LR+ estimate was reduced when MSI-L cases were considered
to be positive index test results (1.42, 95% CI 1.35 to 1.50 in the study by Poynter et al.;34 6.01, 95% CI
4.58 to 7.89 in the study by Barnetson et al.;54 2.28, 95% CI 1.56 to 3.33 in the study by Southey et al.56)
compared with when they were considered to be negative index test results (2.57, 95% CI 2.32 to 2.85 in
the study by Poynter et al.;34 8.94, 95% CI 5.54 to 14.20 in the study by Barnetson et al.;54 5.92, 95% CI
2.48 to 14.10 in the study by Southey et al.56; see Table 12). As before, the LR– could be estimated for
only two of the studies54,56 because there were no false-negative MSI results in the study by Poynter et al.34
Again, the LR– estimate was similar in both studies54,56 and was lower when MSI-L cases were considered to
be positive index test results (0.08, 95% CI 0.02 to 0.30 in the study by Barnetson et al.;54 0.09, 95% CI
TABLE 14 Likelihood ratios and predictive values for MSI (MSI-H +MSI-L vs. MSS)
Study LR+ (95% CI) LR– (95% CI) PPV (95% CI) (%) NPV (95% CI) (%)
Population-based single-gate studies
aPoynter et al., 200834 1.42 (1.35 to 1.50) 0.00 (NE) 12.6 (9.8 to 16.0) 100.0 (97.9 to 100.0)
Barnetson et al., 200654 6.01 (4.58 to 7.89) 0.08 (0.02 to 0.30) 35.9 (25.3 to 47.6) 99.3 (97.4 to 99.9)
Southey et al., 200556 2.28 (1.56 to 3.33) 0.09 (0.01 to 0.65) 50.0 (32.4 to 67.6) 96.0 (79.6 to 99.9)
NE, not estimable.
a Population-based sample.
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0.01 to 0.65 in the study by Southey et al.56) than when MSI-L cases were considered to be negative index
test results (0.36, 95% CI 0.21 to 0.60 in the study by Barnetson et al.;54 0.32, 95% CI 0.15 to 0.67 in the
study by Southey et al.;56 see Table 12).
As before, PPV estimates varied a lot more between the studies, with the lowest estimate still coming from
the study by Poynter et al.34 (12.6%, 95% CI 9.8% to 16.0%) and the highest estimate still coming from
the study by Southey et al.56 (50.0%, 95% CI 32.4% to 67.6%). For all three studies, PPV estimates were
lower when MSI-L cases were considered to be index test positives than when they were considered to be
index test negatives (see Table 12). Conversely, NPV estimates, which were consistent across the three
studies (with all estimates being > 96%), were higher when MSI-L cases were considered to be index test
positives than when they were considered to be index test negatives (see Table 12). However, it should be
noted that, for the unselected CRC population in the study by Poynter et al.,34 the NPV estimate was
100% regardless of whether MSI-L cases were considered to be positive or negative index test results,
although the CIs were slightly wider when MSI-L cases were considered to be positive index test results
(95% CI 97.9% to 100.0%) than when they were considered to be negative index test results (95% CI
99.0% to 100.0%).
Secondary analyses (unclassified variants as reference test positives) As before, secondary analyses
were conducted in which unclassified variants were considered to indicate a positive reference standard
test result. Although five of the included studies34,54,57,60,61 reported unclassified variants in their assessment
of MSI, only one61 provided sufficient data to conduct secondary analyses. However, because this study is a
reference standard-positive study, only sensitivity estimates were made.
When unclassified variants were considered to be reference standard positives and MSI-L cases were
considered to be index test positives, Hendriks et al.61 reported a sensitivity of 93.9% (95% CI 80.3% to
98.3%). As expected, because the threshold for a MSI case is essentially lowered when MSI-L is considered
to be an index test positive, this sensitivity was higher than that reported when MSI-L cases were
considered to be index test negatives and unclassified variants were considered to be reference standard
positives (84.8%, 95% CI 69.0% to 93.3%). When comparing the results from the study by Hendriks
et al.61 when unclassified variants were considered to be reference standard positives (MSI-L as an index
test positive) with those generated when unclassified variants were considered to be reference standard
negatives (MSI-L as an index test positive), sensitivity was very similar (93.9%, 95% CI 80.3% to 98.3% vs.
92.0%, 95% CI 74.0% to 99.0% respectively).
Assessment of test accuracy: immunohistochemistry
Immunohistochemistry was conducted in all 10 studies (11 samples) included in the review of test
accuracy. However, not all studies provided sufficient data to be included in the analyses. Indeed, despite
IHC being conducted for the high-risk sample in the study by Poynter et al.34 and the sample in the study
by Mueller et al.,58 insufficient data were provided for these samples to be included in any of the IHC
analyses. For the population-based sample in the study by Poynter et al.34 and the samples in the studies
by Barnetson et al.,54 Southey et al.,56 Hendriks et al.61 and Okkels et al.,62 the IHC results were reported
according to the particular protein assessed (MLH1, MSH2, MSH6 or PMS2), enabling an assessment of
IHC for at least one of these individual proteins (i.e. whether an absence of a particular protein accurately
identifies a mutation in a particular gene). In seven cases54–57,59–61 an overall result was provided (i.e.
whether a positive IHC result, regardless of which protein this applies to, predicts a positive reference
standard result).
As with the results for MSI, in primary analyses unclassified variants were considered to be reference
standard negatives. When sufficient data were available, secondary analyses were conducted in which
unclassified variants were considered to be reference standard positives.
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Overall immunohistochemistry results
As noted above, seven studies54–57,59–61 provided sufficient data to enable an assessment of the overall test
performance of IHC (i.e. whether a positive IHC result, regardless of which protein this applies to, predicts
a positive reference standard result). All of these studies assessed MLH1, MSH2 and MSH6 proteins.
Therefore, abnormal staining for any of these three proteins was considered to be a positive index test
result. Southey et al.56 and Overbeek et al.59 also assessed PMS2. Therefore, for these two studies an
abnormal PMS2 result was included as a positive index test result.
Sensitivity and specificity estimates Three population-based studies, all based on age-limited
samples,54–56 were included in the primary analyses, in which unclassified variants were considered to be
reference standard negatives. For all three of these studies sensitivity estimates were made, with Limburg
et al.55 providing the lowest estimate (85.7%, 95% CI 41.2% to 99.6%) and Southey et al.56 providing the
highest estimate (100.0%, 81.5% to 100.0%). The study by Southey et al.56 included an assessment of
PMS2 as well as assessments of MLH1, MSH2 and MSH6 and it is possible that this accounted for the
higher sensitivity estimate. Nevertheless, all sensitivity estimates from the population-based studies were
> 85% (Table 15). For two of the population-based studies55,56 specificity estimates were also made for the
overall IHC results; these were > 80% for both studies (91.9%, 95% CI 86.3% to 95.7% for Limburg
et al.55 and 80.5%, 95% CI 65.1% to 91.2% for Southey et al.;56 see Table 15). Specificity could not be
estimated for the study by Barnetson et al.54 because overall IHC results were available only for reference
standard-positive participants.
For the three high-risk, single-gate samples presented in Table 15,57,59,60 sensitivity estimates ranged from
80.8% (95% CI 60.6% to 93.4%) in the study by Shia et al.60 to 96.4% (95% CI 81.7% to 99.9%) in the
study by Caldes et al.57 Two of these high-risk, single-gate studies mentioned unclassified variants57,60 and
these were counted as reference standard negatives in these analyses. The data from the reference
standard-positive study that assessed overall IHC results61 was also used to generate a sensitivity estimate
(91.7%, 95% CI 77.5% to 98.2%).
Because of a potential for spectrum bias, it would be expected that studies recruiting high-risk populations
would have higher sensitivity estimates than population-based studies. However, as discussed in a
systematic review by Palomaki et al.,42 and as with the MSI results reported earlier (see Assessment of test
TABLE 15 Sensitivity and specificity for IHC (overall results)
Study Sensitivity (95% CI) (%) Specificity (95% CI) (%)
Population-based single-gate studies
Barnetson et al., 200654 92.6 (76.6 to 97.9) NE
Limburg et al., 201155 85.7 (42.1 to 99.6) 91.9 (86.3 to 95.7)
Southey et al., 200556 100.0 (81.5 to 100.0) 80.5 (65.1 to 91.2)
Single-gate studies recruiting high-risk samples
Caldes et al., 200457 96.4 (81.7 to 99.9) –
Overbeek et al., 200759 87.5 (52.9 to 97.7) –
Shia et al., 200560 80.8 (60.6 to 93.4) –
Reference standard-positive study sample
Hendriks et al., 200361 91.7 (77.5 to 98.2) –
NE, not estimable.
ASSESSMENT OF TEST ACCURACY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
accuracy: microsatellite instability testing), we did not find great differences between the sensitivity
estimates in the population-based studies and the sensitivity estimates in the high-risk studies. However,
this could be because the three population-based studies with overall IHC data54–56 were based on
age-limited populations and may also be subject to spectrum bias.
Other test accuracy estimates The other test accuracy outcomes included in this review were LRs
(LR+ and LR–), PPV and NPV, accuracy or concordance with the reference standard, diagnostic yield and
test failure rates. As previously mentioned, the last three outcomes (accuracy or concordance with the
reference standard, diagnostic yield and test failure rates) were not reported in any of the included studies.
The other four outcomes (LR+, LR–, PPV and NPV) were calculated for the two population-based studies
with sufficient overall IHC data available.55,56 These outcomes are reported in Table 16. Unclassified variants
were considered to be reference standard negatives. Again, the study by Barnetson et al.54 is not included
in this table because overall IHC results were available only for reference standard-positive participants.
The LR+ was 10.6 (95% CI 5.7 to 19.7) for Limburg et al.55 and 5.1 (95% CI 2.8 to 9.5) for Southey et al.56
The LR– could be estimated only for Limburg et al.55 (0.16, 95% CI 0.02 to 0.95) because there were no
false-negative overall IHC results in the study by Southey et al.56 The PPV was lower in the study by
Limburg et al.55 (33.3%, 95% CI 13.3 to 59.0) than in the study by Southey et al.56 (69.2%, 95% CI 48.2
to 85.7). The NPV was high in both studies, with both estimates being > 99%. Again, when apparent
differences in IHC performance exist between these two studies (e.g. in the PPV results) it should be
considered that Southey et al.56 included an assessment of PMS2 in their results whereas Limburg et al.55
did not. Additionally, the specific techniques and methods used to perform the reference standard
differed between the studies (see Table 8) and this may also have had an impact on the apparent
test performance.
Secondary analyses (unclassified variants as reference test positives) Secondary analyses were
conducted in which unclassified variants were considered to be reference test positives. It was not possible
to include all studies reporting IHC data in these analyses (because sufficient data were not reported);
indeed, only two studies57,61 provided sufficient data to conduct secondary analyses. However, because the
study by Caldes et al.57 was based on a high-risk population and the study by Hendriks et al.61 was a
reference standard-positive study, only sensitivity was estimated.
When unclassified variants were considered to be reference standard positive results, overall IHC sensitivity
was estimated to be 75.0% (95% CI 57.8% to 87.9%) in the study by Caldes et al.57 and 88.6% (95% CI
76.0% to 95.0%) in the study by Hendriks et al.61 For Caldes et al.57 this represents quite a reduction in
sensitivity compared with when unclassified variants were considered to be index test negative results
(96.4%, 95% CI 81.7% to 99.9%), whereas for Hendriks et al.61 sensitivity was only slightly reduced by
categorising unclassified variants as reference standard positives rather than reference standard negatives
(see Table 15).
TABLE 16 Likelihood ratios and predictive values for IHC (overall results)
Study LR+ (95% CI) LR– (95% CI) PPV (95% CI) (%) NPV (95% CI) (%)
Population-based single-gate studies
Limburg et al., 201155 10.6 (5.7 to 19.7) 0.16 (0.02 to 0.95) 33.3 (13.3 to 59.0) 99.3 (96.0 to 100.0)
Southey et al., 200556 5.1 (2.8 to 9.5) 0.00 (NE) 69.2 (48.2 to 85.7) 100.0 (89.4 to 100.0)
NE, not estimable.
DOI: 10.3310/hta21510 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 51
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Immunohistochemical analysis of individual proteins
The analyses described in the previous section (in which overall IHC results are considered) are limited in
what they can demonstrate about the loss of expression of individual proteins and how this relates to
pathogenic mutations. Indeed, Overbeek et al.59 note that tumour cells of MLH1 mutation carriers
generally lacked MLH1 and PMS2 according to IHC staining, those of MSH2 mutation carriers lacked
MSH2 and MSH6, those of MSH6 mutation carriers lacked MSH6 and those of PMS2 mutation carriers
lacked PMS2. Furthermore, Barnetson et al.54 suggest that ‘the absence of MSH6 protein predicted
mutations in MSH2 or MSH6 . . ., as did the absence of MSH2 for mutations in MSH2 or MSH6 . . .,
reflecting the biologic interaction between these proteins’ (p. 2756).
Indeed, the significance of the patterns of IHC abnormality in predicting underlying genetic causes of CRC
predisposition appears to be becoming clearer, if more complex (see Table 4); it is becoming apparent that
not all mutations are associated with loss or abnormality of the corresponding protein and that a specific
IHC abnormality cannot be assumed to be an absolute indicator of the underlying genetic defect.37
However, it was beyond the scope of this review to use data from the included studies to attempt an
assessment of which IHC results were more or less likely to predict the presence of particular pathogenic
mutations (or whether particular patterns or combinations of IHC abnormality correspond to particular
defects). In any case, there were insufficient individual patient data available from the population-based
samples to attempt such an analysis.
However, for the population-based sample in the study by Poynter et al.34 and the samples in the studies
by Barnetson et al.,54 Southey et al.,56 Hendriks et al.61 and Okkels et al.,62 sufficient data were available to
enable an assessment of IHC for at least one individual protein, in terms of whether loss of expression of
that protein was an accurate test for a pathogenic mutation in the corresponding gene (regardless of
whether there was also loss of expression of additional proteins). Three of these studies54,56,61 provided
sufficient data to assess whether loss of protein expression of MLH1, MSH2 or MSH6 was an accurate test
of a pathogenic mutation in the same gene. Southey et al.56 additionally provided data to enable an
assessment of whether loss of protein expression of PMS2 was an accurate test of a pathogenic mutation
in PMS2. The study by Okkels et al.62 was designed to assess whether lack of protein expression of MSH6
would predict a pathogenic mutation in MSH6. For the population-based sample in Poynter et al.,34 limited
IHC data were available for individual proteins. However, sufficient data were available to assess the
specificity of the loss of protein expression of MLH1. Sensitivity was not calculated for this study because
these data were available only for reference standard negatives. The estimates of sensitivity and specificity
generated from these studies (for IHC analysis of individual proteins) are provided in Table 17.
Of the four studies that provided data relevant to whether loss of expression of MLH1 was an accurate test
result for assessing a pathogenic mutation in MLH1, three were population-based single-gate studies34,54,56
and one was a reference standard-positive study.61 The studies by Barnetson et al.,54 Southey et al.56 and
Hendriks et al.61 all provided data from which sensitivities were generated. These ranged from 50.0%
(95% CI 26.0% to 74.0%) for Southey et al.56 to 100.0% (95% CI 73.5% to 100.0%) for Barnetson et al.54
The three population-based studies34,54,56 provided data from which specificities were generated. These
ranged from 70.6% (95% CI 66.8% to 74.2%) for Poynter et al.34 to 96.0% (95% CI 93.1% to 97.9%) for
Barnetson et al.54 The results for MSH2 were even more variable. Three studies provided data relevant to
whether or not loss of expression of MSH2 was an accurate test result for assessing a pathogenic mutation
in MSH2. Two of these were single-gate population-based studies54,56 and one was a reference standard-
positive study.61 Sensitivities ranged from 22.2% (95% CI 6.4% to 47.6%) for Southey et al.56 to 81.8%
(95% CI 48.2% to 97.7%) for Barnetson et al.54 and Hendriks et al.61 The two population-based studies54,56
provided data from which specificities were generated. These were fairly consistent across the studies, with
both specificity estimates being > 92% (see Table 17).
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Four studies provided data relevant to whether loss of expression of MSH6 was an accurate test result for
assessing a pathogenic mutation in MSH6. Two of these were single-gate population-based studies54,56
and two were reference standard-positive studies.61,62 Again, there was more variation in the sensitivities
generated than in the specificities generated: sensitivities ranged from 44.4% (95% CI 21.5% to 69.2%)
for Southey et al.56 to 75.0% (95% CI 19.4% to 99.4%) for both Barnetson et al.54 and Hendriks et al.,61
whereas specificities, which were generated only for the population-based studies,54,56 were similar across
studies, with both studies producing an estimate of > 92% (see Table 17). Only one study56 provided data
to enable an assessment of whether loss of expression of PMS2 was an accurate test result for assessing a
pathogenic mutation in PMS2, producing a sensitivity estimate of 55.6% (95% CI 30.8% to 78.5%) and
a specificity estimate of 87.8 (95% CI 73.8% to 95.9%) (see Table 17).
With the exception of the sensitivity estimates generated from the study by Southey et al.,56 it appears that
the data presented in Table 17 are fairly consistent across studies. The different estimates generated from
the study by Southey et al.56 appear to be the result of higher rates of false-negative results than in the other
studies. It is possible that this is because of specific between-study differences in the assessment of IHC results
(a positive IHC result is a somewhat subjective judgement, made by human assessors, and so inter-rater
variability may have an impact on the results). Again, it is also possible that between-study differences in the
reference standard could, to some extent, account for these differences in sensitivity estimates.
This is further demonstrated in Figure 5, in which sensitivities and specificities from the studies by Barnetson
et al.54 and Southey et al.56 are graphically summarised using a SROC curve. This visually elucidates the
trade-off between sensitivity and specificity across the two studies for each of the individual proteins
assessed (MLH1, MSH2 and MSH6, as well as PMS2 for Southey et al.56). In this figure, unclassified variants























FIGURE 5 Summary receiver operating characteristic curve graph for IHC testing in which unclassified variants are
assumed to be negative reference standard results. B, Barnetson et al.;54 S, Southey et al.56
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Other test accuracy estimates The other test accuracy outcomes included in this review were LRs
(LR+ and LR–), PPV and NPV, accuracy or concordance with the reference standard, diagnostic yield and
test failure rates. As previously mentioned, the last three outcomes (accuracy or concordance with the
reference standard, diagnostic yield and test failure rates) were not reported in any of the included studies.
The other four outcomes (LR+, LR–, PPV and NPV) were calculated for the two population-based studies
with sufficient IHC data by protein available.54,56
The LR+ and LR– estimates are reported in Table 18. Unclassified variants were considered to be reference
standard negative results. For loss of protein expression of MLH1, the LR+ was 25.0 (95% CI 14.4 to 43.5)
for Barnetson et al.54 and 5.1 (95% CI 1.8 to 14.5) for Southey et al.56 For loss of protein expression of
MSH2, the LR+ was 21.6 (95% CI 11.6 to 40.2) for Barnetson et al.54 and 3.0 (95% CI 0.8 to 12.2) for
Southey et al.56 For loss of protein expression in MSH6, the LR+ was 16.2 (95% CI 7.6 to 34.3) for
Barnetson et al.54 and 6.1 (95% CI 1.8 to 20.3) for Southey et al.56 For loss of protein expression in PMS2,
data were available only for Southey et al.,56 with a LR+ of 4.6 (95% CI 1.8 to 11.4). There are several
possible reasons why the LR+ estimates were higher for Barnetson et al.54 than for Southey et al.,56
including the fact that the study by Barnetson et al.54 was a larger study than that by Southey et al.,56 that
the reference standard was not identical in these studies and that there is a possibility that IHC ratings may
have differed across studies (inter-rater reliability).
For loss of protein expression of MLH1, the LR– was estimated for only one study56 (0.6, 95% CI 0.4 to 0.9)
because there were no false-negative results in the study by Barnetson et al.54 For loss of protein expression
of MSH2, the LR– was 0.2 (95% CI 0.1 to 0.7) for Barnetson et al.54 and 0.8 (95% CI 0.7 to 1.1) for Southey
et al.56 For loss of protein expression of MSH6, the LR– was 0.3 (95% CI 0.1 to 1.4) for Barnetson et al.54 and
0.6 (95% CI 0.4 to 0.9) for Southey et al.56 For loss of protein expression of PMS2, data were available only
from Southey et al.,56 with the LR– estimated as 0.5 (95% CI 0.3 to 0.9).
The PPV and NPV estimates are reported in Table 19. Again, unclassified variants were considered to be
reference standard negative results. For loss of protein expression of MLH1 and MSH2, the PPV and NPV
results were largely consistent across the two studies providing data,54,56 although the PPV estimates were
lower in the study by Barnetson et al.54 and the NPV estimates were lower in the study by Southey et al.56
For loss of expression of MSH6, the NPV estimates were consistent across the two studies but the PPV
estimates were vastly different, with the data from Barnetson et al.54 resulting in a PPV of 16.7% (95% CI
3.6% to 41.4%) and the data from Southey et al.56 resulting in a PPV of 72.7% (95% CI 39.0% to 94.0%).
Although the reason for this difference is not completely clear, it is likely, in part, to be because of the very
low number of true positive (TP) results (n = 3) for loss of expression of MSH6 in the study by Barnetson et al.54
Again, only Southey et al.56 provided data for loss of protein expression of PMS2, with the PPV estimated as
66.7% (95% CI 38.4% to 88.2%) and the NPV estimated as 81.8% (95% CI 67.3% to 91.8%).
Secondary analyses (unclassified variants as reference test positives) Secondary analyses were
conducted in which unclassified variants were considered to be positive reference standard test results.
It was not possible to include all five studies34,54,56,61,62 reporting IHC data for individual proteins in these
analyses because sufficient data were not always reported. Indeed, only one study61 provided sufficient
data to conduct secondary analyses and, because this study was a reference standard-positive study, only
sensitivity estimates were made. These sensitivity estimates were very similar to those estimated from data
in which unclassified variants were considered to be reference standard negatives.
Indeed, when unclassified variants were considered to be reference standard positives, loss of protein
expression of MLH1 was estimated to have a sensitivity of 80.0% (95% CI 60.8% to 91.1%) compared
with the previously reported sensitivity of 81.0% (95% CI 58.1% to 94.6%) when unclassified variants
were considered to be reference test negatives. Loss of protein expression of MSH2 was estimated to have
a sensitivity of 83.3% (95% CI 55.1% to 95.3%) compared with the previously reported sensitivity of
81.8% (95% CI 48.2% to 97.7%) when unclassified variants were considered to be reference test
negatives. Loss of protein expression in MSH6 was estimated to have a sensitivity of 80.0% (95% CI
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37.6% to 96.4%) compared with the previously reported sensitivity of 75.0% (95% CI 19.4% to 99.4%)
when unclassified variants were considered to be reference test negatives (see Table 17).
Summary of results from the test accuracy review
Summary of included studies
Ten studies met the test accuracy review inclusion criteria. One of the included studies included two
distinct samples (a population-based sample and a high-risk sample) and these two samples were treated
separately. Thus, although 10 studies were included, 11 populations/data sets were included. The results
from all 11 populations were considered.
The 11 study samples were divided as follows: four single-gate studies with population-based samples,
including one apparently unselected CRC population34 and three age-limited populations;54–56 five single-
gate studies based on high-risk populations;34,57–60 and two studies that used a variation on a two-gate
study design61,62 in which participants with positive reference standard results were recruited but no
reference standard negatives were recruited. For this report, and for clarity, these studies are termed
‘reference standard-positive studies’.
With the exception of the studies by Limburg et al.55 and Okkels et al.,62 all studies assessed MSI. Although
IHC was conducted in all 10 studies (11 samples) included in the review, not all studies provided sufficient
data to be included in the analyses. Indeed, for the high-risk sample in the study by Poynter et al.34 and
the sample in the study by Mueller et al.,58 despite IHC being conducted, insufficient data were provided
for these samples to be included in any of the IHC analyses. None of the studies made a direct comparison
between MSI and IHC. As such, the results are reported separately for these tests.
There was significant methodological and clinical heterogeneity across studies. In particular, the reference
standard differed between studies, as did the index tests. With regard to the reference standard there
were differences in the testing methods used (including the sequencing methods used and genes tested,
the techniques used to test for large genomic alterations and deletions, the genes tested for large genomic
alterations and deletions and whether unclassified variants were investigated). As a result of this, pooling
of data in statistical analyses was not appropriate. In addition, there were insufficient data to conduct
subgroup analyses based on most of these variables. However, test performance statistics were primarily
generated with unclassified variants categorised as negative reference standard results and two studies57,61
provided sufficient data to conduct secondary analyses in which unclassified variants were categorised as
positive reference standard results.
Quality appraisal of all 11 data sets was conducted using phase 3 of the QUADAS-2 tool. Four of the
studies were rated as having a low risk of bias for patient selection, with three of these being population-
based single-gate studies54–56 and one being a reference standard-positive study62 for which only sensitivity
estimates could be made. For all studies included in the review there were no concerns about whether or
not the included participants matched the review question. For both index tests, all studies were rated as
having an unclear risk of bias with regard to whether the conduct and interpretation of the test could have
introduced bias, but there were no concerns (in any of the studies) that the conduct or interpretation of
either of the index tests was different from the review question. All of the included studies apart from that
by Hendriks et al.61 were rated as unclear with regard to whether or not the conduct or interpretation of
the reference standard could have introduced bias. This was because only the study by Hendriks et al.61
specified that the reference standard results were interpreted without knowledge of the results of the
index test, with the rest of the studies not reporting this information. However, in all of the included
studies the reference standard was assessed as being likely to correctly classify the target condition
(because a genetic definition of LS was used in this review) and there were no concerns in any of the
studies that the target condition, as defined by the reference standard, did not match the review question.
For all included studies it was unclear whether the flow of participants through the study could have
introduced bias.
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The index tests included in this review (MSI and IHC) are highly susceptible to spectrum effects in
populations that have been selected on the basis of clinical characteristics. In particular, an increased
presence of MMR mutation carriers in a population would change the apparent sensitivity and specificity
of the index tests.54 However, a previous review did not find that this issue led to significant bias in
estimates of sensitivity.42 Because of this, studies recruiting high-risk populations were used only to
estimate sensitivity. For the four samples included in this review that can be described as population-based
samples,34,54–56 sensitivity, specificity, LR+, LR–, PPV and NPV were all estimated. However, it should be
noted that three of these studies recruited age-limited populations,54–56 for which some spectrum bias may
be expected.
Summary of the results for microsatellite instability
There were a variety of between-study differences in the MSI testing procedures used. In addition,
potential differences between studies in MSI testing methods were not always clear because the methods
used were not always reported in sufficient detail. For example, three34,58,59 of the eight studies assessing
MSI did not report microdissection techniques (microdissection assists in ensuring that malignant tissue
that does not contain DNA from surrounding healthy colonic tissue is analysed). The other differences
between studies with regard to MSI testing methods can be categorised as differences in the panel of
markers used, differences in the way in which MSI was categorised (e.g. as a bimodal or a trimodal
distribution) and differences in the thresholds used to categorise MSI. Indeed, none of the population-
based studies assessed the same panel of markers (differences exist in both the type and the number of
markers assessed). Five studies34,54,56,58,61 defined tumours as MSI-H, MSI-L or MSS, also known as a
trimodal distribution, two59,60 defined tumours as MSI positive or MSI negative, also known as a bimodal
distribution, and one57 used a bimodal distribution but defined tumours as either MSI-H or MSS. Of the
five studies that used the MSI-H, MSI-L and MSS categories (trimodal distribution), the thresholds used to
categorise the tumours varied greatly, with one study34 using the commonly used threshold of ≥ 30% of
unstable markers to define MSI-H tumours, three studies54,56,61 using differing numbers of unstable markers
to define MSI-H tumours and one study58 not providing details on the thresholds used to categorise the
tumours as MSI-H, MSI-L or MSS. Of the two studies that defined tumours as MSI positive or MSI negative
(bimodal distribution), one reported using a threshold of ≥ 30% of unstable markers to define MSI-positive
tumours60 and the other defined MSI-positive tumours as those with more than two unstable Bethesda
panel markers.59 The study by Caldes et al.57 defined MSI-H tumours as those with two or more unstable
Bethesda panel markers (or one marker in the case of BAT26) and MSS tumours as those showing no
instability. It is not clear how cases with only one unstable marker (other than BAT26) were categorised,
but in any case data were presented only for tumours that were categorised as MSS and MSI-H.
In primary analyses unclassified variants were categorised as negative reference standard results. Six study
samples (including both samples in the study by Poynter et al.34) provided data in which MSI-L was
considered to be a negative index test result.34,54,56,58,61 The other three samples utilised a bimodal
distribution of MSI.57,59,60 Across all nine samples, when MSI-L was considered to be a negative index test
result, sensitivity ranged from 66.7% (95% CI 47.2% to 82.7%) in the population-based sample reported
by Barnetson et al.54 to 100.0% (95% CI 93.9% to 100.0%) in the population-based sample reported in
Poynter et al.34 and 100% (95% CI 85.8% to 100.0%) in the high-risk sample reported in Shia et al.60
Sensitivity increased when MSI-L was considered to be a positive index test result (for the six study samples
in which a trimodal distribution of MSI was used, with data remaining unchanged for the three samples in
which a bimodal distribution of MSI was used). Indeed, across the nine study samples, the lower end of
the range for sensitivity increased to 79.4% (95% CI 62.1% to 91.3%) in the high-risk sample recruited by
Caldes et al.,57 with the upper end of the range still being 100%.
In primary analyses (in which unclassified variants were categorised as negative reference standard results)
three population-based study samples provided data in which MSI-L was considered to be a negative index
test result.34,54,56 Across these three samples, when MSI-L was considered to be a negative index test result,
ASSESSMENT OF TEST ACCURACY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
specificity ranged from 61.1% (95% CI 57.0% to 65.1%) in the study by Poynter et al.34 to 92.5% (95% CI
89.1% to 95.2%) in the study by Barnetson et al.54 It should be noted that the study by Barnetson et al.54
included an age-limited sample whereas the study by Poynter et al.34 included an unselected CRC population.
Specificity decreased when MSI-L was considered to be a positive index test result. Indeed, the lower end of
the range decreased to 29.5% (95% CI 25.8% to 33.4%) in the study by Poynter et al.34 and the upper end
of the range decreased to 84.5% (95% CI 80.0% to 88.2%) in the study by Barnetson et al.54
It is unsurprising that, on the whole, sensitivity was higher and specificity was lower when MSI-L was
considered to be a positive result than when MSI-L was considered to be a negative result; including MSI-L
as a positive result essentially lowers the threshold for a positive index test result.
For the three studies that recruited population-based samples,34,54,56 LR+, LR–, PPV and NPV were also
calculated. The LR+ was reduced when MSI-L was considered to be a positive index test result (1.42,
95% CI 1.35 to 1.50 for Poynter et al.;3 6.01, 95% CI 4.58 to 7.89 for Barnetson et al.;54 2.28, 95% CI
1.56 to 3.33 for Southey et al.56) compared with when MSI-L was considered to be a negative index test
result (2.57, 95% CI 2.32 to 2.85 for Poynter et al.;34 8.94, 95% CI 5.54 to 14.20 for Barnetson et al.;54
5.92, 95% CI 2.48 to 14.10 for Southey et al.56) The LR– could be estimated for only two of the studies54,56
because there were no false-negative MSI results in the study by Poynter et al.34 The LR– was similar in both
studies and was lower when MSI-L was considered to be a positive index test result (0.08, 95% CI 0.02 to
0.30 for Barnetson et al.;54 0.09, 95% CI 0.01 to 0.65 for Southey et al.56) than when it was considered to
be a negative index test result (0.36, 95% CI 0.21 to 0.60 for Barnetson et al.;54 0.32, 95% CI 0.15 to 0.67
for Southey et al.56). PPV estimates varied a lot more between the studies but were lower when MSI-L was
considered to be a positive index test result than when it was considered to be a negative index test result.
Conversely, NPV estimates were consistent across the three studies and were higher when MSI-L was
considered to be a positive index test result than when it was considered to be a negative index test result.
However, it should be noted that, for the unselected CRC population in the study by Poynter et al.,34 the
NPV estimate was 100% regardless of whether MSI-L was considered to be a positive or a negative index
test result, although the CIs were slightly wider when MSI-L was considered to a positive result (95% CI
97.9% to 100.0%) than when it was considered to be a negative result (95% CI 99.0% to 100.0%).
Secondary analyses were conducted when data permitted in which unclassified variants were considered to
be positive reference standard results. When MSI-L was considered to be a negative index test result, two
studies57,61 provided sufficient data to conduct secondary analyses of the sensitivity estimates. Caldes et al.57
reported a sensitivity of 81.6% (95% CI 65.7% to 92.3%) and Hendriks et al.61 reported a sensitivity of
84.8% (95% CI 69.0% to 93.3%). These results were similar to those obtained when unclassified variants
were considered to be negative reference standard results (79.4%, 95% CI 62.1% to 91.3% for Caldes
et al.;57 88.8%, 95% CI 68.8% to 97.5% for Hendriks et al.61). When MSI-L was considered to be a positive
index test result, only one study61 provided sufficient data to conduct a secondary analysis of the sensitivity
estimate. In this study, sensitivity was 93.9% (95% CI 80.3% to 98.3%), which was similar to the estimate
when unclassified variants were considered to be negative reference standard results (92.0%, 95% CI 74.0%
to 99.0%).
Summary of the results for immunohistochemistry
In primary analyses unclassified variants were categorised as negative reference standard results. Seven
studies54–57,59–61 provided data to assess the accuracy of an overall IHC result at identifying a positive
reference standard result (i.e. whether a positive IHC result, regardless of which protein this applies to,
identifies a positive reference standard result). For the population-based sample in the study by Poynter et al.34
and the samples in the studies by Barnetson et al.54; Southey et al.,56 Hendriks et al.61 and Okkels et al.,62 IHC
results were reported according to the particular protein assessed (MLH1, MSH2, MSH6 or PMS2), enabling
an assessment of IHC for at least one of these individual proteins (i.e. whether an absence of a particular
protein accurately identifies a mutation in that particular gene).
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All of the seven studies54–57,59–61 assessing the overall test performance of IHC assessed MLH1, MSH2 and
MSH6. Therefore, abnormal staining for any of these three proteins was considered to be a positive index
test result. However, Southey et al.56 and Overbeek et al.59 also assessed PMS2. Therefore, for these two
studies an abnormal PMS2 result was also included as a positive index test result. Three of these studies
were population-based studies,54–56 three were single-gate high-risk studies57,59,60 and one was a reference
standard-positive study (in which only reference standard positives were recruited). Sensitivity estimates
ranged from 80.8% (95% CI 60.6% to 93.4%) in the study by Shia et al.60 to 100.0% (95% CI 81.5% to
100.0%) in the study by Southey et al.56 The study by Southey et al.56 included an assessment of PMS2 as
well as assessments of MLH1, MSH2 and MSH6 and it is possible that this accounted for the higher
sensitivity estimate in this study. Nevertheless, all sensitivity estimates were > 80%. Because of the
potential for spectrum bias, it would be expected that studies recruiting high-risk populations would have
higher sensitivity estimates than those recruiting population-based samples. However, as discussed in a
systematic review by Palomaki et al.,42 and as with the MSI results reported earlier, we did not find great
differences between the sensitivity estimates in the population-based studies and those in the high-risk
studies. This could be because the three population-based studies with overall IHC data54–56 were based on
age-limited populations and may also be subject to spectrum bias.
For two of the population-based studies55,56 specificity, LR+, LR–, PPV and NPV were also estimated for the
overall IHC results. These analyses were not conducted for the third population-based study54 because
overall IHC results were available only for reference standard-positive participants. Specificity was estimated
as 91.9% (95% CI 86.3% to 95.7%) for Limburg et al.55 and 80.5% (95% CI 65.1% to 91.2%) for
Southey et al.56 LR+ was estimated as 10.6 (95% CI 5.7 to 19.7) for Limburg et al.55 and 5.1 (95% CI
2.8 to 9.5) for Southey et al.56 LR– could be estimated for only one study55 (0.16, 95% CI 0.02 to 0.95)
because there were no false-negative overall IHC results in the study by Southey et al.56 PPV was lower in
the study by Limburg et al.55 (33.3%, 95% CI 13.3% to 59.0%) than in the study by Southey et al.56
(69.2%, 95% CI 48.2% to 85.7%). NPV was high in both studies, with both estimates being > 99%.
Again, when apparent differences in IHC performance exist between these two studies (e.g. in the PPV
results), it should be considered that Southey et al.56 included an assessment of PMS2 in their results
whereas Limburg et al.55 did not. Additionally, the specific techniques and methods used to perform the
reference standard differed between studies and this may also impact on the apparent test performance.
Secondary overall IHC analyses were conducted in which unclassified variants were considered to be
positive reference standard results. Only two studies57,61 provided sufficient data to conduct these
secondary analyses and, because the study by Caldes et al.57 included a high-risk population and that by
Hendriks et al.61 was a reference standard-positive study, only sensitivity was estimated (75.0%, 95% CI
57.8% to 87.9% for Caldes et al.;57 88.6%, 95% CI 76.0% to 95.0% for Hendriks et al.61). For Caldes
et al.57 this represented quite a reduction in sensitivity compared with when unclassified variants were
considered to be reference test negatives (96.4%, 95% CI 81.7% to 99.9%).
For the population-based sample in the study by Poynter et al.34 and the samples in the studies by
Barnetson et al.,54 Southey et al.,56 Hendriks et al.61 and Okkels et al.,62 an assessment was made of IHC for
at least one individual protein. Four studies provided data relevant to whether loss of expression of MLH1
was an accurate test result for assessing a pathogenic mutation in MLH1, of which three were population-
based single-gate studies34,54,56 and one was a reference standard-positive study.61 The studies by Barnetson
et al.,54 Southey et al.56 and Hendriks et al.61 all provided data from which sensitivities were generated;
these ranged from 50.0% (95% CI 26.0% to 74.0%) for Southey et al.56 to 100.0% (95% CI 73.5% to
100.0%) for Barnetson et al.54 The three population-based studies34,54,56 provided data from which
specificities were generated; these ranged from 70.6% (95% CI 66.8% to 74.2%) for Poynter et al.34 to
96.0% (95% CI 93.1% to 97.9%) for Barnetson et al.54 The results for MSH2 were even more variable.
Three studies provided data for MSH2,54,56,61 with sensitivities ranging from 22.2% (95% CI 6.4% to
47.6%) for Southey et al.56 to 81.8% (95% CI 48.2% to 97.7%) for both Barnetson et al.54 and Hendriks
et al.61 The two population-based studies54,56 provided data from which specificities were generated, with
both being > 92%. Four studies provided data for MSH6 and, again, there was more variation in the
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sensitivities generated than in the specificities generated: sensitivities ranged from 44.4% (95% CI 21.5%
to 69.2%) for Southey et al.56 to 75.0% (95% CI 19.4% to 99.4%) for both Barnetson et al.54 and Hendriks
et al.,61 whereas specificities, which were generated only for the population-based studies,54,56 were > 92%
in both studies. It was clear that, for loss of expression of MLH1, MSH2 and MSH6, the sensitivity estimates
generated from the study by Southey et al.56 were lower than those in the other studies. It is possible that
this is because of specific between-study differences in the assessment of IHC (a positive IHC result is a
somewhat subjective judgement, made by human assessors, and so inter-rater variability may impact on the
results). Again, it is also possible that between-study differences in the reference standard could, to some
extent, account for these differences in sensitivity. Only the study by Southey et al.56 provided IHC data for
PMS2, with a sensitivity estimate of 55.6% (95% CI 30.8% to 78.5%) and a specificity estimate of 87.8%
(95% CI 73.8% to 95.9%).
The LR+, LR–, PPV and NPV were calculated for the two population-based studies with sufficient IHC data
available by protein.54,56 For MLH1, MSH2 and MSH6, LR+ was greater in the study by Barnetson et al.54
than in the study by Southey et al.56 (MLH1: 25.0, 95% CI 14.4 to 43.5 for Barnetson et al.54 and 5.1,
95% CI 1.8 to 14.5 for Southey et al.;56 MSH2: 21.6, 95% CI 11.6 to 40.2 for Barnetson et al.54 and
3.0, 95% CI 0.8 to 12.2 for Southey et al.;56 MSH6: 16.2, 95% CI 7.6 to 34.3 for Barnetson et al.54 and
6.1, 95% CI 1.8 to 20.3 for Southey et al.56) For PMS2, data were available only from Southey et al.,56 with
the LR+ estimated as 4.6 (95% CI 1.8 to 11.4). There are several possible reasons why the LR+ estimates
were higher in the study by Barnetson et al.54 than in the study by Southey et al.,56 including that the study
by Barnetson et al.54 was a larger study than that by Southey et al.,56 that the reference standard was not
identical in these studies and that there is a possibility that IHC ratings may have differed across studies
(inter-rater reliability). For MLH1, the LR– was estimated for only one study56 (0.6, 95% CI 0.4 to 0.9)
because there were no false-negative results in the study by Barnetson et al.54 For MSH2, the LR– was 0.2
(95% CI 0.1 to 0.7) for Barnetson et al.54 and 0.8 (95% CI 0.7 to 1.1) for Southey et al.56 and, for MSH6,
the LR– was 0.3 (95% CI 0.1 to 1.4) for Barnetson et al.54 and 0.6 (95% CI 0.4 to 0.9) for Southey et al.56
For loss of protein expression of PMS2, data were available only from Southey et al.,56 with the LR–
estimated as 0.5 (95% CI 0.3 to 0.9). PPV and NPV estimates for MLH1 and MSH2 were largely consistent
across the two studies.54,56 For MSH6, NPV estimates were consistent across the two studies but PPV
estimates were vastly different, with data from Barnetson et al.54 resulting in a PPV of 16.7% (95% CI
3.6% to 41.4%) and data from Southey et al.56 resulting in a PPV of 72.7% (95% CI 39.0% to 94.0%).
Although the reason for this difference is not completely clear, in part it is likely to be because of the very
low number of true-positive results (n = 3) for loss of expression of MSH6 in the study by Barnetson et al.54
Again, only Southey et al.56 provided data for PMS2, with the PPV estimated as 66.7% (95% CI 38.4% to
88.2%) and the NPV estimated as 81.8% (95% CI 67.3% to 91.8%).
Secondary IHC analyses for individual proteins were conducted in which unclassified variants were
considered to be reference standard negatives. However, only one study61 provided sufficient data to
conduct secondary analyses and, because this study was a reference standard-positive study, only
sensitivity was estimated. These sensitivity estimates were very similar to those estimated from data in
which unclassified variants were considered to be reference standard negatives.
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Chapter 3 Assessment of end-to-end studies
End-to-end studies have an important place in the health technology assessments of tests. They arebroadly defined in the methods guidance as ‘studies that follow patients from testing, through
treatment, to final outcomes’ (p. 70).70 Such studies can have a wide variety of designs but, when available,
randomised controlled trials (RCTs) are noted to be of great importance because they provide comparative
evidence with high internal validity. If end-to-end studies are found it may avoid the need for modelling as
the end-to-end studies provide a direct linkage between a testing strategy and patient outcomes, which
otherwise could be achieved only by linkage in an economic model. For these reasons we specifically
performed a systematic review of end-to-end studies, with a particular focus on RCTs and controlled clinical
trials (CCTs), recognising a priori that such studies were unlikely to exist for an intervention as complex as
screening for LS.
Methods for reviewing effectiveness
Identification of studies
The same search was performed as for the review of diagnostic accuracy studies (see Chapter 2). This was
appropriate as there were no restrictions by study design. In the protocol71 we did not rule out the use of a
methods filter to focus the search on intervention studies; however, this was not used to maximise the
sensitivity of the searches.
Inclusion and exclusion criteria
The full inclusion criteria are provided in Table 20. Concerning study design we agreed to consider other
study designs if no RCTs or CCTs were identified.
Screening was performed by one primary screener (CH), with a 10% random sample checked by a second
reviewer (TS). In the screen, any study that appeared to investigate the impact of introducing the tests of
interest on the outcomes of interest was retrieved in full, irrespective of the apparent study design or
whether it appeared to be reported in abstract form only. In total, 3920 records were screened for
eligibility by title and abstract.
Twenty-two articles were retrieved in full text (details can be obtained from the authors on request). These
reported 20 studies as two articles were duplicate publications (both abstracts that were subsequently
published in full). The final inclusion/exclusion decisions and abstraction of brief details about all articles
retrieved in hard text was performed by a single reviewer (CH).
Further aspects of the methods including the data abstraction strategy, critical appraisal strategy and
methods of data synthesis are not reported as none of the studies reviewed in full text were included in
the review.
Results
Quantity and quality of research available
Eleven studies were excluded through failure to meet the first inclusion criterion applied, introduction of
the index tests of interest. The remaining nine studies were all reported in abstract form and so were
excluded because they provided insufficient information to confirm the detailed nature of the testing
introduced or to perform a proper quality assessment.
Even if the criterion about publication in full had been relaxed, only three studies could have been
considered for inclusion because six of the abstracts appeared to report no comparator. The three abstracts
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that did report a comparator were all pre–post studies measuring changes surrounding the introduction of
testing for LS. None provided any contact details and so it was not possible to easily enquire whether
further information or a full publication of the results was available.
Two RCTs were identified among the full-text articles reviewed. The first was a protocol from a RCT
comparing whole exome sequencing with ‘current practice’ in screening for LS.72 The second was a cluster
RCT investigating the effect of quality improvement initiatives.73 The effect of quality improvement was
further examined in a time-series analysis.74 Only one study assessed patient survival.75 This examined
whether conclusive follow-up testing, or not, following initial screen-positive IHC testing in CRC cases in a
specific institution was associated with better outcome. Thus, it did not directly examine the effect of the
introduction of screening for LS. In addition, this study was presented only in abstract form and limited
contact details were provided.
Assessment of effectiveness
Critical review and synthesis of information
We were not able to draw any conclusions on the effectiveness of screening for LS from the systematic
review of end-to-end studies.
TABLE 20 Inclusion and exclusion criteria for the review of end-to-end studies
Criteria Include Exclude
Participants Studies of unselected or randomly selected CRC
patients or CRC patients selected according to an age
limit
Studies using retained samples as storage
methods may adversely affect test accuracy
Index tests Molecular MSI testing (with or without BRAF V600E
mutation testing and with or without MLH1 promoter
methylation testing), including studies in which BRAF
V600E and/or MLH1 promoter methylation tests were
performed according to MSI test results, followed
by constitutional MMR mutation testing; MMR IHC
(with or without BRAF V600E mutation testing and
with or without MLH1 promoter methylation testing),
followed by the reference standard, followed by
constitutional MMR mutation testing
Studies that do not include either of the index
tests, studies in which mutation testing is limited
to seeking only founder mutations
Comparators Index tests may be compared with each other, no
testing for LS or direct constitutional MMR mutation
testing
Outcomes Number of individuals receiving MSI and/or IHC
testing, number of individuals receiving subsequent
tumour-based tests, number of individuals receiving
constitutional MMR mutation testing, number of
cascade tests on relatives, number of LS diagnoses,
number of colonoscopies, morbidity, mortality and/or
life expectancy, costs associated with interventions
and comparators, health-related quality of life
Study design RCTs, CCTs Non-experimental, preclinical and animal studies,
studies published only in abstract form,
systematic reviews of RCTs or CCTs
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Discussion
Although the review identified some interesting near-miss excluded studies providing evidence of indirect
relevance to other aspects of the appraisal, no sufficiently relevant end-to-end studies were reported in
enough detail to obviate the need for a linked evidence approach using modelling. The three studies that
were closest to meeting the inclusion criteria were reported only in abstract form and it may be that if full
details had been available they would still have been excluded. All three employed pre–post designs and
were hence highly susceptible to bias.
The review reinforces the lack of usefulness of studies that are reported only in abstract form, which is
further compounded by the fact that few abstracts provide any means to contact authors for further
information. The review also invites consideration of whether or not some study designs that might
currently be considered as end-to-end studies, such as pre–post studies, may be too open to bias to be
worth including in a systematic review of end-to-end studies, even if they are the only evidence available.
This does not preclude them being used to parameterise a model, providing the openness to bias is
fully acknowledged.
We believe that the methods used in the review, particularly the extremely comprehensive search, which
was not restricted by a study design filter as originally planned, make it unlikely that we have missed major
items of published literature. It is possible that we may have overlooked unpublished literature, as this is
extremely difficult to find in a short timescale. We did, however, fully consider conference abstracts
appearing in the main bibliographic databases that we included in the search, although they did not yield
useful information for the reasons already indicated. Ideally, we could have used double screening and
inclusion/exclusion in duplicate; however, this did not seem to be justified after good agreement was
achieved in the 10% random check of screening decisions. Similarly, although not formally checked we are
confident that the limited number of decisions made on inclusion/exclusion, performed by an experienced
reviewer using a well-developed set of inclusion/exclusion criteria, were accurately performed. We did not
feel that checking this review step was a priority among the other tasks required to complete the health
technology assessment.
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Chapter 4 Assessment of existing
cost-effectiveness evidence
The cost-effectiveness of using MSI and IHC testing in strategies to identify LS was assessed byconducting a systematic review of published research evidence.
Objectives
The objectives of this systematic review were to:
l gain insights into the key drivers of cost-effectiveness in this disease area
l obtain an overview of the alternative modelling approaches that have been adopted in this disease and
treatment area
l provide a summary of the findings of previous relevant cost–utility, cost-effectiveness and cost–benefit
studies generalisable to the UK.
Methods
Study identification
This systematic review was an update of the systematic review of cost-effectiveness reported in Snowsill et al.4
The search strategy included the following sources:
l electronic databases – MEDLINE (via Ovid), MEDLINE In-Process & Other Non-Indexed Citations
(via Ovid), EMBASE (via Ovid), Web of Science (Thomson Reuters), NHS Economic Evaluation Database
(NHS EED) (The Cochrane Library) and EconLit (EBSCOhost)
l the reviews by Snowsill et al.4 and Grosse76
l backward citation chasing on included studies.
The searches were developed and run by an information specialist (SB) in February 2016. Search filters
were used to limit the searches to economic or health utilities studies as appropriate and searches were
limited to English-language studies when possible. A date limit of 2013 was used. The search strategies for
each database are detailed in Appendix 1.
The database search results were exported to, and deduplicated using, EndNote X7. Deduplication was
also performed using manual checking. After the reviewers had completed the screening process, the
bibliographies of included papers were scrutinised for further potentially includable studies.
Titles and abstracts returned by the search strategy were examined independently by two researchers
(NH and TS) and screened for possible inclusion. Disagreements were resolved by discussion. Full texts of
potentially relevant studies were ordered. Full publications were assessed by the same reviewers (NH and TS)
for inclusion or exclusion against prespecified criteria. Again, disagreements were resolved by discussion.
Reviewers also examined the studies included in the systematic reviews by Snowsill et al.4 and Grosse76 for
other relevant studies.
Eligibility criteria
Table 21 shows the inclusion criteria used in the current systematic review of published cost-effectiveness
studies compared with the inclusion criteria used in the previous Peninsula Technology Assessment Group
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(PenTAG) review.4 The inclusion criteria for the current review were narrowed to address the decision
problem, meaning that searches needed to be run only for the time period after the previous
PenTAG review.
In the protocol for this project71 it is stated that IHC should be treated as a comparator only and not an
intervention. We updated the inclusion criteria for this review so that IHC was treated as an intervention.
This means that included studies that contained IHC-based strategies did not need to also contain MSI-
based strategies, as specified when IHC is treated as a comparator. This also ensured consistency between
the clinical effectiveness review and the cost-effectiveness review.
Systematic reviews, if identified, were not directly included but their bibliographies were searched for
potentially includable studies.
Data extraction
Data were extracted by one reviewer (NH) using the blank data extraction forms used in the previous
PenTAG review.4
The completed forms for studies included in the previous PenTAG review were reused.
The evidence base was assessed using narrative synthesis supported by summary data extraction tables,
constructed for the previous PenTAG review.4 When studies did not conduct a fully incremental cost-
effectiveness analysis (e.g. if they performed a cost–consequences analysis), but it was possible to conduct
such an analysis based on the reported results, this was carried out.
Currency conversion was not performed but an indication of purchasing power parity exchange rates was
given and, if currency- or country-specific cost-effectiveness thresholds were supplied by the authors, these
were also reported (in the original currency).
TABLE 21 Cost-effectiveness inclusion criteria
PICOS
criteria Previous PenTAG review4 Current review
Population Those who may or may not have LS All people newly diagnosed with CRC
Intervention Any of the following (including combinations):
strategies to identify LS in the population, strategies
to manage LS in the population, strategies to manage
patients in whom LS is identified
One of MSI testing (with or without BRAF V600E
mutation testing and with or without MLH1
promoter methylation testing) or IHC (with or
without BRAF V600E mutation testing and with
or without MLH1 promoter methylation testing)
Comparator Current clinical practice (may or may not include
efforts to identify LS)
At least one of the included interventions, no
testing or direct constitutional MMR mutation
testing
Outcomes Any of the following: costs, clinically relevant
outcomes (e.g. life-years gained, QALYs, CRCs
prevented), mutations detected
Costs and health effects measured in life-years or
QALYs
Study type Any of the following: decision-analytic models
(with or without a cost-effectiveness component),
evaluations of cost-effectiveness within trials
(including cost-effectiveness, cost–utility and
cost–benefit studies; no requirement for
randomisation), cost or resource use studies,
guidelines from national institutions, professional
bodies and international bodies (including working
groups)
Any of the following: decision-analytic models,
economic evaluations within trials, cost or
resource use studies from the UK
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Critical appraisal
For consistency with the previous PenTAG cost-effectiveness review,4 the quality appraisal was conducted
using selected criteria from the Drummond and Jefferson77 checklist. Quality appraisal was conducted by
one reviewer (NH).
Additionally, a set of review-specific criteria was developed for the previous PenTAG review4 and this was
adapted to reflect the current decision problem.
Results
Figure 6 shows the study flow diagram for this update review. The electronic database search for
cost-effectiveness evidence identified 352 records after deduplication. All were screened by title and
abstract, with 11 identified for full-text screening. All 11 full texts were retrieved and assessed for eligibility.
Of the 11 full texts assessed for eligibility, six4,78–82 were deemed to meet the eligibility criteria for
the review.
Of the 33 additional publications identified in the previous reviews,4,76 four additional publications were
deemed to meet the eligibility criteria for the review and were assessed in full.83–86 The remaining 29 were



















• Population, n = 19
• Intervention, n = 7
• Outcomes, n = 7
• Study design, n = 1





















FIGURE 6 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for
cost-effectiveness papers. a, Snowsill et al.4 and Grosse.76 Source: adapted from Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses:
The PRISMA Statement. PLoS Med 6(7):e1000097.63 https://doi.org/10.1371/journal.pmed1000097
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One UK-based cost study was identified87 but in this study the population was identified using clinical
criteria and it was therefore ineligible for inclusion in our review.
Characteristics of the identified cost-effectiveness studies
The characteristics of the 10 included papers3,78–86 and their results are provided in Tables 22 and 23
respectively. Some studies reported results of strategies that used clinical criteria to identify LS; when
possible, these results are excluded. One study is reported in abstract form.78 One study is reported in two
separate papers;4,79 these two papers have been grouped together for reporting purposes, giving a total of
nine separate studies.
The majority of the studies (seven78,80,81,83–86 out of nine) reported results for a US population. Of the other
two studies, one was carried out from the perspective of a German population82 and one was
UK based.4,79
All nine studies included strategies to identify LS in index CRC patients (probands) and relatives of CRC
patients. Five studies4,79,81,85,86 identified relatives through cascade testing in their base-case analyses,
whereas four studies80,82–84 appeared to include only first-degree relatives of the index CRC patient in their
base-cases analyses. The method of identifying relatives was unclear in the remaining study.78
When reported, the modelling approach appears to be similar across studies. Models were split into two
sections: a diagnostic model to identify LS (often a decision tree) and a long-term model to estimate the
costs and benefits associated with the outcomes of the diagnostic model.
All studies included either IHC- or MSI-based diagnostic strategies and a universal testing strategy as a
comparator. Six studies4,79,80,82,84–86 included both IHC- and MSI-based strategies, allowing for a comparison
between the two interventions. The optimal strategy varied across these studies and depended greatly on
the willingness-to-pay threshold of the relevant country, or the main relevant comparator, and so no
strategy was consistently seen to be the most cost-effective.
Lynch syndrome status was confirmed with germ-line testing of MLH1, MSH2, MSH6 and PMS2 in all
studies. Gallego et al.81 considered the use of NGS. However, instead of comparing the cost-effectiveness
of strategies to diagnose LS, Gallego et al.81 investigated the cost-effectiveness of using NGS to identify a
wider range of hereditary CRC predispositions, which included LS. Therefore, this analysis did not include a
strategy without testing.
All studies modelled the benefit of colonoscopic surveillance for LS-positive relatives, with most
(six studies4,79–81,83,85,86) also explicitly offering the same surveillance to probands. The frequency of this
surveillance was different across studies, but was usually modelled on an annual or biannual interval,
based on recommended guidelines.
Four studies4,79,80,85,86 also included prevention for gynaecological cancers [prophylactic hysterectomy and
bilateral salpingo-oophorectomy (H-BSO) or gynaecological screening]. Barzi et al.,80 Ladabaum et al.85 and
Wang et al.86 all included both endometrial cancer and ovarian cancer, whereas Snowsill et al.4,79 included
only endometrial cancer. The studies by Ladabaum et al.85 and Wang et al.86 were the only studies to
include gynaecological screening and, in their base cases, only a cost was applied for this screening; no
benefit was assumed.
One study considered the use of aspirin prevention.82 Severin et al.82 used data from the CAPP2 study to
apply a hazard ratio (HR) of 63% for a maximum of 11 years (observation time of the CAPP2 study) to
reduce the incidence of CRC in patients taking daily aspirin. We discuss this trial in more detail in Chapter 5
(see Chemoprevention). Both the cost of treatment with aspirin and the cost of complications from aspirin
were included, with a total annual cost of €596 (2012 costs).
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Of the nine cost-effectiveness studies, five were cost–utility studies.4,78,79,81,84,86 These are the five studies
that we focus on for the rest of the review.
Mvundura et al.84
Mvundura et al.84 produced a decision model of newly diagnosed CRC patients and their relatives in the
USA. It compared IHC (with or without BRAF V600E testing), MSI testing, no testing and universal genetic
testing. Relatives were identified through genetic testing. Although the study did include both MSI and
IHC testing strategies, it did not include all of the interventions identified in the NICE scope.88
Relatives with a confirmed mutation were offered colonoscopy every 1–2 years from the age of 20–25 years
until the age of 79 years. LS-negative relatives and some of those who were LS positive and who declined
the intensive LS surveillance were offered colonoscopy every 10 years from the age of 50 years.
The analysis did not include LS-related cancers other than CRC or the differences in CRC incidence
between males and females. It also did not include all of the comparators identified in the NICE scope.88
In their base case Mvundura et al.84 reported only life-years gained (LYGs) as opposed to QALYs. All
strategies with preliminary tests were found to be cost-effective compared with no testing. IHC followed
by BRAF V600E testing was the optimal strategy, with an incremental cost-effectiveness ratio (ICER) of
US$22,552 per LYG. To turn their analysis into a cost–utility analysis, the ICERs were scaled by a factor of
1.18 LYGs per QALY. This did not impact on the order of the strategies and increased the ICERs for all
strategies. This approach required a number of assumptions to be made and therefore it is unlikely to
reflect the true cost per QALY gained for each testing strategy.
The model results were sensitive to CRC risk in relatives, the number of relatives and adherence
to surveillance.
Wang et al.86
Wang et al.86 provided an update of the study by Ladabaum et al.,85 looking at the cost–utility of strategies
to identify LS in newly diagnosed CRC patients and their relatives in the USA. The difference between the
two models was the inclusion of utilities in the update model.
Wang et al.86 included strategies that started with clinical criteria (ACII and revised Bethesda or prediction
models) as well as those that began with tumour-based testing (IHC and/or MSI). We do not focus on the
strategies that began with clinical criteria as these are not considered as part of our analysis. As with the
study by Mvundura et al.,84 not all interventions identified by the NICE scope88 were included.
The model used a decision tree with Markov subtrees to model newly diagnosed CRC patients and their
relatives. For people identified with a LS mutation or with an unconfirmed diagnosis of LS (plus their
first-degree relatives), annual colonoscopy (from the age of 25 years) was offered. Women were offered
gynaecological screening from the age of 35 years and prophylactic total abdominal hysterectomy and
bilateral salpingo-oophorectomy (TAH-BSO) from the age of 40 years. When LS was not diagnosed, people
were offered 10-yearly colonoscopy from the age of 50 years.
The strategy that used IHC (with or without BRAF V600E mutation testing) was found to be the most
cost-effective strategy, with an ICER of US$59,719 per QALY gained. With the exception of MSI in
combination with IHC (with or without BRAF V600E testing) and universal germ-line testing (both of which
had ICERs of > US$100,000 compared with the next most cost-effective strategy), all other strategies were
dominated or extendedly dominated.
The results were most sensitive to the age of relatives, the effectiveness of LS surveillance for CRC and the
prevalence of LS.
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Gallego et al.78
Gallego et al.78 examined the cost-effectiveness and cost–utility of strategies to identify LS in CRC patients
and their relatives. Details of the modelling are scarce as this study was reported only in abstract form.
The main comparison appears to look at targeted sequencing compared with NGS. It was unclear whether
this study used the same underlying model as that reported in the study by Gallego et al.,81 but the author
list suggests that the two studies are likely to be related. For relatives in whom LS was detected, CRC
surveillance was offered, although, again, details are not provided. The reference strategy was a combination
of IHC and MSI followed by targeted sequencing. Replacing targeted sequencing with NGS gave an ICER of
US$71,000 per QALY gained and a strategy of NGS for all patients compared with the reference strategy
gave an ICER of US$196,000 per QALY gained.
As with most other analyses, the most influential parameters included the number of relatives tested,
the prevalence of LS in CRC and the cost of CRC surveillance in relatives.
Snowsill et al.4,79
Snowsill et al.4,79 report the previous work by PenTAG, which assessed the cost-effectiveness of strategies
to diagnose LS in newly diagnosed CRC patients aged < 50 years and their relatives. Snowsill et al.4,79
presented a cost–utility analysis from the perspective of the NHS and Personal Social Services (PSS) and
included both CRC and endometrial cancer as outcomes. They stated that, when possible, they adhered to
the NICE reference case.89 The model included a decision tree diagnostic section and an individual sampling
model to calculate long-term outcomes and survival for each of the diagnoses from the diagnostic section.
Probands and relatives who received a confirmed (mutation-positive) diagnosis or assumed LS diagnosis
(probands and relatives who were offered but who declined germ-line testing and first-degree relatives of
probands who were assumed to have LS) were offered colonoscopic surveillance, with women also offered
prophylactic TAH-BSO at the age of 40 years.
In this analysis, all testing strategies had ICERs of < £10,000 per QALY gained. When compared
incrementally, MSI followed by BRAF V600E testing was the most cost-effective strategy at a willingness-
to-pay threshold of £20,000. Scenario analyses demonstrated that increasing the age of the population
increased the ICERs for each strategy compared with no testing, although MSI plus BRAF V600E testing
remained the most cost-effective strategy. The model appeared most sensitive to the disutilities for
endometrial cancer and prophylactic TAH-BSO. Other sensitive parameters included the number of
relatives, the prevalence of LS, the cost of colonoscopy complications, CRC incidence and the effectiveness
of colonoscopy to prevent CRC.
Although we believe that this previous work was the first UK-based model to assess the cost–utility of
strategies to diagnose LS and has been described by Ladabaum et al.3 as the ‘most comprehensive decision
model’, this model still does not fully answer the decision problem set out in this assessment. The
strategies included in the study by Snowsill et al.4,79 are not in line with the current scope,88 with several
strategies including a combination of MSI and IHC testing, and methylation testing included only as a
scenario analysis, in place of BRAF V600E testing. The parameters are also now several years old and were
chosen for CRC patients aged < 50 years and so they are unlikely to represent the overall population and
the current clinical experience.
Gallego et al.81
Gallego et al.81 presented a cost–utility analysis of CRC patients and their relatives from a US perspective.
They used a decision tree model with long-term outcome estimates based on the results presented by
Mvundura et al.84 As such, the concerns that we have over the cost–utility analysis by Mvundura et al.84
are equally relevant here.
In this study the strategies were IHC followed by BRAF V600E testing prior to germ-line testing. The
intervention strategies were NGS panels. The relevant intervention strategy for our analysis was panel 1,
which looked at LS only. CRC surveillance was offered to both probands and relatives, although details of
DOI: 10.3310/hta21510 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 51
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snowsill et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
this surveillance were not provided. As the study by Mvundura et al.84 was stated to be the source of the
long-term outcomes, we assumed that surveillance was modelled as in this study.
Next-generation sequencing for LS compared with standard care gave an ICER of US$144,235 per QALY
gained. Sensitivity analyses were not reported for this scenario, as it was not the base case.
Quality of the identified cost-effectiveness studies
The results of the quality appraisal of the included studies are provided in Tables 24 and 25.
In general, reporting ranged from mixed to quite good. The study by Snowsill et al.4,79 appeared to be the
most comprehensively reported study. Very few studies considered endometrial cancer and only the studies
by Barzi et al.,80 Wang et al.86 and Ladabaum et al.85 considered ovarian cancer.
Discussion
The studies identified in this review reported a wide variety of analyses, with varying quality in reporting.
No single study answered our decision problem in full and the most common reason for this was that
studies did not include all of the interventions identified by the NICE scope88 or they were not carried out
from a UK perspective and therefore were hard to generalise.
It is difficult to draw specific conclusions about which was the most cost-effective strategy, as this varied
across studies and depended greatly on the willingness-to-pay threshold applied. Most studies stated that
at least one strategy to identify LS could be cost-effective according to the perspective used and, when a






































✗ ✓ ✓ ✓ ✗ ✓ ✓
Mvundura
et al., 201084
✓ ✓ ✓ ✓ ✓ ✓ ✓
Ladabaum
et al., 201185
✓ ✓ ✓ ✓ ✓ ✓ ✓
Wang et al.,
201286




✓ ✓ ✓ ✓ ✓ ✓ ✓
Barzi et al.,
201580
✓ ✓ ✗ ✗ ✓ ✓ ✗
Gallego
et al., 201581
✗ ✓ ✓ ✗ ✗ ✗ ✓
Severin et al.,
201582
✓ ✓ ✓ ✓ ✓ ✓ ✓
Source: criteria reproduced from Guidelines for authors and peer reviewers of economic submissions to the BMJ,
Drummond MF, Jefferson TO, vol. 313, pp. 275–83, 1996,77 with permission from BMJ Publishing Group Ltd.
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Patients are tested for MLH1
mutations
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Patients are tested for MSH2
mutations
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Patients are tested for MSH6
mutations
✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Patients are tested for PMS2
mutations
✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Appropriate informed consent
and counselling is included
✓ ✓ ✓ ✓ ✓ ? ✓ ✓
The study considers patients
declining counselling
? ✓ ? ? ✓ ? ✓ ?
The study considers patients
declining genetic testing
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
The effect of diagnostic errors
is considered
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
The study considers the impact
of a national strategy on the
proportion of patients who do
not already know their LS
status
✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗
Management
The study considers CRC ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
The study considers
endometrial cancer
✗ ✗ ✓ ✓ ✓ ✓ ✗ ✗
The study considers ovarian
cancer
✗ ✗ ✓ ✓ ✗ ✓ ✗ ✗
The study considers other
LS-associated cancers




NA NA ? ? ✗ ? NA NA
Colonoscopic surveillance in
the study is explicitly justified
(e.g. by reference to guidelines
or clinical practice)
✓ ✓ ✗ ✗ ✓ ✓ ✗ ✓
The study considers patients
declining recommended
surveillance
✓ ✓ ✓ ✓ ✓ ✓ ? ✓
The study considers the
difference in incidence of CRC
between males and females
✗ ✗ ✓ ✓ ✓ ✓ ✗ ✓
The study considers varying
incidence of LS-associated
cancers between mutations of
different MMR genes
✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗
continued
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universal genetic testing strategy was included, strategies that used tumour-based tests to enrich the
population appeared to improve cost-effectiveness (reducing the ICERs). Most studies agreed that the
effectiveness of colonoscopy screening, the number of relatives and the prevalence of LS had most impact
on the cost-effectiveness of the models.
Conclusions
The economic analysis that came closest to answering the current decision problem was that by Snowsill
et al.4 However, this analysis requires updating to fully answer the current problem posed in the NICE
scope.88 Therefore, our approach was to further adapt and develop the model created by Snowsill et al.4 to
suit the current decision problem.



















The study accounts for the
improved survival of LS CRCs
relative to sporadic CRCs
? ✓ ✓ ✓ ✓ ✓ ? ✓
The study considers the
potential psychological impact
of genetic testing
✗ ✓ ✗ ✓ ✓ ✗ ✗ ✗
NA, not applicable.
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Chapter 5 Independent economic assessment
Methods
The economic assessment reported in this chapter builds on the model described in Snowsill et al.4,79
Where the current model has not changed, reference is made to these articles, with direct quotations
provided, and therefore these aspects are described here only briefly for clarity. Focus instead is given to
alterations to the model.
Population
The base-case population specified by the NICE scope includes all newly diagnosed CRC patients
(probands) and their biological relatives (henceforth referred to as ‘relatives’). This is a broader population
than that previously specified in the study by Snowsill et al.,4 which considered only CRC patients aged
< 50 years and their relatives.
Four subgroups based on age (< 50, < 60, < 70 and ≥ 70 years) were also specified in the scope and are
presented in this report as subgroup analyses, separate from the main base-case analysis. Parameters that
have been identified as age dependent are reported as such and include the number of probands, the
proportions of probands and relatives who are men and the prevalence of LS in the population. When
data are unavailable for age subgroups, the base-case values are used.
Number of probands
To estimate the number of probands we used the same approach as in the study by Snowsill et al.,4
that is, taking the number of probands from the most recent Office for National Statistics (ONS) cancer
registration statistics for England.21 The figures for the overall population and the age subgroups are
provided in Table 26.
Number of relatives
The method for estimating the number of relatives was discussed in detail in Snowsill et al.4 In summary,
the number of relatives included in the model represents the possible group of identifiable relatives. For
example, for probands in whom a LS mutation is identified, this is the possible number of relatives who
both are contactable and may be identified through cascade testing.
The number of relatives in the study by Snowsill et al.4 was set to five, based on previous data from
Barrow et al.90 (2.35 relatives per proband) and unpublished data provided by Ian M Frayling (Institute
of Cancer and Genetics, University Hospital of Wales, Cardiff, UK, 18 December 2012, personal
communication). Data recently collected from the Manchester Regional Lynch Syndrome Registry, as part
TABLE 26 Number of probands by age
Age subgroup (years) Number of CRC registrations Proportion of mena (%)
Base case (no age limit) 34,025 55
< 50 2107 52
< 60 5880 55
< 70 13,823 58
≥ 70 20,202 53
a Pooled ONS data 2006–14.
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of a PhD thesis investigating the diagnosis of LS,91 suggested an average of 9.95 relatives per index
patient. As such, the base case number of relatives in the current model was increased slightly to six to
better account for this new information. As in the study by Snowsill et al.,4 this number was varied from 0
to 12 in univariate sensitivity analysis, to acknowledge the wide variation among the data sources. The
number of relatives per proband was assumed not to alter with the age of the proband, given a paucity of
evidence to demonstrate otherwise.
The Manchester Regional Lynch Syndrome Registry estimated an average of eight first-degree relatives per
index patient,91 but this seems exceptionally high and so we have assumed that this figure actually represents
the results of cascade testing to identify index patients. As such, our estimated number of first-degree relatives
remained as 42% of all relatives (2.5 relatives per proband), which is based on a combination of published92,93
and unpublished (Ian M Frayling, personal communication) data, as reported in Snowsill et al.4
The proportion of relatives who are male was taken from pooled analysis of unpublished data (Ian M
Frayling, personal communication; Munaza Ahmed, Wessex Clinical Genetics Service, University Hospital
Southampton NHS Foundation Trust, 23 January 2013, personal communication), giving a value of 38%,
as used previously in the analysis reported in Snowsill et al.4
Prevalence of Lynch syndrome
The prevalence of LS among CRC probands was estimated from the study by Hampel et al.,92 as in the
study by Snowsill et al.4 The base-case value (2.8%) and the age subgroup values are presented in Table 27.
In the study by Snowsill et al.4 it was important to subdivide the proportion of the population with LS by
mutation, as several parameters relied on this information, including the sensitivity and specificity of MSI
and IHC. In the current analysis, the test accuracy was assumed to apply for all mutations, as new test
accuracy evidence is not available to predict the effect that these mutations may have. This is a result of
restricting the test accuracy studies to those that answer the decision problem and not including studies
with high-risk input populations. Mutation type does still affect some costs and therefore is still included in
the model.
As in the study by Snowsill et al.,4 the proportions for each LS mutation were taken from the supplementary
evidence in the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) review,42 which
stated that, for all true LS-positive patients, 32% have a MLH1 mutation, 39% have a MSH2 mutation,
14% have a MSH6 mutation and 15% have a PMS2 mutation (Table 28). Reported family registry data
can differ significantly from these values, particularly with respect to the proportion of PMS2 mutations
identified91,94,95 (see Table 28). This may potentially be because of PMS2 testing having historically
occurred less in current practice than in the trials on which the EGAPP review based its values. Therefore, if
systematic testing were more common in UK practice, these values might change. We explore the possibility
of the proportion of each mutation being closer in value to the reported registry data in a sensitivity
analysis, using the Manchester Regional Lynch Syndrome Registry data as these are UK-based data.91
TABLE 27 Prevalence of LS in CRC population
Age subgroup (years) Prevalence of LS in CRC population (%)





Source: Hampel et al.92
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
For relatives of probands with LS, the proportion of relatives expected to test positive was estimated using
a meta-analysis of studies (Table 29), as reported in Snowsill et al.;4 this gave a value of 44%. This value
falls below 50% for a number of reasons (Box 2).
Age on entry
In the base case there was no age threshold for CRC patients for screening for LS.
The age on entry for probands was based on the age distribution of CRC diagnoses. For probands without
LS, the age distribution was estimated from cancer registration statistics in England from 2006 to
2014.21,96–103 These statistics are grouped into 5-year age groups. It was assumed that registrations were
uniform within these age groups.
TABLE 28 Lynch syndrome-positive population by mutation
Source
Gene
MLH1 MSH2 MSH6 PMS2 Notes
EGAPP review supplementary
evidence42
32% 39% 14% 15% Based on trial data
Sjursen et al.94 18% 50% 26% 6% Registry data from Norway (up to 2009)
Sjursen et al.95 36% 44% 17% 2% Registry data from New South Wales, Australia
(up to 2010)
Barrow91 40% 46% 11% 2% Registry data from Manchester, UK (up to 2013)
TABLE 29 Meta-analysis of the proportion of relatives testing positive
Study Proportion (%) 95% CI (%)
Jenkins 200693 44.1 37.0 to 51.5
Hampel 200892 43.8 37.7 to 50.0
Ian M Frayling (personal communication) 40.4 31.5 to 49.7
Munaza Ahmed (personal communication) 45.5 40.1 to 50.9
Random-effects meta-analysis 44.0 40.7 to 47.4
Source: reproduced from Snowsill et al.4 under the terms of the UK government’s non-commercial licence for public
sector information.32
BOX 2 Reasons why the proportion of first-degree relatives testing positive is < 50%
l De novo mutations can occur, which mean that no relatives of the index case will have the mutation [in the
study by Jenkins and colleagues (2006),93 1 of 18 probands had a de novo mutation].
l Non-paternity can occur.
l Mortality bias can occur, meaning that mutation carriers are more likely to have died before being able to
receive predictive testing.
Reproduced from Snowsill et al. (p. 143)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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For probands with LS, the age distribution was estimated from the parametric CRC incidence function
(see Incidence rates for individuals with Lynch syndrome).
The cumulative registrations were used to estimate an empirical cumulative incidence function. The
cumulative incidence function was truncated as appropriate for the different age subgroups. Figure 7
shows the age distribution of probands in the base case.
For relatives without LS, the age distribution was assumed to be equal to the age distribution of the
general population, which was taken from the mid-2014 population estimates for England104 and
mid-2014 population estimates of the very old (including centenarians) for the UK.105
For relatives with LS, the age distribution was estimated by multiplying the population estimate for
the general population by an estimate of the CRC mortality-free survival for individuals with LS
(i.e. incorporating the raised incidence of CRC in relatives with LS).
As previously,4 the age distribution of relatives was right-truncated at 75 years as it is unlikely that any
intervention would be offered to individuals aged > 75 years and was left-truncated at 18 years as few
relatives are offered predictive testing before the age of 18 years. Figure 8 shows the age distribution of













































FIGURE 7 Age distribution of simulated probands.
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Model structure
The model structure remains broadly similar to that reported in the study by Snowsill et al.4,79 The model
consists of two distinct sections: a decision tree model to investigate the short-term outcomes of strategies
to identify LS patients and an individual patient simulation model to assess the long-term implications of
strategies to identify and manage LS. The model was built in Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA). A brief summary of the model structure and parameters is provided in the following
sections, with detailed discussion of any changes made to the model.
Diagnostic testing model
The section of the model that calculates diagnoses was built as a decision tree with no time component
included. As in the study by Snowsill et al.,4 this assumes that the diagnosis of LS in probands and relatives
occurs instantaneously, although in reality this may take up to several months or years. As before, it was
also assumed that probands’ treatment will not be influenced by a LS diagnosis, following the assumption
that the results of LS testing will be unavailable prior to treatment. In most cases this treatment will be
surgical resection with the possibility of chemotherapy or radiotherapy, depending on the stage of
the cancer.
An overview of the diagnostic model is given in Figure 9. This is unchanged from that in Snowsill et al.4
Diagnostic strategies for probands
The NICE scope88 for this project specifies diagnostic strategies for probands that are significantly altered
from those reported in Snowsill et al.4
The 10 new strategies considered are:
1. No systematic testing to identify LS (all probands assumed not to have LS).
2. IHC four-panel test for MLH1, MSH2, MSH6 and PMS2 followed by genetic testing if IHC results
are abnormal.
3. IHC four-panel test followed by BRAF V600E testing for abnormal MLH1 results. Genetic testing is
carried out for any other (not MLH1) abnormal IHC results or after a negative BRAF V600E test.
4. IHC four-panel test followed by MLH1 promoter methylation testing for abnormal MLH1 results.
Genetic testing is carried out for any other (not MLH1) abnormal IHC results or after a negative MLH1
promoter methylation test.
5. IHC four-panel test followed by BRAF V600E testing for abnormal MLH1 results. A negative BRAF
V600E test is followed by MLH1 promoter methylation testing. Genetic testing is carried out for any
other (not MLH1) abnormal IHC results or after a negative MLH1 promoter methylation test.
6. MSI test followed by genetic testing for MSI-H result.
7. MSI test followed by BRAF V600E testing for MSI-H result. Genetic testing is carried out after a
negative BRAF V600E test.
8. MSI test followed by MLH1 promoter methylation testing for MSI-H result. Genetic testing is carried
after a negative MLH1 promoter methylation test.
9. MSI test followed by BRAF V600E testing for MSI-H result. A negative BRAF V600E test is followed by
MLH1 promoter methylation testing. Genetic testing is carried after a negative MLH1 promoter
methylation test.
10. Universal genetic testing (i.e. as the first and only test for all probands).
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These strategies are presented in Figures 10–13.
Strategies 5 and 9 include both BRAF V600E and MLH1 promoter methylation testing. These are
performed in sequence with either test able to rule out LS, for example a patient with BRAF V600E would
not receive further testing. The ordering of these tests was informed by discussion at the NICE scoping
workshop (11 January 2016).
In clinical practice it is expected that a number of patients with stage II CRC will undergo MSI or IHC
analysis to inform treatment options. To highlight this, the model includes costs for MSI or IHC testing for
all stage II CRC patients (≈27% of probands) in strategy 1 (no testing), but assumes that this does not lead
to any further testing for LS.
For the purposes of the base case it was assumed that a MSI result corresponds to MSI-H. This assumption
was explored in a scenario analysis, in which it was assumed that a MSI result corresponds to MSI-L; this is
detailed further in Model parameters.
A certain proportion of probands in the MSI strategies were assumed to receive IHC to help interpret their
genetic test results. For example, a variant of uncertain significance may be identified in MSH2 and IHC
was conducted to identify whether the tumour cells were MSH2 deficient (indicating that the variant is
likely to be pathogenic). Clinical opinion appears to be that this proportion can be quite low [Ottie O’Brien,
Northern Molecular Genetics Service, personal communication, 7 April 2016 (value of < 5%); Samantha
Butler, West Midlands Regional Genetics Laboratory, personal communication, 13 July 2016 (value of
10%)], so the value was set to 5% in the base case. The impact of this parameter was explored in
univariate sensitivity analysis, with the proportion varied from 0% to 10%.
The potential results of the testing strategies for patients are as reported previously:4 LS mutation positive,
LS assumed and LS negative. LS mutation positive occurs when a proband receives a positive genetic test
result and LS negative occurs when a proband is ruled out by one of the tests in the strategy.
In the study by Snowsill et al.,4 the outcome of LS assumed could occur when genetic testing either was
uninformative or was simply not carried out (the proband declined testing). A negative genetic test result
was assumed to be uninformative for probands, meaning that, although the test did not detect LS, it did
not rule it out. The Amsterdam II criteria were used as an additional test for those probands who were LS
mutation negative and those who declined genetic testing to decide whether they were LS assumed. In
this update to the model, any use of the Amsterdam II criteria was removed, in line with the focus of the
decision problem, which does not include clinical criteria. It was also assumed in the current model that
only probands who decline testing can become LS assumed, and this was set to 10% for all patients
[lower than the average proportion of probands who were LS assumed after declining testing in the 2014
model (21%)]. We adjusted this number for each age subgroup using the three age limit scenarios from
Snowsill et al.4 (21% for probands aged < 50 years, 17% for probands aged < 60 years, 13% for
probands aged < 70 years) and set the value for the ≥ 70 years subgroup to a significantly lower value
(5%) to reflect that, in higher age groups, few people are likely to be diagnosed with LS without
genetic testing.
Unlike in the study by Snowsill et al.,4 in which testing for PMS2 was modelled only for probands who
were negative for MLH1, MSH2 and MSH6 but who had a family history that was indicative of LS, in the
current model it was assumed that all patients who accept genetic testing will receive testing for all four
LS negativeCRC probands 
Strategy 1
No testing
FIGURE 10 Proband diagnostic strategy: no testing.
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known genes (MLH1, MSH2, MSH6 and PMS2). The exception to this was that probands who follow
strategies that use IHC followed by either BRAF V600E or MLH1 promoter methylation testing receive only
MLH1 and PMS2 germ-line testing. Mutations related to EPCAM were assumed to be identified through
testing for MSH2. This is believed to be in line with current clinical practice; when clinical practice differs
from this, the model will overestimate costs associated with tumour-based testing strategies.
As in the study by Snowsill et al.,4 only a proportion of patients diagnosed as LS positive or LS assumed
accept an offer of LS surveillance.
Testing outcomes for probands
The primary outputs from the short-term model for each testing strategy that lead into the survival
(i.e. long-term) section of the model are the same as those reported in Snowsill et al.4 (Box 3).
Probands who are diagnosed with LS (either mutation positive or assumed) but who refuse surveillance
may still be offered prophylactic surgery for mCRC or endometrial cancer.
Diagnostic strategies for relatives
The diagnostic strategies for relatives are unchanged from those in the study by Snowsill et al.;4 these
strategies are summarised in Figures 14–16. As with probands, relatives could decline any testing or LS











FIGURE 13 Universal genetic testing strategy for probands. GC, genetic counselling; GT, genetic testing.
BOX 3 Primary outputs from the short-term model relating to probands
l Number of probands with LS receiving LS surveillance.
l Number of probands with LS not receiving LS surveillance (probands will receive some surveillance in line
with BSG guidelines;46 these are split into those identified as LS positive, but declined surveillance and those
who were diagnosed LS negative.
l Number of probands without LS receiving LS surveillance.
l Number of probands without LS who do not receive LS surveillance (probands will receive some surveillance
in line with BSG guidelines46); these are split into those identified as LS positive, but declined surveillance
and those who were diagnosed LS negative.
Other outcomes include overall sensitivity and specificity of each diagnostic strategy.
Reproduced from Snowsill et al. (p. 98)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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Testing outcomes for relatives
The testing outcomes for relatives are as stated in the study by Snowsill et al.4 (Box 4).
Long-term outcomes model
As described previously,4 long-term outcomes were modelled for all probands and relatives regardless of
the diagnostic path that they follow. An individual patient sampling model was used to simulate 240,000
patients, distributed across 24 groups, representing all combinations of the variables shown in Table 30.
An individual patient sampling model was justified because no patient interactions were modelled but
there were too many patient states for a cohort model.
Mean long-term outcomes were then estimated for each of the 24 groups. These were then used to
estimate the long-term outcomes for each of the diagnostic strategies in the decision tree.
Patients were simulated for 1 year at a time. Each patient starts each year in a particular state, which
determines the events that can occur during that year. The events in turn determine the costs incurred and
the state of the patient in the next year if the patient is still alive. The hazard rate for events (except
Proband diagnosed 
LS assumed





Decline, no further action
FIGURE 15 Diagnostic strategy for relatives of probands diagnosed as LS assumed. FDR, first-degree relative.
Source: reproduced from figure 13 of Snowsill et al.4 under the terms of the UK government’s non-commercial
licence for public sector information.32
Proband no LS No further action
FIGURE 16 Diagnostic strategy for relatives of probands diagnosed as LS mutation negative. Source: reproduced
from figure 14 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for public
sector information.32
BOX 4 Primary outputs from the short-term model relating to relatives
The primary short term model outputs are:
l number of relatives with LS receiving LS surveillance
l number of relatives with LS not receiving LS surveillance (split into those identified as LS positive, but
declined surveillance and those who were diagnosed LS negative)
l number of relatives without LS receiving LS surveillance
l number of relatives without LS who do not receive surveillance (split into those identified as LS positive, but
declined surveillance and those who were diagnosed LS negative)
The sensitivity and specificity for each testing strategy for relatives is recorded.
Reproduced from Snowsill et al. (p. 100)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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elective events such as surveillance colonoscopy) was assumed to be constant during each year but could
change between years.
Life-years and QALYs were calculated based on a patient’s state at the beginning of the year and any
events occurring during the year, for example if a patient starts the year without cancer and develops
cancer after 3 months, then the patient accrues 3 months of life with a non-cancer utility and 9 months of
life with the utility decrement from cancer (assuming that the patient does die within the year).
Table 31 shows the different events included in the model. Mortality events are competing – no other
events can occur after the patient dies.
Figure 17 presents a model diagram for the long-term outcomes model, indicating the mortality events
and cancer incidence events, as well as prophylactic H-BSO. Gynaecological surveillance is indicated to
reduce the risk of endometrial cancer mortality, but this is only if the individual is receiving surveillance
prior to cancer incidence.
TABLE 30 Patient groups in the long-term outcomes model
Variable Values
Patient type Proband, relative
Actually has LS Yes, no
LS diagnosis and management Diagnosed and surveillance colonoscopy accepted, diagnosed and surveillance
colonoscopy not accepted, not diagnosed
Sex Male, female
TABLE 31 Competing and non-competing events in the PenTAG model for different patient groups
Patient group Competing events Non-competing events
All patients General mortality
Patients undergoing LS
surveillance (aged 25–75 years)
Mortality following
colonoscopy
Colonoscopy, adverse events (including bleeding and
perforation) following colonoscopy




Colonoscopy, adverse events (including bleeding and
perforation) following colonoscopy
Patients with CRC CRC mortality
Patients with an index CRC
(without mCRC)
mCRC incidence
Patients without CRC CRC incidence








Women diagnosed with LS without




Commence gynaecological surveillance, stop gynaecological
surveillance, decline risk reduction for gynaecological cancer,
prophylactic H-BSO
Source: adapted from table 39 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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Patient state
The state of each simulated individual at any time is defined by a number of properties, which collectively
provide all of the information necessary to select appropriate treatment pathways and calculate risks of
events. The patient state is composed of:
l whether or not the patient is alive
l the patient’s age (at the start of the year)
l the patient’s sex
l the patient’s bowel state (defined in the following section)
l patient’s gynaecological state [see Patient’s gynaecological state (women only)]
l the patient’s LS status and diagnosis status
l the patient’s acceptance of LS surveillance colonoscopies if offered.
Patient’s bowel state
The patient’s bowel state encapsulates whether the patient has a clinically diagnosed CRC and the extent
of any bowel surgery. Although it is possible within an individual sampling model to track a number of
primary CRCs and their properties, we make the simplifying assumption that each patient will have no
more than two primary CRCs throughout their life (as in other decision models, e.g. Mvundura et al.84).
Each CRC is staged using the modified Dukes’ stage (A–D) or American Joint Committee on Cancer stage
(I–IV), which are effectively equivalent. The tumour–node–metastasis (TNM) system is used clinically to give
finer staging detail, but incidence and survival statistics are currently not widely available for TNM stages.
The model tracks the stage of each CRC and the time since diagnosis (to determine the hazard of CRC
mortality).
We modelled two portions of the bowel: the colon and the rectum. CRCs can develop in any portion of
the bowel still intact. We modelled four surgery types, based on the extent of bowel removed (Table 32).
This is a small extension to the three surgery types used in the study by Maeda et al.106 to account for the
fact that rectal cancer can be the first primary cancer in our cohort. Colorectal surgery pathways gives
details on surgical management.
Bowel state on entry All probands enter the model with an index CRC (i.e. without a mCRC). The
Dukes’ stage for probands is sampled randomly using the distribution described in Model parameters,
Stage on diagnosis.
Probands entering the simulation are randomly assigned a surgical state in accordance with the estimated
probability that they had colon cancer compared with rectal cancer (Table 33) and the probabilities of
different types of surgery for those cancers (Table 34). Table 35 gives the resulting distribution of initial
surgical states for probands entering the model, according to their sex and LS status.
TABLE 32 Extent of bowel removed for included surgeries
Surgery Bowel removed
Segmental colon resection Part (but not all) of the colon
Subtotal colectomy All of the colon
Anterior resection All of the rectum
Proctocolectomy All of the colon and rectum
Source: reproduced from table 46 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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Relatives enter the model without CRC, that is, they are at risk of up to two CRCs (index and metachronous).
In reality, some relatives would be survivors of a previous CRC.
Table 36 provides estimates of what proportions of relatives would be survivors of previous CRCs. Estimates
for relatives without LS are based on 10-year CRC prevalence data published by the (UK) National Cancer
Intelligence Network,109 assuming that the proportion of CRC survivors with colon cancer is the same as the
proportion of incident CRCs that are colon cancer. The prevalence of previous CRC for relatives with LS
was estimated by multiplying by a scale factor of 38%/2.6% = 14.8 for males and 31%/1.7% = 18.1 for
females, with 38% and 31% being estimates of the cumulative risk of CRC up to age 70 years for males
and females with LS, respectively,18 and 2.6% and 1.7% being estimates of the cumulative risk of CRC up
to age 70 years for males and females without LS, respectively, calculated using population, CRC incidence
and CRC mortality statistics for England and Wales in 2010.100,110–112 Again, it was assumed that the
proportion of survivors with colon cancer would match the proportion of incident cases, this time estimated
by Dinh et al.107
TABLE 33 Probability that the index CRC of the proband entering the PenTAG model is colon cancera
Proband type Male Female Source
With LS 0.94 0.94 Dinh online appendix107
Without LS ONS Cancer registration statistics, England 2013103
Base case 0.63 0.72
< 50 years 0.61 0.70
< 60 years 0.56 0.66
< 70 years 0.57 0.68
≥ 70 years 0.67 0.75
a International Classification of Diseases, 10th Revision code C18.
TABLE 34 Surgery for CRC according to location (general population)
Location of CRC Surgery (% of cases) Source
Colon Segmental resection (96%), subtotal colectomy (4%) National Bowel Cancer Audit 2011108
Rectum Anterior resection (98%), proctocolectomy (2%) National Bowel Cancer Audit 2011108
Source: adapted from table 51 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
TABLE 35 Distribution of initial surgical states for probands entering the model
Surgery
With LS Without LS
Men Women Men Women
Segmental resection 0.907 0.907 0.603 0.696
Subtotal colectomy 0.033 0.033 0.022 0.026
Anterior resection 0.059 0.059 0.368 0.274
Proctocolectomy 0.001 0.001 0.007 0.005
Source: partially based on table 52 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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Relatives with previous CRC would experience a higher mortality rate than relatives without previous CRC
and therefore preventing a further CRC would be expected to give a smaller LYG. These CRC survivors
would be likely to have early-stage CRC, to have undergone segmental resection and to be followed up
for recurrence or metachronous cancer.
The model incorporates initial surgical states for relatives entering the model (Table 37; proportions based
on surgical choice for people not known to have LS and the prevalence of colon and rectal cancer, as in
Table 36). Most relatives have not had previous surgery (as most relatives have no previous CRC) and, of
those who have undergone previous surgery, the majority have had a previous segmental resection, which
imparts no risk reduction in the model. A very small number (<< 1%) of relatives enter the model having
had previous surgery that does impart a risk reduction. As all of these relatives enter with a risk reduction
irrespective of the diagnostic strategy, this would decrease the potential LYG of correctly identifying
relatives as having LS; we therefore expect that including initial surgical states has a very small (probably
negligible) negative impact on the cost-effectiveness of strategies identifying LS (i.e. ICERs for testing
strategies slightly increased compared with no testing).
Patient’s gynaecological state (women only)
A patient’s gynaecological state encapsulates what risk-reducing measures she has employed and whether
or not she has had endometrial cancer.
Although endometrial cancer can be staged and there are some survival estimates according to stage,113
the staging system has been changed recently and most patients are diagnosed in the early stage of
cancer. Therefore, the stage of endometrial cancer is not tracked in the model; rather, the time since
diagnosis is tracked.
It was assumed that patients will not get more than one primary endometrial cancer as they will undergo a
hysterectomy, which is very effective at preventing endometrial cancer when used prophylactically.26
TABLE 36 Estimated proportions of relatives who would have previously had CRC
CRC prevalence
With LS Without LS
Men Women Men Women
None 0.9683 0.9748 0.9979 0.9986
Colon cancer 0.0298 0.0237 0.0013 0.0010
Rectal cancer 0.0019 0.0015 0.0009 0.0004
TABLE 37 Distribution of initial surgical states for relatives entering the model
Surgery
With LS Without LS
Men Women Men Women
None 0.9683 0.9748 0.9979 0.9986
Segmental resection 0.0288 0.0229 0.0012 0.0009
Subtotal colectomy 0.0011 0.0008 0.0000 0.0000
Anterior resection 0.0019 0.0015 0.0009 0.0004
Proctocolectomy 0.0000 0.0000 0.0000 0.0000
Source: partially based on table 54 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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Risk-reducing measures available to patients are gynaecological surveillance and prophylactic hysterectomy
(and bilateral salpingo-oophorectomy). Patients can start and stop surveillance but prophylactic hysterectomy
is irreversible and surveillance cannot be performed in patients after hysterectomy (Figure 18).
Gynaecological state on entry All simulated individuals were assumed to start without endometrial cancer.
Probands and relatives who have been diagnosed with LS may be offered surveillance or prophylactic
H-BSO depending on their age.
Table 38 shows the assumed distribution of risk-reducing strategies according to age at diagnosis,
based on audit data from the Northern Genetics Service (Lorraine Cowley, Principal Genetic Counsellor,
Newcastle upon Tyne Hospitals NHS Foundation Trust, 20 November 2012, personal communication).
Outcomes
For each of the 24 patient groups (see Long-term outcomes model), the following outcomes were
recorded from the simulation:
l costs (discounted and undiscounted)
l QALYs (discounted and undiscounted)
l overall survival (and whether or not censored on reaching age 100 years)
l CRC-, endometrial cancer- and overall cancer-free survival (and whether censored because of death or
on reaching age 100 years)
l event-free survival (and whether or not censored on reaching age 100 years)
l number of incident CRCs
l number of incident endometrial cancers
l number of colonoscopies performed





FIGURE 18 Gynaecological state model diagram.
TABLE 38 Gynaecological cancer risk reduction for women with LS on entry
Age (years) at LS diagnosis No risk reduction Surveillance Prophylactic H-BSO
0–34 1.000 0.000 0.000
35–44 0.200 0.600 0.200
45–59 0.167 0.458 0.375
60–69 0.000 0.143 0.857
≥ 70 0.143 0.000 0.857
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Colorectal cancer
The simulation model includes four events relating to CRC:
l index CRC incidence
l index CRC mortality
l mCRC incidence
l mCRC mortality.
The incidence events transform the patient’s bowel state (e.g. index CRC incidence transforms the bowel
state from ‘no CRC’ to ‘index CRC’ with a particular stage). The mortality events result in the patient dying
with no further events occurring.
Figure 19 shows the 21 different bowel cancer histories included in the model.
The probability that a CRC incidence event occurs within a year is dependent on the incidence rate,






















FIGURE 19 Colorectal cancer and mCRC incidence model diagram.
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l whether or not the patient has had a previous CRC
l time since first CRC
l LS status
l risk-reducing measures, that is, regular colonoscopies and aspirin, as described in Colorectal surgery
pathways and Aspirin chemoprevention respectively.
Different annual incidence rates are provided for the eight combinations of sex, previous cancer (yes/no)
and LS status and then risk-reducing measures are incorporated as HRs, which have a simple multiplicative
effect on the incidence rate.
Incidence rates for individuals without Lynch syndrome The incidence rates for males and females
without previous cancer without LS were estimated from pooled registration statistics for CRC in England
between 2006 and 2014 inclusive21,96–103 and the estimated population in the midpoints of those years.114
Following the methodology adopted by the ONS,100 we calculated the age-specific rate of CRC incidence
by dividing the number of CRC registrations within a time period by an estimate of the person-years lived
during that period. Incidence figures were pooled across 5 years to achieve a large sample size but not
further back than 2006 as such data may not reflect more recent developments in cancer detection
and registration.
Cancer registration statistics are not provided for each year of age but for age groups, generally of 5 years.
We assumed that within each of these age groups the incidence rate would remain constant. The resulting
cumulative risk of CRC for individuals without LS is shown in Figure 20.
We estimated the incidence of mCRC (i.e. the incidence in individuals who had had a previous CRC) for
individuals without LS by adjusting the incidence of the first CRC by a HR of 1.4 for the first 3 years after
the first CRC and 1.3 for the following 7 years, as in the study by Mulder et al.115 Mulder et al.115 studied
10,283 Dutch patients with CRC undergoing standard follow-up. After 10 years no additional hazard
was applied.
Incidence rates for individuals with Lynch syndrome Previously,4 we conducted a literature review to





























FIGURE 20 Cumulative risk of CRC for individuals without LS. Note: this does not account for non-CRC mortality.
Source: reproduced from figure 22 of Snowsill et al.4 under the terms of the UK government’s non-commercial
licence for public sector information.32
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Subsequent reviews2,16,116 have not identified any additional studies.
Møller et al.5 have subsequently published estimates of the cancer risk for individuals with LS while
undergoing colonoscopic surveillance; this does not address the need here (i.e. for the cancer risk in the
absence of interventions).
In the absence of new evidence to consider, the model includes an incidence rate for CRC based on the
study by Bonadona et al.18
A logistic model for cumulative risk was fitted to data from Bonadona et al.18 using the following
parameterisation and ordinary least-squares regression:
F(x) =
β0
1 + exp −β1(x−β2)
  . (8)
The 95% CIs for the cumulative risk to age 70 years from the study by Bonadona et al.18 were used in
sensitivity analyses (by varying β0 appropriately). Table 39 shows the parameters used in the base-case and
sensitivity analyses and Figures 21 and 22 show graphically the fit to the data from Bonadona et al.18
Stage on diagnosis The CRC stage on diagnosis is an important predictor of survival. Historically, the
modified Dukes’ stage (A–D) has been used for cancer staging, but it is more common now to refer to
stages by Roman numerals (I–IV).
We assumed that the stage on diagnosis would be independent of age, sex, LS status and whether it was
the first (index) CRC or a mCRC (Fajobi et al.117 conclude that stages for mCRC are no worse than those
TABLE 39 Logistic model parameters for CRC incidence in individuals with LS
Parameter Base case Sensitivity analyses (95% CI)
β0 M 0.464, F 0.435 M 0.303 to 0.715; F 0.265 to 0.697
β1 M 0.107, F 0.108
β2 M 55.5, F 61.3
F, women with LS; M, men with LS.



















































FIGURE 21 Colorectal cancer incidence for men with LS. Source: reproduced from figure 23 of Snowsill et al.4 under
the terms of the UK government’s non-commercial licence for public sector information.32
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for index CRC and there was no consensus on whether they might be better). We also assumed that stage
on diagnosis of mCRC was independent of the stage of the index CRC and the CRC site. CRC stage was
assumed to depend only on whether the person was undergoing LS surveillance colonoscopies.
The stage distributions are provided in Model parameters, Stage on diagnosis.
Colorectal cancer site As stated in Patient’s bowel state we model two sections of the bowel, the colon
and the rectum. We grouped rectosigmoid cancer (International Classification of Diseases, 10th Revision
code C19) into rectal cancer. The site of incident CRCs was dependent on sex, whether or not the person
had LS and any previous surgery (Table 40).
It was assumed that all CRCs are colon cancers following anterior resection (AR) and that all CRCs are
rectal cancers following subtotal colectomy. If there is no previous surgery or a previous segmental
resection the probability of the CRC being situated in the colon for a person with LS was estimated as 0.94
based on the study by Dinh et al.107 For males and females without LS the probability of colon cancer was



















































FIGURE 22 Colorectal cancer incidence for women with LS. Source: reproduced from figure 24 of Snowsill et al.4
under the terms of the UK government’s non-commercial licence for public sector information.32
TABLE 40 Probability that incident CRC is situated in the colon
Previous surgery With LS
Without LS
Men Women
None 0.94 0.63 0.72
Segmental resection 0.94 0.63 0.72
Subtotal colectomy 0.00 0.00 0.00
Anterior resection 1.00 1.00 1.00
Proctocolectomy NAa NAa NAa
NA, not applicable.
a NA as zero CRC incidence following proctocolectomy.
Source: partially based on table 52 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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Colorectal cancer survival We assumed that mortality from CRC depends on the following:
l CRC stage at diagnosis
l years since diagnosis
l age at diagnosis
l LS status (see Lynch syndrome colorectal cancer survival).
We did not consider the effect of the following on mortality from CRC:
l patient’s sex
l site of CRC
l surgery for CRC.
The baseline annual rate of mortality from CRC was derived from data provided by the (UK) National
Cancer Intelligence Network109 by extracting 1-, 2-, 3-, 4- and 5-year relative survival from survival curves
and assuming constant rates of mortality within each year (Table 41 and Figure 23). It was assumed that
the mortality rate for 4–5 years since diagnosis also applied after 5 years (Table 42).
The assumption that the mortality rate after 5 years is equal to the mortality rate for 4–5 years is likely to
be a slight overestimate of CRC mortality (Table 43). The result of this would be a slight improvement in
the cost-effectiveness of strategies with a high yield of LS mutations.
TABLE 41 Relative survival of patients with CRC by Dukes’ stage across all ages
Years since diagnosis
Dukes’ stage
A B C D
1 0.969 0.917 0.815 0.380
2 0.965 0.872 0.681 0.193
3 0.957 0.831 0.583 0.116
4 0.945 0.799 0.522 0.083
5 0.932 0.770 0.477 0.066
Source: National Cancer Intelligence Network.109 Reproduced from table 63 of Snowsill et al.4 under the terms of the UK




























FIGURE 23 Colorectal cancer survival in the model. Source: reproduced from figure 28 of Snowsill et al.4 under the
terms of the UK government’s non-commercial licence for public sector information.32
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The HRs for CRC mortality by age compared with CRC mortality across all ages were estimated using
net survival statistics from the ONS118 and are shown in Table 44. Details of the calculations are given in
appendix 6 of Snowsill et al.4
Metachronous colorectal cancer survival As previously,4 mortality from mCRC was modelled by adding
the mortality rates for both the index CRC and the mCRC as calculated above, assuming that mortality from
the metachronous cancer would be no different from mortality from the index cancer for the same Dukes’
stage (as assumed by, for example, Mvundura et al.84 and Dinh et al.107). The same approach was used
independent of the LS status of the patient. As the mortality rates are dependent on the time since diagnosis
in the model, we kept track of time since diagnosis of the index cancer and the metachronous cancer.
Lynch syndrome colorectal cancer survival As previously,4 the model assumed improved survival for
individuals with LS and local CRC compared with individuals with sporadic CRC. A HR of 0.57 was applied
TABLE 42 Mortality rate from CRC (per 100,000 person years) by Dukes’ stage
Years since diagnosis
Dukes’ stage, n
A B C D
0–1 3102 8709 20,460 96,729
1–2 419 5000 17,971 67,733
2–3 843 4761 15,465 51,116
3–4 1279 4000 11,060 32,857
> 4 1400 3667 9068 23,375
Source: reproduced from table 64 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32











1 0.730 0.722 0.788 0.788 0.757
5 0.544 0.551 0.546 0.575 0.530
10 0.501 0.508 0.473 0.521 0.421
Source: Cancer Research UK, https://web.archive.org/web/20130302050315/http://www.cancerresearchuk.org/cancer-info/
cancerstats/types/bowel/survival/, accessed August 2017.1 Copyright © 2013, Cancer Research UK. Adapted from table 65
of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for public sector information.32
TABLE 44 Hazard ratios for CRC mortality by age at diagnosis compared with CRC mortality across all ages
Age group (years)
HR for CRC mortality
First year Following 4 years Thereafter
< 70 0.599 0.972 1
70–79 0.956 0.966 1
≥ 80 1.797 1.116 1
Source: reproduced from table 66 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
for Dukes’ A and Dukes’ B CRC if the simulated individual had LS, based on the study by Lin et al.119
Survival for individuals with Dukes’ C and Dukes’ D CRC was equal for patients with and without LS,
based on the study by Barnetson et al.54
Endometrial cancer
The lifetime risk of endometrial cancer in the general population is one in 41.120 The lifetime risk in women
with LS (in the absence of risk-reducing measures) is around 35%.18 As previously,4 endometrial cancer
was modelled only for women with LS.
Endometrial cancer incidence As previously,4 and as for CRC, the incidence rates for endometrial cancer
in women with LS were estimated from the study by Bonadona et al.18
A piecewise constant hazard of endometrial cancer was used per decade of life to achieve the cumulative
risk profile observed in the study by Bonadona et al.18 and it was assumed that the incidence of
endometrial cancer would be zero after age 80 years. Figure 24 shows the cumulative risk used in the
model as well as the data from Bonadona et al.18 for reference.
Endometrial cancer survival Survival from uterine cancer in England and Wales has recently been
estimated by the London School of Hygiene and Tropical Medicine and published by Cancer Research UK
(Figure 25).121
Endometrial cancer cases make up the vast majority of uterine cancer cases, so uterine cancer cases are
expected to closely approximate survival of endometrial cancer.
The survival curve was used to estimate a piecewise constant rate of mortality for each year since
diagnosis. After 10 years the rate of mortality is zero.
General mortality
Death from other causes was modelled by using mortality rates separately for men and women from life
tables for England and Wales, 2008–10,122 adjusted to remove the proportion of mortality resulting from
CRC, which was estimated by dividing the number of deaths from CRC in each age group by the total
number of deaths in that age group from mortality data for England in 2010.110 We did not adjust for
mortality from endometrial cancer as this accounted for < 1% of deaths in the general population
(whereas CRC accounted for 2.8% of deaths) and we did not adjust for mortality from other LS-associated
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FIGURE 24 Endometrial cancer incidence. Gynaecological surveillance was not assumed to affect the incidence of
endometrial cancer (see Gynaecological surveillance).
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Surveillance pathways
Colorectal surveillance Previously,4 a colorectal surveillance pathway was modelled based on the
synthesis of a number of relevant recommendations,46,47,123 which included biennial (every 2 years)
colonoscopies for individuals diagnosed with LS.
The recently published guidelines from the European Mallorca group advocate an interval of 1–2 years
between colonoscopies for individuals with LS.19
The evidence underpinning the effectiveness estimates for colonoscopic surveillance in the model is based
on 3-yearly surveillance124 (see Colonoscopy).
To avoid excessive inconsistency between the effectiveness evidence and the associated costs of
colonoscopic surveillance, an interval of 2 years was modelled for individuals with LS.
Colorectal cancer patients are assumed to also receive a carcinoembryonic antigen (CEA) test every 3 months
for 2 years and then every 6 months for a further 3 years; computerised tomography (CT) scans of the chest,
abdomen and pelvis at 12 months and 24 months; and colonoscopy at 12 months and then 5-yearly (unless
diagnosed with LS).4,47,123
Gynaecological surveillance The European Society for Medical Oncology guidelines recommend annual
gynaecological examination, pelvic ultrasound, CA-125 (cancer antigen 125) analysis and aspiration biopsy
for gynaecological surveillance, starting at age 30–35 years.125 This was used as the basis for modelling
gynaecological surveillance, with surveillance initially offered at age 35 years (or immediately if the
diagnosis of LS is after the age of 35 years) and continuing until 70 years of age.
Colorectal surgery pathways
As previously,4 colorectal surgical pathways were based on published guidelines46 with input from
clinical experts.
Patients undergo surgical management if they are diagnosed with CRC and the cancer is deemed to be
operable (this includes surgery when intent is palliative rather than curative). We made the simplifying
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FIGURE 25 Net survival for uterine cancer in England and Wales. Source: based on a graphic created by Cancer
Research UK.121
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National Bowel Cancer Audit108 were treated surgically). In each case, surgery would remove the bowel
portion affected by the cancer and, in some cases, additional portions, depending on previous surgery and
whether LS had been diagnosed (Figure 26). Our clinical expert advice was that, in general, surgery for
patients without LS tends to be conservative, without a risk-reducing element (Mr Ian Daniels, Consultant
Colorectal Surgeon, Royal Devon and Exeter Hospital, 24 October 2012, personal communication.)
Clinical guidelines indicate that there is a place for more aggressive surgery, with a risk-reducing element,
for patients known to have LS on CRC diagnosis; in particular, Cairns et al.46 stated that, ‘For patients with
proximal tumours, colectomy and ileorectal anastomosis is most relevant’ (p. 678). Input from our clinical
expert suggested that this particular guidance would rarely be followed as it was based on a low category
of evidence (evidence obtained from expert committee reports or opinions or clinical experiences of
respected authorities) and colonoscopic surveillance is deemed effective enough to negate the need for
aggressive surgery (Mr Ian Daniels, personal communication). To resolve this disagreement we included a
parameter in the model that defines the probability that more aggressive surgery would be used for LS
patients, which could be varied from 0 (ignore guidelines; surgical treatment not affected by Lynch
diagnosis) to 1 (full adherence to guidelines; aggressive surgery always used). Previous analyses by Snowsill
et al.4 demonstrated that altering this parameter had a minimal impact on cost-effectiveness and therefore
sensitivity analyses on this parameter have not been repeated.
When surgery removes the rectum because of cancer in the rectum there are two common operations:
AR, which preserves the anus, and abdominoperineal excision of the rectum (APER), which results in
permanent stoma. We grouped these operations together and assumed that they are both as effective at
preventing metachronous rectal cancer. Some patients would require a permanent stoma, which would
affect health-related quality of life (HRQoL) and costs. Rather than modelling this on an individual patient
basis we assumed an average effect across all patients.
Any subsequent surgery depends on the location of the CRC, the nature of the previous surgery and
















Includes right hemicolectomy, extended right hemicolectomy, 
transverse colectomy, left hemicolectomy and sigmoid colectomy
None No surgery
SEG Segmental colon resection
AR Anterior resection
SUB subtotal colectomy
IPAA Ileal pouch anal anastomosis (total proctocolectomy)
Colon cancer
Rectal cancer
Synchronous colon cancer or polyps in distant sections of colon or aggressive management
of colon cancer in LS patient
Synchronous colon and rectal cancer or synchronous rectal cancer and colonic polyps or 
aggressive management of rectal cancer in LS patient
Metachronous colon cancer
Metachronous rectal cancer
Includes anterior resection, 





FIGURE 26 Surgical management pathways for CRC. APER, abdominoperineal excision of the rectum. Source:
reproduced from figure 19 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information32 (adapted from Maeda et al.106).
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Surgery distributions for CRC patients diagnosed with LS were adjusted by the parameter representing the
probability of aggressive surgery. If this probability is denoted as p, then for colon cancer patients:
Pr(SEGjLS diagnosed) = (1−p)Pr(SEGjLS not diagnosed) Pr(SUBjLS diagnosed)
= 1−Pr(SEGjLS diagnosed)), (9)
where SEG is segmental resection and SUB is subtotal colectomy. For rectal cancer patients:
Pr(ARjLS diagnosed) = (1−p)Pr(ARjLS not diagnosed) Pr(IPAAjLS diagnosed)
= 1−Pr(ARjLS diagnosed)), (10)
where IPAA is ileal pouch anal anastomosis.





colectomy (%) AR (%) Proctocolectomy (%) Source
None 96a 4b 0 0 National Bowel
Cancer Audit108
Segmental resection 0 100 0 0 Assumption
Subtotal colectomy NAc NAc NAc NAc Assumption
AR 0 0 0 100 Assumption
Proctocolectomy NAc NAc NAc NAc Assumption
NA, not applicable.
a In total, 8850 colon cancer patients underwent right hemicolectomy (n= 6627), transverse colectomy (n= 86), left
hemicolectomy (n= 978) or sigmoid colectomy (n= 1159).108
b In total, 325 colon cancer patients underwent total or subtotal colectomy.108
c NA because subtotal colectomy and proctocolectomy are assumed to completely eliminate the risk of colon cancer.
Source: reproduced from table 48 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32





colectomy (%) AR (%) Proctocolectomy (%) Source
None 0 0 98a 2b National Bowel
Cancer Audit108
Segmental resection 0 0 0 100 Assumption
Subtotal colectomy 0 0 0 100 Assumption
AR NAc NAc NAc NAc Assumption
Proctocolectomy NAc NAc NAc NAc Assumption
NA, not applicable.
a In total, 4341 rectal cancer patients underwent AR (n= 2890), APER (n= 1139) or the Hartmann procedure (n= 312).108
b In total, 82 rectal cancer patients underwent total or subtotal colectomy.108
c NA because AR and proctocolectomy are assumed to completely eliminate the risk of rectal cancer.
Source: reproduced from table 49 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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In the base case, this parameter was set to 0 for the following reasons:
l the clinical guidelines [e.g. the BSG/Association of Coloproctology of Great Britain and Ireland (ACPGBI)
guidelines46] are not based on high-quality evidence
l the model does not incorporate any utility decrement for more aggressive surgery, even though
function can be affected (see Colorectal cancer treatment)
l the model does not incorporate excess surgical mortality from more aggressive surgery.
Aspirin chemoprevention
Aspirin has been shown in observational studies to reduce the CRC burden126 and the CAPP2 RCT in
individuals with LS mutations demonstrated a protective effect from aspirin against CRC and other
LS-associated cancers in individuals completing the protocol.
As the balance of risks and benefits is favourable for prescribing regular aspirin to individuals with LS
(unless contraindicated), and aspirin use in this context is highly likely to be cost-effective (and patients
may also purchase aspirin over the counter if not prescribed), it was judged that aspirin chemoprevention
should be included as part of the base-case analysis.
It should be noted that, at present, individuals with LS are most likely to receive aspirin as part of the ongoing
Cancer Prevention Programme 3 (CaPP3) dosing study rather than by being directly prescribed aspirin.
A scenario analysis was also conducted in which aspirin was not prescribed.
Perspective, time horizon and discounting
Costs were included from a NHS and PSS perspective.
The perspective on health outcomes was all direct health effects on patients, which in this case included
individuals newly diagnosed with CRC (probands) and their blood relatives who may be at risk of LS.
A lifetime time horizon was used, with a maximum age of 100 years modelled.
Costs and QALYs were discounted at 3.5% per annum (unless otherwise stated). Life-years and natural
outcomes (e.g. number of CRCs) were not discounted (unless otherwise stated).
Model parameters
A summary table of all of the model parameters is provided in Appendix 4.
Treatment effectiveness and extrapolation
Diagnostic performance
Estimates of test accuracy (sensitivity and specificity) were taken from the available literature, identified through
the diagnostic accuracy and cost-effectiveness literature reviews reported in Chapters 2 and 4 respectively.
In Snowsill et al.,4 test accuracy for IHC and MSI was taken from the EGAPP review reported by Palomaki
et al.42 In the EGAPP review, studies with very different input populations were synthesised, not all of which
were relevant to this review. In the current model, population-based studies identified in Chapter 234,54–56
were used to produce estimates of test accuracy. In Chapter 2 it was explained that a meta-analysis of the
included studies was not conducted because of the heterogeneity of the studies. In particular, although they
were population-based studies, the studies by Barnetson et al.,54 Southey et al.56 and Limburg et al.55 all used
age limits in their input population, which will influence the prevalence of these populations and potentially
the sensitivity and specificity of the tests.
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The results of these studies were synthesised using the multilevel mixed-effects logistic regression command
‘melogit’ in Stata®/SE 14.1 (StataCorp LP, Texas, USA). The code for this analysis is presented in Appendix 5.
The results of this analysis (with 95% CIs), plus the EGAPP results, are presented in Table 47. The values from
Snowsill et al.4 lie well within the CIs of the new estimates, although the new point estimates for sensitivity
appear higher and for specificity appear slightly lower than those reported by the EGAPP review.
Because of the low number of studies (three for MSI, two for IHC) it was not possible to estimate the
correlation between true sensitivity and true specificity across studies, so this parameter was removed from
the estimation (i.e. independence of random effects was assumed).
As indicated in Chapter 2, this synthesis may not be entirely appropriate to determine test accuracy for
the purposes of review. This is because of the small number of studies, the variation in methodology
(e.g. heterogeneity in the reference standard) and the heterogeneity in the accuracy estimates (e.g. Poynter
et al.34 predicted much higher sensitivity and lower specificity for MSI than the other two studies). The small
number of studies means that it is not possible to adequately explore sources of heterogeneity and it is
also not possible to assess the likelihood of publication bias (e.g. using a funnel plot). However, the CIs are
sufficiently wide that for modelling purposes a range likely to include the true values can be implemented in
univariate sensitivity analyses.





































BRAF V600E Sensitivity 0.96
(0.60 to 0.99)














a Ladabaum et al.3 0.93 Bouzourene et al.128


















a Same as in the base case.
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Accuracy results for BRAF V600E and MLH1 promoter methylation testing were taken from the recent
technical review by Ladabaum et al.,3 which was identified from the searches run in the cost-effectiveness
review (see Chapter 4, Study identification). In this technical review 14 studies reporting MLH1 promoter
methylation testing and 11 studies reporting BRAF V600E testing were synthesised. These studies included
a variety of previous tests, including MSI and IHC. These values update the values used in the study by
Snowsill et al.,4 which were based on very few studies.
The accuracy of genetic testing in probands and relatives is unchanged in the current model from the
values used in Snowsill et al.4 and is taken from published literature. Diagnostic genetic testing for PMS2 is
assumed to have a lower sensitivity than testing for the other genes, given the greater complexity of the
molecular analysis for this gene (which results in a lower pick-up rate) and the greater difficulties in
interpreting mutations (when found) as pathogenic (given the lower penetrance of mutations in PMS2).5,45
One other important component of the effectiveness of a strategy is the acceptance rate of the tests.
Acceptance rates of diagnostic tests and their sources are reported in Table 48. With the exception of the
acceptance of counselling and genetic testing for relatives, which was updated to use UK data from the
Manchester Regional Lynch Syndrome Registry, as reported in Barrow,91 the acceptance rates remain
unchanged from those used in the study by Snowsill et al.4 Previously these values were taken from the
study by Palomaki et al.42 and were not UK specific.
Surveillance
Colonoscopy Colonoscopy is assumed to lead to improved health outcomes by reducing the incidence of
CRC (as adenomas that could have become adenocarcinomas are identified and removed) and by improving
the cancer stage distribution on diagnosis (i.e. catching the cancer earlier), which leads to improved survival.
The model assumed that the majority of patients diagnosed with LS will be offered and will accept
surveillance colonoscopies.
Data from 591 individuals from the Manchester Familial Colorectal Cancer Registry, as reported in
Barrow,91 were used to estimate the acceptance rates for relatives diagnosed with LS. We assumed that
these rates would be the same for probands as for relatives, as in the study by Snowsill et al.4 the
acceptance of surveillance in probands was the same as or higher than that in relatives. Previously, these
estimates were taken from the study by Ladabaum et al.,85 which was a study of a US population and
TABLE 48 Rates of acceptance of diagnostic tests and genetic counselling
Test Proband/relative
Acceptance
rate (%) Original source
MSI Proband 100 Ramsey et al.,83 confirmed by expert (IF) in
Snowsill et al.4
IHC Proband 100 Assumed
BRAF V600E Proband 100 Assumed
MLH1 promoter methylation Proband 100 Assumed
Genetic test following counselling
(proband)
Proband 90 Ladabaum et al.85
Genetic counselling (proband) Proband 92.5 Clinical expert (IMF) gave range 90–95% in
Snowsill et al.4
Genetic test following counselling
(relative)
Relative 77 Calculated from Manchester Familial Colorectal
Cancer Registry data, reported in Barrow91
Genetic counselling (relative) Relative 78 Calculated from Manchester Familial Colorectal
Cancer Registry data, reported in Barrow91
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which therefore does not reflect the acceptance rate in the UK population. The current values appear to
suggest higher acceptance rates than previously modelled. However, as these values are taken from only
one UK institution and acceptance of surveillance has been previously shown to be an influential
parameter with regard to cost-effectiveness, we examined the impact of these rates in sensitivity analyses.
Table 49 shows the assumed acceptance rates used in the model.
Colorectal cancer incidence Previously,4 event times were extracted from figure 1 of Järvinen et al.124
and used in a Cox proportional hazards regression to estimate the effectiveness of colonoscopy in reducing
CRC incidence. The resulting HR estimate was 0.387 (95% CI 0.169 to 0.885).
Subsequently, other evidence has also been collected relating to this question.
The American Gastroenterological Association published a technical review on the diagnosis and
management of LS in 2015.3 This review identified five observational studies (including that by Järvinen
et al.124), which allowed estimation of the effectiveness of colonoscopy in reducing CRC incidence. The
pooled effect estimate (odds ratio) was 0.23 (95% CI 0.13 to 0.41).
Møller et al.5 reported on the cancer risks in a prospectively identified population of LS carriers, in whom
surveillance is widespread. This study included 1942 LS carriers from across Europe (and Australia), with
195 of these from the UK. The authors found high rates of CRC in spite of regular surveillance.
Figure 27 illustrates the contradictory nature of the evidence. ‘Bonadona’ and ‘Møller’ are the estimated
incidence rates in the studies, whereas ‘Bonadona + Järvinen’ is a counterfactual incidence rate profile
TABLE 49 Initial rates of acceptance of LS surveillance for CRC
Patient characteristic Initial acceptance of surveillance91 (%)
Value in Snowsill et al.4
(based on Ladabaum et al.85) (%)
Proband tested LS mutation positive 97 80
Proband LS assumed 70 70
Relative tested LS mutation positive 97 80
























FIGURE 27 Comparison of CRC incidence rates in the absence of surveillance (Bonadona) and with surveillance
(Møller). Notes: assumes that 41% have MLH1 mutation, 44% have MSH2 mutations and 16% have MSH6
mutations (figures do not sum to 100% because of rounding). Sources: Bonadona et al.18 and Møller et al.5
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
obtained by applying the HR of 0.387 to the ‘Bonadona’ data. If all of these studies were conducted
without bias and in similar populations and with enough statistical power, one would expect the ‘Møller’
data to closely align with the ‘Bonadona + Järvinen’ data rather than the ‘Bonadona’ data.
There are a number of potential reasons why the results of Møller et al.5 might not confirm the
effectiveness of colonoscopy observed in the study by Järvinen et al.:124
l the limited statistical power in both the Bonadona et al.18 study and the Møller et al.5 study
(i.e. random chance)
l the naive comparison of the results from the Bonadona et al.18 study and the Møller et al.5 study,
with no adjustment for differences in populations (other than for gene distribution and age)
l the biased effect estimate in the study by Järvinen et al.124
It is difficult to assess the similarity of the Bonadona et al.18 and Møller et al.5 patient populations. The
population in Bonadona et al.18 seems to have a more even balance between men and women whereas
the population in Møller et al.5 included somewhat more women. It is possible that there are differences in
the proportions of patients with clearly pathogenic mutations – Bonadona et al.18 included 7% (35/537)
of families with variants of uncertain significance, whereas Møller et al.5 included only patients with
mutations judged pathogenic by their reporting centre (although 31% of patients had mutations not
reported on the Leiden Open Variant Database by October 2015).
The two main sources of potential bias in the Järvinen et al.124 study are confounding because of:
l self-selection of the intervention group (i.e. participants chose whether or not to receive the
intervention) – this would be expected to exaggerate the effectiveness estimate as participants
choosing to receive surveillance are more likely to engage in other healthy behaviours and to have
other characteristics predictive of good outcomes
l treatment switching (i.e. participants who initially declined surveillance who later opted into
surveillance) – this would be expected to attenuate the effectiveness estimate.
Furthermore, the results from Järvinen et al.124 may not generalise to current surveillance in the NHS
because of developments in technology or differences in service delivery and behaviour, which could result
in a different distribution of screening intervals.
However, in the absence of compelling alternative effectiveness estimates, we continued to use the HR of
0.387 from the study by Järvinen et al.124
In a worst-case scenario analysis it was assumed that surveillance does not reduce the incidence of CRC,
that is, a HR of 1 was used.
Stage on diagnosis As previously,4 the stage on diagnosis was assumed to be dependent only on
whether an individual has been offered and accepted LS surveillance colonoscopies. Whether the individual
has a LS mutation, their previous history of cancer and their sex and age were not modelled as affecting
the stage distribution.
The stage on diagnosis for individuals not accepting surveillance was estimated from national data from
England. In England in 2012, 11% of CRCs were not staged (or the stage was not recorded).131 The
National Cancer Intelligence Network used multiple imputation methods, based on patient and cancer
characteristics that were recorded, to estimate the stage distribution for the unstaged patients (Table 50).
When this stage distribution is combined with the data for patients whose cancers were staged, the
resulting distribution for stages I–IV is 17.6 : 27.0 : 29.5 : 25.9 respectively. Previously,4 a distribution of
16.4 : 31.7 : 27.1 : 24.8 for stages I–IV, respectively, was estimated from 2009/10 data by excluding
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patients whose cancer stage was not recorded. The effect of the change is to reduce the number of
patients with stage II CRC and increase the number of patients with other stages.
For individuals accepting LS surveillance colonoscopies, a stage distribution of 68.6 : 10.5 : 12.8 : 8.1 for
stages I–IV, respectively, was used, as previously,4 based on data from Mecklin et al.132
Gynaecological surveillance A literature review was conducted previously of the effectiveness of
surveillance for endometrial and ovarian cancer.4 Conceptually, surveillance was expected to reduce the
incidence of gynaecological cancers by the detection of premalignancies, which are either individually
removed or which prompt hysterectomy. Malignancies identified during surveillance were also expected to
have a more favourable stage profile.
No experimental studies (e.g. RCTs) were identified, but three non-experimental studies were identified.133–135
Two of these studies134,135 considered cohorts of women with LS eligible for gynaecological surveillance and
compared patients receiving surveillance with patients refusing or not receiving surveillance during the study
(Figures 28 and 29). These study designs could provide estimates of the effectiveness of surveillance in
reducing the incidence of gynaecological cancer; however, they were both at high risk of bias because
of potential confounding factors between the groups and neither could provide satisfactory effect size
estimates because of the limited control group sizes and the limited number of events. The limited number of
events also means that these studies are not informative for the stage distribution of gynaecological cancers.
TABLE 50 Stage distribution of CRCs in England
Stage
Observed data for all patients Imputed stage distribution of ‘unknown’ Combined data
n % n % n %
I 5255 15.5 734 2.16 5989 17.6
II 8402 24.7 768 2.26 9170 27.0
III 9258 27.2 778 2.29 10,036 29.5
IV 7351 21.6 1465 4.31 8816 25.9
Unknown 3745 11.0
Total 34,011 100.0 3745 11.02 34,011 100.0
Source: calculated from tables 1 and 4 from National Cancer Intelligence Network.131










At least one scan
(n = 222)
FIGURE 28 Patient flow diagram for the study by Dove-Edwin et al.134 EC, endometrial cancer.
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The study by Renkonen-Sinisalo et al.,133 in contrast, considered patients before and after institution of a
surveillance programme. The outcomes of 385 women with LS mutations were compared with the
outcomes of 83 women with LS mutations who were affected by endometrial cancer before surveillance
was instituted (Figure 30).
This study design cannot be used to estimate the effect of surveillance on cancer incidence, but it can be
used to estimate the impact of surveillance on the stage of cancer at diagnosis (Figure 31).
An ordered logistic regression was used to estimate the impact of surveillance. The regression coefficient
for surveillance was not statistically significant (z = –0.45, p = 0.651) but was suggestive that surveillance
could improve the stage distribution. Predicted stage distributions from the regression are shown in
Figure 32.
These stage distributions were not used directly but were instead used to estimate a HR for survival from
endometrial cancer.
Lewin et al.113 estimated the 5-year survival from endometrial cancer according to stage at diagnosis
(Table 51). The weighted average 5-year survival for patients in the surveillance and control groups was
estimated as 83.4% and 81.8%, respectively, from which a HR of 0.898 was derived.
Because of the significant uncertainty in this HR, a scenario analysis is included in which there is no survival
benefit (i.e. no benefit at all) from gynaecological surveillance.
It should be noted that the women in the study by Renkonen-Sinisalo et al.133 were offered surveillance
with 2- or 3-year intervals, whereas current European guidelines propose annual surveillance,125 so it is
possible that a study of annual surveillance could find greater effectiveness than what is modelled here.
Chemoprevention
There is evidence from the CAPP2 RCT that aspirin reduces the incidence of cancer in individuals with LS
mutations.29 In this study participants were randomised to receive aspirin (600 mg of enteric coated aspirin
EC cases
(n = 83)
Historical controls (mutation carriers 
from same families with symptomatic EC)
(n = 83)
Exclusions 















Did not enter surveillance
(n = 72)
FIGURE 30 Patient flow diagram for the study by Renkonen-Sinisalo et al.133 EC, endometrial cancer.
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daily) or aspirin placebo (alongside resistant starch or starch placebo in a two-by-two factorial design) for
up to 4 years.
Intention-to-treat and per-protocol analyses were conducted. Per-protocol analyses considered patients
who continued to take aspirin (or aspirin placebo) for at least 2 years.
Analyses were conducted using Cox proportional hazards regression (to obtain a HR for the incidence of
first cancer) and Poisson regression (to obtain an incidence rate ratio accounting for multiple cancers
within each individual).
In total, 861 participants were randomised to aspirin (n = 427) or aspirin placebo (n = 434). At the time of
publication the mean follow-up was 55.7 months (4.6 years), with a maximum follow-up of 128.0 months
(10.7 years).
The intention-to-treat proportional hazards analysis showed a reduction in CRC incidence in those taking
aspirin compared with those taking aspirin placebo (HR 0.63, 95% CI 0.35 to 1.13), but this did not reach
statistical significance (p = 0.12). A number of other analyses did reach statistical significance and the
authors concluded that aspirin is effective at reducing the risk of LS cancers (Table 52).
Not all patients recruited to the trial (n = 1071) were randomised to aspirin or aspirin placebo; 134 were
ineligible to receive aspirin or withdrew before treatment and 76 participants requested not to receive
aspirin. On this basis it was estimated that 80.4% of patients would be offered and would accept aspirin























FIGURE 31 International Federation of Gynecology and Obstetrics (FIGO) stage distribution of endometrial cancers
in the study by Renkonen-Sinisalo et al.133 (a) Surveillance; and (b) control.
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The majority (59%) of participants randomised to aspirin or aspirin placebo were treated for ≥ 2 years. It
was assumed that 59% of individuals accepting aspirin chemoprevention would receive aspirin for 4 years
and would have a reduced incidence of CRC and endometrial cancer (incidence rate ratios of 0.37 and
0.49 respectively), whereas the remaining individuals would receive no aspirin and would see no change in
their incidence rates.
As the estimates are taken from a study with a maximum follow-up of just over 10 years, it was assumed
conservatively that the duration of effect would be 10 years.
Health-related quality of life
Systematic searches were conducted for utilities associated with CRC, endometrial cancer and prophylactic




















FIGURE 32 Predicted stage distribution based on the results of Renkonen-Sinisalo et al.133 (a) Surveillance; and
(b) control.
TABLE 51 Five-year survival from endometrial cancer according to stage at diagnosis





FIGO, International Federation of Gynecology and Obstetrics.
Source: calculated from results presented by Lewin et al.113
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(via Ovid). Searches consisted of population terms for hysterectomy and salpingo-oophorectomy, CRC and
endometrial cancer, combined with relevant utility terminology. The searches for CRC utility studies were
date limited from 2005 to February 2016, with literature published prior to 2005 identified using the study
by Snowsill et al.4 The hysterectomy and salpingo-oophorectomy and the endometrial cancer searches
were not date limited. Searches for each population group were conducted separately and were then
combined and deduplicated using EndNote X7. The full search strategies and the number of hits per
database and in total are detailed in Appendix 1.
The searches were screened (first by title and abstract and then by full text) by one reviewer (NH), who also
carried out data extraction and assessed the studies for suitability for parameterising the model.
Colorectal cancer
Twelve full texts reporting CRC and related utilities were identified, six of which reported the effect of CRC
on utility estimates and six of which reported the effect of CRC treatment on utilities. An overview of the
first group of studies is provided in Table 53. Several studies reported multiple utility measures, but only
those that are most relevant to the review are presented here.
The findings of these results were consistent with what has been previously modelled (Table 54). As such,
the base case in the current study remains unchanged from the model in Snowsill et al.,4 with no disutility
assumed for individuals diagnosed with Dukes’ A, B or C and a disutility of 0.13 for individuals diagnosed
with Dukes’ D.142,143 A scenario analysis was used to investigate the possibility of an increased disutility
associated with CRC, using the figures from Ness et al.,144 as reported previously in Snowsill et al.4 This is
consistent with other cost-effectiveness analyses that have used the same sources.145–148
Colorectal cancer treatment Four studies149–152 all reported that more extensive colorectal surgery does
not appear to impact on quality of life in CRC patients with familial cancer syndromes, including patients
with LS. These studies reported findings from a variety of countries (the Netherlands, USA, Australia and
New Zealand), although none were UK based. The quality-of-life questionnaires used in these studies were
the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C-30 or Short Form
questionnaire-36 items (SF-36) and so the presented utility estimates cannot be directly compared with each
other or with the EuroQol-5 Dimensions (EQ-5D); however, the message appears consistent that the type of
surgery does not adversely impact quality of life in CRC patients. These findings agree with those reported
in Snowsill et al.4 and, as such, in our base case we assume no disutility for more extensive surgeries.
TABLE 52 Summary of key results from the CAPP2 trial
Analysis HR (95% CI) Incidence rate ratio (95% CI)
Intention to treat
CRC 0.63 (0.35 to 1.13) 0.56 (0.32 to 0.99)
LS cancers except CRC 0.63 (0.34 to 1.19) 0.63 (0.34 to 1.16)
All LS cancers 0.65 (0.42 to 1.00) 0.59 (0.39 to 0.90)
Per protocola
CRC 0.41 (0.19 to 0.86) 0.37 (0.18 to 0.78)
LS cancers except CRC 0.47 (0.21 to 1.06) 0.49 (0.23 to 1.05)
All LS cancers 0.45 (0.26 to 0.79) 0.42 (0.25 to 0.72)
a HRs and incidence rate ratios refer to patients taking aspirin for ≥ 2 years vs. patients taking aspirin placebo for ≥ 2 years.
Source: data from table 2 of Burn et al.29
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One study153 presented Short Form questionnaire-6 Dimensions results for US CRC survivors with or
without an ostomy. The authors indicated that disutility from an ostomy could be explained by other
patient characteristics. No other studies reported HRQoL results for CRC survivors according to whether
or not they had received an ostomy. We therefore assumed no disutility for patients with an ostomy
compared with those without in our base case.
Another study154 presented SF-36 scores for CRC patients in the Netherlands who were receiving either
radiotherapy or radiotherapy and chemotherapy. The results from this study suggested that the addition of
chemotherapy did not have a significant impact on quality of life. No other studies reported HRQoL results
for CRC survivors according to whether or not they were receiving chemotherapy. We therefore assume no
disutility according to treatment in our base case.
Colorectal cancer prevention One study155 presented SF-36 results for 100 individuals undergoing
colonoscopy for various reasons and indications, including surveillance for CRC (surveillance following CRC,
n = 21; family history of CRC, n = 13), in Israel. General health was found to be comparable before and
after (both immediately and 1 month after) colonoscopy for non-inflammatory bowel disease patients
(n = 88), including those receiving surveillance for CRC, and no single component of the SF-36 was found
to be statistically significantly different after colonoscopy. No other studies were identified that reported
HRQoL for individuals receiving colonoscopy. Therefore, no disutility for asymptomatic individuals resulting
from colonoscopy was assumed in the base case.
Endometrial cancer
Five studies156–160 were identified that reported endometrial cancer quality-of-life estimates; two reported
the PORTEC-2 (Postoperative Radiation Therapy for Endometrial Carcinoma) Phase III RCT at multiple time
points,156,160 which had the largest population (n = 427 at baseline, n = 80 at 10 years’ follow-up) and
longest follow-up (maximum 10 years) and compared the quality-of-life estimates for endometrial cancer
with general population estimates. This trial included stage 1, high-risk endometrial cancer and reported
HRQoL from the EORTC QLQ-C30. Nout et al.156 demonstrated an equal or improved HRQoL as time
progressed after diagnosis and initial treatment (TAH-BSO) compared with the general population.
Although the PORTEC-2 RCT was based in the Netherlands, this finding was supported by the results of
the other three studies, which were based in Italy,159 Germany157 and Turkey.158
We therefore used the PORTEC-2 trial as our source of disutility for endometrial cancer compared with the
general population. We mapped the EORTC QLQ-C30 results to the EQ-5D using the algorithm provided
by Longworth et al.,161 which has been validated by Doble and Lorgelly.162 Longworth et al.161 created the
algorithm to map from the EORTC QLQ-C30 to the EQ-5D based on 771 patients with multiple myeloma
[Velcade as Initial Standard Therapy (VISTA trial)], breast cancer and lung cancer (Vancouver Cancer clinic).
Their work was funded by the UK Medical Research Council and, as such, was conducted from a UK
TABLE 54 Disutilities associated with CRC
CRC stage
Base case Sensitivity analysis
Disutility Source Disutility Source
Dukes’ A 0.00 Ramsey et al.142 0.11 Ness et al.144
Dukes’ B 0.00 Ramsey et al.142 0.23 Ness et al.144
Dukes’ C 0.00 Ramsey et al.142 0.26 Ness et al.144
Dukes’ D 0.13 Mittmann et al.143 0.60 Ness et al.144
Source: adapted from table 82 of Snowsill et al.4 under the terms of the UK government’s non-commercial licence for
public sector information.32
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perspective, although the EORTC QLQ-C30 data came from international sources. The algorithm provides
estimates for each of the dimensions of the EQ-5D, which can then be transformed into utilities using the
results from Dolan,163 which uses a UK-validated set to estimate utilities from EQ-5D data. Doble and
Lorgelly162 assessed the external validity of 10 mapping algorithms that mapped from the EORTC QLQ-C30
onto the EQ-5D using data from the Cancer 2015 prospective longitudinal study.164 This study included
1834 patients with a range of cancer tumour sites, excluding leukaemia, and a range of disease stages,
including both local and metastatic disease. Doble and Lorgelly162 reported that the algorithm created by
Longworth et al.161 was one of the most computationally heavy but also performed well on a number of
criteria, including extreme health states and having no statistically significant difference between observed
and predicted QALYs over time.
By estimating the baseline EQ-5D utilities in the PORTEC-2 trial (0.837 general population, 0.819 external
beam radiation therapy receiving patients, 0.783 vaginal brachytherapy receiving patients) and averaging
the utility across the two treatments to give a utility estimate for the endometrial cancer population, the
disutility for endometrial cancer was estimated to be –0.036. As the PORTEC-2 trial indicates that quality of
life improves over time for endometrial cancer patients, reverting to (or exceeding) the quality of life of the
general population, this disutility is applied only for the first year following an endometrial cancer diagnosis.
Prophylactic hysterectomy
No studies were identified that could inform the disutility of prophylactic hysterectomy. In the base case
we assumed that there was no disutility from prophylactic hysterectomy, to reflect our belief that quality of
life would be similar to or better than the long-term quality of life for endometrial cancer patients who
have received hysterectomy and recovered from cancer. In the PORTEC-2 trial this was at least as good as
the general population utility and therefore results in a utility decrement of 0. In sensitivity analysis we
set the disutility equal to the utility decrement from endometrial cancer, under the assumption that
prophylactic hysterectomy should not have a higher disutility than endometrial cancer.
Psychological impacts of Lynch syndrome testing and management on quality of life
No additional literature was identified to that in Snowsill et al.4 to estimate the psychological impact of LS
testing on individuals offered testing for LS. Box 5 describes the existing evidence, as reported in Snowsill et al.4
BOX 5 Evidence on the psychological impact of LS testing on HRQoL
Although diagnosis of LS can lead to interventions to reduce the chance of developing colorectal,
gynaecological and other cancers, it can also lead to anxiety about developing these cancers and the need
to make difficult decisions about whether or not to undergo risk-reducing surgeries. Furthermore, those
diagnosed with LS must decide whether or not and how to inform relatives about their test results so that
these relatives can consider whether or not they wish to be tested themselves. Given that anxiety is one
aspect of HRQoL, such effects should be considered in the estimation of health-state utilities of probands
and relatives.
We identified just a single study of the cost-effectiveness of strategies for testing for LS [Wang and
colleagues (2012)86] that incorporates disutilities associated with the psychological impact of testing. In this
study it was assumed that such disutilities are transient, lasting 1 year in the base-case analysis. . . .
Disutilities due to testing itself and the test results were taken from the empirical study by Kuppermann
and colleagues (2013).
Reproduced from Snowsill et al. (p. 162)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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The disutility associated with testing for relatives was calculated using the utilities reported by Kuppermann
et al.,165 as previously4 (Box 6), as was the disutility associated with testing for probands4 (Box 7).
Table 55 summarises the disutilities included in the model relating to the psychological impact of genetic testing.
BOX 6 Methods used to calculate the disutility associated with testing in relatives
[We] assume that relatives who decline testing incur a disutility over 4 months of 0.04, equal to the utility
of 0.76 (siblings who undergo testing, and test negative) minus 0.72 (siblings who decline testing). This
disutility reflects anxiety the relative may feel in not knowing whether or not he or she has LS, with the
corresponding substantial risk of developing cancer. Next, we assume a disutility of 0.02 for male relatives
who are diagnosed with LS, equal to 0.76 for siblings who undergo testing and test negative, minus 0.74
for males who are tested positive for LS. Similarly, we assume a disutility of 0.06 for women who test
positive and undergo TAHBSO, equal to 0.76 minus 0.70, and a disutility of 0.09 for women who test
positive and decline TAHBSO, equal to 0.76 minus 0.67. The disutility is greater for women who decline
TAHBSO presumably because they know that there remains a chance that they will develop gynaecological
cancers. For women who test positive but are not offered TAHBSO as they are not at the appropriate age,
we assume that the disutility of testing positive will be the same as for men who test positive, i.e. 0.02.
Reproduced from Snowsill et al. (p. 163)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
BOX 7 Methods used to calculate the disutility associated with testing in probands
Kuppermann and colleagues did not measure the utility for probands who accepted testing and were
diagnosed as LS negative. In the absence of this information, we assume that these individuals have no
associated disutility due to genetic testing . . . . Next, we estimate the disutility for probands of declining
testing as 0.04, equal to the corresponding value for relatives. . . . Kuppermann and colleagues do not
measure the utility for probands who accepted testing and were diagnosed with LS but were not offered
any risk-reducing surgery, so we assume that the disutility for testing positive for male probands is the
same as the disutility for male relatives, i.e. 0.02. For female probands who test positive and are not
offered any risk-reducing surgery, we again assume the same disutility as for males, i.e. 0.02. For female
probands who test positive and are offered prophylactic TAHBSO, we assume disutilities of 0.03 for those
accepting surgery and 0.09 for those declining it. These disutilities are estimated by subtracting the utilities
of 0.67 and 0.61 reported in Kuppermann and colleagues from the imagined utility of probands testing
negative, which we estimate as the utility of probands declining testing (0.66) plus a utility of 0.04 for not
declining testing taken from the relatives, to give a utility for probands testing negative for LS of 0.70. If a
proband or relative declines testing but is still diagnosed with LS (by FH [family history] for probands or on
account of being a FDR [first-degree relative] of a known carrier for relatives) and offered TAHBSO, we
assume a disutility of 0.01 for probands and 0.04 for relatives (i.e. the same disutility as for probands or
relatives testing positive), with an additional disutility of 0.06 for probands declining TAHBSO and 0.03 for
relatives declining TAHBSO. For example, the total disutility for a proband declining testing and accepting
TAHBSO would be 0.04 (declined testing) + 0.01 (offered TAHBSO) = 0.05, while the total disutility for a
relative declining testing and declining TAHBSO would be 0.04 (declined testing) + 0.04 (offered
TAHBSO) + 0.03 (declined TAHBSO) = 0.11.
Reproduced from Snowsill et al. (p. 164)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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Resources and costs
Adjustments to 2016/17 prices
Costs were inflated to 2014/15 prices using the Hospital and Community Health Services (HCHS) pay and
prices index and then to 2016/17 prices according to the average inflation in the 3 most recent recorded
years (Figure 33).166
TABLE 55 Base-case disutilities resulting from genetic testing




Test declined, risk reduction not offered 0.04 0.04
Test declined, accept risk reduction NA 0.05
Test declined, decline risk reduction NA 0.11
Test accepted, LS negative 0 0
Test accepted, LS positive, risk reduction not offered 0.02 0.02
Test accepted, LS positive, accept risk reduction NA 0.03
Test accepted, LS positive, decline risk reduction NA 0.09
Relative
Test declined, risk reduction not offered 0.04 0.04
Test declined, accept risk reduction NA 0.08
Test declined, decline risk reduction NA 0.11
Test accepted, LS negative 0 0
Test accepted, LS positive, risk reduction not offered 0.02 0.02
Test accepted, LS positive, accept risk reduction NA 0.06
Test accepted, LS positive, decline risk reduction NA 0.09
NA, not applicable.




































































































FIGURE 33 Historical and projected inflation of the HCHS pay and prices index. a, Projection.
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Resource use
Colorectal surveillance As described earlier (see Surveillance pathways, Colorectal surveillance), the model
assumed that individuals diagnosed with LS would undergo biennial colonoscopy. The majority of those
diagnosed with LS take up surveillance: 97% of those with a confirmed pathogenic mutation and 70% of
those in whom LS is suspected without a causative mutation being identified (see Surveillance, Colonoscopy).
Although acceptance is high, it is also recognised that implementation of or concordance with the
surveillance regimen is imperfect, for a number of reasons (e.g. service delivery, patient circumstances and
factors). It was estimated that 12.7% of planned colonoscopies would be missed, based on a Regional
Familial Colorectal Cancer Registry study by Newton et al.167 This parameter is not assumed to affect the
effectiveness of colonoscopy and therefore its impact on cost-effectiveness is not as expected – increasing
this parameter in a sensitivity analysis would reduce the costs of surveillance without reducing effectiveness
and would therefore improve the cost-effectiveness of diagnostic strategies. For this reason, this parameter
was not subjected to sensitivity analyses.
It is important (especially for individuals with LS who are more susceptible to proximal colon cancer than the
general population) that colonoscopy is complete (including intubation of the caecum). For this reason it is
recommended that repeat colonoscopies are conducted when colonoscopy is incomplete. The probability of
any colonoscopy being incomplete and needing repeating was estimated as 7.7%, based on a national
colonoscopy audit.168 It was assumed that, at most, one repeat colonoscopy would be performed.
It was assumed that surveillance colonoscopies for LS would start at age 25 years and end at age 75 years,
based on BSG/ACPGBI guidelines.46
Complications Based on a national colonoscopy audit168 it was assumed that, for each 100,000
colonoscopies, there would be 260 bleeding events and 40 perforation events. It was also assumed that
there would be 8.3 deaths per 100,000 colonoscopies.46
Bleeding events were modelled only if they resulted in admission and it was estimated that 21% of bleeds
would result in admission.168 Of these, approximately 18% would be ‘moderate’ bleeds and 9% would be
‘severe’ bleeds.168
Aspirin As described in Chemoprevention, 80.4% of individuals with LS are offered aspirin chemoprevention
and accept it. Of these, 59.0% are concordant with the protocol and receive aspirin for 4 years, with the
remaining individuals assumed to discontinue immediately. The daily dose of aspirin modelled was 600 mg.
Colorectal cancer
Diagnosis All CRC patients were assumed to incur the cost of diagnosis once, in the year of diagnosis.
Primary chemotherapy and radiotherapy
Rectal cancer For rectal cancer patients, 79% are estimated to be operable and, of these, 42.5% are
estimated to present as emergency cases, with the remaining 57.5% undergoing elective surgery.123 Of the
emergency cases, 11% are estimated to receive postoperative chemoradiotherapy (for 2 weeks). Of the
elective cases, 82% are predicted by magnetic resonance imaging to have clear margins after resection and
60% of these have preoperative chemoradiotherapy. A further 4.4% have postoperative chemoradiotherapy
(11% of the 40% not receiving preoperative chemoradiotherapy). All patients not predicted to have clear
margins after resection receive a course of chemoradiotherapy and 88% of these go on to have surgery.123
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Post-surgery chemotherapy courses are given to 28% of patients with Dukes’ B rectal cancer and 75% of
patients with Dukes’ C rectal cancer. Chemotherapy is not given to Dukes’ A patients and Dukes’ D
patients receive palliative therapy, which is detailed in Palliative care.
Colon cancer Adjuvant chemotherapy is given to 0% of Dukes’ A, 39% of Dukes’ B and 89% of Dukes’ C
colon cancer patients.123
Dukes’ D colon cancer patients may receive downstaging chemotherapy for liver metastases, but this is
costed under recurrence chemotherapy and surgery.
Primary surgery All patients diagnosed with CRC are assumed to receive primary surgery, as described in
Colorectal surgery pathways.
Surveillance In the first 5 years after diagnosis, CRC patients follow a surveillance pathway that includes
CEA tests, CT scans, colonoscopies and clinical consultations. Patients are assumed to receive 3-monthly CEA
tests for the first 2 years, then 6-monthly tests for the following 3 years, plus CT scans at 12 and 24 months
and an annual clinical consultation. Patients are also assumed to receive a colonoscopy at 12 months and
then every 5 years thereafter (unless they already receive LS surveillance colonoscopies). Table 56 shows this
pathway. As in the study by Trueman et al.,123 a weighted average cost per year was calculated.
Surgery and chemotherapy for recurrence All patients dying from CRC within 5 years of diagnosis
incur the cost of surgery and chemotherapy for recurrence in the year of their death.
Stoma care All patients with CRC incur average stoma care costs (i.e. the model does not actually track
whether a patient has a stoma or not). It was estimated from the study by Trueman et al.123 that 67% of rectal
cancer patients would require a stoma after surgery compared with 14.5% of colon cancer patients. Of these,
26.6% would be reversed, with patients not requiring long-term stoma care. On this basis it was estimated
that 11% of colon cancer patients and 49% of rectal cancer patients would require a permanent stoma.
Palliative care All patients dying from CRC (at any time after diagnosis) incur the cost of palliative care in
the year of their death.
Gynaecological cancer risk reduction Women diagnosed with LS may be offered interventions to
reduce their risk of developing gynaecological cancers (in the model only endometrial cancer is included).
Women with LS were assumed to be offered gynaecological surveillance at age 35 years (in line with
European Society for Medical Oncology guidelines125) or at the time of their diagnosis (whichever is later).
TABLE 56 Surveillance pathway resource use
Year CEA test CT scan Clinical consultation
1 4 0 1
2 4 1 1
3 2 1 1
4 2 0 1
5 2 0 1
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Initial risk reduction As described earlier (see Gynaecological state on entry), the probability that a
woman diagnosed with LS opts for surveillance, prophylactic surgery or no intervention, at the time of
diagnosis, was estimated based on the results of the Northern Genetics Service audit (Table 57) by dividing
the number of women opting for each intervention in each age range (except those aged ≤ 35 years) by
the total number of women, excluding those with previous cancer or whose results were not recorded.
The resulting probabilities of opting for surveillance or prophylactic surgery at the time of diagnosis are
provided in Table 58.
Subsequent risk reduction Women diagnosed with LS can change their risk reduction subsequently. It
was assumed that all women still receiving surveillance would stop receiving surveillance at age 70 years.
It was assumed that at age 35 years women would be offered surveillance or prophylactic H-BSO and
at age 45 years and 60 years women would be offered prophylactic H-BSO. The probability of receiving
prophylactic H-BSO at age 45 years was estimated as 21.9% to achieve the desired increase in H-BSO
between the 35–44 and 45–59 years age groups (17.5 percentage points). Similarly, it was estimated that
77.1% of women would receive prophylactic H-BSO at age 60 years (Table 59).
Endometrial cancer As previously,4 endometrial cancer treatment was assumed to consist of surgery for
all patients and adjuvant radiotherapy and/or chemotherapy for some patients.
TABLE 58 Initial gynaecological cancer risk reduction
Age at diagnosis (years) Surveillance (%) Prophylactic H-BSO (%)




≥ 70 0.0 85.7
TABLE 59 Subsequent gynaecological cancer risk reduction




TABLE 57 Risk-reducing measures used by 87 women with LS mutations in a Northern Genetics Service audit
Age group (years) Discussed only Surveillance Prophylactic surgery Previous cancer Not recorded
≤ 35 10 6 0 0 1
36–45 3 9 3 0 1
46–60 4 11 9 6 2
> 60 0 2 12 4 4
Source: Northern Genetics Service audit (Lorraine Cowley, personal communication).
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Surgery All women diagnosed with endometrial cancer were assumed to receive surgery.
Radiotherapy It was assumed that radiotherapy was given to 33% of stage I patients, 100% of stage II/III
patients and 0% of stage IV patients.169 It was estimated that this results in radiotherapy being given to
47% of patients overall.
Adjuvant chemotherapy It was assumed that chemotherapy was given to 0% of stage I patients, 50%
of stage II/III patients and 100% of stage IV patients.169 It was estimated that this results in chemotherapy
being given to 18% of patients overall.
We modelled a combination regimen of carboplatin and paclitaxel (Table 60). This has been noted to be a
popular and reasonable regimen in the British Gynaecological Cancer Society draft guidelines,170 which also
state that there is currently no evidence to conclude that any adjuvant chemotherapy regimen is superior
to any other.
The dose required to obtain a specific carboplatin area under the curve (AUC) is given by the
Calvert formula:171
Dose (mg) = target AUC (mg ⋅ minute/ml) × ½glomerular filtration rate (ml/minute) + 25. (11)
We assumed an average glomerular filtration rate of 82.7 ml/minute, based on a Belgian study of 1218
patients.172 We therefore obtained a dose of 592.35 mg of carboplatin per cycle (assuming a target AUC
of 5.5 mg · minute/ml). We assumed an average body surface area of 1.71 m2, based on the average body




Costs of tumour testing The costs of the preliminary tumour tests were obtained directly from
laboratories in the UK (Table 61). When possible, these were sourced from multiple genetics services
through the UK Genetic Testing Network (UKGTN) to produce costs that were representative across the
UK. Unit costs from personal communications received during the completion of this report and from
Snowsill et al.4 were inflated to 2016/17 prices.
Costs of genetic testing Costs for the genetic tests (for probands and relatives) were taken directly from
genetic testing laboratories, as reported through the UKGTN.175 As in the study by Snowsill et al.,4 only
costs applicable to the NHS were collected (private fees were excluded when possible) and the overall cost
for each test was calculated across the laboratories that supply that test. The available genetic tests were
individual sequencing tests for probands for MLH1, MSH2, MSH6 and PMS2; individual targeted tests for
relatives for MLH1, MSH2, MSH6 and PMS2; a combined MLH1 and MSH2 sequencing test for probands;
a combined MSH2 and MSH6 sequencing test for probands; a combined MLH1, MSH2 and MSH6
sequencing test for probands; and, at one centre, a combined sequencing test for all four genes. As the
TABLE 60 Chemotherapy regimen for endometrial cancer
Day Drug Dose Administration
1 Paclitaxel 175 mg/m2 IV over 3 hours
1 Carboplatin AUC 5–6mg · minute/ml IV over 60 minutes
AUC, area under the curve; IV, intravenous.
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PenTAG model assumed that probands will receive testing for four genes (MLH1, MSH2, MSH6 and
PMS2), the total cost for testing all four genes was based on the average of the plausible combinations of
tests that can be found in current practice. This cost does not include the added costs of having to use
multiple centres to produce the results. There is some indication that laboratories are increasingly testing
MMR genes as part of NGS multigene panels (based on clinical opinion from Dr Ian M Frayling, 2016). The
result of this is both to reduce costs and to increase the yield of conditions causative of CRC. Costs were
therefore explored in univariate sensitivity analyses.
As in the study by Snowsill et al.,4 genetic counselling was assumed to occur after initial tumour testing
and before genetic testing. Genetic counselling remains a parameter without a standard unit cost. As such,
the cost was calculated using the same approach as detailed in Snowsill et al.,4 with updating to 2016/17
prices. To calculate the time and staff involved in genetic counselling, Snowsill et al.4 corresponded with
Professor Mary Porteous of the South East Scotland Genetic Service, based at the Western General
Hospital in Edinburgh (2013, personal communication). Box 8 details the resulting resource use involved in
genetic counselling.
TABLE 61 Costs of diagnostic tests and genetic counselling
Test Patient
Base-case
cost (£)a Base-case source
MSI Proband 202 Average from UKGTN175 (reported for Newcastle,
Oxford, Birmingham and Sheffield)
IHC Proband 210 Average of UKGTN175 (reported for University College
London only), Dr Mark Arends (Department of
Pathology, University of Cambridge, 31 October 2012,
personal communication) and Dr Ian M Frayling
(personal communication) (£220–240)
BRAF V600E Proband 119 Average of £140 (Mr Michael Gandy, UCL Advanced
Diagnostics, 14 September 2012, personal
communication), £117 (East of Scotland Regional
Genetic Service174) and £85 (All Wales Molecular
Genetics Laboratory176) from Snowsill et al.4 and £65
(North West Regional Genetics Service175)
MLH1 promoter methylation testing Proband 136 UKGTN175 (reported for Newcastle, Cardiff and London)
Proband genetic test, all four genes Proband 1276 UKGTN175 (weighted average of available tests)
Proband genetic counselling Proband 64 PSSRU166,177 and Professor Mary Porteous (South East
Scotland Genetic Service, 2013, personal communication)
Targeted genetic test for relatives
(MLH1)
Relative 166 UKGTN175
Targeted genetic test for relatives
(MSH2)
Relative 161 UKGTN175
Targeted genetic test for relatives
(MSH6)
Relative 161 UKGTN175
Targeted genetic test for relatives
(PMS2)
Relative 165 UKGTN175
Genetic counselling for relatives Relative 64 PSSRU166,177 and Professor Mary Porteous (personal
communication)
PSSRU, Personal Social Services Research Unit.
a All costs updated to 2016/17 prices.
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The cost per hour of the band 7 counsellor (£50) was taken from the 2014 edition of Unit Costs of Health
and Social Care177 and uprated to 2016 costs, as no equivalent cost was available from the most recent
edition. The cost per hour of a band 5 hospital nurse (£43) was taken from Unit Costs of Health and Social
Care 2015166 and uprated to 2016 costs.
As different genetic centres have different approaches to genetic counselling, sensitivity analyses were
performed on the cost of counselling, with the time spent on each individual halved and doubled.
Colorectal surveillance The unit costs of surveillance colonoscopies for individuals with LS were
estimated from NHS Reference Costs 2014–15178 and uprated to 2016/17 prices, as described in
Adjustments to 2016/17 prices. The Healthcare Resource Group (HRG) codes FZ51Z, FZ52Z and FZ53Z
were used as previously,4 giving a unit cost of £585.80 per colonoscopy (Table 62).
Complications The unit costs of complications from colonoscopies were estimated from NHS Reference
Costs 2014–15178 (Table 63).
Colorectal cancer As previously,4 many of the costs associated with CRC in the model are based on the
work of Trueman et al.123 The main exception to this is the cost of primary surgery (see Primary surgery).
Diagnosis The cost of diagnosis is incurred at the time of CRC diagnosis and is estimated to be £1022 in
2016/17 prices (inflated from £790 in 2004/5 prices).123
TABLE 62 Reference costs for colonoscopies
HRG code Description
Number of
colonoscopies Unit cost (£) Total cost (£)
FZ51Z Diagnostic Colonoscopy, ≥ 19 years 162,933 519.42 84,630,117
FZ52Z Diagnostic Colonoscopy with
Biopsy, ≥ 19 years
153,795 604.02 92,894,549
FZ53Z Therapeutic Colonoscopy, ≥ 19 years 116,071 601.86 69,858,823
Weighted average (2014–15 prices) 432,799 571.59 247,383,489
Weighted average (2016–17 prices) 585.80
Source: NHS Reference Costs 2014–15.178
BOX 8 Estimating resource use involved in genetic counselling
In this centre genetic counselling occurred, where applicable, after the tumour tests (IHC and/or MSI) for
the proband. Generally, probands received a maximum of a single 45-minute session with a band 7
counsellor before gene testing, and a 30-minute session to discuss the results. The same was also true of
the relatives, though in practice the total 75 minutes could be split in various ways (for example,
sometimes relatives would have a group session then return for a shorter individual session before they
were tested). In this centre the cost of genetic counselling incurred for a relative of a proband was
therefore the same as that for the proband.
Reproduced from Snowsill et al. (p. 168)4 under the terms of the UK government’s non-commercial licence
for public sector information.32
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In addition, it was assumed that patients with stage II (Dukes’ B) colon cancer will receive MSI testing to
predict their response to 5-FU-based chemotherapy, at a cost of £202 (see Table 61).
Primary chemotherapy and radiotherapy Trueman et al.123 modelled pre/postoperative
chemoradiotherapy and adjuvant chemotherapy.
Rectal cancer In the study by Trueman et al.123 the cost of pre/postoperative chemoradiotherapy was £2263
(2004/5 prices) and the cost for a full chemotherapy course after surgery was £11,209 (2004/5 prices).
When weighted by resource use, the relevant costs according to rectal cancer stage are shown in Table 64.
Colon cancer The cost of chemotherapy for colon cancer was £11,209 in 2004/5 prices in the study by
Trueman et al.,123 corresponding to a cost of £14,494 in 2016/17 prices.
Primary surgery As previously,4 the costs of CRC surgery were estimated according to the type of surgery
performed and whether the patient had LS or not (as proximal CRCs are more common in individuals with
LS). Stoma reversal costs were included as previously.4 Unit costs were updated using NHS Reference Costs
2014–15178 and uprated to 2016/17 prices (Tables 65 and 66).
Surveillance We estimated that CEA tests cost £13.64 each (by inflating the cost of £10.55 from
Trueman et al.123). CT scans were assumed to include three areas with contrast, at a cost of £127.63
(inflated from £124.53 in NHS Reference Costs 2014–15178). Clinical consultations were estimated to cost
£128.17 each, inflated from £125.06 in NHS Reference Costs 2014–15 (consultant-led, service code 104
colorectal surgery).
TABLE 64 Costs of chemotherapy and radiotherapy for rectal cancer patientsa
Rectal cancer stage
Pre/postoperative chemoradiotherapy Chemotherapy
Total (£)% Subtotal (£) % Subtotal (£)
Dukes’ A 35.9 1049.30 0 0.00 1049.30
Dukes’ B 35.9 1049.30 21.8 3156.37 4205.67
Dukes’ C 35.9 1049.30 58.3 8454.57 9503.87
a 2016/17 prices.





Mild FZ38P Gastrointestinal Bleed without Interventions, with CC Score 0–4a 462 473
Moderate FZ38J–FZ38L Gastrointestinal Bleed with Single Interventiona 1110 1138
Severe FZ38G–FZ38H Gastrointestinal Bleed with Multiple Interventionsb 4287 4394
Perforation FZ77C–FZ77E Major Large Intestine Procedures, 19 years and overb 4790 4909
Death Assumed same as perforation 4790 4909
CC, complications and comorbidities.
a Non-elective short stay only.
b Non-elective long stay and non-elective short stay.
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Trueman et al.123 estimated 5 years of surveillance costs for CRC, from which we derived an average cost
per person-year of £232 for rectal cancer and £229 for colon cancer, as shown in Table 67.
The model does not distinguish between colon and rectal cancer after the year of diagnosis, so these costs
were applied as an average, weighted according to whether the patient has LS or not. Corresponding
costs of £229 and £230 were used for patients with and without LS respectively.
In addition to this the model includes colonoscopy every 5 years starting at 12 months, at a cost of £586
(see Colorectal surveillance).
Surgery and chemotherapy for recurrence A single cost of £11,999 was applied if a patient died
within 5 years from diagnosis of rectal cancer and a single cost of £12,354 was applied if a patient died
within 5 years from diagnosis of colon cancer. These costs were inflated from estimates of £9279 and
£9554 (2004/5 prices) in the study by Trueman et al.123
As before, as the model does not track the site of cancer after the year of diagnosis, these were applied as
weighted averages of £12,333 and £12,236 for patients with and without LS respectively.








FZ75 Proximal Colon Procedures, 19 years
and over
6286.10 6442.38
Segmental resection (distal without
exteriorisation)





FZ74 Complex Large Intestine Procedures,
19 years and over
7671.24 7861.95




Stoma reversal FZ50 Intermediate Large Intestine
Procedures, 19 years and over
420.77 431.23
Source: NHS Reference Costs 2014–15.178
TABLE 66 Estimated costs of surgery for CRC
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Stoma care The annual cost of stoma care was estimated as £1279 (2004/5 prices) by Trueman et al.123
and this was inflated to £1654 in 2016/17 prices.
Based on 11% of colon cancer and 49% of rectal cancer patients requiring a permanent stoma, annual
average costs of stoma care of £214 and £388 were applied to patients with or without LS respectively.
Palliative care Trueman et al.123 estimated costs of £7703 and £7016 for palliative care for colon and
rectal cancer patients respectively. These were inflated to £9961 and £9072 in 2016/17 prices and then
used to estimate costs of £9907 and £9665 for patients with and without LS respectively.
Gynaecological surveillance Gynaecological surveillance was assumed to include annual CA-125 testing,
gynaecological examination, transvaginal ultrasound and endometrial aspiration biopsy. The total annual
cost was estimated to be £473.41.
Cancer antigen 125 testing The cost of CA-125 testing was estimated to be £21.71, based on an
approximate cost of £20 given in a NHS news story in 2011.179
Gynaecological examination The cost of a gynaecological examination was estimated to be £122.93.
This was based on the NHS reference cost for HRG code WF01A for consultant-led, non-admitted face-to-
face attendance (follow-up) in the gynaecology service (service code 502) (£119.95 in 2014/15 prices).178
Transvaginal ultrasound The cost of transvaginal ultrasound was estimated to be £160.65. This was
based on the NHS reference cost for HRG code MA36Z (Transvaginal Ultrasound) (£156.75 in 2014/15
prices).
Endometrial aspiration biopsy The cost of endometrial aspiration biopsy was estimated to be £168.12.
This was based on the NHS reference cost for HRG code MA25Z (Minimal Upper Genital Tract Procedures)
(£164.04 in 2014/15 prices).
Prophylactic gynaecological surgery The cost of prophylactic gynaecological surgery (H-BSO) was
estimated to be £3428. This was based on an average cost of £3345 for HRG codes MA07E–MA07G
(Major Open Upper Genital Tract Procedures) and MA08A–MA08B (Major, Laparoscopic or Endoscopic,
Upper Genital Tract Procedures).178
TABLE 67 Derivation of CRC surveillance costs (excluding colonoscopy)
Year Rectal cancer patients Colon cancer patients Unit cost (£)a
1 7029 17,209 182.74
2 4570 11,142 310.36
3 2533 7008 283.08
4 1316 4356 155.45
5 571 2337 155.45
Total person-years 16,019 42,052
Total cost (£) 3,713,208 9,627,079
Average cost per person-year (£) 231.80 228.93
a 2016/17 prices.
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Endometrial cancer
Surgery The cost of surgical management of endometrial cancer was estimated to be £4005. This was
based on an average cost of £3907 for HRG codes MA06A–MA06C (Major, Open or Laparoscopic,
Upper or Lower Genital Tract Procedures for Malignancy).178
Radiotherapy Havrilesky et al.169 estimated a cost of US$7895 for a course of radiotherapy for
endometrial cancer. It was estimated that this corresponded to a cost of £5870 in 2016/17 prices (based
on the same methodology as previously employed4).
Adjuvant chemotherapy The Electronic Market Information Tool (eMit) database180 was used to estimate
the average cost of carboplatin (4.41 pence/mg) and paclitaxel (8.09 pence/mg), reflecting average
acquisition costs (weighted across pack sizes by the total number of milligrams reported).
The cost of administering the chemotherapy regimen was estimated to be £399.09 per cycle. This was
based on a cost of £389.41 for HRG code SB14Z (Deliver Complex Chemotherapy, Including Prolonged
Infusional Treatment, at First Attendance).178
The total cost for a course of chemotherapy was estimated to be £1797.63 per patient receiving chemotherapy.
Aspirin It was assumed that aspirin would be prescribed by general practitioners and dispensed in the
community; therefore, the reference case unit cost is the list price or the price on the NHS drug tariff.
A pack of 100 enteric coated tablets of 300 mg aspirin cost £20.33 in the BNF181 and £20.34 on the NHS
drug tariff.182 The cost of £20.33 was used, which corresponds to a daily cost (600 mg) of £0.41 and an
annual cost of £148.51.
Quality assurance
The independent economic assessment was conducted by extending the model from Snowsill et al.,4
which had already been quality assured. All parts of this model had been checked by at least one
developer not responsible for developing that component, using code review and black box testing.
Extensions to the previous model were highlighted as requiring checking and were then checked by the
developer not responsible for developing that extension. The checking involved code review and checking that
input parameters matched the described sources. A parallel build was also conducted for one component.
This revealed a small discrepancy in the calculated results, which was then resolved through discussion.
Cost-effectiveness results
The population simulated in the model consists of probands (individuals diagnosed with CRC for whom
different diagnostic strategies for LS may be employed) and relatives who would be identified if a LS-causing
mutation were diagnosed in the proband. As the majority of probands do not have LS, the majority of
relatives also do not have LS.
All costs and QALYs in the results section are discounted at 3.5% per annum (unless otherwise stated) and
life-years are not discounted.
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Base-case results
Characteristics of the simulated population
In the base case there are 238,175 simulated individuals (reflecting an annual cohort), of whom 34,025
(14.3%) are probands (i.e. individuals with a CRC diagnosis) and 204,150 (85.7%) are relatives of
probands. Of the probands, 956 (2.8%) are expected to have LS, with 2524 (1.2%) relatives having LS
(Table 68). Of the probands, 55.0% are men, whereas only 37.6% of relatives are men.
The average age of probands at the time of diagnosis was 72.7 years for those without LS and 58.0 years
for those with LS, reflecting the widely observed earlier age of CRC incidence in individuals with LS. The
mean age at entry for relatives was 44.4 years without LS and 43.2 years with LS.
Cost-effectiveness results
Table 69 reports the summary cost-effectiveness results for the 10 different testing strategies. We present
both ICERs compared with no testing (strategy 1) and the comparative ICERs for all strategies. The optimal
TABLE 68 Simulated population
Simulated individuals With LS, n (%) Without LS, n (%) Total, n (%)
Probands 956 (2.8) 33,069 (97.2) 34,025 (100)
Relatives 2524 (1.2) 201,626 (98.8) 204,150 (100)
Total 3480 234,695 238,175
TABLE 69 Summary base-case cost-effectiveness results










(cost per QALY) (£)
1. No test 3,508,052 743,298,306 – – –
2. IHC 3,510,017 767,955,447 12,553 731.5 60,967
3. IHC plus BRAF V600E 3,509,977 765,532,726 11,553 812.9 37,495
4. IHC plus MLH1 promoter
methylation
3,509,965 765,535,788 11,672 793.3 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,509,937 764,048,240 11,005 848.0 11,008
6. MSI 3,509,926 769,249,096 13,849 576.3 Dominated by strategy 2
7. MSI plus BRAF V600E 3,509,832 763,660,095 11,438 762.0 Extendedly dominated
by strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,509,796 763,503,459 11,589 733.2 Extendedly dominated
by strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,509,721 761,784,044 11,076 744.7 Extendedly dominated
by strategies 1 and 5
10. Universal genetic testing 3,509,987 793,380,127 25,884 –569.2 Dominated by strategy 2
INHB, incremental net health benefit; WTP, willingness to pay.
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strategy [highest incremental net health benefit (INHB) at a willingness-to-pay threshold of £20,000 per
QALY gained] is IHC testing followed by both BRAF V600E and MLH1 promoter methylation testing
(strategy 5). Universal genetic testing has the highest ICER compared with no testing, at £25,884 per
QALY gained.
Figure 34 shows that, with the exception of universal genetic testing, all testing strategies are cost-effective
at a willingness-to-pay threshold of £20,000 per QALY compared with the no-testing strategy (strategy 1).
In a fully incremental analysis, four strategies are on the cost-effectiveness frontier: 1 (no testing), 2 (IHC),
3 (IHC plus BRAF V600E testing) and 5 (IHC plus BRAF V600E and MLH1 promoter methylation testing).
The remaining strategies are dominated (i.e. are more costly and less effective than one or more
comparator) or extendedly dominated (i.e. are more costly and less effective than a combination of
other comparators).
We now examine the drivers of these cost-effectiveness results by looking at the test accuracy, life
expectancy and costs of each strategy.
Test accuracy results
Figure 35 shows the number of diagnoses made by each strategy. Of most interest is the number of incorrect
diagnoses. Aside from strategy 1, strategy 9 (MSI followed by BRAF V600E and MLH1 promoter methylation
testing) has the highest number of FNs (people with undiagnosed LS) and the lowest number of FPs (people
diagnosed with LS who do not have it). This means that strategy 9 will likely have few unnecessary LS
prevention costs, but more cancer treatment costs. Universal genetic testing has the lowest number of FNs,
which is likely to reduce cancer treatment costs. The highest number of FPs is found in strategy 2 (IHC) and
strategy 6 (MSI), which is likely to lead to additional unnecessary surveillance costs. Only strategies in which
only one test is used in a sequence have a higher false-positive rate than false-negative rate. This makes








































FIGURE 34 Incremental discounted costs and QALYs for all probands and relatives.
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The sensitivities and specificities of the different strategies are shown in Table 70. These outputs can be
calculated for probands only or for the overall population (including probands and relatives). As can be
seen, diagnostic performance follows a similar pattern in the two populations, but sensitivity and specificity
are generally lower in the overall population. Performance is reduced through two mechanisms. First, in



































FIGURE 35 Number of probands and relatives identified by each strategy. For a description of each strategy see
Table 69. Note: true negatives have not been shown in the interest of clarity. The number of true negatives is
substantially larger than the numbers for the other three diagnoses.
TABLE 70 Sensitivity and specificity for the different strategies
Strategy
Probands only Overall population
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
1. No test 0.00 100.00 0.00 100.00
2. IHC 70.35 99.80 69.67 99.47
3. IHC plus BRAF V600E 69.40 99.94 68.73 99.55
4. IHC plus MLH1 promoter methylation 68.93 99.93 68.26 99.55
5. IHC plus BRAF V600E and MLH1 promoter
methylation
68.04 99.97 67.38 99.57
6. MSI 66.80 99.72 66.17 99.46
7. MSI plus BRAF V600E 64.13 99.93 63.51 99.58
8. MSI plus MLH1 promoter methylation 62.79 99.93 62.18 99.58
9. MSI plus BRAF V600E and MLH1 promoter
methylation
60.28 99.98 59.69 99.63
10. Universal genetic testing 71.43 99.98 71.53 99.55
Note
For each strategy, the sensitivity and specificity are calculated on an intention-to-diagnose basis, in which the numerator is
the number of individuals correctly diagnosed (positive for sensitivity, negative for specificity) and the denominator for
sensitivity (specificity) is the number of individuals offered testing with (without) LS.
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are treated as though they have LS and more distant relatives are treated as though they do not have LS.
Second, some relatives opt not to receive predictive testing for LS.
Long-term clinical outcomes
Figures 36 and 37 give the estimated life expectancy for probands and relatives according to LS status. As
expected, life expectancy is much higher in relatives (they are more likely to enter the model at a younger
age and they are healthy at the time of entry to the model). We found that testing for LS improves the life
expectancy of both relatives and probands, a probable consequence of the reduction in CRC (index and
metachronous) and endometrial cancer from the preventative measures offered to patients in whom LS is
diagnosed. With regard to probands, LS probands consistently have longer life expectancy than probands
without LS because LS patients generally have a better prognosis for CRC than the general population.
The life expectancy of relatives is generally lower for those with LS as they are at increased risk of CRC and
endometrial cancer (women only).
Kaplan–Meier graphs for alternative strategies were produced, applying weights to simulated individuals




















































FIGURE 37 Life expectancy of relatives.
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Figures 38 and 39 show the overall survival for probands and relatives with LS respectively. Kaplan–Meier
graphs are not shown for individuals without LS as there is no separation of the survival functions.
Figure 38 shows that testing for LS has no immediate impact on the overall survival of probands, as it is
not assumed to improve survival for the index CRC but rather to reduce the risk of mCRC. This is why the
overall survival curves do separate after a time, when the hazard of mortality from CRC has lowered.
Figure 39 shows that implementing testing results in sustained improvements in overall survival for relatives
with LS. In reality, there would be expected to be a slightly greater delay before improvement (relatives are
often not diagnosed with LS at the same time as the proband).
Event-free survival (i.e. the time to death, CRC incidence or endometrial cancer incidence) is also improved
for probands and relatives with LS when a testing strategy is employed (Figures 40 and 41 respectively).
Additional outcomes
The average number of colonoscopies for individuals who actually have LS is affected significantly by the
introduction of testing (Figure 42). In the absence of testing the expected number of colonoscopies is 0.42
for relatives and 1.58 for probands. Probands will receive 5-yearly colonoscopy as follow-up, as will






































FIGURE 39 Overall survival for relatives with LS.
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FIGURE 42 Average number of colonoscopies for individuals with LS.
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receive around 3 colonoscopies on average, whereas relatives receive 7.18–8.55 colonoscopies, depending
on the strategy. The variation in the number of colonoscopies here is entirely driven by the number of
false-negative diagnoses.
The average number of colonoscopies for individuals without LS is not significantly affected by the
introduction of testing. There is a small increase in the average number of colonoscopies per relative. This
small increase in the average number of colonoscopies does, however, correspond to a large increase in
the total number of colonoscopies (Figure 43), as relatives without LS make up the largest group of
modelled individuals. For each annual cohort the model predicts around 10,000 additional colonoscopies
in relatives without LS (these may reasonably be considered unnecessary). This increase is attributable to
the number of false-positive diagnoses.
The introduction of testing for LS is expected to reduce the probability of subsequent CRC incidence for
individuals with LS (Figure 44). There is very little impact on the probability of CRC incidence for individuals
without LS, as testing leads to increased surveillance in these individuals only in the event of a false-positive
diagnosis.
Testing is also predicted to reduce the risk of endometrial cancer for probands and relatives with LS (Figure 45).





























































FIGURE 44 Probability of CRC incidence for individuals with LS.
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
Disaggregated costs
Figure 46 shows that the largest cost component for each strategy is the long-term costs. However, given
the small incremental difference between each arm, we see that the diagnostic costs are influential in
terms of the overall incremental costs. We explore these in more detail in Figures 47–49.
The strategy with the highest diagnostic costs is strategy 10 (universal testing) and the strategy with the
lowest diagnostic costs is strategy 1 (the no-testing strategy). Strategy 10 is particularly expensive because
genetic testing is the only test in the strategy and genetic testing is far more expensive than IHC and MSI
testing, both of which are initial tests in the other strategies. In general, the MSI strategies have lower
diagnostic costs, with the exception of strategy 6, in which MSI testing is used on its own. The larger costs
here are driven by a larger proportion of probands going forward for diagnostic genetic testing. The
largest cost component of every strategy is the initial test or the cost of genetic testing for the proband
(see Figure 47).
Long-term costs appear to be broadly similar across the strategies (see Figure 48). However, as Figure 49
shows, this may be because the costs of cancer prevention and the costs of cancer treatment largely

































































FIGURE 46 Summary total undiscounted costs.
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FIGURE 47 Undiscounted diagnostic costs: base case. FH, family history.
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Subgroup analyses
In subgroup analyses, a variety of age limits applied to newly diagnosed CRC patients (probands) were
considered, as requested by the NICE scope. When the age limit of probands is lowered, the prevalence of
LS in probands increases (Table 71) because the incidence of CRC in the general population falls more
rapidly than the incidence of CRC in people with LS. For the same reason, when the age limit is set at a
minimum of 70 years, the prevalence of LS falls significantly (from 2.8% in the base case to 1.1%). The
total annual incidence of CRC also changes with each age limit, with a higher incidence of CRC in people
aged ≥ 70 years than in any other age group (20,202 vs. 13,823 in the those aged < 70 years). As the
number of relatives per proband does not alter, this means that the overall cohort size in our analysis
changes depending on the age limit used.
All parameters that are affected by the subgroup analyses are provided in Table 71.
As shown in Table 72, the mean age of the probands in the cohort alters as expected, according to the
age limit of the probands, although the age of probands without LS is consistently estimated to be higher
than the age of those with LS. For the groups with lower maximum age limits the age of probands with
and without LS do become more similar, reflecting the change in prevalence compared with the change in
CRC incidence rates. The age of the relatives is not linked to the age of the probands, similar to the base















































FIGURE 49 Incremental discounted costs compared with no testing. EC, endometrial cancer. Note: the cost of
aspirin is included in the CRC prevention costs although it also reduces the risk of EC.
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Summary results for the age-limited subgroups are presented in Tables 73–76. Results on the cost-
effectiveness frontier were generally similar for all subgroups (and were similar to the base case), with
strategy 5 remaining the optimal strategy. Larger total discounted costs and QALYs are reported for
subgroups with a higher maximum age limit. This is primarily driven by the size of the cohort.
Primarily because of the higher prevalence of LS in subgroups with a lower age limit, the ICERs are
reduced compared with the base case. For the subgroup in which all probands are aged < 50 years, all
strategies have an ICER of < £13,000 per QALY gained compared with the no testing (strategy 1). The
subgroup with a minimum age limit of 70 years has the largest ICERs compared with no testing, with only
strategies 5 and 9 (IHC or MSI plus BRAF V600E and MLH1 promoter methylation testing) having ICERs
below a cost-effectiveness threshold of £20,000 per QALY gained. These strategies have lower ICERs
because the multiple tests in sequence have enriched the population prior to diagnostic genetic testing,
reducing the diagnostic costs.
The difference in ICERs is also driven by the benefit accrued by probands within the model. Probands aged
< 50 years have a much higher life expectancy than probands aged > 70 years (Figures 50 and 51) and
therefore the potential LYGs from diagnosing LS are higher the lower the age of the probands. However,
there is still benefit in terms of life expectancy for probands in the > 70 years subgroup.
Of note, the higher total costs in the subgroups with the higher age limits are driven entirely by the larger
size of the cohorts. The per-person cost is reduced in the groups with a higher age limit for probands (e.g.
< £5000 for all strategies in the over 70s, but > £5900 for all strategies in the under 50s). This is primarily
driven by the life expectancy of the probands in these strategies (diagnosis at an earlier age will result in
higher prevention and treatment costs).
TABLE 71 Parameters altered in subgroup analyses
Input parameter Base case
Age-limited subgroup (years)
Source< 50 < 60 < 70 ≥ 70
Prevalence of LS in probands (%) 2.8 8.4 5.7 3.8 1.1 Hampel et al.92
Number of probands per annum in England 34,025 2,107 5,880 13,823 20,202 ONS21
Proportion of probands who are male (%) 55.6 51.8 55.5 59.2 53.0 ONS21,96–103
Proportion of probands assumed to have LS (tumour
test results available only) (%)
10 21 17 13 5 Snowsill et al.4
model and
assumptions
CRC incidence in male probands without LS 0.63 0.61 0.56 0.57 0.67 ONS103
CRC incidence in female probands without LS 0.72 0.70 0.66 0.68 0.75 ONS103
TABLE 72 Mean age of probands at diagnosis by age subgroup
Age-limited subgroup (years)
Mean age of probands at diagnosis (years)
Without LS With LS
Base case 72.7 58.0
< 50 41.6 39.8
< 60 51.1 47.1
< 70 60.0 52.3
≥ 70 77.1 72.9
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TABLE 73 Summary cost-effectiveness results: proband maximum age 50 years









(cost per QALY) (£)
1. No test 225,106 52,979,766 – – –
2. IHC 225,489 56,319,403 8731 215.5 34,526
3. IHC plus BRAF V600E 225,482 56,098,834 8293 220.2 19,903
4. IHC plus MLH1 promoter
methylation
225,481 56,087,979 8298 219.2 Extendedly dominated by
strategies 5 and 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
225,476 55,970,603 8090 220.1 8090
6. MSI 225,469 56,333,761 9229 195.7 Dominated by strategy 2
7. MSI plus BRAF V600E 225,454 55,873,734 8304 203.8 Extendedly dominated by
strategies 8 and 5
8: MSI plus MLH1 promoter
methylation
225,447 55,831,834 8358 198.6 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
225,433 55,659,876 8184 193.5 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 225,490 57,714,180 12,336 147.1 1,096,665
WTP, willingness to pay.
TABLE 74 Summary cost-effectiveness results: proband maximum age 60 years









(cost per QALY) (£)
1. No test 625,933 142,438,302 – – –
2. IHC 626,623 149,410,482 10,106 341.3 54,320
3. IHC plus BRAF V600E 626,613 148,866,574 9454 358.5 25,681
4. IHC plus MLH1 promoter
methylation
626,609 148,851,044 9482 355.6 Extendedly dominated by
strategies 5 and 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
626,601 148,551,307 9156 362.0 9156
6. MSI 626,588 149,549,494 10,857 299.4 Dominated by strategy 2
7. MSI plus BRAF V600E 626,562 148,382,032 9447 332.0 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
626,549 148,307,783 9528 322.6 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
626,524 147,905,444 9243 318.1 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 626,625 153,518,956 16,018 137.7 2,233,950
WTP, willingness to pay.
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TABLE 75 Summary cost-effectiveness results: proband maximum age 70 years









(cost per QALY) (£)
1. No test 1,454,988 322,566,730 – – –
2. IHC 1,456,078 334,746,310 11,175 480.9 59,733
3. IHC plus BRAF V600E 1,456,059 333,636,101 10,333 517.8 31,707
4. IHC plus MLH1 promoter
methylation
1,456,053 333,625,144 10,383 512.1 Extendedly dominated by
strategies 5 and 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
1,456,039 332,980,152 9912 529.9 9912
6. MSI 1,456,025 335,222,782 12,205 404.2 Dominated by strategy 2
7. MSI plus BRAF V600E 1,455,979 332,749,603 10,275 481.9 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
1,455,958 332,649,631 10,390 466.3 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
1,455,918 331,857,287 9984 466.0 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 1,456,072 344,821,179 20,528 –28.6 Dominated by strategy 2
WTP, willingness to pay.
TABLE 76 Summary cost-effectiveness results: proband minimum age 70 years









(cost per QALY) (£)
1. No test 2,075,242 430,082,601 – – –
2. IHC 2,075,648 439,327,880 22,794 –56.7 146,300
3. IHC plus BRAF V600E 2,075,640 438,172,824 20,342 –6.8 105,987
4. IHC plus MLH1 promoter
methylation
2,075,638 438,205,815 20,512 –10.1 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
2,075,633 437,415,128 18,774 23.9 18,839
6. MSI 2,075,629 440,240,971 26,305 –121.7 Dominated by strategy 2
7. MSI plus BRAF V600E 2,075,611 437,375,080 19,789 3.9 Extendedly dominated by
strategies 9 and 5
8. MSI plus MLH1 promoter
methylation
2,075,603 437,374,272 20,205 –3.7 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
2,075,588 436,573,720 18,766 21.3 18,766
10. Universal genetic testing 2,075,621 454,981,317 65,701 –866.0 Dominated by strategy 2
WTP, willingness to pay.
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Scenario analyses
Scenario 1: microsatellite instability-low corresponds to a Lynch syndrome-positive
MSI result
As previously described, different thresholds are used to decide whether a tumour has MSI. Broadly, these
fall into two categories, MSI-L and MSI-H, with MSI-H having a higher level of MSI than MSI-L (but both
have some level of instability). Exact measures and cut-offs can differ according to the specific test used.
Further discussion of these is provided in Chapter 1 (see Microsatellite instability testing).
In the base case, only MSI-H tumours are assumed to be indicative of LS. However, clinical opinion
suggests that MSI-L tumours may also be indicative of LS and we explore the impact of this in this scenario
analysis. As MSI-L requires a lower threshold for instability, the number of people diagnosed with MSI
increases. This has the impact of altering the accuracy of the tests as the numbers of TPs and FPs increase,
whereas the numbers of true negatives (TNs) and FNs decrease. Table 77 shows that this increases
sensitivity [TP/(TP + FN)] and decreases specificity [TN/(TN + FP)] compared with the base case, in which
MSI-H is the chosen threshold.
The cost-effectiveness results for this scenario are provided in Table 78. As expected, the cost and QALY
results for strategies 1–5 and 10 are unaffected as MSI testing is not part of these diagnostic pathways. For
strategies 6–9 both the discounted costs and the QALYs increase from the base case; however, the change


















































FIGURE 51 Life expectancy of probands: minimum age 70 years.
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increase of 110–160 QALYs, depending on the strategy). Therefore, the ICERs compared with no testing
for all MSI strategies are increased compared with the base case.
The additional costs and QALYs for the MSI strategies are driven by the increased number of probands
and relatives identified as LS positive (Figure 52), leading to additional downstream costs and benefits
associated with CRC and endometrial cancer risk reductions (Figure 53). Table 79 demonstrates that the
sensitivity of strategies 6–9 are now increased and specificity is slightly decreased. Interestingly, in both
the probands-only subpopulation and the overall population the specificity is not greatly affected, despite
the specificity of MSI testing reducing to 59%. This is a result of the downstream tests in each strategy
correcting for the poorer specificity of using MSI-L as being indicative of LS. Indeed, the difference in
specificity from the base case falls from a difference of 0.42% (probands only) in the MSI-only strategy
(strategy 6) to 0.02% when MSI is followed by both BRAF V600E and promoter methylation testing
(strategy 9). Similarly, the difference in sensitivity also reduces as additional tests, with imperfect sensitivity,
are added to the strategy, although the difference from the base case remains about 4% for all strategies.
Figure 54 demonstrates that using MSI-L as indicative of LS results in much higher costs of tests
subsequent to MSI testing, a result of more probands receiving results indicative of LS. This leads to the
higher overall costs of diagnosis, as demonstrated in Figure 53.
TABLE 78 Summary cost-effectiveness results: MSI-L is indicative of LS









(cost per QALY) (£)
1. No test 3,508,052 743,298,306 – – –
2. IHC 3,510,017 767,955,447 12,553 731.5 60,967
3. IHC plus BRAF V600E 3,509,977 765,532,726 11,553 812.9 37,495
4. IHC plus MLH1 promoter
methylation
3,509,965 765,535,788 11,626 800.8 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,509,937 £764,048,240 £11,008 847.5 11,008
6. MSI 3,510,086 781,391,603 18,729 129.2 193,128
7. MSI plus BRAF V600E 3,509,958 768,160,279 13,044 662.9 Dominated by strategy 2
8. MSI plus MLH1 promoter
methylation
3,509,920 768,141,508 13,305 625.1 Dominated by strategy 2
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,509,833 764,450,482 11,877 723.3 Dominated by strategy 5
10. Universal genetic testing 3,509,987 793,380,127 25,884 –569.2 Dominated by strategy 6
WTP, willingness to pay.
TABLE 77 Diagnostic accuracy of MSI testing according to MSI-L or MSI-H threshold
Scenario Sensitivity (%) Specificity (%)
MSI =MSI-H (base case) 91.3 83.7
MSI =MSI-H or MSI-L 97.3 59.6
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
Scenario 2: aspirin removed from the model
In the base case, aspirin use for CRC prevention in LS-positive people is estimated as in the CAPP2 trial.29
In this scenario analysis aspirin was not included as a risk-reducing component in the model (and therefore
the costs and benefits associated with its use are removed).
In this scenario there is a slight reduction in QALYs for all strategies and in life expectancy for relatives
compared with the base case (see Figure 37 compared with Figure 55). However, the difference in life
expectancy for relatives without LS is at least partially driven by the new set of simulations, as this holds
even in strategy 1, and is therefore likely to be related to the expected differences when running a new set
of simulations. However, the life expectancy for probands and relatives with LS is also likely to be reduced
by the increase in CRC and endometrial cancer incidence (although again this too is increased for strategy
1 compared with the base case).
Similarly, although the cost of risk reduction is reduced, the cost of treatment for CRC and EC is increased,
resulting in higher overall costs compared with the base case. Again, some of this is related to the simulations,
but by comparing the incremental results of each strategy compared with no testing (Table 80), we can see
that the overall outcome of removing aspirin from the model is to marginally increase the ICERs.
In this scenario, strategy 5 remains the optimal strategy, with an ICER of £11,659 per QALY gained
(compared with £11,008 per QALY gained in the base case).
Scenario 3: gynaecological surveillance assumed to have no benefit
In the base case, gynaecological surveillance is offered to women diagnosed with LS and, if accepted, incurs
both a cost and reduces the risk of mortality from endometrial cancer. However, the true benefit of this
surveillance is disputed. As such, we investigated the impact of gynaecological surveillance, first, by assuming
that the surveillance has no benefit (but still incurs a cost) (scenario 3) and, second, by removing gynaecological
surveillance from the model entirely (so that no associated costs or benefits are modelled) (scenario 4).




































FIGURE 52 Number of probands and relatives identified by each strategy: MSI-L is indicative of LS. Note: TNs have
not been shown in the interest of clarity. The number of TNs is substantially larger than the numbers with the
other three diagnoses.
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FIGURE 53 Incremental discounted costs compared with no testing: MSI-L is indicative of LS. EC, endometrial cancer.
TABLE 79 Sensitivity and specificity of strategies: MSI-L indicative of LS
Strategy
Probands only Overall population
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
1 0.00 100.00 0.00 100.00
2 70.35 99.80 69.67 99.47
3 69.40 99.94 68.73 99.55
4 68.93 99.93 68.26 99.55
5 68.04 99.97 67.38 99.57
6 71.19 99.30 70.54 99.22
7 68.35 99.83 67.69 99.50
8 66.92 99.83 66.28 99.51
9 64.24 99.96 63.62 99.59
10 71.43 99.98 71.53 99.55
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Summary results for this scenario are presented in Table 81. Both the incremental costs and QALYs are
slightly reduced compared with the base case. Although a decrease in the incremental costs may seem
counterintuitive (as the cost of surveillance is still incorporated in the model), this is likely offset by a
reduction in life expectancy for women in strategies 2–10 of the model (Figures 56 and 57), resulting in
fewer total costs and QALYs accrued over their lifetime compared with the base case. Overall, this slight
reduction in incremental costs is not as pronounced as the incremental QALY loss compared with no testing
and therefore the ICERs are very slightly increased compared with the base case (as expected). The optimal
strategy remains strategy 5 (IHC followed by BRAF V600E and MLH1 promoter methylation testing), with an


































































FIGURE 55 Life expectancy of relatives: aspirin removed as a risk-reducing measure.
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TABLE 80 Summary cost-effectiveness results: aspirin removed as a risk-reducing measure









(cost per QALY) (£)
1. No test 3,506,867 731,729,637 – – –
2. IHC 3,508,703 756,230,300 13,350 610.2 76,621
3. IHC plus BRAF V600E 3,508,671 753,822,657 12,248 699.2 41,422
4. IHC plus MLH1 promoter
methylation
3,508,660 753,826,465 12,326 687.8 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,508,636 752,343,957 11,659 737.4 11,659
6. MSI 3,508,614 757,522,873 14,766 457.1 Dominated by strategy 2
7. MSI plus BRAF V600E 3,508,536 751,959,893 12,128 656.6 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,508,501 751,805,586 12,290 629.7 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,508,433 750,096,269 £11,729 647.7 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 3,508,680 781,664,560 £27,541 –683.7 Dominated by strategy 2
WTP, willingness to pay.
TABLE 81 Summary cost-effectiveness results: no benefit assumed from gynaecological surveillance









(cost per QALY) (£)
1. No test 3,518,332 729,775,566 – – –
2. IHC 3,520,216 754,377,439 13,053 654.6 80,413
3. IHC plus BRAF V600E 3,520,186 751,943,691 11,954 746.0 40,972
4. IHC plus MLH1 promoter
methylation
3,520,175 751,947,401 12,031 734.3 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,520,150 750,457,773 11,375 784.1 11,375
6. MSI 3,520,124 755,682,001 14,453 497.2 Dominated by strategy 2
7. MSI plus BRAF V600E 3,520,046 750,076,890 11,839 699.7 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,520,011 749,921,886 11,998 671.8 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,519,942 748,200,353 11,441 689.2 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 3,520,197 779,782,852 26,815 –635.5 Dominated by strategy 2
WTP, willingness to pay.
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Scenario 4: gynaecological surveillance not included
As described in the previous section, in this scenario all gynaecological surveillance was removed from the
model (i.e. the probability of being offered gynaecological surveillance becomes 0).
This scenario results in similar incremental QALY gains compared with no testing as in scenario 3 (absolute
QALYs differ because this is a different simulation run), but additional reductions in incremental costs
because of the removal of the cost of gynaecological surveillance (Table 82). The resulting ICERs compared
with no testing are slightly reduced compared with both scenario 3 and the base case, with the exception
of universal genetic testing (strategy 10), which has a larger ICER than in the base case. This strategy
differs as the change in surveillance costs is less influential on the overall incremental costs, given that the
cost of diagnosing LS is the main driver of the overall incremental costs compared with no testing
(Figure 58).
As with scenario 3, strategy 5 remains the optimal strategy, with an ICER of £10,241 per QALY gained.
Scenario 5: colorectal cancer utilities taken from Ness et al.144
In the base case, quality of life (as measured by the EQ-5D) for all CRC stages except Dukes’ D was

























































FIGURE 56 Life expectancy of probands: no benefit assumed from gynaecological surveillance. Note: the increase in
life expectancy for male probands is a result of the simulation run and appears more pronounced because of the
scale of the figure.
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non-zero disutility of 0.13. Our review of CRC utilities provided some evidence to support this approach.
However, it is important to investigate a scenario in which all stages of CRC incur a quality-of-life
decrement, to assess the impact that this has on the cost-effectiveness results. The study by Ness et al.,144
which reports CRC utilities, has been widely cited in previous cost-effectiveness analyses of CRC (including
by Snowsill et al.4) and was therefore chosen for this scenario analysis. A comparison of the disutilities
between the base case and the scenario analysis is provided in Table 83.
A summary of the results of this scenario analysis are provided in Table 84. As expected, the ICERs for
strategies 2–10 compared with no testing are reduced compared with the base case. Incremental cost
differences compared with strategy 1 remain broadly similar (again, absolute costs differ from the base
case because this is a different simulation run). However, the incremental QALYs gained compared with
strategy 1 are increased from the base case; for example, incremental QALYs gained in strategy 5 increase
from 1885 in the base case to 2116 in this scenario compared with no testing. This reflects the additional
benefit of reducing CRC incidence in probands and relatives diagnosed with LS (i.e. the avoidance of
quality-of-life loss associated with CRC).
Strategy 5 remains the optimal strategy, with an ICER of £9775 per QALY gained compared with
no testing.
Scenario 6: colonoscopic surveillance assumed to have no impact on colorectal
cancer incidence
As discussed in Surveillance, Colorectal cancer incidence, there is some evidence suggesting that our
base-case assumption for the effectiveness of colonoscopy for CRC incidence may be optimistic. We therefore
investigated a ‘worst-case’ scenario in which the HR for CRC incidence while receiving colonoscopic surveillance
was set to 1 for both the index CRC and mCRCs (i.e. surveillance has no impact on CRC incidence). Previously,
the HRs were set as 0.387 for index cancers (applicable to only relatives) and 0.533 for metachronous cancers
(applicable to probands and relatives). The costs of colonoscopic surveillance remained as in the base case.
TABLE 82 Summary cost-effectiveness results: no gynaecological surveillance









(cost per QALY) (£)
1. No test 3,524,850 729,116,320 – – –
2. IHC 3,526,553 749,618,872 12,033 678.8 109,979
3. IHC plus BRAF V600E 3,526,533 747,412,582 10,866 769.1 44,025
4. IHC plus MLH1 promoter
methylation
3,526,523 747,439,747 10,950 757.2 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,526,502 746,042,546 10,241 806.4 10,241
6. MSI 3,526,465 751,010,931 13,553 520.7 Dominated by strategy 2
7. MSI plus BRAF V600E 3,526,406 745,828,322 10,736 721.0 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,526,374 745,742,636 £10,909 692.7 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,526,314 744,227,411 10,318 709.0 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 3,526,539 775,139,777 27,239 –611.6 Dominated by strategy 2
WTP, willingness to pay.
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Summary results are presented in Table 85. As expected, the ICERs are increased for all strategies, resulting
from lower QALYs in strategies 2–10 than in the base case, but similar costs. This lower QALY gain is
driven by the increase in CRC incidence in these arms and the resulting reduction in life expectancy. This is
seen particularly for relatives (Figure 59 compared with Figure 37), who in the base case receive the most
benefit from colonoscopic surveillance (particularly as the base-case HR for index CRC incidence with
colonoscopic surveillance is lower than that for mCRC).
TABLE 83 Colorectal cancer disutility parameters
Stage Base-case disutilities142,143 Scenario analysis disutilities144
Dukes A 0 0.11
Dukes B 0 0.23
Dukes C 0 0.26
Dukes D 0.13 0.60














































FIGURE 58 Incremental discounted costs compared with no testing: no gynaecological surveillance.
EC, endometrial cancer.
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TABLE 85 Summary cost-effectiveness results: no impact of colonoscopic surveillance on CRC incidence









(cost per QALY) (£)
1. No test 3,516,035 734,308,670 – – –
2. IHC 3,517,362 763,001,311 21,613 –107.1 125,265
3. IHC plus BRAF V600E 3,517,342 760,495,764 20,028 –1.8 62,975
4. IHC plus MLH1 promoter
methylation
3,517,334 760,472,422 20,131 –8.5 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,517,317 758,927,199 19,194 51.7 19,194
6. MSI 3,517,296 764,111,396 23,625 –228.7 Dominated by strategy 2
7. MSI plus BRAF V600E 3,517,244 758,324,753 19,861 8.4 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,517,219 758,092,893 20,087 –5.2 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,517,171 756,219,424 19,284 40.7 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 3,517,331 788,502,246 41,796 –1413.0 Dominated by strategy 2
WTP, willingness to pay.
TABLE 84 Summary cost-effectiveness results: CRC disutilities increased









(cost per QALY) (£)
1. No test 3,459,708 729,043,142 – – –
2. IHC 3,461,906 753,654,444 11,195 967.9 62,734
3. IHC plus BRAF V600E 3,461,867 751,217,817 10,268 1050.9 34,368
4. IHC plus MLH1 promoter
methylation
3,461,854 751,221,527 10,335 1037.1 Dominated by strategy 3
5. IHC plus BRAF V600E and
MLH1 promoter methylation
3,461,824 749,731,129 9775 1081.9 9775
6. MSI 3,461,801 754,960,430 12,380 797.5 Dominated by strategy 2
7. MSI plus BRAF V600E 3,461,705 749,350,705 10,169 981.6 Extendedly dominated by
strategies 8 and 5
8. MSI plus MLH1 promoter
methylation
3,461,663 749,195,658 10,305 948.0 Extendedly dominated by
strategies 9 and 7
9. MSI plus BRAF V600E and
MLH1 promoter methylation
3,461,582 747,472,833 9833 952.8 Extendedly dominated by
strategies 1 and 5
10. Universal genetic testing 3,461,891 779,058,290 22,904 –317.1 Dominated by strategy 2
WTP, willingness to pay.
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Deterministic sensitivity analyses
In this section we present the results of the deterministic sensitivity analyses. Summary results for all analyses
are provided in Table 86 and the subset of analyses that most influences the results is discussed further in the
text. In Table 86 we identify the optimal strategy and report the INHB for this strategy compared with no
testing. This provides a more meaningful comparison than an isolated ICER. The net health benefit (NHB)
is defined as the total QALYs minus (the total costs divided by the willingness-to-pay threshold) of each
strategy. Strategies with the highest NHB are found to be the optimal strategy for a chosen willingness-to-pay
threshold. In real terms, as reported in Snowsill et al.,4 ‘the total discounted QALYs for a man who lives to age
80 years, allowing for age-related quality of life, is approximately 25 (p. 215)’.
The deterministic sensitivity analyses demonstrate that the model is sensitive to several parameters.
First, the diagnostic accuracy of the strategies affects the NHB ranking of the strategies. To investigate
the impact of diagnostic test performance we considered several scenarios: altering the sensitivity of all
tumour tests, altering the specificity of all tumour tests and altering the sensitivity and specificity of all tumour
tests. The altered sensitivities and specificities were based on the reported or estimated 95% CIs for the
tests. The aim of these analyses was to demonstrate the impact of diagnostic accuracy on the results and
not necessarily to show what we believe to be a true reflection of clinical validity. Table 86 clearly shows that
reducing sensitivity and specificity (either individually or jointly) not only reduces the INHB of strategies 2–9
(strategy 10 remains unchanged as the diagnostic accuracy of gene testing is unchanged), but, in the case of
reduced sensitivity, also affects which strategy is optimal in terms of cost-effectiveness [strategy 4 (IHC followed
by MLH1 promoter methylation) becomes the optimal strategy]. This is likely to be because of the combination
of lower diagnostic costs (fewer people diagnosed as LS positive at each stage) and higher overall sensitivity for
strategy 4 than strategy 5. When both the sensitivity and the specificity of each tumour test are reduced to the
lowest values, the ICER for strategy 5 compared with no testing increases to £16,036 per QALY.
When sensitivity is increased for all tests, strategies with MSI testing become optimal (strategy 9 is optimal
when only sensitivity is altered, strategy 7 is optimal when both sensitivity and specificity are increased).
This occurs despite MSI strategies still having worse diagnostic outcomes than IHC strategies in terms of
overall sensitivity and specificity and is the result of a combination of factors, including the additional costs
in the IHC arms from identifying a higher rate of TPs not being entirely offset by the additional benefits.
Acceptance of genetic tests by probands also influences the cost-effectiveness results. In the base case,
acceptance of genetic testing is relatively high (90% acceptance of tests following genetic counselling, with
92.5% acceptance of counselling). By setting both of these parameters to 50%, the ICER for strategy 5
























FIGURE 59 Life expectancy of relatives: no impact of colonoscopic surveillance on CRC incidence.
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not likely to have produced an ICER of > £20,000 per QALY gained is that a proportion of probands are
assumed to have LS and therefore still receive CRC and endometrial cancer risk-reducing measures.
However, the diagnosis of LS assumed is also shown to have a big impact on the results. If all LS assumed
probands and relatives are instead diagnosed as LS negative, the ICER for strategy 5 decreases significantly
to £5225 per QALY gained. This is likely to be because the number of FPs in the LS assumed population is
similar to the number of TPs in the base case (48–65% depending on the strategy), which increases risk
reduction costs without providing a significant benefit.
Of the diagnostic costs, those for IHC and MSI testing have the biggest impact on the results, as they are
the most significant drivers of the overall diagnostic cost (as they are applied to all probands in the relevant
arms). They also affect the costs of strategy 1, in which the costs of MSI and IHC are included for stage II
colon cancers. For all analyses, adjusting the cost of IHC or MSI testing results in the ICERs remaining
below the £20,000 per QALY cost-effectiveness threshold.
As in Snowsill et al.,4 including only probands in the model increases the ICERs for all strategies (the ICER
for strategy 5 vs. no testing increases to £17,921 per QALY gained) and reduces the INHB compared with
no testing. Increasing the number of relatives to 12 decreases the ICERs as expected (the size of the cohort
that can benefit from CRC and endometrial cancer risk reduction increases), but the impact does not
appear to be significant (the ICER for strategy 5 vs. no testing decreases to £10,068 per QALY gained).
The model is also sensitive to the incidence of CRC for people with LS. With a high incidence of CRC
the ICER for strategy 5 compared with no testing decreases to £6689 per QALY gained and with a low
incidence of CRC the ICER for strategy 5 compared with no testing increases to £19,300 per QALY gained.
This is expected as a lower CRC incidence results in fewer benefits from the risk-reducing measures.
The model is also sensitive to the cost of colonoscopy, particularly to increases in this cost. When the
cost of colonoscopy is doubled, all ICERs increase compared with no testing, with the ICER for strategy 5
increasing to £16,630 per QALY gained.
One other parameter that has an impact on the results is the disutility associated with prophylactic H-BSO.
In the base case the disutility was assumed to be 0. In sensitivity analysis we increased this to 0.04 for
1 year, matching the disutility associated with endometrial cancer. This decreases the INHB and increases
the ICER for all strategies compared with no testing, with the ICER for strategy 5 compared with no testing
increasing to £14,441 per QALY gained. As the disutility associated with prophylactic H-BSO is relatively
uncertain (no literature was identified to provide estimates), it is important to recognise the impact that
this parameter can have on the model.
The results are also moderately sensitive to the acceptance rate for colonoscopic surveillance. Reducing the
acceptance rate for surveillance from > 90% for people with a confirmed LS mutation status to 70%
(the acceptance rate for people assumed to have LS) results in a reduction in the INHB and an increase
in the ICERs compared with no testing. Although we were unable to assess the acceptance rate for
gynaecological surveillance in the same way, it is likely to affect the results in a similar manner as fewer
LS-positive people will be receiving risk-reducing measures.
All other deterministic sensitivity analyses did not appear to significantly alter the cost-effectiveness results
when applied in isolation.
Discussion
The analyses conducted suggest that screening for LS in CRC patients using tumour-based tests
(in particular IHC, BRAF V600E and MLH1 promoter methylation testing) would be cost-effective at a
INDEPENDENT ECONOMIC ASSESSMENT
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threshold of £20,000 per QALY. Direct MMR mutation testing was predicted not to be cost-effective at
any cost-effectiveness threshold as it was not on the cost-effectiveness frontier.
Subgroup analyses suggest that the use of a maximum age limit for testing does not significantly affect the
cost-effectiveness of testing, although it does significantly affect the number of individuals affected. For
this reason, budget impact and total health benefits are smaller when a lower age limit is used. Using a
minimum age limit for testing significantly worsens cost-effectiveness but, when a minimum age of
70 years is employed, testing is still predicted to be cost-effective at a threshold of £20,000 per QALY.
Scenario and sensitivity analyses indicate that there are some assumptions or parameters to which the
cost-effectiveness results are sensitive. The most important costs in this respect are the cost of colonoscopy
and the costs of MSI and IHC testing. Cost-effectiveness is also sensitive to the accuracy of the tumour
tests, the acceptance rate for genetic counselling and testing and the number of relatives identified
through cascade testing per proband. The effectiveness of surveillance colonoscopy and the lifetime risk of
CRC for people with LS are also key determinants of cost-effectiveness.
The results are expected to be valid for the NHS (i.e. the results are expected to generalise to the NHS),
partially as key costs were estimated from NHS sources, including NHS reference costs. Also, survival rates
for CRC and endometrial cancer were estimated from English or UK patients. Survival rates for cancers can
vary even among high-income countries in Europe. The effectiveness of colonoscopic surveillance was
estimated from a Finnish study and so it is possible that surveillance in the NHS may not have the same
effectiveness. It is considered likely that the cancer risks estimated for individuals with LS are appropriate as
they were estimated from a French population. The prevalence of LS in CRC patients was estimated from a
US study, but there is no obvious reason to think that prevalence would differ markedly in the UK as
neither the UK nor the USA has significant founder mutations.
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Chapter 6 Assessment of factors relevant to the
NHS and others
Current variability in implementation
The Royal College of Pathologists’ data set for CRC indicates the value of assessing MMR status (Box 9).
This has been in place for 2 years now and there have been efforts from the charity Bowel Cancer UK,
through freedom of information requests, to document compliance with this core item (MMR IHC for
patients aged < 50 years).183
Of the 130 hospitals in England that responded (82% of the 159 contacted), 90 (69%) indicated that all
patients diagnosed with bowel cancer aged < 50 years are tested with MSI or IHC, but only 49 hospitals
(54%) conducted these tests as reflex tests (i.e. automatically, without referral).
Hospitals that have not implemented routine testing cited finances and practicalities as the principal
barriers to implementation.183
This suggests that there is current variability in the level of implementation (some hospitals implement testing
for CRC patients aged < 50 years whereas others do not) and the pathway (reflex testing vs. referral).
Use and impact of age limits
Age limits for testing and surveillance in LS have been suggested by numerous expert groups,19,31,49,125
usually with the intention of balancing clinical benefits against resource implications and clinical risks.
The Equality Act 2010184 applies to NICE, which is required to have due regard to the need to eliminate
discrimination.185 Age is a protected characteristic in this context.
In the context of screening for LS in CRC patients, age is a proxy for the pretest probability of having LS92
and is therefore directly related to the potential for an individual to benefit from screening. Although there
are other observable characteristics that could also be used to identify a higher-risk group (such as tumour
morphology associated with MMR deficiency49), assessing these would increase the complexity of the
service pathway and could result in reduced implementation.
BOX 9 Extract from the Royal College of Pathologists’ data set for CRC
MMR status has prognostic significance, possible predictive significance and can help detect Lynch
syndrome families. As such, a strong case can now be made for performing MMR immunohistochemistry
in all cases of CRC. However, given the resource implications of implementing this, it is not considered a
core data item for all colorectal cancers currently. We now consider MMR immunohistochemistry a core
dataset item for patients under 50 years at time of diagnosis
Loughrey et al. (p. 5)49; reproduced with permission from the Royal College of Pathologists
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In accordance with the NICE scope,88 subgroup analyses were conducted on a number of age groups.
As in the base case, strategy 5 was the cost-effective strategy in all subgroup analyses (except when an
age limit of 50 years was used, in which it was a close second, assuming a cost-effectiveness threshold of
£20,000 per QALY). Figure 60 shows the incremental costs and QALYs for strategy 5 compared with
strategy 1 in the different analyses. The greatest INHB (at a willingness to pay of £20,000 per QALY) is
obtained in the base case (848 QALYs). This is because the base case includes the largest population and
the ratio of incremental costs to QALYs is relatively stable as the maximum age limit is progressively lifted.
Imposing a minimum age limit of 70 years has a detrimental impact on cost-effectiveness and has not
been recommended by any organisations. However, using the base-case assumptions and parameter
values, testing using strategy 5 in this scenario is still cost-effective at a cost-effectiveness threshold of
£20,000 per QALY (ICER £18,774 per QALY).
The decision modelling has assumed that there is no direct cost to imposing an age threshold (which is
probably a reasonable assumption) but also that the imposition of an age threshold does not result in
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FIGURE 60 Incremental costs and QALYs for strategy 5 compared with strategy 1 in the base case and across
different subgroup analyses.
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Chapter 7 Discussion
Review of test accuracy evidence
Findings in relation to previous studies
Ten studies met the test accuracy review inclusion criteria. One of the included studies34 had two distinct
samples (a population-based sample and a high-risk sample); therefore, the 10 studies included 11
populations/samples. IHC was conducted in all 10 studies (11 samples); however, not all studies provided
sufficient data to be included in the IHC analyses. Indeed, the high-risk sample in the study by Poynter et al.34
and the sample in the study by Mueller et al.58 provided too few data to be included in any of the IHC analyses.
A variety of studies were included:
l four single-gate studies with population-based samples, including an unselected CRC sample34 and
three age-limited populations54–56
l five single-gate studies based on high-risk populations34,57–60
l two studies that used a variation on a two-gate study design61,62 in which participants with positive
reference standard results were recruited but no reference standard-negative participants were
recruited (termed reference standard-positive studies for the purposes of this report).
Overall, there were no concerns about whether or not the included participants matched the review
question. The reference standard was assessed as being likely to correctly classify the target condition and
there were no concerns that the target condition, as defined by the reference standard, did not match
the review question. However, all studies were rated as unclear with regard to whether the conduct and
interpretation of the test could have introduced bias. It was also unclear for all studies whether the flow of
participants through the study could have introduced bias.
Only four studies were rated as having a low risk of bias for patient selection.54–56,62 However, none of the
studies was rated as having a high risk of bias for patient selection, even though the index tests are highly
susceptible to spectrum effects in populations that have been selected on the basis of clinical characteristics.
This is because it was decided prior to conducting the review that only sensitivity estimates would be made
for studies recruiting high-risk samples. This decision was based on the fact that a previous review42 did not
find significant bias in estimates of sensitivity after recruitment of high-risk samples.
Evidence for microsatellite instability testing
With the exception of the studies by Limburg et al.55 and Okkels et al.,62 all studies assessed MSI testing.
Sensitivity results for microsatellite instability testing
Across all nine study samples (population-based and high-risk samples), sensitivity ranged from 66.7%
(95% CI 47.2% to 82.7%)54 to 100.0% (95% CI 93.9% to 100.0%)34 when MSI-L was considered to be a
negative result. In a previous review by Palomaki et al.42 data from 11 studies (one age-limited sample and
10 high-risk samples) were pooled in a random-effects model and the sensitivity of MSI was reported to be
85% (95% CI 75% to 92%) for identifying MLH1 mutations and 85% (95% CI 73% to 93%) for identifying
MSH2 mutations. Data were pooled from five studies to produce a sensitivity of MSI of 69% (95% CI 46%
to 85%) for identifying MSH6 mutations. In all of these analyses, MSI-L was considered to be a negative
index test result. It is difficult to compare the results of Palomaki et al.42 with the results of this review,
primarily because different inclusion criteria were used, in particular for the reference standard. In addition,
data were not pooled in this review and were not split according to gene. Nevertheless, the sensitivities and
CIs reported by Palomaki et al.42 were similar to those in this review. Similarly, a review by Bonis et al.17
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provided an overall sensitivity of 56–100% for MSI-H compared with MSS, based on 16 studies. Again,
although these results appear to be similar to those from this review, because of differences in the inclusion
criteria used in the study by Bonis et al.17 and this review any comparison made may not be particularly
meaningful. For example, in the study by Bonis et al.,17 any genetic testing was included as the reference
standard and so a wider range of studies was included.
In this review of test accuracy, it was noted that sensitivity increased if MSI-L was considered to be a
positive index test result. Indeed, across the nine study samples, the lower end of the range for sensitivity
increased to 79.4% (95% CI 62.1% to 91.3%),57 with the higher end of the range remaining at 100%.
The review by Bonis et al.17 included seven studies in which MSI-L was considered to be a positive index
test result and also found increased sensitivity estimates, with pooled data producing a summary estimate
for sensitivity of 94% (95% CI 86% to 97%). Indeed, when MSI-L tumour results were excluded from the
analyses, summary sensitivity was reported as 80% (95% CI 63% to 90%) because the number of positive
results was reduced. As previously mentioned, it is unsurprising that including MSI-L as a positive index test
result increases sensitivity because this essentially decreases the threshold for a positive test result.
Another review, by Snowsill et al,4 also reported sensitivity data for MSI testing, with sensitivity ranging
from 88% to 100% when MSI-L was considered to be a positive index test result. Again, although these
estimates are similar to those reported in this review, comparison may not be particularly useful because of
the different inclusion criteria used. The review by Snowsill et al.4 included nine high-risk or age-limited
studies (studies were included if the participants were at risk of LS as a result of being aged < 50 years at
diagnosis or because of clinical criteria or family history indicators); studies were also included in which not
all patients received the reference standard; and looser criteria were applied to the reference standard than
those applied in this review. It is notable, however, that despite these differences, the results are similar.
This may, in part, be because of a lack of data identified in this review from unselected CRC populations.
Specificity results for microsatellite instability testing
Three population-based study samples provided data in which MSI-L was considered to be a negative index
test result.34,54,56 Across these three samples, specificity ranged from 61.1% (95% CI 57.0% to 65.1%)34
to 92.5% (95% CI 89.1% to 95.2%).54 It should be noted that the study by Barnetson et al.54 included an
age-limited sample whereas the sample in the study by Poynter et al.34 was based on an unselected CRC
population. Six studies that provided data in which MSI-L was considered to be a negative index test result
were pooled in the review by Palomaki et al.,42 with summary specificity given as 90.2% (95% CI 87.7% to
92.7%). This result is closer to the specificity reported by Barnetson et al.54 in this review and this may be, in
part, because the study by Palomaki et al.42 included only high-risk or age-limited populations. The review
by Bonis et al.17 reported an overall specificity of between 17% and 93% for MSI-H compared with MSS,
based on 16 studies, indicating substantial heterogeneity. Again, it is difficult to compare the results
from these previous reviews with the results of this review because of key differences in the inclusion
criteria applied.
In this review, and as expected, specificity decreased when MSI-L was considered to be a positive index
test result. The lower end of the range decreased to 29.5% (95% CI 25.8% to 33.4%)34 and the upper
end of the range decreased to 84.5% (95% CI 80.0% to 88.2%).54 Pooling data from seven studies
included in the review by Bonis et al.17 resulted in a specificity of 83% (95% CI 77% to 88%) when MSI-L
was considered to be a positive index test result, whereas specificity was 88% (95% CI 83% to 91%)
when MSI-L tumours were excluded. However, the authors noted that there was substantial statistical
heterogeneity in both analyses. Snowsill et al.4 reported a specificity range of 68–84% when MSI-L was
considered to be a positive index test result, the upper end of which is comparable to the upper end of the
range in this review. However, the review by Snowsill et al.4 was based on high-risk or age-limited studies
only and so does not include the population-based sample from the study by Poynter et al.34
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Evidence for immunohistochemistry
Seven studies54–57,59–61 provided data to assess the accuracy of an overall IHC result at identifying a positive
reference standard result (i.e. whether a positive IHC result, regardless of which protein this applies to,
identifies a positive reference standard result). All seven of these studies assessed MLH1, MSH2 and MSH6
proteins. The studies by Southey et al.56 and Overbeek et al.59 also assessed PMS2. Five studies34,54,56,61,62
split IHC data according to the particular protein assessed (MLH1, MSH2, MSH6 or PMS2).
Overall sensitivity and specificity results for immunohistochemistry
Sensitivity estimates ranged from 80.8% (95% CI 60.6% to 93.4%)60 to 100.0% (95% CI 81.5% to
100.0%)56 for IHC overall. The study by Southey et al.56 included an assessment of PMS2 as well as MLH1,
MSH2 and MSH6, which may account for the higher sensitivity estimate in this study. Nevertheless, all
sensitivity estimates were > 80%. Specificity was estimated as 91.9% (95% CI 86.3% to 95.7%)55 and
80.5% (95% CI 65.1% to 91.2%).56
Other reviews have produced similar results, but, again, it must be noted that these reviews used different
inclusion criteria from the inclusion criteria used in this review. The review by Bonis et al.17 produced a
summary sensitivity of 74% (95% CI 54% to 87%) and specificity of 77% (95% CI 61% to 88%) for
IHC overall, based on six studies considered to be of good or fair quality. Similar results were reported by
Palomaki et al.42 based on pooled data from three studies; overall sensitivity was estimated as 77%
(95% CI 69% to 84%) and overall specificity as 88.8% (95% CI 67.6% to 94.8%), although statistical
heterogeneity was noted. Similarly, without pooling data, Snowsill et al.4 reported a sensitivity range of
73.3–100.0% and a very wide ranging specificity of 12.5–100.0%. Indeed, Snowsill et al.4 discuss how
specificity appears to be the greatest concern with regard to IHC, as the high number of false-positive
results means that individuals may be told that they have LS when they do not. However, in the two
studies included in this review, the specificity of IHC was > 80%. This difference is likely to occur because
the specificity data from the review by Snowsill et al.4 were based on high-risk as well as age-limited
studies, whereas, to mitigate spectrum effects, the specificity data in this review were based on only two
studies that recruited age-limited populations.
Sensitivity and specificity of immunohistochemistry by individual protein
For the population-based sample from Poynter et al.34 and the study samples from Barnetson et al.,54
Southey et al.,56 Hendriks et al.61 and Okkels et al.,62 an assessment of IHC was made for at least one
individual protein. With regard to estimating sensitivity, three of these studies54,56,61 provided data relevant
to whether loss of expression of MLH1 was an accurate test result for assessing a pathogenic mutation in
MLH1. Sensitivities ranged from 50.0% (95% CI 26.0% to 74.0%)56 to 100.0% (95% CI 73.5% to
100.0%).54 The results for MSH2 were even more variable; the same three studies reported sensitivities
ranging from 22.2% (95% CI 6.4% to 47.6%)56 to 81.8% (95% CI 48.2% to 97.7%).54,61 Four studies
provided data for MSH654,56,61,62 and, again, there was substantial variability in the results, with sensitivities
ranging from 44.4% (95% CI 21.5% to 69.2%)56 to 75.0% (95% CI 19.4% to 99.4%).54,61 Only the study
by Southey et al.56 provided IHC data for PMS2, with a sensitivity estimate of 55.6% (95% CI 30.8%
to 78.5%).
The results for specificity displayed less variability. Three population-based studies34,54,56 provided data
enabling the estimation of the specificity of loss of expression of MLH1 for identifying pathogenic
mutations in MLH1. These specificities ranged from 70.6% (95% CI 66.8% to 74.2%)34 to 96.0%
(95% CI 93.1% to 97.9%).54 Two population-based studies54,56 provided data for MSH2 and MSH6, with
all specificities being > 92%. Only the study by Southey et al.56 provided data for PMS2, with a specificity
estimate of 87.8% (95% CI 73.8% to 95.9%).
The review by Palomaki et al.42 investigated whether overall IHC results indicated gene-specific pathogenic
mutations. However, none of the previous systematic reviews identified through database searching
provided an evaluation of whether loss of expression of a particular protein indicates a pathogenic
mutation in that protein.
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Strengths
The strengths of this systematic review are that it was conducted by an independent, experienced research
team using the latest evidence and working to a prespecified protocol (PROSPERO CRD42016033879) that
followed a robust methodology.
The search strategy was devised by an information specialist and did not restrict the results by study design
and also included both forward and backward citation chasing. The studies were independently screened
by two reviewers, with data extraction and quality appraisal performed by one reviewer and checked by
a second.
Weaknesses
The relatively low prevalence of LS means that comprehensive MMR gene testing among all CRC patients
in the general population would be expensive. Therefore, as mentioned previously, five34,57–60 of the
10 studies included in this review were single-gate studies based on high-risk populations. There is some
concern that the increased presence of MMR mutation carriers in a population may change the apparent
sensitivity and specificity of the index tests. However, we did not use these studies to estimate specificity and
we did not find great differences between the studies with regard to sensitivity, although this may be
because the three population-based studies with overall IHC data54–56 were based on age-limited populations
and therefore may also be subject to spectrum bias. Palomaki et al.42 also suggest that spectrum bias does
not seem to have been an issue for estimating sensitivity. For example, when the population-based results for
those aged < 55 years (80% for MLH1 and 82% for MSH2) are compared with the results of the other four
studies that were based on strong family histories regardless of age (82% for MLH1 and 88% for MSH2),
the results are remarkably similar. This may be because similar spectrum bias is obtained in the high-risk
(age-unrestricted) population and the general age-limited population. The inclusion of high-risk studies in
this review could therefore have introduced spectrum bias in the sensitivity estimates, although this does not
appear to be the case. The inclusion of high-risk studies in this review does mean that there are several
studies from which sensitivity estimates could be made, despite the low number of population-based studies
identified (only one unselected CRC sample and three age-limited samples). However, the low number of
population-based studies resulted in limited specificity data, as well as limited data for other outcomes
(predictive values and LRs).
Although not a weakness of the review methods per se, significant methodological and clinical heterogeneity
were noted across the included studies and this impacts on both the type of synthesis that could be
conducted and the way in which the findings should be considered. In particular, when considering the
results, it is important to note that the reference standard differed between studies, as did the index tests.
With regard to the reference standard there were differences in the testing methods used, including the
sequencing methods and the genes tested, the techniques used to test for large genomic alterations and
deletions, the genes tested for large genomic alterations and deletions and whether unclassified variants
were investigated.
For MSI testing, microdissection techniques were not always reported and the panel of markers varied,
as did the thresholds and the categorisation of MSI. Indeed, none of the population-based studies in this
review assessed the same panel of MSI markers. Issues with heterogeneity have also been reported in other
similar reviews. For example, Bonis et al.17 reported that they could not explain heterogeneity among the
estimates of sensitivity and specificity based on ‘the overall study quality, the comprehensiveness of the
genetic testing, the presence of microdissection, the use of National Cancer Institute (NCI)-recommended
marker sets or whether the study used a transparent sample selection process’. As with this review, Palomaki
et al.42 found weaknesses in the studies included in their review, as well as clinical and methodological
heterogeneity between studies. For example, none of the studies included in their review explicitly reported
laser microdissection, which has been reported to be the optimal method for sample preparation. In
addition, none of the studies reported a minimum proportion of tumour cells. Roughly half of the studies
relied solely on the 1998 NCI-recommended panel, which includes only two mononucleotide markers,
whereas the remaining studies utilised three or more mononucleotide markers. When the results were
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stratified by this quality measure, the clinical sensitivities in studies using three or more mononucleotide
markers were higher than those in studies using two mononucleotide markers.42 This provides some evidence
to suggest that additional mononucleotide markers (up to five) should be included in a MSI panel for clinical
testing. It was not possible to confirm this by running similar analyses in this review; to focus on the best
reference standard testing methods, fewer studies were included and so insufficient homogeneous data
were available to perform similar analyses. Indeed, the clinical and methodological heterogeneity in the
studies included in this review precluded any statistical pooling of data. Instead, the results were discussed in
a narrative synthesis.
It should also be noted that the review of test accuracy included only published studies in the English
language. To enable a full evaluation of the methodological quality of included studies to be carried out,
those studies published only as abstracts were also excluded.
It is possible that the estimates derived from the included studies are subject to some amount of publication
bias. However, insufficient data were available from the included studies to perform a statistical assessment
of publication bias.
The bibliographic searches were conducted in February 2016 and therefore it is possible that further relevant
studies have been published or indexed since this date that have not been identified. There were also no
attempts to review grey literature, such as technical reports, that would not have been peer reviewed.
Areas of uncertainty
The greatest area of uncertainty is in the generalisability of the results from high-risk and age-limited
studies to the general CRC population. As discussed earlier, only one study sample was identified that was
based on an unselected CRC population.34 This is unsurprising given that large population-based studies in
which all participants receive both the index test and the reference standard would be costly. Performing
the reference standard on a random sample of index test negative participants would be methodologically
acceptable and would somewhat decrease the costs of performing a population-based study in which all
participants receive all tests.
Another area of uncertainty relates to the categorisation of unclassified variants [three34,54,55 of the four
population-based studies reported on unclassified variants (i.e. mutations for which the association with LS
is unclear)]. This can complicate the assessment of MSI, in particular, as the variants have uncertain
pathogenicity and may occur in cases with either MSI-H or MSS tumours. In this review, in primary analyses,
unclassified variants were counted as negative reference standard results. However, secondary analyses
were also conducted, as appropriate, in which unclassified variants were considered to be positive reference
standard results.
Unclassified variants: microsatellite instability
Two studies57,61 provided sufficient data to conduct secondary analyses in which unclassified variants were
categorised as positive reference standard results. The study by Caldes et al.57 included a high-risk population
and the study by Hendriks et al.61 was a reference standard-positive study and so only sensitivity estimates
were made. When MSI-L was considered to be a negative index test result, Caldes et al.57 reported a
sensitivity of 81.6% (95% 65.7% to 92.3%) and Hendriks et al.61 reported a sensitivity of 84.8% (95% CI
69.0% to 93.3%). These results were similar to those obtained when unclassified variants were considered to
be negative reference standard results (79.4%, 95% CI 62.1% to 91.3%;57 88.8%, 95% CI 68.8 to 97.561).
When MSI-L was considered to be a positive index test result, only one study61 provided sufficient data to
conduct a secondary analysis of the sensitivity estimate. In this study, sensitivity was 93.9% (95% CI 80.3%
to 98.3%), which was similar to when unclassified variants were considered to be negative reference
standard results (92.0%, 95% CI 74.0% to 99.0%).
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Unclassified variants: immunohistochemistry
As for MSI, only two studies57,61 provided sufficient data to conduct secondary analyses. Again, because
the study by Caldes et al.57 included a high-risk population and the study by Hendriks et al.61 was a
reference standard-positive study, only sensitivity estimates were made. Sensitivity was 75.0% (95% CI
57.8% to 87.9%) for Caldes et al.57 and 88.6% (95% CI 76.0% to 95.0%) for Hendriks et al.61 For Caldes
et al.57 this represents quite a reduction in sensitivity compared with when unclassified variants were
considered to be negative reference standard results (96.4%, 95% CI 81.7% to 99.9%).
Review of end-to-end studies
Findings in relation to previous studies
No studies were identified that met the inclusion criteria for the review of end-to-end studies.
The review by Bonis et al.17 also attempted to identify end-to-end studies (their key question 1) but no
studies were found.
Strengths
The review was conducted by an experienced researcher and the searches employed were very sensitive as
no study design filters were employed. A second reviewer parallel screened a random sample of bibliographic
records and excellent agreement was achieved. Although no studies were eventually included in the review,
the prospective protocol prespecified the quality appraisal strategy to be used.
Weaknesses
The review focused on published literature indexed by bibliographic databases, meaning that grey
literature was not identified. The searches were conducted in February 2016 and therefore it is possible
that further relevant studies have been published or indexed since this date that have not been identified.
Areas of uncertainty
As no studies were identified for inclusion, there is no high-quality published evidence (up to February 2016)
that screening for LS in CRC patients using MSI or IHC testing improves health outcomes.
Given that it is widely believed that such screening would improve health outcomes, it is unlikely that
high-quality evidence will be generated in the future, for example in the form of a RCT. What evidence
may be produced in the future will likely be observational and, although statistical methods may be used
to remove certain biases, it is likely that there will be certain biases that cannot be adjusted for and that
statistical power will be low compared with what could be produced by a RCT.
Review of existing cost-effectiveness evidence
Findings in relation to previous studies
The cost-effectiveness review found that, although no study fully answered the decision problem specified
by the NICE scope,88 studies generally found that some testing strategy was cost-effective (according to the
relevant perspective) and that tumour-based testing usually improved cost-effectiveness compared with
direct genetic testing. The effectiveness of colonoscopy, the number of relatives receiving cascade genetic
testing and the prevalence of LS in the population were generally identified as key parameters to which
the results were sensitive.
These results are similar to the results of the previous review by the authors.4
Other reviews of cost-effectiveness have been published. Grosse76 similarly found that studies usually
produced one or more cost-effective strategy, but that these sometimes used age limits or clinical criteria.
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The number of first-degree relatives identified for cascade genetic testing and the cost of gene sequencing
were found to have a significant effect on cost-effectiveness, as did the frequency and cost of surveillance
colonoscopy and the inclusion of extracolonic surveillance.
Ladabaum et al.3 also reviewed the health economic literature on tumour testing and concluded that it is
estimated to be cost-effective, especially if cascade genetic testing is employed.
Strengths
This review was conducted by an independent, experienced research team using the latest evidence and
working to a prespecified protocol (PROSPERO CRD42016033879). Screening was conducted independently
by two reviewers.
Weaknesses
Data extraction and quality appraisal were conducted by one reviewer. This has the potential to lead to
inconsistencies and misinterpretation between the published studies and the review reporting.
As with all reviews of published literature, this review is open to publication bias and so some information
may have been missed. The searches were conducted in February 2016 and therefore it is possible that
further relevant studies have been published or indexed since this date that have not been identified.
More recent quality appraisal tools are available than that of Drummond and Jefferson,77 which was used
in this review for consistency with the previous review.4 The Philips et al.186 or Evers et al.187 checklists may
now be more appropriate.
Areas of uncertainty
The reporting was of mixed quality and some studies were reported only in abstract form and therefore
the data extracted from the studies and the conclusions drawn are likely to reflect this.
The results of the review highlighted the need for a cost-effectiveness analysis specific to the decision
problem. No individual study was able to address this and the study results could not be adequately
synthesised, given the combination of different strategies and modelling techniques used and the different
perspectives of the studies.
Although the included studies indicated that a strategy of diagnostic testing for LS is likely to be
cost-effective for each of the described contexts, conclusions could not be drawn with regard to which
strategies would be most cost-effective, particularly from the perspective of the NHS.
Independent economic assessment
Findings in relation to previous studies
The base-case estimates from the independent economic assessment suggest that testing for LS in CRC
patients would be cost-effective (compared with not testing) at a willingness-to-pay threshold of £20,000
per QALY, except in the case in which patients are offered comprehensive genetic testing for LS without
any tests being conducted on the tumour. In this case, testing is estimated to be cost-effective compared
with no testing at a willingness-to-pay threshold of £30,000 per QALY. This universal testing strategy is,
however, not predicted to be cost-effective in a fully incremental analysis (in which testing with MMR IHC,
BRAF V600E testing and MLH1 hypermethylation testing is cost-effective). Indeed, it is estimated that the
universal genetic testing strategy would be more expensive and less effective than another strategy.
These findings are similar to those in the previous PenTAG economic evaluation4 (in particular the scenario
analysis, in which the age limit for testing was raised to 70 years), even though in the base case of this
assessment there was no age limit and a number of changes have been made to the analysis (e.g. new
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diagnostic strategies, new parameter estimates for diagnostic accuracy, inclusion of aspirin chemoprevention
and gynaecological surveillance).
The current analysis suggests that IHC-based testing would be more cost-effective than MSI-based testing,
whereas the previous PenTAG analysis suggested the opposite. This is partially because the sensitivity of
IHC modelled in this study is higher than that modelled previously and the specificity of MSI testing is
lower. There is no compelling evidence that either test has superior diagnostic performance and the costs
for both tests can vary between settings (e.g. in some hospitals a pathologist will be able to perform IHC
but there will be no facility for MSI testing and samples will need to be sent elsewhere at a cost). BRAF
V600E and/or MLH1 hypermethylation testing are conducted only on patients with abnormal MLH1
protein staining on IHC testing, whereas these tests are conducted for all patients with MSI (so all else
being equal there would be a reduction in downstream costs if IHC were used). IHC-based testing is also
required in a small minority of cases to assist in the interpretation of MMR mutation testing and therefore
some individuals receiving MSI testing initially may later undergo IHC-based testing as well.
There are no other UK-based cost–utility analyses for further comparison, but the results of this study
are also comparable to those of a number of studies from elsewhere. For example, Mvundura et al.84
(a US study) found that tumour-based testing (using IHC and BRAF V600E testing) was cost-effective
(ICER US$22,552 per life-year), whereas direct genetic testing was not cost-effective (ICER > US$142,289
per life-year compared with no testing and ICER US$737,025 per life-year in a fully incremental analysis).
Wang et al.86 (another US study) found that tumour-based testing may be cost-effective (ICER US$59,719
per QALY) but that direct genetic testing would not be cost-effective (ICER US$271,219 per QALY).
Strengths
The economic evaluation was conducted by an independent academic group with experience in reviewing
and modelling in this disease area. The population, interventions, comparators and outcomes were based
on the NICE scope.88
The model was built by extending an existing model that had previously been quality assured and peer
reviewed. The extensions mean that the model now more closely matches likely clinical practice.
The model methodology (individual patient simulation) allowed for detailed modelling, including of
multiple cancers, different CRC stages, evolving strategies for gynaecological risk reduction and event
probabilities that can be dependent on the time since previous events. This means that there was no need
to make assumptions about constant hazards of events (i.e. exponential survival distributions).
The evidence for diagnostic test accuracy parameters was identified through systematic review. Evidence
for key model parameters was identified by reviewing the published literature and critically appraising
alternative sources.
Scenario and sensitivity analyses were conducted to identify key sources of decision uncertainty.
The model was quality assured by developers testing each other’s components.
Weaknesses
The weaknesses of the systematic review of test accuracy are carried through to the economic assessment,
as the cost-effectiveness of the testing strategies is sensitive to the test accuracy parameter values.
The model base case used sensitivity and specificity estimates for MSI and IHC from a meta-analysis of
studies identified in the systematic review of test accuracy, even though for a number of reasons
meta-analysis was not felt to be appropriate for the review.
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The model assumed that the diagnosis of LS in the probands and relatives occurs at the model start, that is,
that there are no delays to testing and that surveillance does not commence before testing is completed.
To achieve convergence in model estimates, 240,000 individual patients were simulated. A probabilistic
sensitivity analysis was not conducted because of the computational requirements of such an analysis and
therefore decision uncertainty was explored only using scenario analyses and sensitivity analyses, with
limited numbers of parameters varied simultaneously.
The model does not include ovarian cancer, small bowel cancer, gastric cancer or other cancers associated
with LS. Of these, ovarian cancer would be most likely to have an affect on cost-effectiveness, as the
model already includes the costs of risk-reducing interventions for ovarian cancer (these are the same as
those for endometrial cancer) but none of the benefits.
Areas of uncertainty
There is significant uncertainty as to the true risk of CRC for individuals with LS not receiving colorectal
surveillance and the true effectiveness of colorectal surveillance in reducing the risk of CRC. The
cost-effectiveness of the testing strategies was sensitive to both of these parameters. Neither parameter is
likely to be directly investigated in an experimental context (e.g. a RCT) for ethical reasons. The parameter
values for each were chosen with care following a review of the literature and are more conservative than
estimates made in other economic evaluations and systematic reviews. For example, a recent technical
review3 estimated that CRC incidence would be reduced more heavily by colorectal surveillance than we
have estimated and most reports quote a higher range of lifetime CRC risks than we have modelled.
Univariate sensitivity analyses were conducted on these parameters but two-way sensitivity analysis was
not conducted.
There remains substantial uncertainty in the estimates of test accuracy measures for MSI- and IHC-based
testing, as there are few studies investigating test accuracy that are not at high risk of bias (e.g. because of
applying the reference standard only when the index test is positive or some family history criteria are met).
If the true sensitivity and specificity of MSI are as low as explored in sensitivity analysis, it would not be
cost-effective (compared with not testing) to screen using MSI-based strategies (at a willingness-to-pay
threshold of £20,000 per QALY).
It is possible that the costs of genetic counselling included in the economic evaluation are too low. The
economic evaluation assumes a base-case total cost of £63 for each person offered genetic testing for LS.
A specialist committee member in the NICE Diagnostics Assessment Programme process noted that the
NHS reference costs for outpatient clinics in clinical genetics are significantly higher than this, with an
average cost of £432 per clinic (2014/15 prices).178 In addition, the 2013 NICE clinical guidelines on familial
breast cancer188 made recommendations informed by an economic evaluation that (breast cancer-) affected
individuals would require two counselling sessions in relation to BRCA mutation testing and unaffected
individuals would require three counselling sessions. The costing report estimated that these would cost
£125 each, whereas the economic evaluation estimated that they would cost approximately £400 each for
the index individual and £300 each for a family member. A separate microcosting study of ‘standard’
cancer genetics pathways for BRCA mutation testing estimated that referral and counselling costs for an
index individual would be £460 and for a relative would be £335 (based on supplementary Tables 1 and
2).189 If these costs (uprated from 2013/14 prices) were used in our economic evaluation, testing would
become less cost-effective compared with no testing, with the ICER for strategy 5 increasing from £11,008
per QALY to £11,764 per QALY. However, the Mainstreaming Cancer Genetics programme has operated
successfully including only one post-test counselling session for index individuals found to have a
pathogenic BRCA mutation, one pretest counselling session for relatives and one post-test counselling
session for relatives with the mutation.190,191 Such a regime would reduce costs further, as generally half or
fewer of those tested for LS mutations are found to have a pathogenic MMR mutation.
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It was also suggested by a specialist committee member in the NICE Diagnostics Assessment Programme
process that the costs of genetic testing included in the economic evaluation are too high. Base-case costs of
£1276 to test all four MMR genes and £949 to test only MLH1 and PMS2 were included in the model. The
UKGTN database was searched in December 2016 and two laboratories were found to offer sequencing and
copy number analysis of all four MMR genes for £650 and £860.175 Replacing the base-case costs with £755
improves the cost-effectiveness of testing compared with no testing, with the ICER for strategy 5 decreasing
from £11,008 per QALY to £10,596 per QALY.
The economic evaluation assumed that the diagnostic performance of MLH1 promoter methylation testing
would be independent of the BRAF V600E status of tested individuals. This may be an unrealistic and optimistic
assumption if these tumour markers are correlated, even after controlling for LS status. A literature review by
Parsons et al.192 identified three studies that evaluated MMR mutation, BRAF V600E and MLH1 promoter
methylation status. A total of 107 tumours were included in these studies, of which 35 had a MMR mutation.
The sensitivity and specificity of MLH1 promoter methylation to detect a MMR mutation (not conditional on
BRAF V600E status) were 91.4% and 75.0% respectively. When this was limited to tumours without BRAF
V600E, the specificity dropped to 60.9% (the sensitivity estimate was unchanged). Changing the economic
evaluation base-case specificity of 75% for MLH1 promoter methylation testing following BRAF V600E testing
to 60.9% leads to a lower cost-effectiveness for strategies 5 and 9 (which include BRAF V600E and MLH1
promoter methylation testing), with the ICER of strategy 5 increasing from £11,008 per QALY to £11,140 per
QALY. Strategy 5 remains the optimal strategy assuming a willingness-to-pay threshold of £20,000 per QALY.
The economic assessment has also, by necessity, incorporated evidence from countries other than the UK.
For example, the effectiveness of colonoscopic surveillance was estimated from a Finnish study,124 the
prevalence of LS among CRC patients was estimated from a US study92 and the lifetime risks of CRC and
endometrial cancer were estimated from a French study.18 Although there is no evidence to suggest that
these findings will not generalise to the UK, this remains an area of uncertainty.
It appears that gynaecological surveillance and aspirin chemoprevention do not have a significant impact
on cost-effectiveness and therefore the uncertainty in the extent to which they are offered to patients is
unlikely to translate into decision uncertainty.
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Chapter 8 Conclusions
There is evidence that MSI testing and MMR IHC are effective tests to identify CRC patients who may haveLS. This evidence comes from 10 published studies that were judged not to be at high risk of bias. Some
studies did not include patients known not to have LS and could not therefore provide estimates of specificity
for the tests. The reference standard (comprehensive genetic testing) was variable across the studies and
cannot be considered a gold standard, particularly because of the number of variants of uncertain significance
identified. A number of studies used clinical criteria (or other means) to select from a high-risk population for
testing, which puts their results at risk of spectrum bias.
Because of the limited number of population-based studies and the heterogeneity in test accuracy
estimates from these studies, it was judged that quantitative synthesis (meta-analysis) should not be
conducted as part of the systematic review.
It is primarily cost considerations that prohibit a large-scale high-quality assessment of the diagnostic test
accuracy of MSI- and IHC-based testing in CRC patients. Conducting both index tests and the reference
standard would cost > £1000 per patient.
No end-to-end studies were identified that directly investigated the impact of screening for LS in CRC
patients on long-term outcomes such as survival or cancer incidence.
It is unlikely that any high quality end-to-end studies will be conducted (e.g. RCTs or cluster RCTs) because
of ethical considerations; it is believed, and supported by modelling, that identifying LS-causing mutations
and offering risk-reducing interventions leads to clinical benefits for patients and so there would not be
clinical equipoise.
The majority of health economic evaluations of screening for LS in CRC patients have suggested that it
may be cost-effective to screen using MSI- or IHC-based testing. However, these studies may not reliably
generalise and therefore a new economic evaluation was conducted as part of this study.
The results of the economic evaluation suggest that it is likely to be cost-effective (at a willingness-to-pay
threshold of £20,000 per QALY) to screen CRC patients using IHC, BRAF V600E testing and MLH1
promoter methylation testing. This is estimated to extend the life expectancy of patients with LS by around
1 year and the life expectancy of their relatives with LS-causing mutations by 2 years. There are estimated
to be 956 such patients (CRC patients with LS) and 2524 corresponding relatives per year. The diagnosis
costs are estimated to be around £10.5M per year (compared with an estimated £1.9M cost of MSI/IHC
conducted to predict 5-FU chemotherapy response). It is estimated that additional QALYs would be gained
at an incremental cost of £11,000 per QALY.
The cost-effectiveness of screening for LS is estimated to be most sensitive to the:
l effectiveness of surveillance colonoscopy in reducing CRC incidence
l diagnostic test accuracy of MSI testing and IHC
l proportion of patients declining genetic counselling and/or genetic testing after tumour testing
l lifetime risk of CRC for individuals with LS-causing mutations
l number of relatives identified through cascade testing
l cost of colonoscopy.
Of these, the cost of colonoscopy is most precisely known (on average, the cost does vary between trusts),
although the frequency of colonoscopy should be considered; the model assumes biennial colonoscopy but
costs would be significantly increased if annual colonoscopy was implemented.
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The number of relatives identified through cascade testing and the proportion of patients declining genetic
counselling and/or genetic testing after tumour testing can be estimated retrospectively from clinical
records or can be monitored prospectively, although the values employed in sensitivity analyses are likely to
be worst-case scenarios.
The sensitivity and specificity of MSI and IHC testing cannot be directly monitored by introducing the tests
into clinical practice (although the PPV could be estimated). As explained earlier, a comparative diagnostic
test accuracy study would be relatively expensive to conduct. When the sensitivity and specificity of IHC,
BRAF V600E and MLH1 promoter methylation testing are all estimated from their respective lower 95%
confidence limits it is still predicted that screening is cost-effective at a willingness-to-pay threshold of
£20,000 per QALY.
The effectiveness of surveillance colonoscopy and the lifetime risk of CRC for individuals with LS-causing
mutations (in the absence of risk-reducing interventions) are subject to significant uncertainty, for the
reason that they cannot be simply observed without bias.
The effectiveness of surveillance colonoscopy cannot be examined in a RCT for ethical reasons and is
therefore generally estimated by comparing the risks observed in individuals undergoing screening with
the risks in those diagnosed with LS and declining surveillance or those not diagnosed with LS but later
established to have LS. Neither of these comparisons is between like groups.
The lifetime risk of CRC for individuals with LS-causing mutations but without risk-reducing interventions
can generally be estimated only by studying the cancer incidence prior to diagnosis and the commencement
of risk-reducing interventions and also correcting for ascertainment bias. Estimates are therefore of limited
precision, even from large studies.
When either of these parameters is modelled at its extreme value, the cost-effectiveness of screening is
marginal at a willingness-to-pay threshold of £20,000 per QALY (ICERs ≈£19,000 per QALY). The extreme
value for the effectiveness of colonoscopy (zero effectiveness) may not be considered clinically likely, but the
extreme value for the lifetime CRC risk is the lower 95% confidence limit. The base-case estimates for these
parameters are from different populations from different studies, but if a study were designed to estimate
both parameters there would be significant correlation in the parameter estimates, as a low observed cancer
risk in those undergoing surveillance could result from surveillance being highly effective or the underlying
risk already being low. This would mean that the precision in estimated cost-effectiveness would not be
increased as much as if the parameters were not correlated.
One way to partially ameliorate this issue might be to delay colorectal surveillance for individuals with
MSH6 or PMS2 mutations to 10–20 years later than for individuals with MLH1 or MSH2 mutations.2,5 It is
considered that this could save 5–10 colonoscopies per individual, with a minimal increase in the number
of CRCs.
It is also possible that other developments in the management of individuals with LS-causing mutations or
the management of CRC or endometrial cancer will lead to shifts in the cost-effectiveness of screening.
For example, a vaccine targeting frameshift peptides, which are produced by MSI-H cancer cells, is considered
to be a promising avenue for treating MSI-H cancer and for cancer prevention in individuals with LS.193
We have also assumed that treatment for CRC does not include monoclonal antibody chemotherapy,
which means that the costs associated with CRC may be underestimated. If CRC treatment is (or becomes)
more expensive than is modelled in this report, the cost-effectiveness of screening for LS will be improved.
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Recommendations for research
Screening for Lynch syndrome in endometrial cancer patients
Given the excellent survival of endometrial cancer patients (compared with colorectal and ovarian cancer
patients), there is an argument that endometrial cancer patients (either early-onset or all patients) should
be screened for LS, as they will stand a good chance of benefiting from colorectal surveillance and other
risk-reducing interventions. It is recommended that the diagnostic test accuracy of tumour-based tests
should be established in endometrial tumours and the cost-effectiveness of screening should be
investigated through modelling of a similar nature to that employed in this report.
Screening for other colorectal cancer predisposition genes in colorectal cancer patients
There are other CRC predisposition genes beyond those responsible for LS. It may be economical to test
CRC patients for all such genes using NGS technology, but not if tumour-based tests are used that enrich
the population specifically for LS testing. An assessment of the yield of clinically actionable diagnoses
based on large cancer risk gene panels compared with targeted testing for LS-causing mutations could be
conducted, along with an economic evaluation of whether such screening would be cost-effective
compared with screening for LS (if this is recommended).
Costs of diagnostic tests
The cost estimates for diagnostic tests have generally been reported by genetics laboratories, rather than
being formally costed. It may be worthwhile to perform a full costing exercise for these tests to determine
accurate costs from a NHS and PSS perspective. The potential for cost savings through the use of NGS
technology should also be assessed.
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Appendix 1 Literature search strategies
Test accuracy searches
MEDLINE (via Ovid)
Data parameters: 1946 to January Week 3 2016.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. Colorectal Neoplasms, Hereditary Nonpolyposis/
14. or/4-13
15. (EPCAM? or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2).tw.
16. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
17. 15 and 16
18. Amsterdam criteria.tw.
19. 3 or 14 or 17 or 18
20. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
21. (Bethesda adj3 (marker* or panel*)).tw.
22. (immunohistochemistry or (IHC adj3 test*)).tw.
23. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
24. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.
25. (MLH1 adj3 (methylation or hypermethylation or ‘hyper methylation’)).tw.
26. exp Immunohistochemistry/
27. or/20-26
28. 19 and 27
29. exp animals/ not humans.sh.
30. 28 not 29
31. limit 30 to (english language and yr=‘2006 -Current’)
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MEDLINE In-Process & Other Non-indexed Citations (via Ovid)
Data parameters: 29 January 2016.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. or/4-12
14. (EPCAM? or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2).tw.
15. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
16. 14 and 15
17. Amsterdam criteria.tw.
18. 3 or 13 or 16 or 17
19. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
20. (Bethesda adj3 (marker* or panel*)).tw.
21. (immunohistochemistry or (IHC adj3 test*)).tw.
22. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
23. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.
24. (MLH1 adj3 (methylation or hypermethylation or ‘hyper methylation’)).tw.
25. or/19-24
26. 18 and 25
27. limit 26 to (english language and yr=‘2006 -Current’)
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EMBASE (via Ovid)
Data parameters: 1974 to 2016 January 29.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. hereditary nonpolyposis colorectal cancer/
14. or/4-13




19. mismatch repair protein PMS2/
20. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
21. or/15-19
22. 20 and 21
23. Amsterdam criteria.tw.
24. 3 or 14 or 22 or 23
25. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
26. (Bethesda adj3 (marker* or panel*)).tw.
27. (immunohistochemistry or (IHC adj3 test*)).tw.
28. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
29. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.




34. 24 and 33
35. limit 34 to (english language and yr=‘2006 -Current’)
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Web of Science [Science Citation Index (SCI) and Conference Proceedings Citation Index –
Science (CPCI-S)] (Thomson Reuters)
Data parameters: not applicable.




1. TS=(lynch* near/2 syndrome)
2. TS=((lynch* near/2 famil*) and (cancer* or neoplasm*))
3. #2 OR #1
4. TS=(‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’)
5. TS=(HNPCC)
6. TS=(((hereditary or inherited) near/2 (colon* or colorectal*)) and (cancer or neoplasm*))
7. TS=((hereditary near/2 nonpolyposis) and (colon* or colorectal*))
8. TS=((hereditary near/2 non-polyposis) and (colon* or colorectal*))
9. TS=((hereditary near/2 (cancer or neoplasm*)) and (colon* or colorectal*))
10. TS=((Familial near/2 Nonpolyposis) and (colon* or colorectal*))
11. TS=((Familial near/2 Non-polyposis) and (colon* or colorectal*))
12. TS=(familial near/2 (colon* or colorectal*))
13. #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4
14. TS=(EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2)
15. TS=(colon* or colorectal* or lynch* or HNPCC or hereditary)
16. #15 AND #14
17. TS=(Amsterdam criteria)
18. #17 OR #16 OR #13 OR #3
19. TS=((microsatellite near/2 instabilit*) or (msi near/2 test*))
20. TS=(Bethesda near/2 (marker* or panel*))
21. TS=(immunohistochemistry or (IHC near/2 test*))
22. TS=((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/2 antibod*)
23. TS=((BRAFV600E or ‘BRAF V600E’) near/2 mutation*)
24. TS=(MLH1 near/2 (methylation or hypermethylation or ‘hyper methylation’))
25. #24 OR #23 OR #22 OR #21 OR #20 OR #19
26. (#25 AND #18) AND LANGUAGE: (English)
Timespan=2006-2016
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The Cochrane Library [Cochrane Database of Systematic Reviews (CDSR), Cochrane
Central Register of Controlled Trials (CENTRAL), Health Technology Assessment (HTA)
database] (Cochrane Collaboration)
Data parameters: CDSR and CENTRAL: Issue 1 of 12, January 2016; HTA database: Issue 1 of 4, January 2016.
Date searched: 1 February 2016.
Searcher: SB.
Hits: CDSR = 0; CENTRAL = 9; HTA = 0.
Strategy
1. (lynch* near/3 syndrome):ti or (lynch* near/3 syndrome):ab
2. ((lynch* near/3 famil*) and (cancer* or neoplasm*)):ti or ((lynch* near/3 famil*) and (cancer* or neoplasm*)):ab
3. #1 or #2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’):ti or (‘Hereditary
Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’):ab
5. HNPCC:ti or HNPCC:ab
6. (((hereditary or inherited) near/3 (colon* or colorectal*)) and (cancer or neoplasm*)):ti or (((hereditary or inherited)
near/3 (colon* or colorectal*)) and (cancer or neoplasm*)):ab
7. ((hereditary near/3 nonpolyposis) and (colon* or colorectal*)):ti or ((hereditary near/3 nonpolyposis) and (colon* or
colorectal*)):ab
8. ((hereditary near/3 non-polyposis) and (colon* or colorectal*)):ti or ((hereditary near/3 non-polyposis) and (colon* or
colorectal*)):ab
9. ((hereditary near/3 (cancer or neoplasm*)) and (colon* or colorectal*)):ti or ((hereditary near/3 (cancer or neoplasm*))
and (colon* or colorectal*)):ab
10. ((Familial near/3 Nonpolyposis) and (colon* or colorectal*)):ti or ((Familial near/3 Nonpolyposis) and (colon* or
colorectal*)):ab
11. ((Familial near/3 Non-polyposis) and (colon* or colorectal*)):ti or ((Familial near/3 Non-polyposis) and (colon* or
colorectal*)):ab
12. (familial near/3 (colon* or colorectal*)):ti or (familial near/3 (colon* or colorectal*)):ab
13. MeSH descriptor: [Colorectal Neoplasms, Hereditary Nonpolyposis] this term only
14. {or #4-#13}
15. ((EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) and (colon* or
colorectal* or lynch* or HNPCC or hereditary)):ti or ((EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or
hPMS2 or hMSH6 or PMS2) and (colon* or colorectal* or lynch* or HNPCC or hereditary)):ab
16. Amsterdam criteria:ti or Amsterdam criteria:ab
17. #15 or #16
18. #3 or #14 or #17
19. ((microsatellite near/3 instabilit*) or (msi near/3 test*)):ti or ((microsatellite near/3 instabilit*) or (msi near/3 test*)):ab
20. (Bethesda near/3 (marker* or panel*)):ti or (Bethesda near/3 (marker* or panel*)):ab
21. (immunohistochemistry or (IHC near/3 test*)):ti or (immunohistochemistry or (IHC near/3 test*)):ab
22. (MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/3 antibod*:ti or (MLH1 or MSH2
or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/3 antibod*:ab
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23. ((BRAFV600E or ‘BRAF V600E’) near/3 mutation*):ti or ((BRAFV600E or ‘BRAF V600E’) near/3 mutation*):ab
24. (MLH1 near/3 (methylation or hypermethylation or ‘hyper methylation’)):ti or (MLH1 near/3 (methylation or
hypermethylation or ‘hyper methylation’)):ab
25. MeSH descriptor: [Immunohistochemistry] explode all trees
26. {or #19-#25}
27. #18 and #26 Publication Year from 2006, in Cochrane Reviews (Reviews and Protocols), Trials and Technology
Assessments
Health Management Information Consortium (HMIC) (via Ovid)
Data parameters: 1979 to November 2015.




See Strategy for MEDLINE In-Process & Other Non-Indexed Citations.
Number of hits per database and in total
Database Hits
MEDLINE 1274
MEDLINE In-Process & Other Non-Indexed Citations 134
EMBASE 2928







Total unique records 3920
APPENDIX 1




Data parameters: 1946 to January Week 3 2016.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. Colorectal Neoplasms, Hereditary Nonpolyposis/
14. or/4-13
15. (EPCAM? or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2).tw.
16. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
17. 15 and 16
18. Amsterdam criteria.tw.
19. 3 or 14 or 17 or 18
20. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
21. (Bethesda adj3 (marker* or panel*)).tw.
22. (immunohistochemistry or (IHC adj3 test*)).tw.
23. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
24. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.
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33. exp ‘economics, hospital’/
34. (economic* or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration* or
expenditure or expenditures or budget* or afford* or pharmacoeconomic or pharmaco-economic*).tw.
35. (cba or cea or cua).ti,ab.
36. exp ‘fees and charges’/
37. (fee or fees or charge* or preference*).tw.
38. (fiscal or funding or financial or finance).tw.
39. exp ‘costs and cost analysis’/
40. exp Health Care Costs/
41. cost*.tw.
42. exp decision support techniques/
43. exp models, economic/




48. monte carlo method/
49. (decision adj2 (tree* or analy* or model*)).tw.
50. (survival adj3 analys*).tw.
51. ‘deductibles and coinsurance’/
52. exp Health expenditures/
53. uncertain*.tw.
54. uncertainty/
55. (quality adj3 life).tw.
56. quality of life/
57. value of life/
58. Quality-adjusted life years/
59. (qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales).tw.
60. (sensitivity analys* or ‘willingness to pay’ or quality-adjusted life year* or quality adjusted life year* or





65. 19 and 27 and 64
66. Animals/ not humans.sh.
67. 65 not 66
68. limit 67 to (english language and yr=‘2013 -Current’)
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Data parameters: 29 January 2016.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. or/4-12
14. (EPCAM? or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2).tw.
15. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
16. 14 and 15
17. Amsterdam criteria.tw.
18. 3 or 13 or 16 or 17
19. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
20. (Bethesda adj3 (marker* or panel*)).tw.
21. (immunohistochemistry or (IHC adj3 test*)).tw.
22. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
23. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.
24. (MLH1 adj3 (methylation or hypermethylation or ‘hyper methylation’)).tw.
25. or/19-24
26. (economic* or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration* or
expenditure or expenditures or budget* or afford* or pharmacoeconomic or pharmaco-economic*).tw.
27. (cba or cea or cua).ti,ab.
28. (fee or fees or charge* or preference*).tw.
29. (fiscal or funding or financial or finance).tw.
30. cost*.tw.
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33. (decision adj2 (tree* or analy* or model*)).tw.
34. (survival adj3 analys*).tw.
35. uncertain*.tw.
36. (quality adj3 life).tw.
37. (qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales).tw.
38. (sensitivity analys* or ‘willingness to pay’ or quality-adjusted life year* or quality adjusted life year* or




42. 18 and 25 and 41
43. limit 42 to yr=‘2013 -Current’
EMBASE (via Ovid)
Data parameters: 1974 to 2016 January 29.




1. (lynch* adj3 syndrome).tw.
2. ((lynch* adj3 famil*) and (cancer* or neoplasm*)).tw.
3. or/1-2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’).tw.
5. HNPCC.tw.
6. (((hereditary or inherited) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).tw.
7. ((hereditary adj3 nonpolyposis) and (colon* or colorectal*)).tw.
8. ((hereditary adj3 non-polyposis) and (colon* or colorectal*)).tw.
9. ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).tw.
10. ((Familial adj3 Nonpolyposis) and (colon* or colorectal*)).tw.
11. ((Familial adj3 Non-polyposis) and (colon* or colorectal*)).tw.
12. (familial adj3 (colon* or colorectal*)).tw.
13. hereditary nonpolyposis colorectal cancer/
14. or/4-13
15. (EPCAM? or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2).tw.
16. protein MLH1/
APPENDIX 1




19. mismatch repair protein PMS2/
20. (colon* or colorectal* or lynch* or HNPCC or hereditary).tw.
21. or/15-19
22. 20 and 21
23. Amsterdam criteria.tw.
24. 3 or 14 or 22 or 23
25. ((microsatellite adj3 instabilit*) or (msi adj3 test*)).tw.
26. (Bethesda adj3 (marker* or panel*)).tw.
27. (immunohistochemistry or (IHC adj3 test*)).tw.
28. ((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) adj3 antibod*).tw.
29. ((BRAFV600E or ‘BRAF V600E’) adj3 mutation*).tw.









39. exp ‘economics, hospital’/
40. (economic* or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration* or
expenditure or expenditures or budget* or afford* or pharmacoeconomic or pharmaco-economic*).tw.
41. (cba or cea or cua).ti,ab.
42. exp ‘fees and charges’/
43. (fee or fees or charge* or preference*).tw.
44. (fiscal or funding or financial or finance).tw.
45. exp ‘costs and cost analysis’/
46. exp Health Care Costs/
47. cost*.tw.
48. exp decision support techniques/
49. exp models, economic/




54. monte carlo method/
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55. (decision adj2 (tree* or analy* or model*)).tw.
56. (survival adj3 analys*).tw.
57. ‘deductibles and coinsurance’/
58. exp Health expenditures/
59. uncertain*.tw.
60. uncertainty/
61. (quality adj3 life).tw.
62. quality of life/
63. value of life/
64. Quality-adjusted life years/
65. (qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales).tw.
66. (sensitivity analys* or ‘willingness to pay’ or quality-adjusted life year* or quality adjusted life year* or





71. 24 and 33 and 70
72. limit 71 to (english language and yr=‘2013 -Current’)
Web of Science [Science Citation Index (SCI) and Conference Proceedings Citation Index –
Science (CPCI-S)] (Thomson Reuters)
Data parameters: not applicable.




1. TS=(lynch* near/2 syndrome)
2. TS=((lynch* near/2 famil*) and (cancer* or neoplasm*))
3. #2 OR #1
4. TS=(‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’)
5. TS=(HNPCC)
6. TS=(((hereditary or inherited) near/2 (colon* or colorectal*)) and (cancer or neoplasm*))
7. TS=((hereditary near/2 nonpolyposis) and (colon* or colorectal*))
8. TS=((hereditary near/2 non-polyposis) and (colon* or colorectal*))
9. TS=((hereditary near/2 (cancer or neoplasm*)) and (colon* or colorectal*))
10. TS=((Familial near/2 Nonpolyposis) and (colon* or colorectal*))
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11. TS=(familial near/2 (colon* or colorectal*))
12. TS=((Familial near/2 Non-polyposis) and (colon* or colorectal*))
13. #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4
14. TS=(EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2)
15. TS=(colon* or colorectal* or lynch* or HNPCC or hereditary)
16. #15 AND #14
17. TS=(Amsterdam criteria)
18. #17 OR #16 OR #13 OR #3
19. TS=((microsatellite near/2 instabilit*) or (msi near/2 test*))
20. TS=(Bethesda near/2 (marker* or panel*))
21. TS=(immunohistochemistry or (IHC near/2 test*))
22. TS=((MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/2 antibod*)
23. TS=((BRAFV600E or ‘BRAF V600E’) near/2 mutation*)
24. TS=(MLH1 near/2 (methylation or hypermethylation or ‘hyper methylation’))
25. #24 OR #23 OR #22 OR #21 OR #20 OR #19
26. TS=(economic* or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration*
or expenditure or expenditures or budget* or afford* or pharmacoeconomic or pharmaco-economic*)
27. TS=(cba or cea or cua)
28. TS=(fee or fees or charge* or preference*)




33. TS=(decision near/1 (tree* or analy* or model*))
34. TS=(survival near/2 analys*)
35. TS=(uncertain*)
36. TS=(quality near/2 life)
37. TS=(qol* or qoly or qolys or hrqol* or qaly or qalys or qale or qales)
38. TS=(sensitivity analys* or ‘willingness to pay’ or quality-adjusted life year* or quality adjusted life year* or
quality-adjusted life expectanc* or quality adjusted life expectanc*)
39. TS=(utilit*)
40. TS=(valu*)
41. #40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR
#26
42. #18 AND #25 AND #41
Timespan=2013-2016
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NHS Economic Evaluation Database (NHS EED) (The Cochrane Library)
Data parameters: Issue 2 of 12, February 2016.




1. (lynch* near/3 syndrome):ti or (lynch* near/3 syndrome):ab in Economic Evaluations
2. ((lynch* near/3 famil*) and (cancer* or neoplasm*)):ti or ((lynch* near/3 famil*) and (cancer* or neoplasm*)):ab in
Economic Evaluations
3. #1 or #2
4. (‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’):ti or (‘Hereditary
Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’):ab in Economic Evaluations
5. HNPCC:ti or HNPCC:ab in Economic Evaluations
6. (((hereditary or inherited) near/3 (colon* or colorectal*)) and (cancer or neoplasm*)):ti or (((hereditary or inherited)
near/3 (colon* or colorectal*)) and (cancer or neoplasm*)):ab in Economic Evaluations
7. ((hereditary near/3 nonpolyposis) and (colon* or colorectal*)):ti or ((hereditary near/3 nonpolyposis) and (colon* or
colorectal*)):ab in Economic Evaluations
8. ((hereditary near/3 non-polyposis) and (colon* or colorectal*)):ti or ((hereditary near/3 non-polyposis) and (colon* or
colorectal*)):ab in Economic Evaluations
9. ((hereditary near/3 (cancer or neoplasm*)) and (colon* or colorectal*)):ti or ((hereditary near/3 (cancer or neoplasm*))
and (colon* or colorectal*)):ab in Economic Evaluations
10. ((Familial near/3 Nonpolyposis) and (colon* or colorectal*)):ti or ((Familial near/3 Nonpolyposis) and (colon* or
colorectal*)):ab in Economic Evaluations
11. ((Familial near/3 Non-polyposis) and (colon* or colorectal*)):ti or ((Familial near/3 Non-polyposis) and (colon* or
colorectal*)):ab in Economic Evaluations
12. (familial near/3 (colon* or colorectal*)):ti or (familial near/3 (colon* or colorectal*)):ab in Economic Evaluations
13. MeSH descriptor: [Colorectal Neoplasms, Hereditary Nonpolyposis] this term only
14. {or #4-#13} in Economic Evaluations
15. ((EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) and (colon* or colorectal*
or lynch* or HNPCC or hereditary)):ti or ((EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or
hMSH6 or PMS2) and (colon* or colorectal* or lynch* or HNPCC or hereditary)):ab in Economic Evaluations
16. Amsterdam criteria:ti or Amsterdam criteria:ab in Economic Evaluations
17. #15 or #16
18. #3 or #14 or #17
19. ((microsatellite near/3 instabilit*) or (msi near/3 test*)):ti or ((microsatellite near/3 instabilit*) or (msi near/3 test*)):ab
in Economic Evaluations
20. (Bethesda near/3 (marker* or panel*)):ti or (Bethesda near/3 (marker* or panel*)):ab in Economic Evaluations
21. (immunohistochemistry or (IHC near/3 test*)):ti or (immunohistochemistry or (IHC near/3 test*)):ab in Economic Evaluations
22. (MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/3 antibod*:ti or (MLH1 or MSH2
or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) near/3 antibod*:ab in Economic Evaluations
23. ((BRAFV600E or ‘BRAF V600E’) near/3 mutation*):ti or ((BRAFV600E or ‘BRAF V600E’) near/3 mutation*):ab in
Economic Evaluations
24. (MLH1 near/3 (methylation or hypermethylation or ‘hyper methylation’)):ti or (MLH1 near/3 (methylation or
hypermethylation or ‘hyper methylation’)):ab in Economic Evaluations
25. MeSH descriptor: [Immunohistochemistry] explode all trees
26. {or #19-#25}
27. #18 and #26 Publication Year from 2013 to 2016, in Economic Evaluations
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EconLit (EBSCOhost)
Data parameters: not applicable.




1. TI lynch* N2 syndrome OR AB lynch* N2 syndrome
2. TI ( (lynch* N2 famil*) AND (cancer* or neoplasm*) ) OR AB ( (lynch* N2 famil*) AND (cancer* or neoplasm*) )
3. S1 OR S2
4. TI ( ‘Hereditary Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’ ) OR AB ( ‘Hereditary
Nonpolyposis Colorectal Cancer’ or ‘Hereditary Non-polyposis Colorectal Cancer’ )
5. TI HNPCC OR AB HNPCC
6. TI ( ((hereditary or inherited) N2 (colon* or colorectal*)) and (cancer or neoplasm*) ) OR AB ( ((hereditary or inherited)
N2 (colon* or colorectal*)) and (cancer or neoplasm*) )
7. TI ( (hereditary N2 nonpolyposis) and (colon* or colorectal*) ) OR AB ( (hereditary N2 nonpolyposis) and (colon* or
colorectal*) )
8. TI ( (hereditary N2 non-polyposis) and (colon* or colorectal*) ) OR AB ( (hereditary N2 non-polyposis) and (colon* or
colorectal*) )
9. TI ( (hereditary N2 (cancer or neoplasm*)) and (colon* or colorectal*) ) OR AB ( (hereditary N2 (cancer or neoplasm*))
and (colon* or colorectal*) )
10. TI ( (Familial N2 Nonpolyposis) and (colon* or colorectal*) ) OR AB ( (Familial N2 Nonpolyposis) and (colon* or
colorectal*) )
11. TI ( ((Familial N2 Non-polyposis) and (colon* or colorectal*)) ) OR AB ( (Familial N2 Non-polyposis) and (colon* or
colorectal*) )
12. TI ( (familial N2 (colon* or colorectal*)) ) OR AB ( (familial N2 (colon* or colorectal*)) )
13. S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
14. TI ( EPCAM* or MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2 ) OR AB ( EPCAM* or
MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2 )
15. TI ( colon* or colorectal* or lynch* or HNPCC or hereditary ) AND AB ( colon* or colorectal* or lynch* or HNPCC or
hereditary )
16. S14 AND S15
17. TI Amsterdam criteria OR AB Amsterdam criteria
18. S3 OR S13 OR S16 OR S17
19. TI ( (microsatellite N2 instabilit*) or (msi N2 test*) ) OR AB ( (microsatellite N2 instabilit*) or (msi N2 test*) )
20. TI ( (Bethesda N2 (marker* or panel*)) ) OR AB ( (Bethesda N2 (marker* or panel*)) )
21. TI ( immunohistochemistry or (IHC N2 test*) ) OR AB ( immunohistochemistry or (IHC N2 test*) )
22. TI ( (MLH1 or MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) N2 antibod* ) OR AB ( (MLH1 or
MSH2 or MSH6 or hMSH2 or hMLH1 or hPMS2 or hMSH6 or PMS2) N2 antibod* )
23. TI ( (BRAFV600E or ‘BRAF V600E’) N2 mutation* ) OR AB ( (BRAFV600E or ‘BRAF V600E’) N2 mutation* )
24. TI ( (MLH1 N2 (methylation or hypermethylation or ‘hyper methylation’)) ) OR AB ( (MLH1 N2 (methylation or
hypermethylation or ‘hyper methylation’)) )
25. S19 OR S20 OR S21 OR S22 OR S23 OR S24
26. S18 AND S25
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Number of hits per database and in total
Database Hits
MEDLINE 85
MEDLINE In-Process & Non-Indexed Citations 30
EMBASE 256





Total unique records 352
Utilities searches
Hysterectomy and salpingo-oophorectomy
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Data parameters: 1946 to present.





2. (‘salpingo oophorectom*’ or ‘salpingo ovariectom*’ or salpingooophorectom*).tw.
3. (salpingectom* adj7 (oophorectom* or ovariectom*)).tw.





9. 4 or 8
10. (HRQOL or HRQL or QOL or QALY*).tw.
11. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
12. 10 or 11
13. 9 and 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. limit 15 to english language
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EMBASE (via Ovid)
Data parameters: 1974 to 2016 February 24.





2. (‘salpingo oophorectom*’ or ‘salpingo ovariectom*’ or salpingooophorectom*).tw.
3. (salpingectom* adj7 (oophorectom* or ovariectom*)).tw.




8. 4 or 7
9. (HRQOL or HRQL or QOL or QALY*).tw.
10. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
11. 9 or 10
12. 8 and 11
13. Limit 12 to english language
Colorectal cancer
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Data parameters: 1946 to present.




1. ((colorectal or colon or colorectum or colonic or rectal or rectum or bowel or intenstin*) adj3 (cancer* or carcinom*
or neoplasm* or malignan* or tumo?r*)).tw.
2. (CRC or mCRC).tw.
3. exp Colorectal Neoplasms/
4. or/1-3
5. (HRQOL or HRQL or QOL or QALY*).tw.
6. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
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7. (‘QLQ-C30’ or ‘FACT-G’).tw.
8. or/5-7
9. 4 and 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. limit 11 to (english language and yr=‘2005 -Current’)
EMBASE (via Ovid)
Data parameters: 1974 to 2016 February 24.




1. ((colorectal or colon or colorectum or colonic or rectal or rectum or bowel or intenstin*) adj3 (cancer* or carcinom*
or neoplasm* or malignan* or tumo?r*)).tw.
2. (CRC or mCRC).tw.
3. exp colon tumor/
4. exp rectum tumor/
5. or/1-4
6. (HRQOL or HRQL or QOL or QALY*).tw.
7. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
8. (‘QLQ-C30’ or ‘FACT-G’).tw.
9. or/6-8
10. 5 and 9
11. limit 10 to (english language and yr=‘2005 -Current’)
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Endometrial cancer
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Data parameters: 1946 to present.




1. ((endometrial or endometrium or uterine or uterus) adj3 (cancer* or carcinom* or neoplasm* or malignan* or
tumo?r*)).tw.
2. exp Endometrial Neoplasms/
3. 1 or 2
4. (HRQOL or HRQL or QOL or QALY*).tw.
5. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
6. (‘QLQ-C30’ or ‘FACT-G’).tw.
7. or/4-6
8. 3 and 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. limit 10 to english language
EMBASE (via Ovid)
Data parameters: 1974 to 2016 February 24.




1. ((endometrial or endometrium or uterine or uterus) adj3 (cancer* or carcinom* or neoplasm* or malignan* or
tumo?r*)).tw.
2. exp endometrium tumor/
3. 1 or 2
4. (HRQOL or HRQL or QOL or QALY*).tw.
5. (EQ-5D or EQ-5D-3L or EQ-5D-5L or EQ-VAS or SF-6D or SF-12 or SF-36 or HUI2 or HUI3 or 15D or PROMIS).tw.
6. (‘QLQ-C30’ or ‘FACT-G’).tw.
7. or/4-6
8. 3 and 7
9. limit 8 to english language
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Number of hits per database and in total
Database Hits
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (hysterectomy) 13
EMBASE (hysterectomy) 27
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (colorectal cancer) 757
EMBASE (colorectal cancer) 1833
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (endometrial cancer) 137
EMBASE (endometrial cancer) 330
Total records 3097
Duplicates 906
Total unique records 2191
Forward citation chasing on included test accuracy studies
Scopus (Elsevier)
Data parameters: not applicable.
Date searched: 14 April 2016.
Searcher: SB.
Number of hits per study and in total
Study Hits
Barnetson et al., 200654 258
Hendriks et al., 200361 132
Limburg et al., 201155 24
aNiessen 2006194 64
Okkels et al., 201262 5
Overbeek et al., 200759 23
Poynter et al., 200834 97
Shia et al., 200560 85
Southey et al., 200556 137
Total records 825
Duplicates 138
Duplicates in search results for test accuracy studies 118
Total unique records 569
a This study was considered eligible at the time of forward citation chasing, but was subsequently excluded on the basis of
its study design.
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Appendix 2 Quality assessment
Quality appraisal was performed using phase 3 of the QUADAS-2 tool53 [reproduced with permission;see www.quadas.org (accessed 27 June 2017)].
Phase 3: risk of bias and applicability judgments
QUADAS-2 is structured so that four key domains are each rated in terms of the risk of bias and the
concern regarding applicability to the research question (as defined above). Each key domain has a set of
signalling questions to help reach the judgments regarding bias and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
l Was a consecutive or random sample of patients enrolled? Yes/no/unclear
l Was a case–control design avoided? Yes/no/unclear
l Did the study avoid inappropriate exclusions? Yes/no/unclear
Could the selection of patients have introduced bias? Risk: low/high/unclear
B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting):
Is there concern that the included patients do not match the review question? Concern: low/high/unclear
Domain 2: index test(s)
If more than one index test was used, please complete for each test.
A. Risk of bias
Describe the index test and how it was conducted and interpreted:
l Were the index test results interpreted without knowledge of the results
of the reference standard? Yes/no/unclear
l If a threshold was used, was it prespecified? Yes/no/unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low/high/unclear
B. Concerns regarding applicability
Is there concern that the index test, its conduct, or interpretation differs from
the review question? Concern: low/high/unclear
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
l Is the reference standard likely to correctly classify the target condition? Yes/no/unclear
l Were the reference standard results interpreted without knowledge of the
results of the index test? Yes/no/unclear
Could the reference standard, its conduct or its interpretation have
introduced bias? Risk: low/high/unclear
B. Concerns regarding applicability
Is there concern that the target condition as defined by the reference
standard does not match the review question? Concern: low/high/unclear
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2 × 2
table (refer to flow diagram):
Describe the time interval and any interventions between the index test(s) and the reference standard:
l Was there an appropriate interval between the index test(s) and the
reference standard? Yes/no/unclear
l Did all patients receive a reference standard? Yes/no/unclear
l Did patients receive the same reference standard? Yes/no/unclear
l Were all patients included in the analysis? Yes/no/unclear
Could the patient flow have introduced bias? Risk: low/high/unclear
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Appendix 3 Tables of excluded studies
with rationale
S tudies excluded at the full-text stage came from four sources: electronic searches (n = 71), searchingsystematic reviews (n = 38), forward citation chasing (n = 4) and backward citation chasing (n = 11).
The reasons for exclusion were:
l population – the study did not recruit the population specified in the protocol
l index test – there was no index test or the study did not use an index test as specified in the protocol
l reference standard – there was no reference standard or the study did not include a reference standard
as specified in the protocol
l outcomes – the study did not report outcomes as specified in the protocol
l study design – the study design was not as specified in the protocol, including when the reference
standard was not given to all participants (for high-risk studies) or was not given to a representative
sample of index test-negative participants (for population-based studies)
l abstract only – the study was published only as an abstract that was not linked to an included study
that was published in full
l duplicate – the reference was a duplicate of a study that had already been assessed for inclusion but
this was either missed or not evident at an earlier stage.




Abbott DE, Cantor SB, Rodriguez-Bigas MA, Chang GJ, Lynch PM, Feig BW, et al. Detecting
hereditary nonpolyposis colorectal cancer syndrome (HNPCC) in patients with colorectal cancer
(CRC): optimal strategies at lower costs. J Clin Oncol 2012;30(4 Suppl.):396
Abstract only
Akagi K, Kakuta M, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, et al. Molecular screening with
colorectal tumor tissue for Lynch syndrome. Fam Cancer 2011;10:S43
Study design
Alemayehu A, Tomkova K, Zavodna K, Ventusova K, Krivulcik T, Bujalkova M, et al. The role of
clinical criteria, genetic and epigenetic alterations in Lynch-syndrome diagnosis. Neoplasma
2007;54:391–401
Study design
Alenda C, Paya A, Perez L, Alcaraz E, Soto JL, Guillen C, et al. Usefulness of p16
immunohistochemistry in the diagnosis of Lynch’s syndrome. Lab Invest 2009;9:122–3A
Abstract only
Alvarez K, Hurtado C, Hevia MA, Wielandt AM, de la Fuente M, Church J, et al. Spectrum of MLH1
and MSH2 mutations in Chilean families with suspected Lynch syndrome. Dis Colon Rectum
2010;53:450–9. https://doi.org/10.1007/DCR.0b013e3181d0c114
Study design
Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, et al. Colorectal cancer in HNPCC:
cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven
mutations. Clin Genet 2008;74:233–42
Study design
Barrow E, Evans DG, McMahon R, Byers R, Hill J. A comparative study of quantitative
immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification
in Lynch Syndrome. Colorectal Dis 2009;11:15
Abstract only
Barrow E, Jagger E, Brierley J, Wallace A, Evans G, Hill J, McMahon R. Semiquantitative assessment
of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology
2010;56:331–44. https://doi.org/10.1111/j.1365-2559.2010.03485.x
Reference standard
Barrow E, Evans DG, McMahon R, Hill J, Byers R. A comparative study of quantitative
immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification
in Lynch syndrome. J Clin Pathol 2011;64:208–14
Reference standard
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Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F, et al. A prospective, multicenter,
population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin
Gastroenterol Hepatol 2008;6:206–14
Study design
Canard G, Lefevre J, Colas C, Coulet F, Soubrier F, Svreck M, et al. Screening HNPCC syndrome in
colorectal cancer: are we doing enough? Colorectal Dis 2010;12:13–14
Study design
Canard G, Lefevre JH, Colas C, Coulet F, Svrcek M, Lascols O, et al. Screening for Lynch syndrome
in colorectal cancer: are we doing enough? Ann Surg Oncol 2012;19:809–16. https://doi.org/
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Appendix 4 Summary of parameters used in the
health economic model
Parameter name Base-case value Source
Population characteristics
Maximum age 100 years
Number of probands 34,025 ONS21
Proportion of probands who are men 55% ONS4,21,101–103
Number of relatives per proband 6 Assumption, based on Snowsill
et al.4 and Barrow91
Proportion of relatives who are first-degree
relatives
42% Snowsill et al.4 (published and
unpublished data)
Proportion of relatives who are men 38% Unpublished data reported in
Snowsill et al.4
Prevalence of LS 2.8% Hampel et al.92
Proportion of LS gene mutations




Probability that relative has LS if proband has LS 44% Meta-analysis of published and
unpublished data reported in
Snowsill et al.4
Age on entry (probands)
General population Distribution (mean 73.0 years –
model outcome)
ONS21,96–103
With LS Distribution (mean 59.2 years –
model outcome)
Estimated from the parametric
CRC incidence function
Age on entry (relatives)
General population Distribution (mean 44.4 years –
model outcome)
ONS104,105
With LS Distribution (mean 43.2 years –
model outcome)
Without LS data multiplied by
CRC mortality-free survival for LS.




Sensitivity (95% CI) 0.913 (0.426 to 0.993) Barnetson et al.,54 Poynter et al.,34
Southey et al.56
Specificity (95% CI) 0.837 (0.638 to 0.937)
IHC
Sensitivity (95% CI) 0.962 (0.694 to 0.996) Limburg et al.,55 Southey et al.56
Specificity (95% CI) 0.884 (0.790 to 0.940)
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Parameter name Base-case value Source
BRAF V600E
Sensitivity (95% CI) 0.96 (0.60 to 0.99) Ladabaum et al.3
Specificity (95% CI) 0.76 (0.60 to 0.87)
MLH1 promoter methylation
Sensitivity (95% CI) 0.94 (0.79 to 0.98) Ladabaum et al.3
Specificity (95% CI) 0.75 (0.59 to 0.86)
Diagnostic testing probands
Sensitivity MLH1, MSH2, MSH6 0.90;
PMS2 0.67
Dinh et al.107
Specificity 0.997 Senter et al.130
Predictive testing relatives
Sensitivity 1.00 Assumed (Snowsill et al.4)
Specificity 1.00
Acceptance of diagnostic tests and genetic counselling
MSI – proband 100% Ramsey et al.,83 confirmed by
expert Dr Ian M Frayling in
Snowsill et al.4
IHC – proband 100% Assumed
BRAF V600E – proband 100% Assumed
MLH1 promoter methylation – proband 100% Assumed
Genetic test following counselling – proband 90% Ladabaum et al.85
Genetic counselling – proband 92.5% Clinical expert (Dr Ian M Frayling)
estimated range 90–95% as
reported in Snowsill et al.4
Genetic test following counselling – relative 77% Manchester Familial Colorectal
Cancer Registry data reported in
Barrow91Genetic counselling – relative 78%
Proportion of genetic tests in MSI strategies
requiring IHC analysis
5% Personal communication
(Ottie O’Brien and Samantha Butler)
Proportion of probands who decline testing
assumed to have LS
10% Assumption based on results in
Snowsill et al.4
Psychological disutility associated with testing for LS
Proband
Test declined, surgery not offered 0.04 Kuppermann et al.,165
Snowsill et al.4
Test declined, accept TAH-BSO 0.05 (women only)
Test declined, decline TAH-BSO 0.11 (women only)
Test accepted, LS negative 0
Test accepted, LS positive, surgery not
offered
0.02
Test accepted, LS positive, accept TAH-BSO 0.03 (women only)
Test accepted, LS positive, decline TAH-BSO 0.09 (women only)
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Parameter name Base-case value Source
Relative
Test declined, surgery not offered 0.04 Kuppermann et al.,165
Snowsill et al.4
Test declined, accept TAH-BSO 0.08 (women only)
Test declined, decline TAH-BSO 0.11 (women only)
Test accepted, LS negative 0
Test accepted, LS positive, surgery not
offered
0.02
Test accepted, LS positive, accept TAH-BSO 0.06 (women only)
Test accepted, LS positive, decline TAH-BSO 0.09 (women only)
Diagnostic costs
MSI £202 UKGTN175
IHC £210 UKGTN175 and personal
communication (Dr Mark Arends
and Dr Ian M Frayling) from
Snowsill et al.4
BRAF V600E £119 UKGTN175 and personal
communication (Mr Michael
Gandy), East of Scotland Regional
Genetic Service174 and All Wales
Molecular Genetics Laboratory176
from Snowsill et al.4
MLH1 promoter methylation testing £125 UKGTN175
Proband genetic test, all four genes £1276 UKGTN175
Proband genetic counselling £63 PSSRU166,177 and personal
communication with Professor
Mary Porteous from Snowsill et al.4
Targeted genetic test for relatives (MLH1) £166 UKGTN175
Targeted genetic test for relatives (MSH2) £161 UKGTN175
Targeted genetic test for relatives (MSH6) £161 UKGTN175
Targeted genetic test for relatives (PMS2) £165 UKGTN175
Relative genetic counselling £63 PSSRU166,177 and personal
communication with Professor
Mary Porteous from Snowsill et al.4
CRC parameters
Acceptance of LS surveillance for CRC
Proband tested LS mutation positive 97% Manchester Familial Colorectal
Cancer Registry91
Proband LS assumed 70%
Relative tested LS mutation positive 97%
Relative LS assumed 70%
Start age LS surveillance colonoscopy 25 years Snowsill et al.4
End age (years) LS surveillance colonoscopy 75 years
HR associated with surveillance colonoscopy 0.387 Järvinen et al.124
Colonoscopy complication probability
Bleeding resulting in admission 0.0546% Gavin et al.168
Perforation 0.04%
Death 0.0083% Cairns et al.46
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Parameter name Base-case value Source
CRC stage on diagnosis





CRC stage on diagnosis with LS surveillance colonoscopies




Probability proband has colon cancer
With LS







Segmental resection 96% Finan et al.108
Subtotal colectomy 4%
Rectum
AR 98% Finan et al.108
Proctocolectomy 2%
Initial surgical state for probands
With LS Segmental resection 90.7%,




Men Segmental resection 60.3%,
subtotal colectomy 2.2%, AR
36.8%, proctocolectomy 0.7%
Calculated from above
Women Segmental resection 69.6%,
subtotal colectomy 2.6%, AR
27.4%, proctocolectomy 0.5%
Proportion of relatives who have previously had CRC
With LS
Men None 96.8%, colon 2.98%,
rectal 0.19%
Bonadona et al.,18 ONS,100,110,111
Welsh Cancer Intelligence and
Surveillance Unit,112 Dinh et al.107
Women None 97.5%, colon 2.37%,
rectal 0.15%
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Parameter name Base-case value Source
Without LS




Women None 99.9%, colon 0.10%,
rectal 0.04%
Initial surgical state for relatives
With LS
Men None 96.8%, segmental
resection 2.88%, subtotal
colectomy 0.11%, AR 0.19%,
proctocolectomy 0.00%
Calculated from above
Women None 97.5%, segmental
resection 2.29%, subtotal
colectomy 0.08%, AR 0.15%,
proctocolectomy 0.00%
Without LS
Men None 99.8%, segmental
resection 0.12%, subtotal
colectomy 0.00%, AR 0.09%,
proctocolectomy 0.00%
Calculated from above
Women None 99.9%, segmental
resection 0.09%, subtotal
colectomy 0.00%, AR 0.04%,
proctocolectomy 0.00%
Logistic model parameters for CRC incidence in individuals with LS
β0
Men 0.464 Fit based on Bonadona et al.18
Women 0.435
β1
Men 0.107 Fit based on Bonadona et al.18
Women 0.108
β2
Men 55.5 Fit based on Bonadona et al.18
Women 61.3
Probability incident CRC is situated in the colon
With LS
No previous surgery 0.94 Dinh et al.107
Segmental resection 0.94
Subtotal colectomy 0.00 Assumption
AR 1.00 Assumption
Proctocolectomy Not applicable Assumption
Without LS
No previous surgery Men 0.63, women 0.72 ONS100
Segmental resection Men 0.63, women 0.72
Subtotal colectomy 0.00 Assumption
AR 1.00 Assumption
Proctocolectomy Not applicable Assumption
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Parameter name Base-case value Source
Mortality rate from CRC (per 100,000 person years)
0–1 years since diagnosis





1–2 years since diagnosis





2–3 years since diagnosis





3–4 years since diagnosis





> 4 years since diagnosis





HRs for CRC mortality, age at diagnosis vs. all ages
< 70 years
First year 0.599 Estimated using net survival
statistics from the ONS;118 details
in appendix 5 of Snowsill et al.41–4 years 0.972
After 4 years 1
70–79 years
First year 0.956 Estimated using net survival
statistics from the ONS;118 details
in appendix 5 of Snowsill et al.41–4 years 0.966
After 4 years 1
≥ 80 years
First year 1.797 Estimated using net survival
statistics from the ONS;118 details
in appendix 5 of Snowsill et al.41–4 years 1.116
After 4 years 1
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Parameter name Base-case value Source
HRs for CRC survival with LS
Dukes’ A and B 0.57 Lin et al.119
Dukes’ C and D 1 Barnetson et al.54
Disutilities associated with CRC
Dukes’ A 0.00 Ramsey et al.142
Dukes’ B 0.00
Dukes’ C 0.00
Dukes’ D 0.13 Mittmann et al.143
Disutility associated with CRC treatment (surgery,
ostomies, chemotherapy)
0 Assumption based on literature
review149–154
Disutility associated with colonoscopy 0 Assumption based on literature
review155
Resource use colonoscopy
LS surveillance Every 2 years from LS diagnosis
(age 25–75 years)
Snowsill et al.4
Post-CRC surveillance Every 5 years post CRC
diagnosis
Snowsill et al.4
Unit cost colonoscopy £585.80 NHS Reference Costs 2014–15178
(HRG codes FZ51Z, FZ52Z, FZ53Z)
Cost of colonoscopy complications
Bleeding
Mild £473 NHS Reference Costs 2014–15178
(HRG code FZ38P)
Moderate £1138 NHS Reference Costs 2014–15178
(HRG codes FZ38J–FZ38L)
Severe £4394 NHS Reference Costs 2014–15178
(HRG codes FZ38G–FZ38H)
Perforation £4909 NHS Reference Costs 2014–15178
(HRG codes FZ77C–FZ77E)
Death £4909 Assumed same as perforation
CRC costs
Diagnosis £1022 (+£202 if stage II for
MSI testing)
Trueman et al.123
Primary chemotherapy and radiotherapy
Colon £14,494 Trueman et al.123
Rectal Dukes’ A £1049
Rectal Dukes’ B £4206
Rectal Dukes’ C £9504
Primary surgery
Segmental resection
General population £6501 NHS Reference Costs 2014–15178
(HRG codes FZ74–76, FZ50)
LS £6605
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Parameter name Base-case value Source
Follow-up surveillance costs (excluding colonoscopy) per year
With LS £229 Trueman et al.,123 NHS Reference
Costs 2014–15178
Without LS £230
Surgery and chemotherapy for recurrence
With LS £12,333 Trueman et al.123
Without LS £12,236
Stoma care
With LS £214 Trueman et al.123
Without LS £388
Palliative care
With LS £9907 Trueman et al.123
Without LS £9665
Endometrial cancer-related parameters
Gynaecological risk reduction for women with LS on entry
0–34 years at diagnosis No risk reduction 100.0%,
surveillance 0.00%,
prophylactic H-BSO 0.00%
Balmana et al.,125 Lorraine Cowley
(personal communication)
35–44 years at diagnosis No risk reduction 20.0%,
surveillance 60.0%,
prophylactic H-BSO 20.0%
45–59 years at diagnosis No risk reduction 16.7%,
surveillance 45.8%,
prophylactic H-BSO 37.5%
60–69 years at diagnosis No risk reduction 0.0%,
surveillance 14.3%,
prophylactic H-BSO 85.7%
≥ 70 years at diagnosis No risk reduction 14.3%,
surveillance 0.0%, prophylactic
H-BSO 85.7%
Lifetime endometrial cancer risk in model
With LS 35% Bonadona et al.18
Without LS 0% Assumption based on expected 1
in 41120
Endometrial cancer survival
< 10 years since diagnosis Piecewise constant rate of
mortality for each year since
diagnosis (77.5% alive at
10 years)
Cancer Research UK121
≥ 10 years since diagnosis No further mortality Assumed
Impact of gynaecological surveillance on
endometrial cancer survival (hazard ratio)
0.898 Lewin et al.113
Disutility associated with endometrial cancer 0.036 Nout et al.,156 Longworth et al.161
Length of time endometrial cancer disutility
applied
1 year Nout et al.156
Disutility associated with prophylactic H-BSO 0 Assumption based on disutility of
endometrial cancer treatment and
long-term disutility
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
234
Parameter name Base-case value Source
Costs related to endometrial cancer
Gynaecological surveillance £473 NHS,179 NHS Reference Costs
2014–15178 (HRG codes WF01A,
MA36Z, MA25Z)
Prophylactic H-BSO £3428 NHS Reference Costs 2014–15178
(HRG codes MA07E–MA07G,
MA08A–MA08B)
Surgery £4005 NHS Reference Costs 2014–15178
(HRG codes MA06A–MA06C)
Radiotherapy £5870 Havrilesky et al.169
Adjuvant chemotherapy £1798 eMit database,180 NHS Reference
Costs 2014–15178 (HRG code
SB14Z)
Aspirin
Offered and accept chemoprevention 80.4% Burn et al.29
Proportion receiving aspirin for 4 years 59.0%
Incidence rate ratio CRC 0.37
Incidence rate ratio endometrial cancer 0.49
Time that aspirin effect lasts for 10 years
Daily dose 600 mg
Annual cost aspirin £149 BNF181
Other parameters
General mortality Age dependent England and Wales, 2008–10,122
adjusted by CRC mortality for
England in 2010110
Discounting
Costs 3.5% NICE reference case89
QALYs 3.5%
PSSRU, Personal Social Services Research Unit.
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Appendix 5 Diagnostic meta-analysis code (Stata)
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